Document:

Exhibit 10.1

 

EXECUTION VERSION

 

 

 

FIRST
LIEN NOTE PURCHASE AGREEMENT

 

dated as of June 29, 2017

 

among

 

BIOSCRIP,
INC.,

as Issuer,

 

THE PURCHASERS FROM TIME TO TIME PARTY HERETO,

 

and

 

WELLS
FARGO BANK, NATIONAL ASSOCIATION,

as Collateral Agent

 

 

 

     

     

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	ARTICLE I DEFINITIONS; CONSTRUCTION	1
	Section 1.1	Definitions	1
	Section 1.2	Classifications of Notes and Issuances	38
	Section 1.3	Accounting Terms and Determination	38
	Section 1.4	Terms Generally	39
	 	 	 
	ARTICLE II AMOUNT AND TERMS OF THE COMMITMENTS	39
	Section 2.1	General Description of Facilities	39
	Section 2.2	Commitments	39
	Section 2.3	Purchase of Notes	39
	Section 2.4	Interest Elections	40
	Section 2.5	Termination of Commitments	40
	Section 2.6	Repayment of Notes	40
	Section 2.7	Evidence of Indebtedness	40
	Section 2.8	Optional Prepayments; Prepayment Premium	41
	Section 2.9	Mandatory Prepayments	41
	Section 2.10	Interest on Notes	42
	Section 2.11	Fees	43
	Section 2.12	Computation of Interest and Fees	43
	Section 2.13	Inability to Determine Interest Rates	43
	Section 2.14	Illegality	43
	Section 2.15	Increased Costs	44
	Section 2.16	Funding Indemnity	45
	Section 2.17	Taxes	45
	Section 2.18	Payments Generally; Pro Rata Treatment; Sharing of Set-offs	47
	Section 2.19	Mitigation of Obligations	48
	Section 2.20	Replacement of Purchasers	49
	Section 2.21	Defaulting Purchasers	49
	Section 2.22	Legend	49
	Section 2.23	Transfer and Exchange of Notes	50
	Section 2.24	Replacement of Notes	50
	Section 2.25	Representations of Purchasers	50
	Section 2.26	Prepayment Premium	51
	 	 	 
	ARTICLE III CONDITIONS PRECEDENT TO PURCHASE OF NOTES	51
	Section 3.1	Conditions to Effectiveness	51
	Section 3.2	Delivery of Documents	55
	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES	55
	Section 4.1	Existence; Power	55
	Section 4.2	Organizational Power; Authorization	55
	Section 4.3	Governmental Approvals; No Conflicts	55
	Section 4.4	Financial Statements; Material Adverse Effect	56
	Section 4.5	Litigation and Environmental Matters	56
	Section 4.6	Compliance with Laws and Agreements	56
	Section 4.7	Investment Company Act	56
	Section 4.8	Taxes	57
	Section 4.9	Margin Regulations	57

 

    -i-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 4.10	ERISA	57
	Section 4.11	Ownership of Property; Insurance	58
	Section 4.12	Disclosure	58
	Section 4.13	Labor Relations	59
	Section 4.14	Subsidiaries	59
	Section 4.15	Solvency	59
	Section 4.16	Deposit and Disbursement Accounts	59
	Section 4.17	Collateral Documents	59
	Section 4.18	Material Agreements	60
	Section 4.19	Sanctions; Anti-Terrorism and Anti-Corruption Laws	60
	Section 4.20	Compliance with Healthcare Laws	62
	Section 4.21	HIPAA/HITECH Compliance	64
	Section 4.22	Reimbursement	65
	Section 4.23	Fraud and Abuse	65
	Section 4.24	EEA Financial Institutions; Other Regulations	65
	Section 4.25	Offer of Notes; Private Offering	66
	Section 4.26	Designation as Credit Facilities	66
	 	 	 
	ARTICLE V AFFIRMATIVE COVENANTS	66
	Section 5.1	Financial Statements and Other Information	66
	Section 5.2	Notices of Material Events	68
	Section 5.3	Existence; Conduct of Business	70
	Section 5.4	Compliance with Laws	70
	Section 5.5	Payment of Obligations	70
	Section 5.6	Books and Records	70
	Section 5.7	Visitation and Inspection	71
	Section 5.8	Maintenance of Properties; Insurance; Credit Ratings	71
	Section 5.9	Use of Proceeds; Margin Regulations	71
	Section 5.10	Casualty and Condemnation	72
	Section 5.11	Cash Management	72
	Section 5.12	Additional Subsidiaries and Collateral	73
	Section 5.13	Additional Real Estate; Leased Locations	74
	Section 5.14	Further Assurances	74
	Section 5.15	Healthcare Matters	74
	Section 5.16	Post-Closing Covenants	75
	Section 5.17	Second Lien Credit Enhancements	75
	Section 5.18	Second Lien Note Documents	75
	Section 5.19	Corporate Compliance and Quality Management Program	76
	 	 	 
	ARTICLE VI FINANCIAL COVENANT	76
	 	 
	ARTICLE VII NEGATIVE COVENANTS	76
	Section 7.1	Indebtedness and Disqualified Capital Stock	76
	Section 7.2	Liens	79
	Section 7.3	Fundamental Changes	80
	Section 7.4	Investments, Loans	80
	Section 7.5	Restricted Payments	82
	Section 7.6	Sale of Assets	82

 

    -ii-

     

    

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 7.7	Transactions with Affiliates	83
	Section 7.8	Restrictive Agreements	84
	Section 7.9	Sale and Leaseback Transactions	84
	Section 7.10	Hedging Transactions	84
	Section 7.11	Amendment to Material Documents	84
	Section 7.12	Accounting Changes	84
	Section 7.13	Compliance with Anti-Terrorism and Anti-Corruption Laws and Sanctions	85
	Section 7.14	Health Care Matters	85
	Section 7.15	ERISA	85
	Section 7.16	Payments in Respect of Senior Notes	85
	Section 7.17	Anti-Layering	85
	Section 7.18	Second Lien Obligations	85
	 	 	 
	ARTICLE VIII EVENTS OF DEFAULT	86
	Section 8.1	Events of Default	86
	Section 8.2	Application of Proceeds from Collateral	89
	 	 	 
	ARTICLE IX THE COLLATERAL AGENT	90
	Section 9.1	Appointment of the Collateral Agent	90
	Section 9.2	Nature of Duties of the Collateral Agent	91
	Section 9.3	Lack of Reliance on the Collateral Agent	91
	Section 9.4	Certain Rights of the Collateral Agent	91
	Section 9.5	Reliance by the Collateral Agent	92
	Section 9.6	The Collateral Agent in its Individual Capacity	92
	Section 9.7	No Filing Obligation	92
	Section 9.8	Successor Collateral Agent	92
	Section 9.9	The Collateral Agent May File Proofs of Claim	93
	Section 9.10	Authorization to Execute Other Note Documents	94
	Section 9.11	Collateral and Guaranty Matters	94
	Section 9.12	Right to Realize on Collateral and Enforce Guarantee	94
	Section 9.13	Secured Bank Product Obligations and Hedging Obligations	95
	Section 9.14	ABDC INTERCREDITOR AGREEMENT	95
	Section 9.15	FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT	95
	 	 	 
	ARTICLE X MISCELLANEOUS 	96
	Section 10.1	Notices	96
	Section 10.2	Waiver; Amendments	97
	Section 10.3	Expenses; Indemnification	99
	Section 10.4	Successors and Assigns	100
	Section 10.5	Governing Law; Jurisdiction; Consent to Service of Process	103
	Section 10.6	WAIVER OF JURY TRIAL	104
	Section 10.7	Right of Set-off	104
	Section 10.8	Counterparts; Integration	104
	Section 10.9	Survival	105
	Section 10.10	Severability	105
	Section 10.11	Confidentiality	105
	Section 10.12	Interest Rate Limitation	106

 

    -iii-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 10.13	Waiver of Effect of Corporate Seal	106
	Section 10.14	Patriot Act	106
	Section 10.15	No Advisory or Fiduciary Responsibility	107
	Section 10.16	First Lien/Second Lien Intercreditor Agreement	107
	Section 10.17	Captions	107
	Section 10.18	Acknowledgement and Consent to Bail-In of EEA Financial Institutions	108
	Section 10.19	Force Majeure	108

 

    -iv-

     

    

 

Table
of Contents

 

Schedules

 

	Schedule I	-	Commitment Amounts
	Schedule II	-	Competitors
	Schedule 4.11(a)	-	Real Estate
	Schedule 4.11(c)	-	Insurance
	Schedule 4.14	-	Subsidiaries
	Schedule 4.16	-	Permitted Third Party Banks; Deposit and Disbursement Accounts
	Schedule 4.18	-	Material Agreements
	Schedule 4.20(a)	-	Healthcare Matters
	Schedule 4.20(g)	-	Health Care Audits
	Schedule 4.22(a)	-	Company Reimbursement Approval Compliance
	Schedule 5.16	-	Post-Closing Covenants
	Schedule 7.1	-	Existing Indebtedness
	Schedule 7.2	-	Existing Liens
	Schedule 7.4	-	Existing Investments
	Schedule 7.7	-	Existing Transactions with Affiliates

 

Exhibits

 

	Exhibit A	-	Form of Assignment and Assumption
	Exhibit B	-	Form of Note
	Exhibit 2.4	-	Form of Notice of Conversion/Continuation
	Exhibit 3.1(b)(ii)	-	Form of Secretary’s Certificate
	Exhibit 3.1(b)(v)	-	Form of Closing Date Certificate
	Exhibit 5.1(c)	-	Form of Compliance Certificate

 

    -v-

     

    

 

FIRST LIEN NOTE PURCHASE AGREEMENT

 

THIS FIRST LIEN NOTE PURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of June 29, 2017, by and among BIOSCRIP,
INC., a Delaware corporation (the “Issuer”), the several financial institutions and purchasers from time to
time party hereto (the “Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral
agent for itself and the Purchasers (the “Collateral Agent”).

 

WITNESSETH:

 

WHEREAS, the Issuer
has agreed to issue, and the Purchasers have severally (and not jointly) agreed to purchase from the Issuer, notes in the aggregate
principal amount of $200,000,000 upon and subject to the terms and conditions set forth in this Agreement;

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants herein contained, the Issuer, the Purchasers and the Collateral Agent agree
as follows:

 

ARTICLE I 

 

DEFINITIONS; CONSTRUCTION

 

Section 1.1          Definitions.  
In addition to the other terms defined herein, the following terms used herein shall have the meanings herein specified (to
be equally applicable to both the singular and plural forms of the terms defined):

 

“ABDC”
shall mean AmerisourceBergen Drug Corporation, a Delaware corporation.

 

“ABDC Obligations”
shall mean all obligations of the Note Parties or any of their Subsidiaries owing to ABDC under the ABDC Prime Vendor Agreement
and any other agreement, instrument, certificate or other document pursuant to which any Note Party or any Subsidiary of a Note
Party grants (or purports to grant) in favor of ABDC a security interest in or a Lien on any property of such Note Party or such
Subsidiary now or at any time hereafter to secure such obligations.

 

“ABDC Intercreditor
Agreement” shall mean that certain Intercreditor Agreement dated as of the Closing Date by and between the Collateral
Agent, the Second Lien Collateral Agent and ABDC, as amended, restated, supplemented or otherwise modified from time to time in
accordance therewith and herewith.

 

“ABDC Lien”
shall mean (a) initially, the Lien of ABDC on the Inventory and Accounts of the Issuer and its Subsidiaries and the products and
proceeds thereof, as described more particularly and defined in the definition of “Second Priority Collateral” (as
defined in the ABDC Intercreditor Agreement) and, in all events, subject to the provisions of the ABDC Intercreditor Agreement
and (b) following the Issuer’s compliance with Section 6 of Schedule 5.16, the Lien of ABDC on the Inventory acquired
from ABDC pursuant to the ABDC Intercreditor Agreement and, in all events, subject to the provisions of the ABDC Intercreditor
Agreement.

 

“ABDC Prime Vendor
Agreement” shall mean that certain Prime Vendor Agreement dated as of July 1, 2009 by and among the Issuer and ABDC,
as amended by that certain First Amendment dated as of March 25, 2010, that certain Second Amendment dated as of June 1, 2010,
that certain Third Amendment dated as of August 1, 2010, that certain Fourth Amendment dated as of May 1, 2011, that certain Fifth
Amendment dated as of January 1, 2012, that certain Sixth Amendment dated as of September 1, 2012, that certain Seventh Amendment
dated as of December 1, 2012, and that certain Eighth Amendment dated as of April 1, 2013, and as the same may be further amended,
restated, supplemented, waived, extended, refinanced, replaced or otherwise modified from time to time in a manner not prohibited
by the ABDC Intercreditor Agreement.

 

     

     

    

 

“Account Control
Agreement” shall mean any agreement by and among a Note Party, the Collateral Agent and a depositary bank or securities
intermediary at which such Note Party maintains a Controlled Account, that, in each case, complies with all Requirements of Law
and is otherwise in form and substance reasonably satisfactory to the Collateral Agent and the Required Purchasers.

 

“Accreditation”
shall mean, collectively, all accreditations, approvals or other rights issued by any health care accrediting agency including
the Joint Commission, Accreditation Commission for Health Care, National Quality Forum, Community Health Accreditation Program
and URAC.

 

“Acquisition”
shall mean (a) any Investment by the Issuer or any of its Subsidiaries in any other Person organized in the United States (with
substantially all of the assets of such Person and its Subsidiaries located in the United States), pursuant to which such Person
shall become a Subsidiary of the Issuer or any of its Subsidiaries or shall be merged with the Issuer or any of its Subsidiaries
or (b) any acquisition by the Issuer or any of its Subsidiaries of the assets of any Person (other than a Subsidiary of the Issuer)
that constitute all or substantially all of the assets of such Person or a division or business unit of such Person, whether through
purchase, merger or other business combination or transaction (and substantially all of such assets, division or business unit
are located in the United States). With respect to a determination of the amount of an Acquisition, such amount shall include all
consideration (including the maximum amount of any earn-out or other deferred or contingent consideration and any Permitted Seller
Financing in respect thereof) set forth in the applicable agreements governing such Acquisition as well as the principal amount
of any Indebtedness assumed by any Note Party in connection therewith.

 

“Affiliate”
shall mean, as to any Person, any other Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled
by, or is under common Control with, such Person; provided that the Purchasers shall be deemed not to be Affiliates of any
Note Party. For the purposes of this definition, “Control” shall mean the power, directly or indirectly, to direct
or cause the direction of the management and policies of a Person, whether through the ability to exercise voting power, by contract
or otherwise. For purposes of Section 7.7, “Control” shall also include the power, directly or indirectly, to
vote 10% or more of the securities having ordinary voting power for the election of directors (or persons performing similar functions)
of a Person. The terms “Controlled by” and “under common Control with” have the meanings correlative thereto.

 

“Anti-Corruption
Law” shall mean any requirement of law related to bribery or anti-corruption, including the United States Foreign Corrupt
Practices Act of 1977, as now and hereafter in effect, or any successor statute.

 

“Anti-Terrorism
Law” shall mean any requirement of law related to money laundering or financing terrorism, including the Patriot Act,
The Currency and Foreign Transactions Reporting Act (also known as the “Bank Secrecy Act”, 31 U.S.C. §§5311-5330
and 12 U.S.C. §§1818(s), 1820(b) and 1951-1959), Trading With the Enemy Act (50 U.S.C. §1 et seq., as amended),
Executive Order 13224 (effective September 24, 2001) and each of the foreign assets control regulations of the United States Treasury
Department (31 C.F.R., Subtitle B, Chapter V, as amended), in each case, as now and hereafter in effect, or any successor statutes.

 

“Applicable Funding
Office” shall mean, with respect to any Purchaser, the office or offices of such Purchaser specified as its “Funding
Office” beneath its name on the applicable signature page hereto, or such other office or offices of such Purchaser as it
may from time to time notify the Issuer and the Collateral Agent.

 

    	 	2	 

     

    

 

“Applicable Margin”
shall mean, as of any date, with respect to all Notes outstanding on such date, 6.00% per annum with respect to Base Rate
Notes and 7.00% per annum with respect to Eurodollar Notes.

 

“Applicable Premium”
shall mean the greater of (I) 4.0% of the principal amount of the Notes being prepaid or repaid, as applicable, and (II) the excess
of (A) the present value of all remaining required interest payments to the second anniversary of the Closing Date (using the LIBOR
Rate that is determined for a one-month Interest Period commencing on the date of such prepayment and assuming such LIBOR Rate
remains the same for the entire period from the date of such prepayment to the second anniversary of the Closing Date) and principal
payments due on the principal amount of the Notes being prepaid or repaid, as applicable, plus the Prepayment Premium provided
for pursuant to clause (b) of the definition of Prepayment Premium on such principal amount being prepaid or repaid, as applicable,
in each case assuming a prepayment date of the second anniversary of the Closing Date, computed using a discount rate equal to
the Treasury Rate plus 50 basis points over (B) the principal amount of the Notes being prepaid or repaid, as applicable. For purposes
of this definition, “Treasury Rate” means the rate per annum equal to the yield to maturity at the time of computation
of the United States of America Treasury securities with a constant maturity most nearly equal to the period from such date of
prepayment or repayment, as applicable, to the second anniversary of the Closing Date; provided, however, that if
the period from such date of prepayment or repayment, as applicable, to the second anniversary of the Closing Date is not equal
to the constant maturity of a United States of America Treasury security for which a weekly average yield is given, the Treasury
Rate shall be obtained by linear interpolation (calculated to the nearest one-twelfth of a year) from the weekly average yields
of United States of America Treasury securities for which such yields are given, except that if the period from such date of prepayment
or repayment, as applicable, to the second anniversary of the Closing Date is less than one year, the weekly average yield on actually
traded United States of America Treasury securities adjusted to a constant maturity of one year shall be used.

 

“Approved Fund”
shall mean any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing
in commercial loans and similar extensions of credit in the ordinary course of its business and that is administered or managed
by (i) a Purchaser, (ii) an Affiliate of a Purchaser or (iii) an entity or an Affiliate of an entity that administers or manages
a Purchaser.

 

“Assignment and
Assumption” shall mean an assignment and assumption entered into by a Purchaser and an assignee (with the consent of
any party whose consent is required by Section 10.4(b)), substantially in the form of Exhibit A attached hereto or
any other form approved by the Required Purchasers.

 

“Available Amount”
shall mean, at any time (the “Reference Date”) an amount, not less than zero, equal to the sum of (a) the cumulative
portion of Excess Cash Flow for the period commencing on the Closing Date and ending on the Reference Date which has not been and
is not required to be used to prepay the Obligations pursuant to Section 2.9(c) minus (b) the aggregate amount of
any cash dividends, distributions, and share repurchases made by the Issuer pursuant to Section 7.5(g) after the Closing
Date and prior to the Reference Date.

 

“Bail-In Action”
shall mean the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability
of an EEA Financial Institution.

 

    	 	3	 

     

    

 

“Bail-In Legislation”
shall mean, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and
of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in
the EU Bail-In Legislation Schedule.

 

“Bank Product Obligations”
shall mean, collectively, all monetary obligations and other liabilities of any Note Party to any Bank Product Provider arising
with respect to any Bank Products.

 

“Bank Product Provider”
shall mean any Person that, at the time it provides any Bank Product to any Note Party, (i) is a Purchaser or an Affiliate of a
Purchaser and (ii) has provided prior written notice to the Collateral Agent which has been acknowledged by the Issuer of (x) the
existence of such Bank Product, (y) the maximum dollar amount of obligations arising thereunder (the “Bank Product Amount”)
and (z) the methodology to be used by such parties in determining the obligations under such Bank Product from time to time. In
no event shall any Bank Product Provider acting in such capacity be deemed a Purchaser for purposes hereof to the extent of and
as to Bank Products except that each reference to the term “Purchaser” in Article IX and Section 10.3(b)
shall be deemed to include such Bank Product Provider and in no event shall the approval of any such person in its capacity as
Bank Product Provider be required in connection with the release or termination of any security interest or Lien of the Collateral
Agent. The Bank Product Amount may be changed from time to time upon written notice to the Collateral Agent by the applicable Bank
Product Provider. No Bank Product Amount may be established at any time that a Default or Event of Default exists.

 

“Bank Products”
shall mean any of the following services provided to any Note Party by any Bank Product Provider: (a) any treasury or other cash
management services, including deposit accounts, automated clearing house (ACH) origination and other funds transfer, depository
(including cash vault and check deposit), zero balance accounts and sweeps, return items processing, controlled disbursement accounts,
positive pay, lockboxes and lockbox accounts, account reconciliation and information reporting, payables outsourcing, payroll processing,
trade finance services, investment accounts and securities accounts, and (b) card services, including credit cards (including purchasing
cards and commercial cards), prepaid cards, including payroll, stored value and gift cards, merchant services processing, and debit
card services.

 

“Base Rate”
shall mean, for any day, a floating rate per annum equal to the greater of (x) the higher of (i) the per annum rate publicly quoted
from time to time by The Wall Street Journal as the “Prime Rate” in the United States (or, if The Wall Street Journal
ceases quoting a base rate of the type described, either (a) the per annum rate quoted as the base rate on such corporate loans
in a different national publication as selected by the Required Purchasers or (b) the highest per annum rate of interest published
by the Federal Reserve Board in Federal Reserve statistical release H.15 (519) entitled “Selected Interest Rates” as
the Bank prime loan rate or its equivalent), and (ii) the Federal Funds Rate plus fifty (50) basis points per annum; provided
that if the Federal Funds Rate is less than zero on such day, it shall be deemed to be zero hereunder, and (y) the sum of the LIBOR
Rate calculated for each such day based on an Interest Period of one (1) month determined two (2) Business Days prior to the first
day of such proposed Interest Period (not to be less than 1.00%) plus 1.00% per annum. Each change in any interest rate based upon
the Base Rate shall take effect at the time of such change in the Base Rate.

 

“Beneficial Owner”
shall mean, with respect to any amount paid hereunder or under any other Note Document, the Person that is the beneficial owner,
for U.S. federal income tax purposes, of such payment.

 

“BioScrip Facilities”
shall mean any facility owned, leased or operated by the Issuer or any of its Subsidiaries.

 

    	 	4	 

     

    

 

“Business Day”
shall mean any day other than (i) a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by law to close and (ii) if such day relates to an Issuance of, a payment or prepayment of principal or interest on,
a conversion of or into, or an Interest Period for, a Eurodollar Note or a notice with respect to any of the foregoing, any day
on which banks are not open for dealings in Dollar deposits in the London interbank market.

 

“Capital Expenditures”
shall mean, for any period, without duplication, (i) the additions to property, plant and equipment and other capital expenditures
of the Issuer and its Subsidiaries that are (or would be) set forth on a consolidated statement of cash flows of the Issuer for
such period prepared in accordance with GAAP and (ii) Capital Lease Obligations incurred by the Issuer and its Subsidiaries during
such period.

 

“Capital Lease Obligations”
of any Person shall mean all obligations of such Person to pay rent or other amounts under any lease (or other arrangement conveying
the right to use) of real or personal property, or a combination thereof, which obligations are required to be classified and accounted
for as capital leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized
amount thereof determined in accordance with GAAP.

 

“Capital Stock”
shall mean all shares, options, warrants, general or limited partnership interests, membership interests or other equivalents (regardless
of how designated) of or in a corporation, partnership, limited liability company or equivalent entity whether voting or nonvoting,
including common stock, preferred stock or any other “equity security” (as such term is defined in Rule 3a11-1 of the
General Rules and Regulations promulgated by the Securities and Exchange Commission under the Exchange Act).

 

“Cash Equivalents”
shall mean (i) direct obligations issued by, or unconditionally guaranteed by, the United States government or issued by any agency
thereof and backed by the full faith and credit of the United States, in each case maturing within one year from the date of acquisition;
(ii) certificates of deposit, time deposits, eurodollar time deposits or overnight bank deposits having maturities of one year
or less from the date of acquisition issued by any commercial bank organized under the laws of the United States or any state thereof
having combined capital and surplus of not less than $500,000,000; (iii) commercial paper of an issuer rated at least A-1 by S&P
or P-1 by Moody’s, or carrying an equivalent rating by a nationally recognized rating agency if both of the two named rating
agencies cease publishing ratings of commercial paper issuers generally, and maturing within one year from the date of acquisition;
(iv) fully collateralized repurchase obligations of any commercial bank satisfying the requirements of clause (ii) of this definition,
having a term of not more than thirty days with respect to securities issued or fully guaranteed or insured by the United States
government; (v) marketable securities with maturities of one year or less from the date of acquisition issued or fully guaranteed
by any state, commonwealth or territory of the United States, by any political subdivision or taxing authority of any such state,
commonwealth or territory, the securities of which state, commonwealth, territory, political subdivision or taxing authority (as
the case may be) are rated at least A-1 by S&P or P-1 by Moody’s; (vi) securities with maturities of one year or less
from the date of acquisition backed by standby letters of credit issued by any Purchaser or any commercial bank satisfying the
requirements of clause (ii) of this definition; (vii) shares of money market mutual or similar funds which invest exclusively in
assets satisfying the requirements of any of clauses (i) through (vi) of this definition; and (viii) other short-term investments
utilized by Foreign Subsidiaries in accordance with the normal investment practices for cash management in investments of a type
analogous to the foregoing.

 

“CFC Subsidiary”
shall mean any Subsidiary of the Issuer that is organized under the laws of the United States or any state or district thereof
and substantially all of the assets of which consist (directly, or indirectly through one or more disregarded entities) of Capital
Stock of one or more Subsidiaries of the Issuer organized under the laws of a jurisdiction other than the United States or any
state or district thereof.

 

    	 	5	 

     

    

 

“Change in Control”
shall mean the occurrence of one or more of the following events: (i) the acquisition of ownership, directly or indirectly, beneficially
or of record, by any Person or “group” (within the meaning of the Exchange Act and the rules of the Securities and
Exchange Commission thereunder as in effect on the date hereof, but excluding any employee benefit plan of such person or its subsidiaries,
or any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of such plan) of 35% or more
of the outstanding shares of the voting equity interests (with equivalent economic interests) of the Issuer; (ii) during any period
of 24 consecutive months, a majority of the members of the Governing Body of the Issuer cease to be composed of individuals who
are Continuing Directors; (iii) the acquisition by contract or otherwise by any Person or two or more Persons acting in concert,
or the entering into of a contract or arrangement by any Person or two or more Persons acting in concert that, upon consummation
thereof, will result in its or their acquisition of the power to exercise, directly or indirectly, beneficially or of record, a
controlling influence over the management or policies of the Issuer, or control over 35% or more of the outstanding shares of the
voting equity interests (with equivalent economic interests) of the Issuer, (iv) the Issuer shall cease to directly or indirectly
own, free and clear of all Liens (except those created under the Collateral Documents, the Second Lien Collateral Documents and
non-consensual Liens that arise by operation of law), 100% of the outstanding Capital Stock of each of its Subsidiaries (whether
acquired or formed before or after the Closing Date), and all voting rights and economic interests with respect thereto, other
than pursuant to a transaction that is not prohibited hereunder, or (v) the occurrence of a “Change in Control” (or
any comparable term) under, and as defined in, any document or agreement evidencing any Material Indebtedness.

 

“Change in Law”
shall mean (i) the adoption of any applicable law, rule or regulation after the date of this Agreement, (ii) any change in any
applicable law, rule or regulation, or any change in the interpretation, implementation or application thereof, by any Governmental
Authority after the date of this Agreement, or (iii) compliance by any Purchaser (or its Applicable Funding Office) (or, for purposes
of Section 2.15(b), by the Parent Company of such Purchaser, if applicable) with any request, guideline or directive (whether
or not having the force of law) of any Governmental Authority made or issued after the date of this Agreement; provided
that for purposes of this Agreement, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules,
guidelines or directives in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank
for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United
States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change
in Law”, regardless of the date enacted, adopted or issued.

 

“Closing Date”
shall mean the date on which the conditions precedent set forth in Section 3.1 have been satisfied or waived in accordance
with Section 10.2 and the Notes are issued by the Issuer and purchased by the Purchasers.

 

“CMS”
shall mean the Centers for Medicare and Medicaid Services, formerly known as the Health Care Financing Administration or HCFA,
and any successor thereto.

 

“Code”
shall mean the Internal Revenue Code of 1986, as amended and in effect from time to time, any successor statute, and the regulations
promulgated and rulings issued thereunder.

 

“Collateral”
shall mean all “Collateral” as defined in any Collateral Document and shall include the Mortgaged Properties, but shall
exclude any Excluded Property.

 

    	 	6	 

     

    

 

“Collateral Access
Agreement” shall mean each landlord waiver or bailee agreement granted to, and in form and substance reasonably acceptable
to, the Collateral Agent and the Required Purchasers.

 

“Collateral Agent”
shall have the meaning set forth in the introductory paragraph hereof.

 

“Collateral Documents”
shall mean, collectively, the Guaranty and Security Agreement, any Real Estate Documents, the Account Control Agreements, the Government
Receivables Account Agreements, the Information and Collateral Disclosure Certificate, all Copyright Security Agreements, all Patent
Security Agreements, all Trademark Security Agreements, all Collateral Access Agreements, all assignments of key man life insurance
policies and all other instruments and agreements now or hereafter securing or perfecting the Liens securing the whole or any part
of the Obligations or any Guarantee thereof, all UCC financing statements, fixture filings and stock powers, and all other documents,
instruments, agreements and certificates executed and delivered by any Note Party to the Collateral Agent and the Purchasers in
connection with the foregoing.

 

“Commitment”
shall mean, with respect to each Purchaser, the obligation of such Purchaser to purchase a Note hereunder on the Closing Date,
in an aggregate principal amount not exceeding the amount set forth with respect to such Purchaser on Schedule I. The aggregate
principal amount of all Purchasers’ Commitments as of the Closing Date is $200,000,000.

 

“Commitment Letter”
shall mean that certain Commitment Letter, dated as of June 7, 2017, among Ares Management LLC (on behalf of one or more of its
affiliated funds or accounts), each of the accounts listed on the signature pages thereto that is managed by Western Asset Management
Company, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC and agreed and accepted by the Issuer.

 

“Commodity Exchange
Act” shall mean the Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from time to time, and any successor
statute.

 

“Company Accreditation”
shall have the meaning set forth in Section 4.20(c).

 

“Company Reimbursement
Approval” shall have the meaning set forth in Section 4.22(a).

 

“Company Regulatory
Filings” shall have the meaning set forth in Section 4.20(e).

 

“Competitor”
shall mean each bona fide operating competitor directly engaged in the Issuer’s line of business and set forth on Schedule
II.

 

“Compliance Certificate”
shall mean a certificate from a Responsible Officer of the Issuer in substantially the form of, and containing the certifications
set forth in, the certificate attached hereto as Exhibit 5.1(c).

 

“Consolidated Covenant
Testing Net Leverage Ratio” shall mean, as of any date, the ratio of (i) Consolidated Total Net Debt (other than any
Consolidated Junior Indebtedness, any Subordinated Debt and any unsecured Indebtedness, in each case, not prohibited hereunder
but, notwithstanding the foregoing, including all Permitted Seller Financing) as of such date to (ii) Consolidated EBITDA for the
four consecutive Fiscal Quarters ending on (A) with respect to calculations of the Consolidated Covenant Testing Net Leverage Ratio
required by Article VI, such date and (B) with respect to all other calculations of the Consolidated Covenant Testing Net
Leverage Ratio, the last day of the most recent Fiscal Quarter prior to such date for which financial statements have been delivered
(or were required to be delivered) pursuant to Section 5.1(a) or 5.1(b), as applicable. The Consolidated Covenant
Testing Net Leverage Ratio shall be calculated on a Pro Forma Basis.

 

    	 	7	 

     

    

 

“Consolidated EBITDA”
shall mean, for the Issuer and its Subsidiaries for any period, an amount equal to the sum of (i) Consolidated Net Income for such
period plus (ii) to the extent deducted in determining Consolidated Net Income for such period, and in each case without duplication
and as determined in accordance with GAAP, (a) Consolidated Interest Expense, (b) income tax expense (including any franchise taxes
imposed in lieu of income taxes and taxes based on profit or capital) determined on a consolidated basis, (c) depreciation and
amortization (including amortization of intangibles and goodwill) determined on a consolidated basis, (d) fees, out of pocket costs
and expenses incurred in connection with dispositions, Investments, issuances of Indebtedness (including the Second Lien Obligations)
or Capital Stock and Capital Expenditures (whether or not successfully consummated) to the extent not prohibited hereunder, (e)
extraordinary or non-recurring charges, (f) severance costs, retention bonuses and other similar compensation payments made to
employees of any Note Party, (g) non-cash charges (including deferred compensation, stock option or employee benefits-based and
other equity-based compensation expenses, in each case, made to employees, consultants and advisors of any Note Party), (h) transaction
expenses incurred in connection with this Agreement and the transactions contemplated hereby, (i) restructuring charges, (j) integration
and relocation expenses determined and calculated in each case on a basis not inconsistent with historical practice, (k) prepayment
expense, including fees and premiums, incurred in connection with the retirement of existing indebtedness of the Issuer and its
Subsidiaries, (l) fees and expenses paid to the Collateral Agent and the Purchasers hereunder and to the Second Lien Collateral
Agent and the Second Lien Purchasers under the Second Lien Note Purchase Agreement (in each case, to the extent not otherwise included
in the calculation of Consolidated Interest Expense), (m) transaction expenses and integration expenses incurred in connection
with the Acquisition of Home Infusion Solutions, LLC, (n) losses and expenses from discontinued operations, divested joint ventures
and other divested Investments or incurred in connection with the disposal of discontinued operations or the divestiture of joint
ventures and other Investments, (o) expenses incurred in connection with the settlement of any litigation or claim involving any
Note Party (so long as, with respect to each such litigation or claim, such expenses exceed $100,000); provided, however,
any such amount added back pursuant to this clause (o) shall not exceed $6,300,000 in the aggregate (including related legal fees
not to exceed $500,000) over the term of this Agreement and (p) the cumulative effect of a change in accounting principles; provided
that the aggregate amount that may be added to Consolidated Net Income pursuant to clauses (d), (e), (f), (h), (i), (j), (k), (l),
(m), (n) and (o) above in any period of four consecutive Fiscal Quarters shall not exceed $30,000,000; provided, further,
that, commencing with the fifth full Fiscal Quarter following the Closing Date, (I) the aggregate amount that may be added to Consolidated
Net Income pursuant to clauses (e), (f), (i), (j) and (m) above in any period of four consecutive Fiscal Quarters shall not exceed
$20,000,000 and (II) the aggregate amount that may be added to Consolidated Net Income pursuant to clauses (d), (h), (k), (l),
(n) and (o) above in any period of four consecutive Fiscal Quarters shall not exceed $10,000,000.

 

“Consolidated Interest
Expense” shall mean, for the Issuer and its Subsidiaries for any period, determined on a consolidated basis in accordance
with GAAP, the sum of (i) total interest expense, (including, without limitation and without duplication, (a) the interest component
of any payments in respect of Capital Lease Obligations, capitalized or expensed during such period (whether or not actually paid
during such period), (b) any premium or penalty payable in connection with the payment of make-whole amounts or other prepayment
premiums payable in connection with any Indebtedness of the Issuer or any of its Subsidiaries, (c) all commissions, discounts and
other fees and charges owed in respect of interest rates to the extent such net costs are allocable to such period in accordance
with GAAP, (d) any interest accrued during such period in respect of Indebtedness of the Issuer or any Subsidiary that is required
to be capitalized rather than paid in cash, (e) interest paid or payable with respect to discontinued operations and (f) the interest
portion of any deferred payment obligations) plus (ii) the net amount payable (or minus the net amount receivable)
with respect to Hedging Transactions during such period (whether or not actually paid or received during such period).

 

    	 	8	 

     

    

 

“Consolidated Junior
Indebtedness” shall mean, as of any date, the aggregate stated principal amount of all Indebtedness of the Issuer and
its Subsidiaries, measured on a consolidated basis as of such date, secured by Liens that are junior in priority to the Liens securing
the Obligations (but excluding the Second Lien Obligations).

 

“Consolidated Net
Income” shall mean, for the Issuer and its Subsidiaries for any period, the net income (or loss) of the Issuer and its
Subsidiaries for such period determined on a consolidated basis in accordance with GAAP, but excluding therefrom (to the extent
otherwise included therein) (i) any extraordinary gains or losses, (ii) any gains or losses attributable to write-ups or write-downs
of assets (including any reappraisal or revaluation of assets (including intangibles, goodwill and deferring financing costs)),
or the sale of assets (other than the sale of assets in the ordinary course of business), (iii) any interest of the Issuer
or any Subsidiary of the Issuer in the unremitted or undistributed earnings of any Person in which the Issuer or any Subsidiary
of the Issuer has an equity interest but that is not a Subsidiary, (iv) any income (or loss) of any Person accrued prior to the
date it becomes a Subsidiary or is merged into or consolidated with the Issuer or any Subsidiary or the date that such Person’s
assets are acquired by the Issuer or any Subsidiary, (v) any income (or loss) for such period attributable to the early extinguishment
of Indebtedness, (vi) any interest of the Issuer or any Subsidiary of the Issuer in the unremitted or undistributed earnings of
any Subsidiary of the Issuer or another Subsidiary of the Issuer to the extent that such remittance or distribution of earnings
is prohibited by the organizational documents of such Subsidiary, contractual restrictions applicable to such Subsidiary, or by
applicable Requirements of Law, and (vii) any unrealized income (or loss) in respect of Hedging Obligations.

 

“Consolidated Total
Assets” shall mean, as of any date, the total assets of the Issuer and its Subsidiaries set forth on the consolidated
balance sheet of the Issuer and its Subsidiaries as of the end of the most recently ended Fiscal Quarter for which financial statements
have been delivered (or were required to be delivered) pursuant to Section 5.1(a) or 5.1(b), as applicable, determined
on a consolidated basis in conformity with GAAP.

 

“Consolidated Total
Debt” shall mean, as of any date, the aggregate stated principal amount of all Indebtedness of the Issuer and its Subsidiaries
measured on a consolidated basis as of such date, but excluding (i) Indebtedness of the type described in clause (xi) of the definition
thereof, (ii) Indebtedness of the type described in Section 7.1(a)(xii), (iii) the portion of any earn-out or other deferred
or contingent purchase consideration that is based upon the achievement of future financial or operational criteria and that has
not yet been earned in accordance with the terms of the applicable agreements, and (iv) Indebtedness of the type described in clause
(vi) of the definition thereof (except to the extent of any unreimbursed drawings thereunder).

 

“Consolidated Total
Net Debt” shall mean, as of any date, the sum of (i) Consolidated Total Debt minus (ii) the aggregate amount of
cash and Cash Equivalents held by the Note Parties with respect to which the Collateral Agent has a first-priority perfected lien
securing the Obligations included in the consolidated balance sheet of the Note Parties as of such date (other than (a) Restricted
Cash and (b) for purposes of calculating the Consolidated Total Net Leverage Ratio or the Consolidated Covenant Testing Net Leverage
Ratio, as applicable, the aggregate principal amount of any Indebtedness incurred on the date on which such ratio is calculated).

 

    	 	9	 

     

    

 

“Consolidated Total
Net Leverage Ratio” shall mean, as of any date, the ratio of (i) Consolidated Total Net Debt as of such date to (ii)
Consolidated EBITDA for the four consecutive Fiscal Quarters ending on the last day of the most recent Fiscal Quarter prior to
such date for which financial statements have been delivered (or were required to be delivered) pursuant to Section 5.1(a)
or 5.1(b), as applicable. The Consolidated Total Net Leverage Ratio shall be calculated on a Pro Forma Basis.

 

“Continuing Director”
shall mean, with respect to any period, any individuals (A) who were members of the Governing Body of the Issuer on the first day
of such period, (B) whose election or nomination to that Governing Body was approved by individuals referred to in clause (A) above
constituting at the time of such election or nomination at least a majority of that Governing Body, or (C) whose election or nomination
to that Governing Body was approved by individuals referred to in clauses (A) and (B) above constituting at the time of such election
or nomination at least a majority of that Governing Body.

 

“Contractual Obligation”
of any Person shall mean any provision of any security issued by such Person or of any agreement, instrument or undertaking under
which such Person is obligated or by which it or any of the property in which it has an interest is bound.

 

“Controlled Account”
shall have the meaning set forth in Section 5.11.

 

“Copyright”
shall have the meaning assigned to such term in the Guaranty and Security Agreement.

 

“Copyright Security
Agreement” shall mean any Copyright Security Agreement executed by a Note Party owning registered Copyrights or applications
for Copyrights in favor of the Collateral Agent for the benefit of the Secured Parties, both on the Closing Date and thereafter.

 

“Debtor Relief Laws”
means the Bankruptcy Code of the United States of America, and all other liquidation, conservatorship, bankruptcy, assignment for
the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of
the United States or other applicable jurisdictions from time to time in effect.

 

“Default”
shall mean any condition or event that, with the giving of notice or the lapse of time or both, would constitute an Event of Default.

 

“Default Interest”
shall have the meaning set forth in Section 2.10(c).

 

“Defaulting Purchaser”
shall mean, subject to Section 2.21, any Purchaser that (a) has failed to (i) purchase its Notes within two (2) Business
Days of the date such Notes were required to be purchased hereunder unless such Purchaser notifies the Issuer and each other Purchaser
in writing that such failure is the result of such Purchaser’s good faith determination that one or more conditions precedent
to purchase (each of which conditions precedent, together with any applicable default, shall be specifically identified in such
writing) has not been satisfied, or (ii) pay to the Collateral Agent or any other Purchaser any other amount required to be paid
by it hereunder within two (2) Business Days of the date when due, (b) has notified the Issuer in writing that it does not intend
to comply with its purchase obligations hereunder, or has made a public statement to that effect (unless such writing or public
statement relates to such Purchaser’s obligation to purchase a Note hereunder and states that such position is based on such
Purchaser’s good faith determination that a condition precedent to purchase (which condition precedent, together with any
applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed,
within three (3) Business Days after written request by the Issuer, to confirm in writing to the Issuer that it will comply with
its prospective purchase obligations hereunder (provided that such Purchaser shall cease to be a Defaulting Purchaser pursuant
to this clause (c) upon receipt of such written confirmation by the Issuer), or (d) has, or has a direct or indirect Parent Company
that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian,
conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation
of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority
acting in such a capacity or (iii) become the subject of a Bail-in Action; provided that a Purchaser shall not be a Defaulting
Purchaser solely by virtue of the ownership or acquisition of any equity interest in that Purchaser or any direct or indirect Parent
Company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Purchaser with
immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on
its assets or permit such Purchaser (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or
agreements made with such Purchaser.

 

    	 	10	 

     

    

 

“Disqualified Capital
Stock” shall mean, with respect to any Person, any Capital Stock that by its terms (or by the terms of any other Capital
Stock into which it is convertible or exchangeable) or otherwise (i) matures (other than as a result of a voluntary redemption
or repurchase by the issuer of such Capital Stock) or is subject to mandatory redemption or repurchase (other than solely for Capital
Stock that is not Disqualified Capital Stock) pursuant to a sinking fund obligation or otherwise (except as a result of a change
of control or asset sale so long as any rights of the holder thereof upon the occurrence of a change of control or asset sale event
shall be subject to the prior payment in full in cash of the Obligations (other than any Obligations which expressly survive termination,
Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and
other contingent obligations not then due and payable and as to which no claim has been made) and termination of the Commitments);
or (ii) is convertible into or exchangeable or exercisable for Indebtedness or any Disqualified Capital Stock at the option of
the holder thereof; or (iii) may be required to be redeemed or repurchased at the option of the holder thereof (other than solely
for Capital Stock that is not Disqualified Capital Stock), in whole or in part, in each case specified in (i), (ii) or (iii) above
on or prior to the date that is ninety one days after the Maturity Date; or (d) provides for scheduled payments of dividends to
be made in cash.

 

“Disqualified Institution”
shall mean (a) any Disqualified Purchaser and (b) any Competitor.

 

“Disqualified Purchaser”
shall mean each institutional investor, bank or other financial institution previously identified in writing to the Purchasers
and the Collateral Agent and set forth in that certain letter agreement dated as of the date hereof delivered by the Issuer to
the Purchasers and the Collateral Agent (the “Disqualified Purchaser Letter”), and each Person known to the
applicable Purchaser seeking to sell all or a portion of the Note(s) held by it to be an Affiliate thereof and any Person that
is readily identifiable as an affiliate thereof on the basis of its name; provided that in no event shall any bona fide
(A) debt fund, (B) investment vehicle, (C) regulated bank entity or (D) non-regulated lending entity, in each case, that is primarily
engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary
course of business (each, a “Bona Fide Lending Affiliate”) be a Disqualified Purchaser, unless such Bona Fide
Lending Affiliate is identified in the Disqualified Purchaser Letter.

 

“Dollar(s)”
and the sign “$” shall mean lawful money of the United States.

 

“Domestic Subsidiary”
shall mean each Subsidiary of the Issuer that is organized under the laws of the United States or any state or district thereof
and which is not a CFC Subsidiary.

 

    	 	11	 

     

    

 

“EEA Financial Institution”
shall mean (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision
of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described
in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary
of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with
its parent.

 

“EEA Member Country”
shall mean any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

 

“EEA Resolution
Authority” shall mean any public administrative authority or any person entrusted with public administrative authority
of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

 

“Effective Yield”
means, as to any Indebtedness, the effective yield on such Indebtedness in the reasonable determination of the Required Purchasers
in consultation with the Issuer and consistent with generally accepted financial practices, taking into account the applicable
interest rate margins, any interest rate floors or similar devices and all fees, including upfront or similar fees or original
issue discount (converted to yield assuming a four-year average life to maturity and without any present value discount) payable
generally to lenders or other institutions providing such Indebtedness, but excluding any arrangement, structuring, ticking or
other similar fees payable in connection therewith that are not generally shared with the relevant lenders or other institutions
providing such Indebtedness and, if applicable, consent fees for an amendment paid generally to consenting lenders or other institutions
providing such Indebtedness.

 

“Environmental Indemnity”
shall mean each environmental indemnity made by each Note Party with respect to Real Estate required to be pledged as Collateral
in favor of the Collateral Agent for the benefit of the Secured Parties, in each case in form and substance reasonably satisfactory
to the Collateral Agent and the Required Purchasers.

 

“Environmental Laws”
shall mean all applicable laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, binding notices
or binding agreements issued, promulgated or entered into by or with any Governmental Authority relating in any way to the environment,
preservation or reclamation of natural resources, the management, Release or threatened Release of any Hazardous Material or to
health and safety matters.

 

“Environmental Liability”
shall mean any liability, contingent or otherwise (including any liability for damages, costs of environmental investigation and
remediation, costs of administrative oversight, fines, natural resource damages, penalties or indemnities), of the Issuer or any
of its Subsidiaries directly or indirectly resulting from or based upon (i) any actual or alleged violation of any Environmental
Law, (ii) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (iii) any actual
or alleged exposure to any Hazardous Materials, (iv) the Release or threatened Release of any Hazardous Materials or (v) any contract,
agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.

 

“ERISA”
shall mean the Employee Retirement Income Security Act of 1974, as amended and in effect from time to time, and any successor statute
and the regulations promulgated and rulings issued thereunder.

 

“ERISA Affiliate”
shall mean any person that for purposes of Title IV of ERISA or Section 412 of the Code would be deemed at any relevant time to
be a “single employer” or otherwise aggregated with the Issuer or any of its Subsidiaries under Section 414(b) or (c)
(or, as relevant, Section 414(m) or (o)) of the Code or Section 4001 of ERISA.

 

    	 	12	 

     

    

 

“ERISA Event”
shall mean (i) the occurrence of any “reportable event” as defined in Section 4043 of ERISA with respect to a Plan
(other than an event as to which the PBGC has waived the requirement of Section 4043(a) of ERISA that it be notified of such event);
(ii) any failure to make a required contribution to any Plan that would result in the imposition of a lien or other encumbrance
or the provision of security under Section 430 of the Code or Section 303(k) or 4068 of ERISA, or the arising of such a lien or
encumbrance; (iii) there being or arising any “unpaid minimum required contribution” or “accumulated funding
deficiency” (as defined or otherwise set forth in Section 4971 of the Code or Part 3 of Subtitle B of Title 1 of ERISA),
whether or not waived; (iv) any filing of any request for or receipt of a minimum funding waiver under Section 412 of the Code
or Section 302 of ERISA with respect to any Plan or Multiemployer Plan; (v) any incurrence by the Issuer, any of its Subsidiaries
or any of their respective ERISA Affiliates of any liability under Title IV of ERISA with respect to any Plan or Multiemployer
Plan (other than for premiums due and not delinquent under Section 4007 of ERISA); (vi) any institution of proceedings, or the
occurrence of an event or condition which would reasonably be expected to constitute grounds for the institution of proceedings,
by the PBGC, under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Plan; (vii)
any incurrence by the Issuer, any of its Subsidiaries or any of their respective ERISA Affiliates of any liability with respect
to the withdrawal or partial withdrawal from any Multiemployer Plan, or the receipt by the Issuer, any of its Subsidiaries or any
of their respective ERISA Affiliates of any notice that a Multiemployer Plan is in endangered or critical status under Section
305 of ERISA; (viii) any receipt by the Issuer, any of its Subsidiaries or any of their respective ERISA Affiliates of any notice,
or any receipt by any Multiemployer Plan from the Issuer, any of its Subsidiaries or any of their respective ERISA Affiliates of
any notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to
be, insolvent or in reorganization, within the meaning of Title IV of ERISA; (ix) the occurrence of a non-exempt prohibited transaction
within the meaning of Section 406 of ERISA or Section 4975 of the Code with respect to any Plan such that material liability would
be incurred by the Issuer or any of its Subsidiaries; (x) any filing of a notice of intent to terminate any Plan if such termination
would require material additional contributions in order to be considered a standard termination within the meaning of Section
4041(b) of ERISA; (xi) any filing under Section 4041(c) of ERISA of a notice of intent to terminate any Plan; or (xii) the termination
of any Plan under Section 4041(c) of ERISA.

 

“EU Bail-In Legislation
Schedule” shall mean the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person),
as in effect from time to time.

 

“Eurodollar”,
when used in reference to any Note or Issuance, refers to whether such Note, or the Notes issued pursuant to such Issuance, bears
interest at a rate determined by reference to the LIBOR Rate.

 

“Event of Default”
shall have the meaning set forth in Section 8.1.

 

“Excess Cash Flow”
shall mean, for the Issuer and its consolidated Subsidiaries for any Fiscal Year:

 

(a)         Consolidated
EBITDA for such Fiscal Year,

 

minus 

 

(b)          the sum of the
following, without duplication:

 

(i)        the
aggregate amount of all regularly scheduled principal payments of Indebtedness (including the Notes and the principal
component of any Capital Lease Obligations) made during such Fiscal Year (excluding payments in respect of any revolving
credit facility unless there is an equivalent permanent reduction in commitments thereunder);

 

    	 	13	 

     

    

 

(ii)       the
aggregate amount of all mandatory prepayments or repurchases of Indebtedness for borrowed money (including the Notes and the
Second Lien Notes) (other than in connection with any permitted refinancing) made during such Fiscal Year (excluding payments
in respect of any revolving credit facility unless there is an equivalent permanent reduction in commitments thereunder)
other than any mandatory prepayment required pursuant to Section 2.9(c) and Section 2.9(c) of the Second Lien Note
Purchase Agreement;

 

(iii)      the
aggregate amount of all voluntary prepayments of Indebtedness for borrowed money (other than the Obligations and the Second
Lien Obligations) made during such Fiscal Year (excluding payments in respect of any revolving credit facility unless there
is an equivalent permanent reduction in commitments thereunder);

 

(iv)
    Consolidated Interest Expense paid in cash for such Fiscal Year;

 

(v)      income
taxes (including franchise taxes imposed in lieu of income taxes) paid in cash with respect to such Fiscal Year;

 

(vi)    the
aggregate amount paid in cash during such Fiscal Year on account of Capital Expenditures, Investments, and Restricted
Payments, in each case, to the extent not prohibited hereunder (including the amount of all related fees, costs and expenses
incurred in connection therewith) and excluding the portion of any such Capital Expenditure, Investments, or Restricted
Payments that is financed with funds that do not constitute Internally Generated Cash; provided that, with respect to
any Capital Expenditures and other Investments described in this clause (vi), the Issuer may include in the calculation of
Excess Cash Flow for any Fiscal Year the aggregate amount of expenditures that the Issuer or any of its Subsidiaries becomes
legally obligated to make during such Fiscal Year pursuant to a binding contract, committed purchase order or other binding
agreement but that are not actually made in cash during such Fiscal Year so long as (x) such expenditures are actually made
in cash during the following Fiscal Year, (y) the Issuer includes in the certificate required to be delivered pursuant to Section
2.9(c) a description of such expenditures and a certification that such expenditures will be made during the following
Fiscal Year, and (z) if such expenditures are included in the calculation of Excess Cash Flow for any Fiscal Year, they may
not be included in the calculation of Excess Cash Flow for the following Fiscal Year;

 

(vii)     any
increase in the Working Capital during such period (measured as the excess of such Working Capital at the end of such period
over such Working Capital at the beginning of such period);

 

(viii)    all
other items added back to Consolidated EBITDA pursuant to (and subject to the limitations in) the definition of Consolidated EBITDA
to the extent paid in cash during such Fiscal Year;

 

plus 

 

(c)         without
duplication, any decrease in the Working Capital during such period (measured as the excess of such Working Capital at the
beginning of such period over such Working Capital at the end thereof).

 

    	 	14	 

     

    

 

“Exchange Act”
shall mean the Securities Exchange Act of 1934, as amended and in effect from time to time.

 

“Excluded Account”
shall mean (a) deposit accounts specifically and exclusively used for payroll, payroll taxes and other employee wage and benefit
payments to or for the benefit of any Note Party’s employees, (b) any other zero balance account or disbursement only account,
(c) deposit accounts specifically and exclusively used for escrowing funds and holding funds in trust, (d) Government Receivables
Accounts, (e) any deposit account specifically and exclusively used to hold cash collateral for letters of credit permitted pursuant
to Section 7.1(a)(xix), and (f) any other deposit account, securities account or commodities account, including local or
petty cash accounts, which (i) individually does not have an average daily balance for a period in excess of three (3) Business
Days of more than $1,000,000 in cash or investment property on deposit therein or (ii) collectively with all such other accounts
described in this clause (f), does not have an aggregate balance at any time of more than $3,000,000 in cash or investment property
on deposit therein.

 

“Excluded Property”
shall have has the meaning specified in the Guaranty and Security Agreement.

 

“Excluded Swap Obligation”
shall mean, with respect to any Guarantor, any Swap Obligation if, and to the extent that, all or a portion of the Guarantee of
such Guarantor of, or the grant by such Guarantor of a security interest to secure, such Swap Obligation (or any Guarantee thereof)
is or becomes illegal or unlawful under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading
Commission (or the application or official interpretation of any thereof) by virtue of such Guarantor’s failure for any reason
to constitute an “eligible contract participant” as defined in the Commodity Exchange Act at the time the Guarantee
of such Guarantor or the grant of such security interest becomes effective with respect to such Swap Obligation; provided
that, for the avoidance of doubt, in determining whether any Guarantor is an “eligible contract participant” under
the Commodity Exchange Act, the keepwell agreement set forth in Section 10.19 of the Guaranty and Security Agreement shall be taken
into account. If a Swap Obligation arises under a master agreement governing more than one swap, such exclusion shall apply only
to the portion of such Swap Obligation that is attributable to swaps for which such Guarantee or security interest is or becomes
illegal. For purposes of this definition, the term “Swap Obligations” shall mean any obligation to pay or perform
under any agreement, contract or transaction that constitutes a “swap” within the meaning of section 1a(47) of the
Commodity Exchange Act.

 

“Excluded Taxes”
shall mean, with respect to any payment to be made by or on account of any obligation of the Issuer hereunder, (a) income or franchise
Taxes that are (i) imposed on (or measured by) the Recipient’s (or Beneficial Owner’s) net income by the United States,
or by the jurisdiction under the laws of which such Recipient (or Beneficial Owner) is organized or in which its principal office
is located or, in the case of any Purchaser, in which its Applicable Funding Office is located or (ii) Other Connection Taxes,
(b) any branch profits Taxes imposed by the United States or any similar Taxes that are imposed by any other jurisdiction in which
such Recipient (or Beneficial Owner) is located, (c) in the case of a Purchaser, any U.S. federal withholding Taxes that are imposed
on amounts payable to any Recipient (or Beneficial Owner) at the time such Recipient (or Beneficial Owner) becomes a Recipient
(or Beneficial Owner) under this Agreement or designates a new funding office, except in each case to the extent that amounts with
respect to such Taxes were payable either (i) to such Recipient’s (or Beneficial Owner’s) assignor immediately before
such Recipient (or Beneficial Owner) became a Recipient (or Beneficial Owner) under this Agreement, or (ii) to such Recipient (or
Beneficial Owner) immediately before it designated a new funding office, (d) any Taxes that are attributable to a Recipient’s
(or Beneficial Owner’s) failure to comply with Section 2.17(f), or (e) any Taxes imposed under FATCA.

 

    	 	15	 

     

    

 

“Existing Credit
Agreement” shall mean that certain Credit Agreement dated as of July 31, 2013, by and among the Issuer, the lenders from
time to time party thereto and SunTrust Bank, as administrative agent, issuing bank and swingline lender, as amended, restated,
supplemented, or otherwise modified from time to time prior to the Closing Date.

 

“Existing Priming
Credit Agreement” shall mean that certain Priming Credit Agreement dated as of January 6, 2017, by and among the Issuer,
the lenders from time to time party thereto and SunTrust Bank, as administrative agent, as amended, restated, supplemented, or
otherwise modified from time to time prior to the Closing Date.

 

“Exjade Settlement”
shall mean the Issuer’s payment of an amount equal to $15,000,000, together with applicable interest thereon (plus any amounts
arising out of the Issuer’s obligation to reimburse certain parties for their out of pocket expenses) to settle certain allegations
relating to the prescription drug known as Exjade as described in the Issuer’s Form 8-K filed with the SEC on or about December
16, 2013.

 

“FATCA”
shall mean Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is
substantively comparable and not materially more onerous to comply with), any current or future regulations with respect thereto
or official administrative interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and
any intergovernmental agreements (or related legislation or official administrative rules or practices) implementing the foregoing.

 

“FDA”
shall mean the United Stated Food & Drug Administration.

 

“Federal Funds Rate”
shall mean, for any day, the rate per annum (rounded upwards, if necessary, to the next 1/100 of 1%) equal to the weighted
average of the rates on overnight Federal funds transactions with member banks of the Federal Reserve System arranged by Federal
funds brokers, as published by the Federal Reserve Bank of New York on the next succeeding Business Day or, if such rate is not
so published for any Business Day, the Federal Funds Rate for such day shall be the average (rounded upwards, if necessary, to
the next 1/100 of 1%) of the quotations for such day on such transactions received by the Required Purchasers from three Federal
funds brokers of recognized standing selected by the Required Purchasers.

 

“Federal/State Healthcare
Program Account Debtor” shall mean any account debtor which is (a) the United States of America acting under the Medicaid
or Medicare program established pursuant to the Social Security Act, the Tricare/CHAMPUS Program or any other Federally sponsored
health care program other than the health care programs for which Federal government employees are beneficiaries, (b) any state
or the District of Columbia acting pursuant to a health plan adopted pursuant to a State Medicaid program or (c) any agent, carrier,
administrator or intermediary for any of the foregoing.

 

“Fee Letters”
shall mean, collectively, (a) that certain closing payment letter dated as of June 7, 2017 (the “Ares Closing Payment
Letter”), executed by Ares Management LLC, on behalf of one or more of its affiliated funds or accounts, and accepted
by the Issuer and (b) that certain fee letter dated June 19, 2017 between the Collateral Agent and the Issuer.

 

“First Lien/Second
Lien Intercreditor Agreement” shall mean that certain Intercreditor Agreement, dated as of the Closing Date, between
the Collateral Agent and the Second Lien Collateral Agent, and acknowledged by the Note Parties, as the same may be amended, supplemented,
waived or otherwise modified from time to time in accordance with the terms hereof and thereof.

 

    	 	16	 

     

    

 

“Fiscal Quarter”
shall mean any fiscal quarter of the Issuer.

 

“Fiscal Year”
shall mean any fiscal year of the Issuer.

 

“Flood Insurance
Laws” shall mean, collectively, (i) the National Flood Insurance Act of 1968 as now or hereafter in effect or any successor
statute thereto, (ii) the Flood Disaster Protection Act of 1973 as now or hereafter in effect or any successor statute thereto,
(iii) the National Flood Insurance Reform Act of 1994 as now or hereafter in effect or any successor statute thereto, (iv) the
Flood Insurance Reform Act of 2004 as now or hereafter in effect of any successor statute thereto, in each case, together with
all statutory and regulatory provisions consolidating, amending, replacing, supplementing, implementing or interpreting any of
the foregoing, as amended or modified from time to time.

 

“Food and Drug Laws”
shall mean any applicable laws, rules, regulations, ordinances and administrative manuals, orders, guidelines, guidances and requirements
issued by any Governmental Authority relating to the compounding, development, design, premarket clearance, approval, collection,
manufacture, processing, holding, storing, testing, labeling, packaging, repackaging, packing, transporting, shipping, importing,
exporting, marketing, advertising, promotion, sale, installation, servicing, and distribution of food, drugs, biological products,
cosmetics and/or medical devices including components and accessories including, without limitation, the Federal Food Drug, and
Cosmetic Act, 21 U.S.C. § 321 et seq., and all analogous federal, state, local, municipal, foreign, multinational, foreign
regional, and foreign national laws, rules, orders, binding agreements, regulations, statutes, directives, standards, ordinances,
codes or requirements of any Governmental Authority.

 

“Foreign Person”
shall mean any Person that is not a U.S. Person.

 

“Foreign Subsidiary”
shall mean each Subsidiary of the Issuer other than a Domestic Subsidiary.

 

“GAAP”
shall mean generally accepted accounting principles in the United States applied on a consistent basis and subject to the terms
of Section 1.3.

 

“Governing Body”
shall mean the board of directors, board of managers, board of representatives, board of advisors or similar governing or advisory
body of any Person.

 

“Governmental Authority”
shall mean the government of the United States, any other nation or any political subdivision thereof, whether state or local,
and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative,
judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including, without limitation,
CMS and FDA.

 

“Governmental Payors”
shall mean Medicare, Medicaid, CHAMPUS, CHAMPVA, TRICARE, Veteran’s Administration or any other Governmental Authority or
quasi-public agency providing funding for healthcare services.

 

“Governmental Payor
Arrangements” shall mean arrangements, plans or programs with Governmental Payors for payment or reimbursement in connection
with health care services, products or supplies.

 

“Government Receivables
Account” shall have the meaning set forth in Section 5.11(e).

 

    	 	17	 

     

    

 

“Government Receivables
Account Agreement” shall have the meaning set forth in Section 5.11(e).

 

“Guarantee”
of or by any Person (the “guarantor”) shall mean any obligation, contingent or otherwise, of the guarantor guaranteeing
or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary obligor”)
in any manner, whether directly or indirectly and including any obligation, direct or indirect, of the guarantor (i) to purchase
or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to
advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities
or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (iii) to maintain
working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable
the primary obligor to pay such Indebtedness or other obligation or (iv) as an account party in respect of any letter of credit
or letter of guaranty issued in support of such Indebtedness or obligation; provided that the term “Guarantee”
shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Guarantee shall
be deemed to be an amount equal to the stated or determinable principal amount of the primary obligation in respect of which such
Guarantee is made or, if not so stated or determinable, the maximum reasonably anticipated liability in respect thereof (assuming
such Person is required to perform thereunder) as determined by such Person in good faith. The term “Guarantee” used
as a verb has a corresponding meaning.

 

“Guarantor”
shall mean each of the Subsidiary Note Parties.

 

“Guaranty and Security
Agreement” shall mean the First Lien Guaranty and Security Agreement, dated as of the date hereof, made by the Note Parties
in favor of the Collateral Agent for the benefit of the Secured Parties.

 

“Hazardous Materials”
shall mean all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants,
including petroleum or petroleum distillates, asbestos or asbestos containing materials, polychlorinated biphenyls, radon gas,
infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law.

 

“Health Care Audits”
shall have the meaning set forth in Section 4.20(g).

 

“Healthcare Laws”
shall mean, collectively, any and all federal state or local laws, rules, regulations, ordinances and administrative manuals, orders,
guidelines, guidances and requirements issued by any Governmental Authority under or in connection with Medicare, Medicaid or any
Government Payor program or any law governing the licensure of or regulating healthcare providers, professionals, facilities or
payors or otherwise governing or regulating the provision of, or payment for, medical services, including without limitation, (i)
all federal and state fraud and abuse laws, including but not limited to the federal Anti-Kickback Statute (42 U.S.C. (§1320a-7b(b)),
the Stark Law, the civil False Claims Act (31 U.S.C. §3729 et seq.), Section 1320a-7 and 1320a-7a of Title 42 of the United
States Code and the regulations promulgated pursuant to such statues; (ii) the Health Insurance Portability and Accountability
Act of 1996 (Pub. L. No. 104-191) and the regulations promulgated thereunder, (iii) HIPAA and the HITECH Act, (iv) Medicare; (v)
Medicaid; (vi) the Controlled Substances Act (21 U.S.C. § 801, et seq.) and all applicable requirements, regulations and guidances
issued thereunder by the Drug Enforcement Administration (“DEA”); (vii) Food and Drug Laws, (viii) state pharmacy laws;
(ix) the Clinical Laboratory Improvement Act (42 U.S.C. § 263a, et seq.), (x) the Medicare Prescription Drug, Improvement
and Modernization Act of 2003 (P.L. 108-173, 117 Stat. 2066), (xi) all applicable professional standards regulating healthcare
providers, healthcare professionals, healthcare facilities or healthcare payors, each of (i) through (x) as may be amended from
time to time.

 

    	 	18	 

     

    

 

“Healthcare Material
Adverse Effect” shall mean (a) any Material Adverse Effect or (b) any event, act, condition or occurrence of whatever
nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), whether
singularly or in conjunction with any other event or events, act or acts, condition or conditions, occurrence or occurrences whether
or not related, that (i) has resulted, or is reasonably likely to result, in the suspension or termination of the ability to operate
of one or more BioScrip Facilities, unless (x) the patients serviced by all such BioScrip Facilities that are subject to such suspension
or termination can be moved to, or serviced by, other BioScrip Facilities that are not subject to suspension or termination at
a cost to the Issuer and its Subsidiaries of not more than $2,500,000 in the aggregate and (y) there is no reasonably anticipated
payor contract disruption that is reasonably likely to result in the loss of more than $2,500,000 in gross revenues as a result
of such movement of patients to, or such servicing of patients by, other BioScrip Facilities, (ii) has resulted, or is reasonably
likely to result, in the inability of the Issuer and its Subsidiaries to deliver services to more than 5.0% of the patients of
the Issuer and its Subsidiaries, (iii) has resulted, or is reasonably likely to result, in remediation costs to the Issuer and
its Subsidiaries in excess of $2,500,000 or (iv) results in or is reasonably likely to result in the loss of more than $2,500,000
in gross revenues by the Issuer and its Subsidiaries.

 

“Hedging Obligations”
of any Person shall mean any and all monetary obligations of such Person, whether absolute or contingent and howsoever and whensoever
created, arising, evidenced or acquired under (i) any and all Hedging Transactions, (ii) any and all cancellations, buy backs,
reversals, terminations or assignments of any Hedging Transactions and (iii) any and all renewals, extensions and modifications
of any Hedging Transactions and any and all substitutions for any Hedging Transactions.

 

“Hedge Termination
Value” shall mean, in respect of any one or more Hedging Transactions, after taking into account the effect of any netting
agreement relating to such Hedging Transactions, (a) for any date on or after the date such Hedging Transactions have been closed
out and termination value(s) determined in accordance therewith, such termination value(s) and (b) for any date prior to the date
referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Hedging Transactions, as determined
based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Hedging Transactions
(which may include a Purchaser or any Affiliate of a Purchaser).

 

“Hedging Transaction”
of any Person shall mean (a) any transaction (including an agreement with respect to any such transaction) now existing or hereafter
entered into by such Person that is a rate swap transaction, swap option, basis swap, forward rate transaction, commodity swap,
commodity option, equity or equity index swap or option, bond option, interest rate option, foreign exchange transaction, cap transaction,
floor transaction, collar transaction, currency swap transaction, cross-currency rate swap transaction, currency option, spot transaction,
credit protection transaction, credit swap, credit default swap, credit default option, total return swap, credit spread transaction,
repurchase transaction, reverse repurchase transaction, buy/sell-back transaction, securities lending transaction, or any other
similar transaction (including any option with respect to any of these transactions) or any combination thereof, whether or not
any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related
confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the
International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master
agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including
any such obligations or liabilities under any Master Agreement.

 

    	 	19	 

     

    

 

“HIPAA”
shall mean the Health Insurance Portability and Accountability Act of 1996, Pub. L. 104 191, Aug. 21, 1996, 110 Stat. 1936, and
regulations promulgated pursuant thereto regarding privacy, security and transmission of health information (including the Standards
for Privacy of Individually Identifiable Health Information, the Security Standards for the Protection of Electronic Protected
Health Information and the Standards for Electronic Transactions and Code Sets promulgated thereunder), all as amended from time
to time, and any successor statute and regulations.

 

“HIPAA/HITECH Compliance
Plan” shall have the meaning set forth in Section 4.21.

 

“HIPAA/HITECH Compliant”
shall have the meaning set forth in Section 4.21.

 

“HITECH Act”
shall mean the Health Information Technology for Economic and Clinical Health Act provisions of the American Reinvestment and Recovery
Act of 2009, and regulations promulgated pursuant thereto, all as amended from time to time, and any successor statute and regulations.

 

“Indebtedness”
of any Person shall mean, without duplication, (i) all obligations of such Person for borrowed money (including, without limitation,
the Second Lien Obligations), (ii) all obligations of such Person evidenced by bonds, debentures, notes or other similar instruments,
(iii) all obligations of such Person in respect of the deferred purchase price of property or services (other than current liabilities,
accrued expense obligations and trade payables incurred in the ordinary course of business; provided that any such obligation
that is secured by a Lien (including the ABDC Obligations) shall constitute Indebtedness), (iv) all obligations of such Person
under any conditional sale or other title retention agreement(s) relating to property acquired by such Person, (v) all Capital
Lease Obligations of such Person, (vi) all obligations, contingent or otherwise, of such Person in respect of letters of credit,
acceptances or similar extensions of credit, (vii) all Guarantees of such Person of the type of Indebtedness described in
clauses (i) through (vi) above, (viii) all Indebtedness of a third party secured by any Lien on property owned by such Person,
whether or not such Indebtedness has been assumed by such Person (but limited to the lesser of the fair market value of such property
and the outstanding principal amount of such Indebtedness), (ix) all obligations of such Person, contingent or otherwise, to purchase,
redeem, retire or otherwise acquire for value any Disqualified Capital Stock of such Person, (x) all Off-Balance Sheet Liabilities
and (xi) obligations of such Person under any Hedging Obligations (valued at the lesser of the Hedging Termination Value and the
Net Mark-to-Market Exposure thereof). The Indebtedness of any Person shall include the Indebtedness of any partnership or joint
venture in which such Person is a general partner or a joint venturer, except to the extent that the terms of such Indebtedness
provide that such Person is not liable therefor. The Indebtedness of any Person shall exclude purchase price holdbacks in respect
of a portion of the purchase price of an asset to satisfy warranty or other unperformed obligations of the respective seller.

 

“Indemnified Taxes”
shall mean (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation
of any Note Party under any Note Document and (b) to the extent not otherwise described in clause (a), Other Taxes.

 

“Information and
Collateral Disclosure Certificate” shall have the meaning assigned to such term in the Guaranty and Security Agreement.

 

“Intellectual Property
Rights” shall have the meaning assigned to such term in the Guaranty and Security Agreement.

 

“Interest Period”
shall mean with respect to any Eurodollar Note, a period of one month; provided that:

 

    	 	20	 

     

    

 

(i)           the
initial Interest Period for such Note shall commence on the date of Issuance of such Note (including the date of any
conversion from a Note of another Type), and each Interest Period occurring thereafter in respect of such Note shall commence
on the day on which the next preceding Interest Period expires;

 

(ii)          if any
Interest Period would otherwise end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding
Business Day, unless such Business Day falls in another calendar month, in which case such Interest Period would end on the next
preceding Business Day;

 

(iii)          any
Interest Period which begins on the last Business Day of a calendar month or on a day for which there is no numerically
corresponding day in the calendar month at the end of such Interest Period shall end on the last Business Day of such
calendar month;

 

(iv)         each
principal installment of the Notes shall have an Interest Period ending on each installment payment date and the remaining
principal balance (if any) of the Notes shall have an Interest Period determined as set forth above; and

 

(v)          no
Interest Period may extend beyond the Maturity Date.

 

“Internally
Generated Cash” shall mean internally generated cash of the Issuer and its Subsidiaries (and shall exclude, for the
avoidance of doubt, the proceeds of any disposition of assets, sale of equity, capital contribution or incurrence of Indebtedness).

 

“Investments”
shall have the meaning set forth in Section 7.4.

 

“IRS”
shall mean the Internal Revenue Service of the United States.

 

“Issuance”
shall mean an issuance hereunder consisting of Notes to be issued by or for the benefit of the Issuer to any Purchasers pursuant
to Article II.

 

“Issuer”
shall have the meaning set forth in the introductory paragraph hereof.

 

“LIBOR Rate”
shall mean for each Interest Period, a rate of interest determined by the Required Purchasers (which determination shall be conclusive
in the absence of manifest error) equal to the greater of:

 

(i)         one
percent (1.00%) per annum, and

 

(ii)
        (a)         the rate per annum appearing on Bloomberg L.P.’s service (the
“Service”) (or on any successor to or substitute for the Service) for ICE LIBOR USD interest rates as of 11:00
a.m. (London, England time) two Business Days prior to the commencement of the requested Interest Period, for a term and in
an amount comparable to the Interest Period and the amount of the Eurodollar Note requested (whether as an initial Eurodollar
Note or as a continuation of a Eurodollar Note or as a conversion of a Base Rate Note to a Eurodollar Note) by the Issuer in
accordance with this Agreement. If the Service shall no longer report ICE LIBOR USD interest rates, or such interest rates
cease to exist, the Required Purchasers shall be permitted to select an alternate service that quotes, or alternate interest
rates that reasonably approximate, the rates of interest per annum at which deposits of Dollars in immediately available
funds are offered by major financial institutions reasonably satisfactory to the Required Purchasers in the London interbank
market as of 11:00 a.m. (London, England time) two (2) Business Days prior to the commencement of the requested Interest
Period; divided by

 

    	 	21	 

     

    

 

(b)      a
number equal to 1.0 minus the aggregate (but without duplication) of the rates (expressed as a decimal fraction) of reserve
requirements in effect on the day which is two (2) Business Days prior to the beginning of such Interest Period (including
basic, supplemental, marginal and emergency reserves under any regulations of the Board of Governors of the Federal Reserve
system or other governmental authority having jurisdiction with respect thereto, as now and from time to time in effect) for
Eurocurrency funding (currently referred to as “Eurocurrency liabilities” in Regulation D of such Board) which
are required to be maintained by a member bank of the Federal Reserve System;

 

such rate to be adjusted to the nearest one
sixteenth of one percent (1/16th of 1%) or, if there is not a nearest one sixteenth of one percent (1/16th of 1%), to the next
highest one sixteenth of one percent (1/16th of 1%).

 

“Licenses”
shall mean any and all licenses (including professional licenses), approvals, certificates of need, accreditations, certifications,
permits, franchises, rights to conduct business (by a Governmental Authority or otherwise), Orders and any other governmental authorizations.

 

“Lien”
shall mean any mortgage, pledge, security interest, lien (statutory or otherwise), charge, encumbrance, hypothecation, assignment,
deposit arrangement, or other arrangement having the practical effect of any of the foregoing (including any conditional sale or
other title retention agreement and any capital lease having the same economic effect as any of the foregoing).

 

“Limitation”
shall mean a revocation, suspension, termination, impairment, probation, limitation, non-renewal, forfeiture, restriction, declaration
of ineligibility, loss of status as a participating provider, or the loss of any other rights under any Governmental Payor Arrangement,
Third Party Payor Arrangement, Company Accreditation or License.

 

“Material Adverse
Effect” shall mean any event, act, condition or occurrence of whatever nature (including any adverse determination in
any litigation, arbitration, or governmental investigation or proceeding), whether singularly or in conjunction with any other
event or events, act or acts, condition or conditions, occurrence or occurrences whether or not related, that results in a material
adverse change in, or a material adverse effect on, (i) the business, condition (financial or otherwise), operations, liabilities
(contingent or otherwise), or properties of the Issuer and its Subsidiaries on a consolidated basis and taken as a whole, (ii) the
ability of the Note Parties to perform any of their respective obligations under the Note Documents, or (iii) the rights and remedies
of the Collateral Agent or the Purchasers under any of the Note Documents (other than solely as a result of any action or inaction
on the part of the Collateral Agent or any Purchaser).

 

“Material Agreements”
shall mean all agreements, documents, contracts, indentures and instruments with respect to which a default, breach or termination
thereof would reasonably be expected to result in a Material Adverse Effect.

 

“Material Indebtedness”
shall mean (i) any Indebtedness (other than the Notes) of the Issuer or any of its Subsidiaries individually or in an aggregate
committed or outstanding principal amount exceeding $12,500,000, (ii) the Second Lien Obligations and (iii) the Senior Notes or
any Permitted Refinancing Indebtedness.

 

    	 	22	 

     

    

 

“Material Permitted
Seller Financing” shall mean any Permitted Seller Financing individually or in an aggregate committed or outstanding
principal amount exceeding $10,000,000.

 

“Maturity Date”
shall mean, with respect to the Notes, the earlier of: (i) August 15, 2020 or, if all of the Senior Notes shall have been refinanced
in full with the proceeds of Permitted Refinancing Indebtedness prior to August 15, 2020, June 30, 2022; and (ii) the date on which
the principal amount of all outstanding Notes has been declared or automatically has become due and payable (whether by acceleration
or otherwise).

 

“Medicaid”
shall mean, collectively, the healthcare assistance program established by Title XIX of the Social Security Act (42 U.S.C., Chapter
7, subchapter XIX, §§1396 et seq.) and all laws, rules, regulations, manuals, orders, guidelines or requirements (whether
or not having the force of law) pertaining to such program, in each case as the same may be amended, supplemented or otherwise
modified from time to time.

 

“Medicare”
shall mean, collectively, the health insurance program for the aged and disabled established by Title XVIII of the Social Security
Act (42 U.S.C., Chapter 7, subchapter XVIII, §§1395 et seq.) and all laws, rules, regulations, manuals, orders or guidelines
(whether or not having the force of law) pertaining to such program, in each case as the same may be amended, supplemented or otherwise
modified from time to time.

 

“Moody’s”
shall mean Moody’s Investors Service, Inc.

 

“Mortgaged Property”
shall mean, individually or collectively, any Real Estate that is subject to a Mortgage.

 

“Mortgage”
shall mean each mortgage, deed of trust, deed to secure debt or other real estate security documents delivered by any Note Party
to the Collateral Agent from time to time, all in form and substance reasonably satisfactory to the Collateral Agent and the Required
Purchasers.

 

“Multiemployer Plan”
shall mean any “multiemployer plan” as defined in Section 4001(a)(3) of ERISA, which is contributed to by (or to which
there is or may be an obligation to contribute of) the Issuer, any of its Subsidiaries, or an ERISA Affiliate, and each such plan
for the look-back period during which the Issuer, any of its Subsidiaries, or an ERISA Affiliate continues to be subject to liability,
including contingent liability, for the plan under Title IV of ERISA.

 

“Net Cash Proceeds”
shall mean cash proceeds (including proceeds of any insurance policy) received by any Note Party, net of (i) customary, reasonable
and documented (in summary form) fees and commissions paid or payable in connection therewith, including reasonable and documented
(in summary form) attorneys’ fees, accountants’ fees, broker’s fees and investment banking fees, (ii) other reasonable,
documented (in summary form) and customary fees and expenses paid or payable in connection therewith to the extend paid or payable
to a Person that is not an Affiliate of the Issuer, (iii) Taxes (including transfer and similar taxes) paid or reasonably estimated
to be payable as a result thereof (after taking into account any available tax credits or deductions and any tax sharing arrangements),
to the extent properly attributable to such Prepayment Event, (iv) with respect to Net Cash Proceeds received as a result of a
Prepayment Event under Section 2.9(a), (a) amounts required to be applied to the repayment of Indebtedness secured by a
Lien not prohibited hereunder on any asset which is the subject of such Prepayment Event and prepayment penalties required to be
paid under the terms governing such Indebtedness, (b) reserves required to be established in accordance with GAAP or any applicable
documentation governing any such Prepayment Event, including escrow amounts, indemnification obligations, purchase price adjustments
and other similar retained liabilities, and (c) amounts required to be paid to any party having superior rights to such proceeds
pursuant to clause (ii) of the definition of Requirements of Law and (v) with respect to Net Cash Proceeds received as a result
of a Prepayment Event under Section 2.9(b), underwriting discounts and other customary debt incurrence costs.

 

    	 	23	 

     

    

 

“Net Mark-to-Market
Exposure” of any Person shall mean, as of any date of determination with respect to any Hedging Obligation, the excess
(if any) of all unrealized losses over all unrealized profits of such Person arising from such Hedging Obligation. “Unrealized
losses” shall mean the fair market value of the cost to such Person of replacing the Hedging Transaction giving rise to such
Hedging Obligation as of the date of determination (assuming such Hedging Transaction were to be terminated as of that date), and
“unrealized profits” shall mean the fair market value of the gain to such Person of replacing such Hedging Transaction
as of the date of determination (assuming such Hedging Transaction were to be terminated as of that date).

 

“Non-Defaulting
Purchaser” shall mean, at any time, a Purchaser that is not a Defaulting Purchaser.

 

“Non-U.S. Plan”
shall mean any plan, fund (including, without limitation, any superannuation fund) or other similar program established, contributed
to (regardless of whether through direct contributions or through employee withholding) or maintained outside the United States
by the Issuer or one or more of its Subsidiaries primarily for the benefit of employees of the Issuer or such Subsidiaries residing
outside the United States, which plan, fund or other similar program provides, or results in, retirement income, a deferral of
income in contemplation of retirement, or payments to be made upon termination of employment, and which plan is not subject to
ERISA or the Code.

 

“Note”
and “Notes” shall have the meaning set forth in Section 2.2.

 

“Note Documents”
shall mean, collectively, this Agreement, the Collateral Documents, the First Lien/Second Lien Intercreditor Agreement, the ABDC
Intercreditor Agreement, any other intercreditor agreement or subordination agreement entered into with the Collateral Agent or
any Purchaser in connection with the Obligations, the Fee Letters, all Notices of Conversion/Continuation, all Compliance Certificates,
the Notes, and any and all other instruments, agreements, documents and writings executed by or in favor of the Collateral Agent
or any Purchaser in connection with any of the foregoing. Not in limitation of the foregoing, for purposes of the First Lien/Second
Lien Intercreditor Agreement, the ABDC Intercreditor Agreement and any other intercreditor agreement or subordination agreement
entered into with the Collateral Agent or any Purchaser in connection with the Obligations, the term “Note Documents”
shall include all instruments, agreements, documents and writing executed by or in favor of the Collateral Agent or any Purchaser
in connection with (a) Bank Product Obligations and (b) Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge
Provider.

 

“Note Parties”
shall mean the Issuer and the Subsidiary Note Parties.

 

“Notice of Conversion/Continuation”
shall have the meaning set forth in Section 2.4(b).

 

“Obligations”
shall mean (a) all amounts owing by the Note Parties to the Collateral Agent or any Purchaser pursuant to or in connection with
this Agreement or any other Note Document or otherwise with respect to any Note including, without limitation, all principal, interest
(including any interest accruing after the filing of any petition in bankruptcy or the commencement of any insolvency, reorganization
or like proceeding relating to the Issuer, whether or not a claim for post-filing or post-petition interest is allowed in such
proceeding), reimbursement obligations, fees, expenses, indemnification and reimbursement payments, costs and expenses (including
all fees and expenses of counsel to the Collateral Agent and any Purchaser payable by the Note Parties pursuant to this Agreement
or any other Note Document), whether direct or indirect, absolute or contingent, liquidated or unliquidated, now existing or hereafter
arising hereunder or thereunder, (b) all Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, and
(c) all Bank Product Obligations, together with all renewals, extensions, modifications or refinancings of any of the foregoing;
provided, however, that with respect to any Guarantor, the Obligations shall not include any of such Guarantor’s
Excluded Swap Obligations.

 

    	 	24	 

     

    

 

“OFAC”
shall mean the U.S. Department of the Treasury’s Office of Foreign Assets Control.

 

“Off-Balance Sheet
Liabilities” of any Person shall mean (i) any repurchase obligation or liability of such Person with respect to accounts
or notes receivable sold by such Person, (ii) any liability of such Person under any sale and leaseback transactions that do not
create a liability on the balance sheet of such Person, (iii) any Synthetic Lease Obligation or (iv) any obligation arising with
respect to any other transaction which is the functional equivalent of or takes the place of borrowing but which does not constitute
a liability on the balance sheet of such Person.

 

“Order”
means any order, award, decision, injunction, judgment, ruling, decree, charge, writ, subpoena or verdict entered, issued, made
or rendered by any Governmental Authority or arbitrator.

 

“OSHA”
shall mean the Occupational Safety and Health Act of 1970, as amended from time to time, and any successor statute.

 

“Other Connection
Taxes” shall mean, with respect to any Recipient, Taxes imposed as a result of a present or former connection between
such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered,
become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged
in any other transaction pursuant to or enforced any Note Document, or sold or assigned an interest in any Note or Note Document).

 

“Other Taxes”
shall mean any and all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise
from any payment made hereunder or under any other Note Document or from the execution, delivery, performance or enforcement or
registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, this Agreement or any
other Note Document, except any such Taxes imposed with respect to an assignment (other than an assignment described in Section
2.20), participation or other transfer.

 

“Parent Company”
shall mean, with respect to a Purchaser, the “bank holding company” as defined in Regulation Y, if any, of such Purchaser,
and/or any Person owning, beneficially or of record, directly or indirectly, a majority of the shares of such Purchaser.

 

“Participant”
shall have the meaning set forth in Section 10.4(d).

 

“Participant Register”
shall have the meaning set forth in Section 10.4(d).

 

“Patent”
shall have the meaning assigned to such term in the Guaranty and Security Agreement.

 

“Patent Security
Agreement” shall mean any Patent Security Agreement executed by a Note Party owning Patents in favor of the Collateral
Agent for the benefit of the Secured Parties, both on the Closing Date and thereafter.

 

    	 	25	 

     

    

 

“Patriot Act”
shall mean the USA PATRIOT Improvement and Reauthorization Act of 2005 (Pub. L. 109-177 (signed into law March 9, 2006)), as amended
and in effect from time to time.

 

“PBGC”
shall mean the U.S. Pension Benefit Guaranty Corporation, as referred to and defined in ERISA and any successor entity performing
similar functions.

 

“Permitted Acquisition”
shall mean any Acquisition of a Target, in each instance, to the extent that each of the following conditions shall have been satisfied:

 

(i)         no
Default or Event of Default shall then exist or would exist after giving effect thereto;

 

(ii)        such
Acquisition shall not be hostile and shall have been approved by the Governing Body and, to the extent applicable,
stockholders or other equityholders of the Target;

 

(iii)          (x) if
Consolidated EBITDA for the period of four Fiscal Quarters ended on the last day of the most recent Fiscal Quarter prior to the
date of such Acquisition for which financial statements have been (or were required to be) delivered hereunder is less than $50,000,000,
(A) not less than 75% of the consideration for such Acquisition shall be paid for with Internally Generated Cash, the proceeds
of capital contributions and/or the proceeds of equity issuances and (B) not more than 25% of the consideration for such Acquisition
may be paid for with a combination of Permitted Seller Financing, earn-outs or other deferred or contingent purchase consideration
(provided that, for the avoidance of doubt, for purposes of this clause (iii)(x), the maximum amount of all earn-outs and
other deferred or contingent purchase consideration shall be deemed fully earned and payable on the date of the consummation of
such Acquisition and shall be included in the determination of the consideration for such Acquisition) and/or the proceeds of Second
Lien Delayed Draw Notes, and (y) if Consolidated EBITDA for the period of four Fiscal Quarters ended on the last day of the most
recent Fiscal Quarter prior to the date of such Acquisition for which financial statements have been (or were required to be) delivered
hereunder is greater than or equal to $50,000,000, (A) not less than 50% of the consideration for such Acquisition shall be paid
for with Internally Generated Cash, the proceeds of capital contributions and/or the proceeds of equity issuances and (B) not more
than 50% of the consideration for such Acquisition may be paid for with a combination of Permitted Seller Financing, earn-outs
or other deferred or contingent purchase consideration (provided that, for the avoidance of doubt, for purposes of this
clause (iii)(y), the maximum amount of all earn-outs and other deferred or contingent purchase consideration shall be deemed fully
earned and payable on the date of the consummation of such Acquisition and shall be included in the determination of the consideration
for such Acquisition) and/or the proceeds of Second Lien Delayed Draw Notes;

 

(iv)       the
Issuer shall be in pro forma compliance with the covenant set forth in Article VI after giving effect to such
Acquisition, calculated as of the last day of the most recent Fiscal Quarter for which financial statements have been (or
were required to be) delivered hereunder and for the period of four Fiscal Quarters ending on such date, as evidenced by a
certificate of a Responsible Officer of the Issuer delivered to the Collateral Agent and the Purchasers not less than two (2)
days prior to the consummation of such Acquisition;

 

(v)        the
Person acquiring such Target (if such acquisition is of the type described in clause (b) of the definition of Acquisition) or
the Target (if such acquisition is of the type described in clause (a) of the definition of Acquisition), as applicable,
shall be organized in any state of the United States or in Washington, D.C.;

 

    	 	26	 

     

    

 

(vi)        the
Person acquiring such Target (if such Acquisition is of the type described in clause (b) of the definition of Acquisition) or
the Target (if such Acquisition is of the type described in clause (a) of the definition of Acquisition), as applicable, and
each of its Subsidiaries shall be become a Subsidiary Note Party in accordance with the provisions of Section
5.12;

 

(vii)       the
Target shall be engaged solely in the business of home infusion services (i.e., the preparation, delivery, administration and
clinical monitoring of pharmaceutical treatments that are administered to a patient via intravenous, subcutaneous,
intramuscular, intraspinal and enteral methods) or a line of business reasonably related, ancillary or incidental
thereto;

 

(viii)       the
consideration for such Acquisition shall be paid for solely with Internally Generated Cash, the proceeds of capital
contributions, the proceeds of equity issuances, the proceeds of the Second Lien Delayed Draw Notes, Permitted Seller
Financing or earn-outs or other deferred or contingent purchase consideration;  

 

(ix)         after
giving effect to such Acquisition, the amount available to be funded pursuant to the Second Lien Delayed Draw Notes plus cash
and Cash Equivalents (other than Restricted Cash) of the Issuer and its Subsidiaries is not less than $20,000,000;

 

(x)         such
Acquisition shall not result in the formation of any Specified Strategic Joint Venture; and

 

(xi)         the
Issuer shall have (A) notified the Collateral Agent and the Purchasers of such proposed Acquisition at least fifteen (15)
days (or such shorter period as the Required Purchasers may reasonably agree) prior to the consummation thereof, (B)
furnished to the Collateral Agent and the Purchasers at least ten (10) days (or such shorter period as the Required
Purchasers may reasonably agree) prior to the consummation thereof (1) an executed term sheet and/or letter of intent
(setting forth in reasonable detail the terms and conditions of such Acquisition) and, at the request of the Required
Purchasers, such other information and documents that the Required Purchasers may reasonably request, including, without
limitation, all regulatory and third-party approvals required under the terms of the Acquisition documents, (2) a description
of the proposed Acquisition and a due diligence report (to the extent available) and (3) for any Acquisition with total
consideration in excess of $50,000,000 (for the avoidance of doubt, for purposes of this clause (3), such total consideration
shall include any Permitted Seller Financing and the maximum amount of all earn-outs and other deferred or contingent
purchase consideration, which shall be deemed fully earned and payable on the date of the consummation of such Acquisition)
(or to the extent otherwise reasonably available to the Issuer in connection with such Acquisition), a quality of earnings
report of such Target by a nationally recognized independent accounting firm or such other accounting firm
reasonably satisfactory to the Required Purchasers, (C) furnished to the Collateral Agent and the Purchasers at least five
(5) days (or such shorter period as the Required Purchasers may reasonably agree) prior to the consummation thereof (1)
drafts of the respective material agreements, documents or instruments pursuant to which such Acquisition is to be
consummated (including, without limitation, any related management, non-compete, employment, option or other material
agreements), any schedules to such agreements, documents or instruments, all other material ancillary agreements, instruments
and documents to be executed or delivered in connection therewith, and copies of environmental assessments and (2) pro forma
financial statements of the Issuer and its Subsidiaries after giving effect to the consummation of such Acquisition and (D)
furnished to the Collateral Agent and the Purchasers no later than the date of consummation of such Acquisition executed
counterparts of the respective material agreements, documents or instruments pursuant to which such Acquisition is to be
consummated (including, without limitation, any related management, non-compete, employment, option or other material
agreements), any schedules to such agreements, documents or instruments, all other material ancillary agreements, instruments
and documents to be executed or delivered in connection therewith, and copies of environmental assessments.

 

    	 	27	 

     

    

 

“Permitted Business”
shall mean owning, operating, managing and maintaining infusion services, home health care, hospice services, respiratory care
services, pharmacy benefit management services, durable medical equipment services, or other healthcare services, in each case,
together with any other businesses as are reasonably related, ancillary or incidental thereto.

 

“Permitted Encumbrances”
shall mean:

 

(i)          Liens
imposed by law for taxes, fees, assessments or other governmental charges which are not yet due or which are being contested
in good faith by appropriate proceedings diligently conducted and with respect to which adequate reserves are being
maintained in accordance with GAAP;

 

(ii)
       statutory Liens of landlords, carriers, warehousemen, mechanics, materialmen and other Liens imposed by law in the ordinary
course of business for amounts not yet delinquent for more than sixty (60) days or which are being contested in good faith by
appropriate proceedings diligently conducted and with respect to which adequate reserves are being maintained in accordance
with GAAP;

 

(iii)
       pledges and deposits made in the ordinary course of business in compliance with workers’ compensation, unemployment
insurance and other social security laws or regulations;

 

(iv)
      deposits to secure the performance of bids, trade contracts, leases, statutory obligations, surety and appeal bonds,
performance bonds and other obligations of a like nature or to secure liability to insurance carriers, in each case in the
ordinary course of business;

 

(v)         judgment
and attachment liens not giving rise to an Event of Default or Liens created by or existing from any litigation or legal proceeding
that are currently being contested in good faith by appropriate proceedings diligently conducted and with respect to which adequate
reserves are being maintained in accordance with GAAP;

 

(vi)
      customary rights of set-off, revocation, refund or chargeback under deposit agreements or under the Uniform Commercial Code
or common law of banks or other financial institutions where the Issuer or any of its Subsidiaries maintains deposits (other
than deposits intended as cash collateral) in the ordinary course of business;

 

(vii)       easements, zoning restrictions, rights-of-way, minor defects in title, and similar encumbrances on Real Estate imposed by law
or arising in the ordinary course of business that do not secure any monetary obligations and do not materially detract from
the value of the affected property or materially interfere with the ordinary conduct of business of the Issuer and its
Subsidiaries taken as a whole;

 

(viii)       Liens
in favor of collecting banks arising by operation of law under Section 4-210 of the UCC or, with respect to collecting banks located
in the State of New York, under Section 4-208 of the UCC, or securing reimbursement obligations in respect of documentary letters
of credit or bankers’ acceptances in the ordinary course of business;

 

    	 	28	 

     

    

 

(ix)        Liens
arising out of consignment or similar arrangements for the sale of goods entered into by the Issuer or any of its
Subsidiaries in the ordinary course of business;

 

(x)        Liens in
favor of customs and revenue authorities arising as a matter of law which secure payment of customs duties in connection with the
importation of goods in the ordinary course of business;

 

(xi)       Liens
on insurance policies and the proceeds thereof in favor of the provider of such policies securing the financing of the
premiums with respect thereto;

 

(xii)
     leases, subleases, non-exclusive licenses or non-exclusive sublicences on the property covered thereby, in each case, in the
ordinary course of business which do not (i) materially interfere with the business of the Issuer and its Subsidiaries, taken
as a whole, or (ii) secure any Indebtedness;

 

(xiii)       any
interest of title of a lessor under any lease entered into by the Issuer or any of its Subsidiaries in the ordinary course of
business as a tenant and covering only the assets so leased; and

 

(xiv)       Liens
evidenced by precautionary UCC financing statements relating to operating leases, bailments and consignments of personal property;

 

provided that the term “Permitted
Encumbrances” shall not include any Lien securing Indebtedness for borrowed money.

 

“Permitted Refinancing
Indebtedness” shall mean any Indebtedness issued in exchange for, or the Net Cash Proceeds of which are used to extend,
refinance, renew, replace, defease or refund, the Senior Notes (or previous refinancings thereof constituting Permitted Refinancing
Indebtedness (“Refinanced Senior Notes Indebtedness”)); provided that (a) the principal amount of such
Permitted Refinancing Indebtedness does not exceed the principal amount of the Senior Notes (or Refinanced Senior Notes Indebtedness)
being refinanced plus unpaid accrued interest, fees and premiums thereon plus fees and expenses incurred in connection
with such refinancing, (b)(i) the cash portion of the non-default interest rate with respect to such Permitted Refinancing Indebtedness
does not exceed 10.0% per annum and (ii) the aggregate non-default Effective Yield with respect to such Permitted Refinancing Indebtedness
does not exceed 15.0% per annum (which, for purposes of this clause (b)(ii), shall be calculated exclusive of any original issue
discount or other upfront payments in an amount not in excess of 2.0% of the aggregate principal amount of such Permitted Refinancing
Indebtedness (the “Permitted Refinancing Indebtedness OID Cap”) payable in connection therewith and inclusive
of any original issue discount or other upfront payments in excess of the Permitted Refinancing Indebtedness OID Cap payable in
connection therewith, but otherwise in accordance with the definition of “Effective Yield”), (c) the final maturity
date of such Permitted Refinancing Indebtedness is on or after six months after June 30, 2022, (d) such Permitted Refinancing Indebtedness
is unsecured and is junior or pari passu in payment priority with the Obligations and the Second Lien Obligations, (e) no Permitted
Refinancing Indebtedness shall have obligors that are not obligated with respect to the Senior Notes, the Obligations or the Second
Lien Obligations, (f) the documentation governing such Permitted Refinancing Indebtedness shall not include any amortization or
mandatory redemption, repurchase or repayment provisions (other than customary provisions relating to change of control and asset
sale redemption offers) and (g) the Weighted Average Life to Maturity of such Permitted Refinancing Indebtedness is greater than
or equal to the greater of (x) the Weighted Average Life to Maturity of the Senior Notes (or any Refinanced Senior Notes Indebtedness)
and (y) the Weighted Average Life to Maturity of the Notes.

 

    	 	29	 

     

    

 

“Permitted Seller
Financing” shall mean, with respect to any Permitted Acquisition, subordinated unsecured Indebtedness provided by the
seller of the applicable Target; provided that:

 

(i)         the
obligations in respect of such Indebtedness are subordinated in right of payment to the Obligations and the Second Lien
Obligations on terms acceptable to the Required Purchasers and the Required Purchasers (as defined in the Second Lien Note
Purchase Agreement);

 

(ii)        the
obligations in respect of such Indebtedness shall be unsecured;

 

(iii)       there
shall be no obligors (including guarantors) in respect of such Indebtedness other than (x) in the case of an Acquisition of the
type described in clause (b) of the definition of Acquisition, the Person acquiring the assets of the applicable Target, (y) in
the case of an Acquisition of the type described in clause (a) of the definition of Acquisition, the applicable Target (and for
the avoidance of doubt, no subsidiaries of the applicable Target shall be obligors) and (z) in each case, any parent company of
the Person acquiring such asset or Target, which parent company (A) is a newly-formed holding company that holds no material assets,
and has no material liabilities, other than equity interests in the Person acquiring such assets or Target and (B) complies with
the provisions of Section 5.12 of this Agreement;

 

(iv)       the
documentation governing such Indebtedness shall not include any (x) representations and warranties (other than basic
corporate representations and warranties and representations and warranties concerning the enforceability of the agreements
governing the such financing), covenants (other than customary affirmative (e.g., corporate existence, insurance and
compliance with laws) and reporting covenants), which in no event shall be more restrictive than the representations and
warranties and covenants contained in the Note Documents, or (y) indemnities;

 

(v)       the
documentation governing such Indebtedness shall not require any amortization or mandatory prepayments; and

 

(vi)       (w) the
interest rate with respect to such Indebtedness, exclusive of any default interest rate margin (which shall be customary and in
any event shall not exceed 2.0% per annum), shall not exceed 10.0% per annum, (x) there shall be no original issue discount (except
to the extent of original issue discount issued in respect of an accreting obligation, which original issue discount shall not
result in, together with any other interest (other than default interest) payable in respect of such Indebtedness, an interest
rate in excess of that permitted pursuant to clause (w) above) or other upfront payments in connection with such Indebtedness,
(y) interest payments shall be made no more frequently than quarterly and (z) no cash interest payments shall be permitted at any
time that any Default or Event of Default is continuing.

 

“Permitted Third
Party Bank” shall mean any bank or other financial institution with whom any Note Party maintains (i) a Controlled
Account and with whom an Account Control Agreement has been executed or (ii) a Government Receivables Account and with whom a Government
Receivables Account Agreement has been executed. As of the Closing Date, each of the banks and other financial institutions that
are identified on Schedule 4.16 as an institution at which a Controlled Account or a Government Receivables Account is maintained
by any Note Party shall be deemed to be a Permitted Third Party Bank.

 

    	 	30	 

     

    

 

“Person”
shall mean any individual, partnership, firm, corporation, association, joint venture, limited liability company, trust or other
entity, or any Governmental Authority.

 

“Plan”
shall mean any “employee pension benefit plan” as defined in Section 3 of ERISA (other than a Multiemployer Plan) maintained
or contributed to by (or to which there is or may be an obligation to contribute of) the Issuer, any of its Subsidiaries, or an
ERISA Affiliate, and each such plan for the look-back period during which the Issuer, any of its Subsidiaries, or an ERISA Affiliate
continues to be subject to liability, including contingent liability, for the plan under Title IV of ERISA.

 

“Prepayment Event”
shall mean any sale, lease, assignment, transfer or other disposition by the Issuer or any of its Subsidiaries of any assets or
property pursuant to Section 7.6(e) or Section 7.6(f).

 

“Prepayment Premium”
shall mean, with respect to any optional prepayment of the Notes pursuant to Section 2.8(a), any mandatory prepayment of the Notes
pursuant to Section 2.9(a) or (b) or any repayment of the Notes following the acceleration thereof pursuant to Section 8.1:
(a) at any time prior to the second anniversary of the Closing Date, an amount equal to the Applicable Premium with respect to
the principal amount of the Notes so prepaid or repaid; (b) at any time on or after the second anniversary of the Closing Date
and prior to the third anniversary of the Closing Date, an amount equal to 4.0% of the principal amount of the Notes so prepaid
or repaid; (c) at any time on or after the third anniversary of the Closing Date and prior to the fourth anniversary of the Closing
Date, an amount equal to 2.0% of the principal amount of the Notes so prepaid or repaid; and (d) at any time on or after the fourth
anniversary of the Closing Date, an amount equal to 0.0% of the principal amount of the Notes so prepaid or repaid; provided that
no Prepayment Premium shall be required to be paid with respect to any optional prepayment of the Notes pursuant to Section 2.8(a)
from Internally Generated Cash; provided, further, that the foregoing proviso shall (x) apply only to the prepayment of up to $50
million in aggregate principal amount of the Notes over the term of this Agreement and (y) for the avoidance of doubt, not apply
in connection with the acceleration of the Obligations pursuant to Section 8.1.

 

“Profit Plan”
shall mean, for any calendar year, an annual operating plan for the Issuer and its Subsidiaries, on a consolidated basis, setting
forth (i) a statement of all material assumptions on which such annual operating plan is based, (ii) quarterly balance sheets,
income statements and statements of cash flows for such calendar year, (iii) sales, gross profits, operating expenses, operating
profit, cash flow projections, all prepared on the same basis and in similar detail as that on which operating results are reported
(and in the case of cash flow projections, representing management’s good faith estimates of future financial performance
based on historical performance), and including plans for Capital Expenditures and facilities.

 

“Pro Forma Basis”
shall mean (a) with respect to any Person, business, property or asset sold, transferred or otherwise disposed of, the exclusion
from “Consolidated EBITDA” of the EBITDA (calculated in a manner substantially consistent with the definition of “Consolidated
EBITDA” and giving effect to any adjustments made in accordance with such definition) for such Person, business, property
or asset so disposed of during such period as if such disposition had been consummated on the first day of the applicable period
and (b) with respect to any Target acquired in a Permitted Acquisition, the addition to “Consolidated EBITDA” of the
EBITDA (calculated in a manner substantially consistent with the definition of “Consolidated EBITDA” but without giving
effect to any adjustments made in accordance with such definition and, for the avoidance of doubt, not including any synergies
or other cost savings) of such Target so acquired during such period as if such acquisition had been consummated on the first day
of the applicable period, in each case, in accordance with GAAP.

 

    	 	31	 

     

    

 

“Pro Rata Share”
shall mean with respect to any Commitment or Note of any Purchaser at any time, a percentage, the numerator of which shall be such
Purchaser’s Commitment (or if such Commitment has been terminated or expired or the Notes have been declared to be due and
payable, such Purchaser’s Notes), and the denominator of which shall be the sum of all Commitments of all Purchasers (or
if such Commitments have been terminated or expired or the Notes have been declared to be due and payable, all Notes of all Purchasers).

 

“Purchaser-Related
Hedge Provider” means any Person that, at the time it enters into a Hedging Transaction with any Note Party, (i) is a
Purchaser or an Affiliate of a Purchaser and (ii) has provided prior written notice to the Collateral Agent which has been acknowledged
by the Issuer of (x) the existence of such Hedging Transaction and (y) the methodology to be used by such parties in determining
the obligations under such Hedging Transaction from time to time. In no event shall any Purchaser-Related Hedge Provider acting
in such capacity be deemed a Purchaser for purposes hereof to the extent of and as to Hedging Obligations except that each reference
to the term “Purchaser” in Article IX and Section 10.3(b) shall be deemed to include such Purchaser-Related
Hedge Provider. In no event shall the approval of any such Person in its capacity as Purchaser-Related Hedge Provider be required
in connection with the release or termination of any security interest or Lien of the Collateral Agent.

 

“Purchasers”
shall have the meaning set forth in the introductory paragraph hereof and shall include each Purchaser that joins this Agreement
pursuant to Section 10.4 and each Replacement Purchaser that joins this Agreement pursuant to Section 2.20.

 

“Real Estate”
shall have the meaning set forth in Section 4.11(a).

 

“Real Estate Documents”
shall mean, collectively, with respect to any Real Estate, (i) a Mortgage duly executed by each applicable Note Party, together
with (A) title insurance policies in amounts reasonably satisfactory to the Required Purchasers (but not to exceed 100% of the
fair market value of such Real Estate in any jurisdiction that imposes a material mortgage recording tax or 110% otherwise), current
as-built ALTA/ACSM Land Title surveys certified to the Collateral Agent, zoning letters, building permits and certificates of occupancy,
in each case relating to such Real Estate and reasonably satisfactory in form and substance to the Required Purchasers, (B) (x)
“Life of Loan” Federal Emergency Management Agency Standard Flood Hazard determinations, (y) notices, in the form required
under the Flood Insurance Laws, about special flood hazard area status and flood disaster assistance duly executed by each Note
Party, and (z) if any improved real property encumbered by any Mortgage is located in a special flood hazard area, a policy
of flood insurance that (1) covers such improved real property, (2) is written in an amount not less than the outstanding
principal amount of the Indebtedness secured by such Mortgage reasonably allocable to such real property or the maximum limit of
coverage made available with respect to the particular type of property under the Flood Insurance Laws, whichever is less, and
(3) is otherwise on terms satisfactory to the Collateral Agent and the Required Purchasers and, (C) evidence that counterparts
of such Mortgages have been recorded in all places to the extent necessary or desirable, in the reasonable judgment of the Required
Purchasers, to create a valid and enforceable first priority Lien (subject to Permitted Encumbrances and Specified Permitted Liens)
on such Real Estate in favor of the Collateral Agent for the benefit of the Secured Parties (or in favor of such other trustee
as may be required or desired under local law), (D) an opinion of counsel in each state in which such Real Estate is located in
form and substance and from counsel reasonably satisfactory to the Required Purchasers, (E) a duly executed Environmental Indemnity
with respect thereto, and (F) such other reports, documents, instruments and agreements as the Required Purchasers shall reasonably
request, each in form and substance reasonably satisfactory to Required Purchasers.

 

“Recipient”
shall mean, as applicable, (a) the Collateral Agent and (b) any Purchaser.

 

    	 	32	 

     

    

 

“Regulation D”
shall mean Regulation D of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to
time, and any successor regulations.

 

“Regulation T”
shall mean Regulation T of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to
time, and any successor regulations.

 

“Regulation U”
shall mean Regulation U of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to
time, and any successor regulations.

 

“Regulation X”
shall mean Regulation X of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to
time, and any successor regulations.

 

“Regulation Y”
shall mean Regulation Y of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to
time, and any successor regulations.

 

“Reimbursement Approvals”
shall mean any and all certifications, provider or supplier numbers, provider or supplier agreements (including Medicaid provider
or supplier numbers, Medicaid provider or supplier agreements, Medicare provider or supplier numbers, and Medicare provider or
supplier agreements), participation agreements, Accreditations, and/or any other agreements with or approvals by Medicaid, Medicare,
CHAMPUS, CHAMPVA, TRICARE, Veteran’s Administration and any other Governmental Authority or quasi-public agency, Blue Cross/Blue
Shield, any and all managed care plans and organizations, including Medicare Advantage plans, Medicare Part D prescription drug
plans, health maintenance organizations and preferred provider organizations, private commercial insurance companies, employee
assistance programs and/or any other governmental or third party arrangements, plans or programs for payment or reimbursement in
connection with health care services, products or supplies.

 

“Related Parties”
shall mean, with respect to any specified Person, such Person’s Affiliates and the respective managers, administrators, trustees,
partners, directors, officers, employees, agents, advisors, legal counsel, consultants or other representatives of such Person
and such Person’s Affiliates.

 

“Release”
shall mean any release, spill, emission, leaking, dumping, injection, pouring, deposit, disposal, discharge, dispersal, leaching
or migration into the environment (including ambient air, surface water, groundwater, land surface or subsurface strata) or within
any building, structure, facility or fixture.

 

“Required Purchasers”
shall mean, at any time, Purchasers holding more than 50% of the aggregate outstanding principal amount of the Notes at such time;
provided that, to the extent there are two or more Purchasers that each hold at least 5% of the aggregate outstanding principal
amount of the Notes at any time, Required Purchasers shall mean at least two Purchasers together holding more than 50% of the outstanding
principal amount of the Notes at such time; provided, further, that, for purposes of the foregoing proviso, a Purchaser
together with all of such Purchaser’s Affiliates and Approved Funds shall be deemed to constitute a single Purchaser; provided,
further, that, to the extent that any Purchaser is a Defaulting Purchaser, such Defaulting Purchaser and all of the Notes
held by such Defaulting Purchaser shall be excluded for purposes of determining Required Purchasers.

 

“Requirement of
Law” for any Person shall mean (i) the articles or certificate of incorporation, bylaws, partnership certificate and
agreement, or limited liability company certificate of organization and agreement, as the case may be, and other organizational
and governing documents of such Person, and (ii) any law, treaty, rule or regulation, or determination of a Governmental Authority,
including, without limitation any Healthcare Laws, in each case applicable to or binding upon such Person or any of its property
or to which such Person or any of its property is subject.

 

    	 	33	 

     

    

 

“Responsible Officer”
shall mean any of the president, the chief executive officer, the chief operating officer, the chief financial officer, the general
counsel, the treasurer or a vice president of the Issuer or such other representative of the Issuer as may be designated in writing
by any one of the foregoing with the consent of the Required Purchasers (such consent not to be unreasonably withheld, conditioned
or delayed). With respect to any Person that is a limited liability company or a limited partnership, such Person’s managing
member, sole member, sole manager or general partner, as the case may be, shall constitute a Responsible Officer.

 

“Responsible Officer
of the Collateral Agent” shall mean an officer within Corporate Trust Services who shall have direct responsibility for
the administration of this Agreement.

 

“Restricted Cash”
shall mean, as of any date, all cash and Cash Equivalents held by the Issuer and its Subsidiaries that are legally or contractually
restricted from being used to repay general obligations of the Issuer or any Subsidiary of the Issuer (including the Obligations)
(provided that the terms of this Agreement, the other Note Documents and the Second Lien Note Documents shall not be deemed
to contractually restrict the use of cash and Cash Equivalents by the Issuer and its Subsidiaries) or are otherwise subject to
a Lien (except Liens created under the Collateral Documents, the Second Lien Collateral Documents and non-consensual Liens that
arise by operation of law).

 

“Restricted Payment”
shall mean, for any Person, (i) any dividend or distribution on any class of its Capital Stock, or (ii) any payment on account
of, or the setting aside of assets for a sinking or other analogous fund for, the purchase, redemption, retirement, defeasance
or other acquisition of (a) any shares of its Capital Stock, (b) any Subordinated Debt, (c) any options, warrants or other rights
to purchase such Capital Stock or such Indebtedness, whether now or hereafter outstanding, or (d) any payment of management or
similar fees.

 

“Routine Payor Audit”
shall mean any payor audit conducted by a Governmental Authority or a Third Party Payor so long as the potential liability under
such payor audit does not exceed $200,000 for each such payor audit.

 

“S&P”
shall mean Standard & Poor’s, a division of The McGraw-Hill Companies, Inc.

 

“Sanctioned Country”
shall mean, at any time, a country, territory or region that is, or whose government is, the subject or target of any Sanctions.

 

“Sanctioned Person”
shall mean, at any time, any Person with whom dealings are restricted or prohibited under Sanctions, including (i) any Person listed
in any Sanctions-related list of designated Persons maintained by the United States (including by OFAC, the U.S. Department of
the Treasury, or the U.S. Department of State), or by the United Nations Security Council, the European Union or any EU member
state, Her Majesty’s Treasury of the United Kingdom or any other relevant sanctions authority, (ii) any Person located, operating,
organized or resident in a Sanctioned Country or (iii) any Person owned or controlled, directly or indirectly, by any such Person
described in clause (i) or (ii) of this definition.

 

“Sanctions”
shall mean sanctions or trade embargoes enacted, imposed, administered or enforced from time to time by (i) the U.S. government,
including those administered by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”),
U.S. Department of State, or U.S. Department of Commerce, (ii) the United Nations Security Council, the European Union or any of
its member states, Her Majesty’s Treasury of the United Kingdom, (iii) Canada (or any provincial government) or (iv) any
other relevant sanctions authority.

 

    	 	34	 

     

    

 

“Second Lien Collateral
Agent” shall have the meaning assigned to the term “Collateral Agent” in the Second Lien Note Purchase Agreement.

 

“Second Lien Collateral
Documents” shall mean the “Collateral Documents” under and as defined in the Second Lien Note Purchase Agreement.

 

“Second Lien Delayed
Draw Notes” shall have the meaning assign to the term “Delayed Draw Notes” in the Second Lien Note Purchase
Agreement.

 

“Second Lien Note
Documents” shall mean the Second Lien Note Purchase Agreement and the other “Note Documents” as defined in
the Second Lien Note Purchase Agreement, in each case, as amended, restated and/or modified from time to time in accordance with
the terms thereof and of the First Lien/Second Lien Intercreditor Agreement.

 

“Second Lien Note
Purchase Agreement” shall mean that certain Second Lien Note Purchase Agreement dated as of the Closing Date, by and
among the Issuer, the financial institutions party thereto from time to time and Wells Fargo Bank, National Association, in its
capacity as collateral agent thereunder, as the same may be amended, restated, supplemented, waived, extended or otherwise modified
from time to time in accordance with the First Lien/Second Lien Intercreditor Agreement.

 

“Second Lien Notes”
shall have the meaning assigned to the term “Notes” in the Second Lien Note Purchase Agreement.

 

“Second Lien Obligations”
shall mean the “Obligations” under and as defined in the Second Lien Note Purchase Agreement.

 

“Second Lien Purchasers”
shall mean the “Purchasers” under and as defined in the Second Lien Note Purchase Agreement.

 

“Secured Parties”
shall mean the Collateral Agent, the Purchasers, the Purchaser-Related Hedge Providers and the Bank Product Providers.

 

“Securities Act”
shall mean the Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder from
time to time in effect.

 

“Senior Notes”
shall mean the unsecured 8.875% Senior Notes due 2021 issued by the Issuer pursuant to the Senior Notes Indenture, as amended,
restated, supplemented, or otherwise modified from time to time in accordance with the terms hereof and thereof.

 

“Senior Notes Indenture”
shall mean that certain Indenture dated as of February 11, 2014, by and among the Issuer, the guarantors party thereto, and U.S.
Bank National Association, as trustee, as amended, restated, supplemented, or otherwise modified from time to time in accordance
with the terms hereof and thereof.

 

    	 	35	 

     

    

 

“Solvent”
shall mean, with respect to any Person on a particular date, that on such date (a) the fair value of the property of such Person
is greater than the total amount of liabilities, including subordinated and contingent liabilities, of such Person; (b) the present
fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability
of such Person on its debts and liabilities, including subordinated and contingent liabilities as they become absolute and matured;
(c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability
to pay as such debts and liabilities mature; and (d) such Person is not engaged in a business or transaction, and is not about
to engage in a business or transaction, for which such Person’s property would constitute an unreasonably small capital.
The amount of contingent liabilities (such as litigation, guaranties and pension plan liabilities) at any time shall be computed
as the amount that, in light of all the facts and circumstances existing at the time, represents the amount that would reasonably
be expected to become an actual or matured liability.

 

“Specified Permitted
Liens” shall mean (a) nonconsensual Liens arising by operation of law (including Permitted Encumbrances, but excluding
Permitted Encumbrances securing Indebtedness), (b) Liens permitted by Section 7.2(e), Section 7.2(f) (except to the
extent such Liens are required to be subordinated to the Liens securing the Obligations pursuant to such Section 7.2(f))
and Section 7.2(g), and (c) Liens on cash collateral for letters of credit permitted pursuant to Section 7.1(a)(xix).

 

“Specified Strategic
Joint Venture” shall mean any Subsidiary (other than a Subsidiary formed for the purpose of holding assets of the Issuer
and its Subsidiaries constituting the Issuer’s and its Subsidiaries’ PBM line of business) formed by the Issuer or
any of its Subsidiaries with one or more third parties for the purpose of engaging in any Permitted Business, including any hospital
joint venture or other joint venture providing pharmacy benefit management services.

 

“Stark Law”
shall mean Section 1877 of the Social Security Act, as codified at 42 U.S.C. Section 1395nn (Prohibition Against Certain Referrals),
as the same may be amended, modified or supplemented from time to time, and any successor statute thereto, and any and all rules
or regulations promulgated from time to time thereunder.

 

“Subordinated Debt”
shall mean any Indebtedness of the Issuer or any Subsidiary that is by its terms subordinated in right of payment to the prior
payment of the Obligations and the Second Lien Obligations in a manner reasonably acceptable to the Required Purchasers and the
Required Purchasers (as defined in the Second Lien Note Purchase Agreement).

 

“Subsidiary”
shall mean, with respect to any Person (the “parent”) at any date, any corporation, partnership, joint venture,
limited liability company, association or other entity the accounts of which would be consolidated with those of the parent in
the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such
date, as well as any other corporation, partnership, joint venture, limited liability company, association or other entity (i)
of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting
power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled
or held, or (ii) that is, as of such date, otherwise controlled, by the parent or one or more subsidiaries of the parent or by
the parent and one or more subsidiaries of the parent. Unless otherwise indicated, all references to “Subsidiary” hereunder
shall mean a Subsidiary of the Issuer.

 

“Subsidiary Note
Party” shall mean any Subsidiary that executes or becomes a party to the Guaranty and Security Agreement (other than
any Specified Strategic Joint Venture).

 

“Synthetic Lease”
shall mean a lease transaction under which the parties intend that (i) the lease will be treated as an “operating lease”
by the lessee pursuant to Accounting Standards Codification Sections 840-10 and 840-20, as amended, and (ii) the lessee will be
entitled to various tax and other benefits ordinarily available to owners (as opposed to lessees) of like property.

 

    	 	36	 

     

    

 

“Synthetic Lease
Obligations” shall mean, with respect to any Person, the sum of (i) all remaining rental obligations of such Person as
lessee under Synthetic Leases which are attributable to principal and, without duplication, (ii) all rental and purchase price
payment obligations of such Person under such Synthetic Leases assuming such Person exercises the option to purchase the lease
property at the end of the lease term.

 

“Target”
shall mean any other Person or business unit or asset group of any other Person acquired or proposed to be acquired in a Permitted
Acquisition.

 

“Taxes”
shall mean any and all present or future taxes, levies, imposts, duties, deductions, assessments, fees, charges or withholdings
imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Third Party Payors”
shall mean Blue Cross, Blue Shield, any and all managed care plans and organizations, including Medicare Advantage plans, Medicare
Part D prescription drug plans, health maintenance organizations and preferred provider organizations, private commercial insurance
companies, employee assistance programs and/or any other third party arrangements, plans or programs.

 

“Third Party Payor
Arrangements” shall mean arrangements, plans or programs with Third Party Payors for payment or reimbursement in connection
with health care services, products or supplies.

 

“Trademark”
shall have the meaning assigned to such term in the Guaranty and Security Agreement.

 

“Trademark Security
Agreement” shall mean any Trademark Security Agreement executed by a Note Party owning registered Trademarks or applications
for Trademarks in favor of the Collateral Agent for the benefit of the Secured Parties, both on the Closing Date and thereafter.

 

“Triggering Event
of Default” shall mean an Event of Default of the type described in Section 8.1(a), 8.1(b), 8.1(g),
or 8.1(h).

 

“Type”,
when used in reference to a Note or an Issuance, refers to whether the rate of interest on such Note, or on the Notes issued pursuant
to such Issuance, is determined by reference to the LIBOR Rate or the Base Rate.

 

“Unfunded Pension
Liability” of any Plan shall mean the amount, if any, by which the value of the accumulated plan benefits under the Plan,
as determined pursuant to Section 4001(a)(16) of ERISA, determined on a plan termination basis in accordance with actuarial assumptions
at such time consistent with those prescribed by the PBGC for purposes of Section 4044 of ERISA, exceeds the fair market value
of all Plan assets allocable to such liabilities under Title IV of ERISA (excluding any accrued but unpaid contributions).

 

“Uniform Commercial
Code” or “UCC” shall mean the Uniform Commercial Code as in effect from time to time in the State
of New York or any other state the laws of which are required to be applied in connection with the creation or perfection of security
interests.

 

“United States”
or “U.S.” shall mean the United States of America.

 

“U.S. Person”
shall mean any Person that is a “United States person” as defined in Section 7701(a)(30) of the Code.

 

    	 	37	 

     

    

 

“U.S. Tax Compliance
Certificate” shall have the meaning set forth in Section 2.17(f)(ii).

 

“Weighted Average
Life to Maturity” shall mean, when applied to any Indebtedness at any date, the number of years obtained by dividing
(i) the sum of the products obtained by multiplying (x) the amount of each then remaining installment, sinking fund, serial maturity
or other required payments of principal, including payment at final maturity, in respect thereof, by (y) the number of years (calculated
to the nearest one-twelfth) that will elapse between such date and the making of such payment by (ii) the then outstanding principal
amount of such Indebtedness.

 

“Withdrawal Liability”
shall mean liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such
terms are defined in Part I of Subtitle E of Title IV of ERISA.

 

“Withholding Agent”
shall mean the Issuer or any other Note Party, as applicable.

 

“Working Capital”
shall mean, at any date, the sum of (a) all amounts (other than cash and Cash Equivalents) at such date that, in accordance with
GAAP, would be classified as “current assets” on a consolidated balance sheet of the Issuer and its consolidated Subsidiaries,
minus (b) all amounts (other than the current portion of long-term Indebtedness) at such date that, in accordance with GAAP,
would be classified as “current liabilities” on a consolidated balance sheet of the Issuer and its consolidated Subsidiaries.

 

“Write-Down and
Conversion Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such
EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down
and conversion powers are described in the EU Bail-In Legislation Schedule.

 

Section 1.2         Classifications
of Notes and Issuances.   For purposes of this Agreement, Notes may be
classified and referred to by Type (e.g. “Eurodollar Note” or “Base Rate Note”). Issuances also may
be classified and referred to by Type (e.g. “Eurodollar Issuance”).

 

Section 1.3         Accounting
Terms and Determination.   Unless otherwise defined or specified herein, all accounting terms used herein
shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be
delivered hereunder shall be prepared, in accordance with GAAP as in effect from time to time, applied on a basis consistent
with the most recent financial statements of the Issuer delivered pursuant to Section 5.1(a) or Section 5.1(b)
(subject to any statements made pursuant to Section 5.1(c)(iv)), subject to normal year-end adjustments and the
absence of footnote disclosures in the case of interim financial statements; provided that if the Issuer notifies the
Purchasers that the Issuer wishes to amend the definition or application of GAAP as used herein to eliminate the effect of
any change in GAAP on the operation of any provision of this Agreement (or if the Required Purchasers notify the Issuer that
the Required Purchasers wish to make such amendment), then the Issuer’s compliance with the provisions of this
Agreement shall be determined on the basis of GAAP in effect immediately before the relevant change in GAAP became effective,
until either such notice is withdrawn or this Agreement is amended in a manner satisfactory to the Issuer and the Required
Purchasers. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein
shall be construed, and all computations of amounts and ratios referred to herein shall be made, without giving effect to (a)
any election under Accounting Standards Codification Section 825-10 (or any other Financial Accounting Standard having a
similar result or effect) to value any Indebtedness or other liabilities of any Note Party or any Subsidiary of any Note
Party at “fair value”, as defined therein or (b) any treatment of Indebtedness in respect of convertible debt
instruments under Accounting Standards Codification Section 470-20 (or any other Accounting Standards Codification or
Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated
manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof.
In addition, all financial covenants contained herein shall be calculated without giving effect to any election under
Statement of Financial Accounting Standards 159 (or any similar accounting principle) permitting a Person to value its
financial liabilities at the fair value thereof. In addition, notwithstanding anything in this Agreement to the contrary, any
change in GAAP occurring after the date hereof that would require operating leases to be treated similarly to capital leases
shall not be given effect in the definition of Consolidated EBITDA or Indebtedness or any related definitions or in the
computation of any financial ratio or requirement in any of the Note Documents.

 

    	 	38	 

     

    

 

Section 1.4           Terms
Generally. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.
Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words
“include”, “includes” and “including” shall be deemed to be followed by the phrase “without
limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall”.
In the computation of periods of time from a specified date to a later specified date, the word “from” means “from
and including” and the word “to” means “to but excluding”. Unless the context requires otherwise
(i) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as it was originally executed or as it may from time to time be amended, restated, supplemented
or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (ii) any
reference herein to any Person shall be construed to include such Person’s successors and permitted assigns, (iii) the words
“hereof”, “herein” and “hereunder” and words of similar import shall be construed to refer
to this Agreement as a whole and not to any particular provision hereof, (iv) all references to Articles, Sections, Exhibits and
Schedules shall be construed to refer to Articles, Sections, Exhibits and Schedules to this Agreement and (v) all references
to a specific time shall be construed to refer to the time in New York, New York, unless otherwise indicated. The words “knowledge
of the Issuer” or any like term shall mean the actual knowledge of a Responsible Officer of the Issuer.

 

ARTICLE II

AMOUNT AND TERMS OF THE COMMITMENTS

 

Section 2.1           General
Description of Facilities. Subject to and upon the terms and conditions herein set forth, each Purchaser severally agrees
to purchase a Note from the Issuer on the Closing Date in an aggregate principal amount not exceeding such Purchaser’s Commitment.

 

Section 2.2           Commitments.
Subject to the terms and conditions set forth herein, each Purchaser severally and not jointly agrees to purchase from the
Issuer, and the Issuer agrees to issue to each such Purchaser, on the Closing Date, a note in the form attached hereto as Exhibit
B (each a “Note” and, collectively, the “Notes”) in the amount set forth opposite such
Purchaser’s name on Schedule I under the heading “Note Commitment Amount”. The Notes may be, from time
to time, Base Rate Notes or Eurodollar Notes or a combination thereof. The execution and delivery of this Agreement by the Issuer
and the satisfaction or waiver by the Purchasers of all conditions precedent set forth in Section 3.1 shall be deemed to
constitute the Issuer’s request to the Purchasers to purchase the Notes on the Closing Date. Amounts which are repaid or
prepaid on the Notes may not be reborrowed.

 

Section 2.3           Purchase
of Notes. No Purchaser shall be responsible for any default by any other Purchaser in its obligations hereunder, and each
Purchaser shall be obligated to purchase a Note in an amount not to exceed the amount of such Purchaser’s Commitment, regardless
of the failure of any other Purchaser to purchase a Note hereunder.

 

    	 	39	 

     

    

 

Section 2.4           Interest
Elections.

 

(a)          Each
Note initially shall be a Eurodollar Note. Thereafter, the Issuer may elect to convert all (but not less than all) of the outstanding
Notes into a different Type or to continue such Notes, all as provided in this Section.

 

(b)          To
make an election pursuant to this Section, the Issuer shall give the Purchasers written notice (or telephonic notice promptly confirmed
in writing), substantially in the form of Exhibit 2.4 attached hereto (a “Notice of Conversion/Continuation”)
(x) prior to 12:00 p.m. one (1) Business Day prior to the requested date of a conversion into Base Rate Notes and (y) prior to
12:00 p.m. three (3) Business Days prior to a continuation of or conversion into Eurodollar Notes. Each such Notice of Conversion/Continuation
shall be irrevocable and shall specify (i) the effective date of the election made pursuant to such Notice of Conversion/Continuation,
which shall be a Business Day and (ii) whether the Notes are to be Base Rate Notes or Eurodollar Notes.

 

(c)          If,
on the expiration of any Interest Period in respect of Eurodollar Notes, the Issuer shall have failed to deliver a Notice of Conversion/Continuation,
then, unless the Notes are repaid as provided herein, the Issuer shall be deemed to have elected to convert the Notes to Base Rate
Notes. The Notes may not be converted into, or continued as, Eurodollar Notes if a Default or an Event of Default exists, unless
each of the Purchasers shall have otherwise consented in writing. No conversion of the Eurodollar Notes shall be permitted except
on the last day of the Interest Period in respect thereof.

 

Section 2.5           Termination
of Commitments. The Commitments shall terminate on the Closing Date upon the purchase and sale of the Notes pursuant to
Section 2.2.

 

Section 2.6           Repayment
of Notes.

 

(a)          The
Issuer unconditionally promises to pay to each Purchaser the then unpaid principal amount of the Note held by such Purchaser on
each September 30, December 31, March 31 and June 30 of each Fiscal Year prior to the Maturity Date, commencing on September 30,
2019, in equal consecutive quarterly installments in an aggregate amount for each such quarterly installment equal to six hundred
twenty-five thousandths of one percent (0.625%) of the aggregate principal amount of the Notes issued and sold on the Closing Date
(as adjusted to reflect prepayments of Notes in accordance with this Agreement); provided that, to the extent not previously
paid, the aggregate unpaid principal balance of the Notes shall be due and payable on the Maturity Date.

 

Section 2.7           Evidence
of Indebtedness.

 

(a)          Each
Purchaser shall maintain in accordance with its usual practice appropriate records evidencing the Indebtedness of the Issuer to
such Purchaser evidenced by each Note held by such Purchaser, including the amounts of principal and interest payable thereon and
paid to such Purchaser from time to time under this Agreement. The entries made in such records shall be prima facie evidence
of the existence and amounts of the obligations of the Issuer therein recorded; provided that the failure or delay of any
Purchaser in maintaining or making entries into any such record or any error therein shall not in any manner affect the obligation
of the Issuer to repay the Notes (both principal and unpaid accrued interest) held by such Purchaser in accordance with the terms
of this Agreement.

 

    	 	40	 

     

    

 

Section 2.8           Optional
Prepayments; Prepayment Premium. 

 

(a)          Subject
to Section 2.8(b), the Issuer shall have the right at any time and from time to time to prepay the Notes, in whole or in
part, by giving written notice (or telephonic notice promptly confirmed in writing) to the Purchasers no later than (i) in the
case of any prepayment of Eurodollar Notes, 11:00 a.m. not less than three (3) Business Days prior to the date of such prepayment
and (ii) in the case of any prepayment of Base Rate Notes, not less than one (1) Business Day prior to the date of such prepayment.
Each such notice shall be irrevocable (provided that such notice (x) may be conditioned upon the happening of an event,
in which case, such notice may be revoked to the extent that such event does not occur and (y) may be modified to extend the proposed
date of such prepayment specified therein) and shall specify the proposed date of such prepayment and the principal amount of the
Notes to be prepaid. If such notice is given, the aggregate amount specified in such notice shall be due and payable on the date
designated in such notice, together with accrued interest to such date on the principal amount so prepaid in accordance with Section
2.10(d); provided that if a Eurodollar Note is prepaid on a date other than the last day of an Interest Period applicable
thereto, the Issuer shall also pay all amounts required pursuant to Section 2.16. Each partial prepayment of the Notes
shall be in a minimum principal amount of $5,000,000 and in increments of $1,000,000 in excess thereof. Each prepayment of the
Notes shall be applied in accordance with Section 2.9(d).

 

(b)          In
the event that the Issuer prepays any Notes pursuant to clause (a) above, the Issuer shall pay to each applicable Purchaser the
applicable Prepayment Premium with respect to the principal amount so prepaid.

 

Section 2.9           Mandatory
Prepayments.

 

(a)          Promptly
(but in any event within five (5) Business Days) upon receipt by the Issuer or any of its Subsidiaries of Net Cash Proceeds in
excess of $1,000,000 in the aggregate during any Fiscal Year from any Prepayment Event, the Issuer shall prepay the Obligations
in an amount equal to such excess Net Cash Proceeds; provided that no prepayment under this Section 2.9(a) shall
be required with respect to Net Cash Proceeds from any Prepayment Event so long as no Default or Event of Default is in existence
at the time of receipt of such Net Cash Proceeds and, at the election of the Issuer, to the extent that such proceeds are reinvested
in the business of the Issuer or any of its Subsidiaries within 365 days (or 366 days in a leap year) following receipt thereof
or committed to be reinvested pursuant to a binding contract prior to the expiration of such 365 day (or 366 day in a leap year)
period and actually reinvested within 180 days after the date of such binding contract. Any such prepayment shall be applied in
accordance with clause (d) of this Section and shall be subject to the payment of the Prepayment Premium pursuant to clause (e)
of this Section.

 

(b)          Promptly
(but in any event within five (5) Business Days) upon receipt by the Issuer or any of its Subsidiaries of Net Cash Proceeds from
any issuance of Indebtedness by the Issuer or any of its Subsidiaries (other than any Indebtedness that is not prohibited to be
issued or incurred hereunder), the Issuer shall prepay the Obligations in an amount equal to all such Net Cash Proceeds. Any such
prepayment shall be applied in accordance with clause (d) of this Section and shall be subject to the payment of the Prepayment
Premium pursuant to clause (e) of this Section.

 

(c)          Commencing
with the Fiscal Year ending December 31, 2017, no later than ten (10) days after the date on which the Issuer’s annual audited
financial statements for such Fiscal Year are required to be delivered pursuant to Section 5.1(a), (i) to the extent that
the Consolidated Total Net Leverage Ratio as of the last day of such Fiscal Year is greater than or equal to 3.50:1.00, the Issuer
shall prepay the Obligations in an amount equal to (x) 50% of Excess Cash Flow for such Fiscal Year minus (y) the aggregate
amount of all voluntary prepayments of the Notes and Second Lien Notes made during such Fiscal Year, and (ii) to the extent that
the Consolidated Total Net Leverage Ratio as of the last day of such Fiscal Year is less than 3.50:1.00, the Issuer shall prepay
the Obligations in an amount equal to 0% of Excess Cash Flow for such Fiscal Year. Any such prepayment shall be applied in accordance
with clause (d) of this Section. Any such prepayment shall be accompanied by a certificate signed by a Responsible Officer of the
Issuer, certifying in reasonable detail the manner in which Excess Cash Flow and the resulting prepayment were calculated, which
certificate shall be in form and substance reasonably satisfactory to the Required Purchasers.

 

    	 	41	 

     

    

 

(d)          Any
prepayments made by the Issuer pursuant to clause (a), (b) or (c) of this Section or pursuant to Section 2.8(a) shall be
applied as follows: to the outstanding principal balance of the Notes, until the same shall have been paid in full, pro rata
to the Purchasers based on their Pro Rata Shares of the Notes, and applied first to the immediately succeeding eight (8) scheduled
installments of the Notes on a pro rata basis and thereafter to the remaining scheduled installments of the Notes on a pro
rata basis (including, without limitation, the final payment due on the Maturity Date).

 

(e)          In
connection with any prepayment made by the Issuer pursuant to clause (a) or (b) of this Section, the Issuer shall pay the applicable
Prepayment Premium with respect to the principal amount so prepaid. In connection with any prepayment made by the Issuer pursuant
to clause (a), (b) or (c) of this Section, the Issuer shall pay any amounts due under Section 2.16 with respect to the principal
amount so prepaid.

 

Section 2.10         Interest
on Notes.

 

(a)          The
Issuer shall pay interest on (i) each Base Rate Note at the Base Rate plus the Applicable Margin in effect from time to
time (the “Base Rate Interest Rate”) and (ii) each Eurodollar Note at the LIBOR Rate for the applicable Interest
Period in effect for such Note plus the Applicable Margin in effect from time to time (the “Eurodollar Interest
Rate).

 

(b)          Notwithstanding
clause (a) of this Section, at the written request of the Required Purchasers if a Triggering Event of Default has occurred and
is continuing, and automatically after acceleration of the Obligations or in connection with any Event of Default of the type described
in Section 8.1(g) or 8.1(h), the Issuer shall pay interest (“Default Interest”) (i) with respect
to all Eurodollar Notes, at a rate per annum equal to 200 basis points above the otherwise applicable Eurodollar Interest
Rate until the last day of such Interest Period, and thereafter, at a rate per annum equal to 200 basis points above the
otherwise applicable Base Rate Interest Rate and (ii) with respect to all Base Rate Notes, at a rate per annum equal to
200 basis points above the otherwise applicable Base Rate Interest Rate, in each case, until such Triggering Event of Default has
been waived in writing or the Required Purchasers have revoked the imposition of Default Interest (whichever occurs first).

 

(c)          Interest
on the outstanding principal amount of all Notes shall accrue from and including the date such Notes are issued and sold to but
excluding the date of any repayment thereof. Interest on all outstanding Notes shall be payable monthly in arrears on the last
day of each month, commencing on the last day of the first full month following the Closing Date, and on the Maturity Date. Interest
on any Eurodollar Note which is converted into a Note of another Type or which is repaid or prepaid shall be payable on the date
of such conversion or on the date of any such repayment or prepayment (on the amount repaid or prepaid) thereof. All Default Interest
shall be payable on demand.

 

(d)          The
Required Purchasers shall determine each interest rate applicable to the Notes hereunder and shall promptly notify the Issuer and
the Purchasers of such rate in writing (or by telephone, promptly confirmed in writing). Any such determination shall be conclusive
and binding for all purposes, absent manifest error.

 

    	 	42	 

     

    

 

Section 2.11         Fees.

 

(a)          The
Issuer shall pay to the Collateral Agent for its own account fees in the amounts and at the times previously agreed upon in writing
by the Issuer and the Collateral Agent.

 

(b)          The
Notes shall be issued with original issue discount equal to 1.00% of the original aggregate principal amount of the Notes.

 

(c)          The
Issuer shall pay on the Closing Date to the parties specified therein all amounts in the Ares Closing Payment Letter that are due
and payable on the Closing Date.

 

Section 2.12         Computation
of Interest and Fees. Interest hereunder on Base Rate Notes shall be computed on the basis of a year of 365 days (or 366
days in a leap year) and paid for the actual number of days elapsed (including the first day but excluding the last day). All other
interest and all fees hereunder shall be computed on the basis of a year of 360 days and paid for the actual number of days elapsed
(including the first day but excluding the last day). Each determination by the Required Purchasers of an interest rate or fee
hereunder shall be made in good faith and, except for manifest error, shall be final, conclusive and binding for all purposes.
The Required Purchasers shall, at the request of the Issuer, deliver to the Issuer a statement showing the quotations used by the
Required Purchasers in determining any interest rate hereunder.

 

Section 2.13         Inability
to Determine Interest Rates. If, prior to the commencement of any Interest Period for any Eurodollar Note:

 

(i)            Any
Purchaser shall have determined (which determination shall be conclusive and binding upon the Issuer) that, by reason of circumstances
affecting the relevant interbank market, adequate means do not exist for ascertaining LIBOR for such Interest Period, or

 

(ii)           the
LIBOR Rate does not adequately and fairly reflect the cost to any Purchaser of purchasing or maintaining its Eurodollar Notes for
such Interest Period,

 

such Purchaser shall give written notice (or
telephonic notice, promptly confirmed in writing) to the Issuer and to each other Purchaser as soon as practicable thereafter.
Until such Purchaser shall notify the Issuer and each other Purchaser that the circumstances giving rise to such notice no longer
exist, (i) the obligations of such Purchaser to continue or convert outstanding Notes as or into Eurodollar Notes shall be
suspended and (ii) all such affected Note shall be converted into Base Rate Notes on the last day of the then current Interest
Period applicable thereto unless the Issuer prepays such Notes in accordance with this Agreement.

 

Section 2.14         Illegality.
If any Change in Law shall make it unlawful or impossible for any Purchaser to purchase or maintain any Eurodollar Note and
such Purchaser shall so notify the Issuer, until such Purchaser notifies the Issuer that the circumstances giving rise to such
suspension no longer exist, the obligation of such Purchaser to continue or convert outstanding Notes as or into Eurodollar Notes
shall be suspended. If the affected Eurodollar Note is then outstanding, such Note shall be converted to a Base Rate Note either
(i) on the last day of the then current Interest Period applicable to such Eurodollar Note if such Purchaser may lawfully continue
to maintain such Note to such date or (ii) immediately if such Purchaser shall determine that it may not lawfully continue to maintain
such Eurodollar Note to such date. Notwithstanding the foregoing, the affected Purchaser shall, prior to giving such notice to
the Issuer, designate a different Applicable Funding Office if such designation would avoid the need for giving such notice and
if such designation would not otherwise be disadvantageous to such Purchaser in the good faith exercise of its discretion.

 

    	 	43	 

     

    

 

Section 2.15         Increased
Costs.

 

(a)            If
any Change in Law shall:

 

(i)            impose,
modify or deem applicable any reserve, special deposit or similar requirement that is not otherwise included in the determination
of the LIBOR Rate hereunder against assets of, deposits with or for the account of, or credit extended by, any Purchaser (except
any such reserve requirement reflected in the LIBOR Rate); or

 

(ii)          impose
on any Purchaser or the eurodollar interbank market any other condition affecting this Agreement or any Eurodollar Notes made by
such Purchaser;

 

and the result of any of the foregoing is to
increase the cost to such Purchaser of making, converting into, continuing or maintaining a Eurodollar Note or to reduce the amount
received or receivable by such Purchaser hereunder (whether of principal, interest or any other amount),

 

then, from time to time, such Purchaser may
provide the Issuer with written notice and demand with respect to such increased costs or reduced amounts, and within five (5)
Business Days after receipt of such notice and demand the Issuer shall pay to such Purchaser such additional amounts as will compensate
such Purchaser for any such increased costs incurred or reduction suffered.

 

(b)            If
any Purchaser shall have determined that on or after the date of this Agreement any Change in Law regarding capital or liquidity
requirements has or would have the effect of reducing the rate of return on such Purchaser’s capital (or on the capital of
the Parent Company of such Purchaser) as a consequence of its obligations hereunder to a level below that which such Purchaser
or such Parent Company could have achieved but for such Change in Law (taking into consideration such Purchaser’s policies
or the policies of such Parent Company with respect to capital adequacy and liquidity), then, from time to time, such Purchaser
may provide the Issuer with written notice and demand with respect to such reduced amounts, and within five (5) Business Days after
receipt of such notice and demand the Issuer shall pay to such Purchaser such additional amounts as will compensate such Purchaser
or such Parent Company for any such reduction suffered.

 

(c)            A
certificate of such Purchaser setting forth the amount or amounts necessary to compensate such Purchaser or the Parent Company
of such Purchaser specified in clause (a) or (b) of this Section shall be delivered to the Issuer and shall be conclusive, absent
manifest error.

 

(d)            Failure
or delay on the part of any Purchaser to demand compensation pursuant to this Section shall not constitute a waiver of such Purchaser’s
right to demand such compensation; provided that the Issuer shall not be required to compensate any Purchaser pursuant to
this Section for any increased costs incurred or reductions suffered more than one hundred eighty (180) days prior to the date
that such Purchaser notifies the Issuer of the Change in Law giving rise to such increased costs or reductions, and of such Purchaser’s
intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is
retroactive, then the one hundred eighty (180) day period referred to above shall be extended to include the period of retroactive
effect thereof).

 

    	 	44	 

     

    

 

Section 2.16         Funding
Indemnity. In the event of (a) the payment of any principal of a Eurodollar Note other than on the last day of the Interest
Period applicable thereto (including as a result of an Event of Default), (b) the conversion or continuation of a Eurodollar Note
other than on the last day of the Interest Period applicable thereto, or (c) the failure by the Issuer to borrow, prepay, convert
or continue any Eurodollar Note on the date specified in any applicable notice (regardless of whether such notice is withdrawn
or revoked), then, in any such event, the Issuer shall compensate each Purchaser, within five (5) Business Days after written demand
from such Purchaser, for any loss, cost or expense attributable to such event. In the case of a Eurodollar Note, such loss, cost
or expense shall be deemed to include an amount determined by such Purchaser to be the excess, if any, of (A) the amount of interest
that would have accrued on the principal amount of such Eurodollar Note if such event had not occurred at the LIBOR Rate applicable
to such Eurodollar Note for the period from the date of such event to the last day of the then current Interest Period therefor
(or, in the case of a failure to convert or continue, for the period that would have been the Interest Period for such Eurodollar
Note) over (B) the amount of interest that would accrue on the principal amount of such Eurodollar Note for the same period if
the LIBOR Rate were set on the date such Eurodollar Note was prepaid or converted or the date on which the Issuer failed to convert
or continue such Eurodollar Note. A certificate as to any additional amount payable under this Section submitted to the Issuer
by any Purchaser shall be conclusive, absent manifest error.

 

Section 2.17         Taxes.

 

(a)          Any
and all payments by or on account of any obligation of the Issuer or any other Note Party hereunder or under any other Note Document
shall be made free and clear of and without deduction or withholding for any Indemnified Taxes; provided that if any applicable
law requires the deduction or withholding of any Tax from any such payment, then the applicable Withholding Agent shall make such
deduction and timely pay the full amount deducted to the relevant Governmental Authority in accordance with applicable law and,
if such Tax is an Indemnified Tax, then the sum payable by the Issuer or other Note Party, as applicable, shall be increased as
necessary so that after making all required deductions and withholdings (including deductions and withholdings applicable to additional
sums payable under this Section 2.17) the applicable Recipient shall receive an amount equal to the sum it would have received
had no such deductions or withholdings been made.

 

(b)          In
addition, without limiting the provisions of clause (a) of this Section, the Issuer shall timely pay any Other Taxes to the relevant
Governmental Authority in accordance with applicable law.

 

(c)          The
Issuer shall indemnify each Recipient (and, with respect to U.S. federal withholding taxes, if such Recipient is not the Beneficial
Owner, the Beneficial Owner), within ten (10) days after written demand therefor, for the full amount of any Indemnified Taxes
paid by such Recipient (or Beneficial Owner) on or with respect to any payment by or on account of any obligation of the Issuer
or any other Note Party hereunder or under any other Note Document (including Indemnified Taxes imposed or asserted on or attributable
to amounts payable under this Section) and any reasonable expenses arising therefrom or with respect thereto, whether or not such
Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the
amount of such payment or liability delivered to the Issuer by the applicable Recipient (for its own account or on behalf of one
or more Beneficial Owners) shall be conclusive, absent manifest error.

 

(d)          As
soon as practicable after any payment of Indemnified Taxes or Other Taxes by the Issuer or any other Note Party to a Governmental
Authority, the Issuer or other Note Party, as applicable, shall deliver to the Purchasers an original or a certified copy of a
receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence
of such payment reasonably satisfactory to the Required Purchasers.

 

    	 	45	 

     

    

 

(e)          If
any Recipient determines, in its sole discretion exercised in good faith, that it has received a refund, or a credit in lieu of
a refund, of any Taxes or Other Taxes as to which it has been indemnified by the Issuer or with respect to which the Issuer has
paid additional amounts pursuant to this Section 2.17, it shall pay to the Issuer an amount equal to such refund or credit
(but only to the extent of indemnity payments made, or additional amounts paid, by the Issuer under this Section 2.17 with
respect to the Taxes or Other Taxes giving rise to such refund) net of all out-of-pocket expenses of such Recipient and without
interest (other than any interest paid by the relevant Governmental Authority with respect to such refund); provided that
the Issuer, upon the request of such Recipient, agrees to repay the amount paid over to the Issuer (plus any penalties, interest
or other charges imposed by the relevant Governmental Authority) to such Recipient in the event such Recipient is required to repay
such refund to such Governmental Authority. This Section 2.17(e) shall not be construed to require a Recipient to make available
its tax returns (or any other information relating to its taxes) to the Issuer or any other Person.

 

(f)            Tax
Forms.

 

(i)            Any
Purchaser that is a U.S. Person shall deliver to the Issuer and the Collateral Agent, on or prior to the date on which such Purchaser
becomes a Purchaser under this Agreement (and from time to time thereafter upon the reasonable request of the Issuer), duly executed
originals of IRS Form W-9 certifying, to the extent such Purchaser is legally entitled to do so, that such Purchaser is exempt
from U.S. federal backup withholding tax.

 

(ii)           Any
Purchaser that is a Foreign Person and that is entitled to an exemption from or reduction of withholding tax under the Code or
any treaty to which the United States is a party with respect to payments under this Agreement shall deliver to the Issuer and
the Collateral Agent, at the time or times prescribed by applicable law, such properly completed and executed documentation prescribed
by applicable law or reasonably requested by the Issuer as will permit such payments to be made without withholding or at a reduced
rate of withholding. Without limiting the generality of the foregoing, each Purchaser that is a Foreign Person shall, to the extent
it is legally entitled to do so, (w) on or prior to the date such Purchaser becomes a Purchaser under this Agreement, (x) on or
prior to the date on which any such form or certification expires or becomes obsolete, (y) after the occurrence of any event requiring
a change in the most recent form or certification previously delivered by it pursuant to this clause, and (z) from time to time
upon the reasonable request by the Issuer, deliver to the Issuer and the Collateral Agent (in such number of copies as shall be
requested by the Issuer), whichever of the following is applicable:

 

(A)         if
such Purchaser is claiming eligibility for benefits of an income tax treaty to which the United States is a party (x) with respect
to payments of interest under any Note Document, duly executed originals of IRS Form W-8BEN, or IRS Form W-8BEN-E or any successor
form thereto, establishing an exemption from, or reduction of, U.S. federal withholding tax pursuant to the “interest”
article of such tax treaty, and (y) with respect to any other applicable payments under any Note Document, duly executed originals
of IRS Form W-8BEN, or IRS Form W-8BEN-E, or any successor form thereto, establishing an exemption from, or reduction of, U.S.
federal withholding tax pursuant to the “business profits” or “other income” article of such tax treaty;

 

(B)         duly
executed originals of IRS Form W-8ECI, or any successor form thereto, certifying that the payments received by such Purchaser are
effectively connected with such Purchaser’s conduct of a trade or business in the United States;

 

(C)         if
such Purchaser is claiming the benefits of the exemption for portfolio interest under Section 871(h) or Section 881(c) of the Code,
duly executed originals of IRS Form W-8BEN, IRS Form W-8-BEN-E, or any successor form thereto, together with a certificate (a “U.S.
Tax Compliance Certificate”) upon which such Purchaser certifies that (1) such Purchaser is not a bank for purposes of
Section 881(c)(3)(A) of the Code, or the obligation of the Issuer hereunder is not, with respect to such Purchaser, a loan agreement
entered into in the ordinary course of its trade or business, within the meaning of that Section, (2) such Purchaser is not a 10%
shareholder of the Issuer within the meaning of Section 871(h)(3) or Section 881(c)(3)(B) of the Code, (3) such Purchaser is not
a controlled foreign corporation that is related to the Issuer within the meaning of Section 881(c)(3)(C) of the Code, and (4)
the interest payments in question are not effectively connected with a U.S. trade or business conducted by such Purchaser; or

 

    	 	46	 

     

    

 

(D)         if
such Purchaser is not the Beneficial Owner (for example, a partnership or a participating Purchaser granting a typical participation),
duly executed originals of IRS Form W-8IMY, or any successor form thereto, accompanied by IRS Form W-9, IRS Form W-8ECI, IRS Form
W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate, and/or other certification documents from each Beneficial Owner,
as applicable.

 

(iii)        Each
Purchaser that is a Foreign Person shall, to the extent it is legally entitled to do so, deliver to the Issuer and the Collateral
Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Purchaser becomes
a Purchaser under this Agreement (and from time to time thereafter upon the reasonable request of the Issuer), executed originals
of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding
tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Issuer
to determine the withholding or deduction required to be made.

 

(iv)        If
a payment made to a Purchaser under any Note Document would be subject to U.S. federal withholding tax imposed by FATCA if such
Purchaser were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b)
or 1472(b) of the Code, as applicable), such Purchaser shall deliver to the Issuer and the Collateral Agent at the time or times
prescribed by law and at such time or times reasonably requested by the Issuer such documentation prescribed by applicable law
(including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the
Issuer as may be necessary for the Issuer to comply with its obligations under FATCA and to determine that such Purchaser has complied
with such Purchaser’s obligations under FATCA or to determine the amount to deduct and withhold from such payment; provided
that, solely for purposes of this clause (E), “FATCA” shall include any amendments made to FATCA after the date of
this Agreement.

 

(v)         Each
Purchaser agrees that if any form or certification it previously delivered under this Section expires or becomes obsolete or inaccurate
in any respect, such Purchaser shall update such form or certification; however, if such Purchaser is not legally entitled to provide
an updated form or certification, it shall promptly notify the Issuer and the Collateral Agent of its inability to update such
form or certification.

 

Section 2.18         Payments
Generally; Pro Rata Treatment; Sharing of Set-offs.

 

(a)          The
Issuer shall make each payment required to be made by it hereunder (whether of principal, Prepayment Premium, premium interest
or fees, or of amounts payable under Section 2.15, 2.16 or 2.17, or otherwise) prior to 2:00 p.m. on the date
when due, in immediately available funds, free and clear of any defenses, rights of set-off, counterclaim, or withholding or deduction
of taxes. Any amounts received after such time on any date may, in the discretion of the applicable Person entitled thereto, be
deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All such payments
owing to any Purchaser shall be made to such Purchaser on a pro rata basis, and all such payments owing to the Collateral Agent
shall be made to the Collateral Agent, in each case, to such accounts as may be specified by the applicable Person not less than
five (5) days before the applicable payment is due (provided that, if a Purchaser or the Collateral Agent shall not have
provided any such notice, such payment shall be made to the account most recently identified by such Purchaser or the Collateral
Agent), except that payments pursuant to Sections 2.15, 2.16, 2.17 and 10.3 shall be made directly
to the Persons entitled thereto. If any payment hereunder shall be due on a day that is not a Business Day, the date for payment
shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall
be made payable for the period of such extension. All payments hereunder shall be made in Dollars.

 

    	 	47	 

     

    

 

(b)          If
at any time insufficient funds are received by and available to the Purchasers and the Collateral Agent to pay fully all amounts
of principal, interest, Prepayment Premiums, premiums and fees then due hereunder, such funds shall be applied as follows: first,
to all amounts owed to the Collateral Agent then due and payable pursuant to any of the Note Documents; second, to all reimbursable
expenses of the Purchasers then due and payable pursuant to any of the Note Documents, pro rata to the Purchasers based on their
respective pro rata shares of such fees and expenses; third, to all accrued interest, Prepayment Premiums, premiums and
fees then due and payable hereunder, pro rata to the Purchasers based on their respective pro rata shares of such interest, Prepayment
Premiums, premiums and fees; and fourth, to all principal of the Notes then due and payable hereunder, pro rata to the parties
entitled thereto based on their respective pro rata shares of such principal.

 

(c)          If
any Purchaser shall, by exercising any right of set-off or counterclaim or otherwise, obtain payment in respect of any principal
of or interest on any of its Notes that would result in such Purchaser receiving payment of a greater proportion of the aggregate
amount of its Notes, Prepayment Premium, premium and accrued interest and fees thereon than the proportion received by any other
Purchaser with respect to its Notes, then the Purchaser receiving such greater proportion shall purchase (for cash at face value)
participations in the Notes of other Purchasers to the extent necessary so that the benefit of all such payments shall be shared
by the Purchasers ratably in accordance with the aggregate amount of principal of, Prepayment Premiums, premiums, and accrued interest
on their respective Notes; provided that (i) if any such participations are purchased and all or any portion of the payment
giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such
recovery, without interest, and (ii) the provisions of this clause shall not be construed to apply to any payment made by the Issuer
pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence
of a Defaulting Purchaser) or any payment obtained by a Purchaser as consideration for the assignment of or sale of a participation
in any of its Notes to any assignee or participant, other than to the Issuer or any Subsidiary or Affiliate thereof (as to which
the provisions of this clause shall apply). The Issuer consents to the foregoing and agrees, to the extent it may effectively do
so under applicable law, that any Purchaser acquiring a participation pursuant to the foregoing arrangements may exercise against
the Issuer rights of set-off and counterclaim with respect to such participation as fully as if such Purchaser were a direct creditor
of the Issuer in the amount of such participation.

 

Section 2.19         Mitigation
of Obligations. If any Purchaser requests compensation under Section 2.15, or if the Issuer is required to pay any
additional amount to any Purchaser or any Governmental Authority for the account of any Purchaser pursuant to Section 2.17,
then such Purchaser shall use reasonable efforts to designate a different funding office for purchasing or booking its Notes hereunder
or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the reasonable judgment
of such Purchaser, such designation or assignment (i) would eliminate or reduce amounts payable under Section 2.15 or Section
2.17, as the case may be, in the future and (ii) would not subject such Purchaser to any unreimbursed cost or expense and would
not otherwise be disadvantageous to such Purchaser. The Issuer hereby agrees to pay all reasonable and documented (in summary form)
costs and expenses incurred by any Purchaser in connection with such designation or assignment.

 

    	 	48	 

     

    

 

Section 2.20         Replacement
of Purchasers. If (a) any Purchaser requests compensation under Section 2.15, or if the Issuer is required to pay
any additional amount to any Purchaser or any Governmental Authority for the account of any Purchaser pursuant to Section 2.17,
(b) any Purchaser is a Defaulting Purchaser, or (c) in connection with any proposed amendment, modification, termination, waiver
or consent with respect to any of the provisions hereof as contemplated by Section 10.2(b), the consent of Required Purchasers
shall have been obtained but the consent of one or more of such other Purchasers (each a “Non-Consenting Purchaser”)
whose consent is required shall not have been obtained, then the Issuer may, at its sole expense and effort, upon notice to such
Purchaser, require such Purchaser to assign and delegate, without recourse (in accordance with and subject to the restrictions
set forth in Section 10.4(b)), all of its interests, rights (other than its existing rights to payments pursuant to Section
2.15 or 2.17, as applicable) and obligations under this Agreement to an assignee that shall assume such obligations
(which assignee may be another Purchaser) (a “Replacement Purchaser”); provided that (i) such Purchaser
shall have received payment of an amount equal to the outstanding principal amount of all Notes owed to it, accrued interest thereon,
accrued fees, the Prepayment Premium (other than in the case of a Non-Consenting Purchaser) with respect to the aggregate principal
amount of the Notes being assigned (calculating such Prepayment Premium as if such Notes had been prepaid on the date of such assignment)
and all other amounts payable to it hereunder from the assignee (in the case of such outstanding principal and accrued interest)
and from the Issuer (in the case of all other amounts), (ii) in the case of a claim for compensation under Section 2.15
or payments required to be made pursuant to Section 2.17, such assignment will result in a reduction in such compensation
or payments, (iii) such assignment does not conflict with applicable law, and (iv) in the case of a Non-Consenting Purchaser, each
Replacement Purchaser shall consent, at the time of such assignment, to each matter in respect of which such terminated Purchaser
was a Non-Consenting Purchaser. A Purchaser shall not be required to make any such assignment and delegation if, prior thereto,
as a result of a waiver by such Purchaser or otherwise, the circumstances entitling the Issuer to require such assignment and delegation
cease to apply.

 

Section 2.21         Defaulting
Purchasers.

 

(a)            Defaulting
Purchaser Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Purchaser becomes a Defaulting
Purchaser, then, until such time as such Purchaser is no longer a Defaulting Purchaser, to the extent permitted by applicable law:

 

(i)          Such
Defaulting Purchaser’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall
be restricted as set forth in the definition of Required Purchasers and in Section 10.2.

 

(b)          Defaulting
Purchaser Cure. If the Required Purchasers and the Issuer agree in writing that a Purchaser is no longer a Defaulting Purchaser,
the Issuer will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions
set forth therein, that Purchaser will cease to be a Defaulting Purchaser; provided that, except to the extent otherwise
expressly agreed by the affected parties, no change hereunder from Defaulting Purchaser to Purchaser will constitute a waiver or
release of any claim of any party hereunder arising from that Purchaser’s having been a Defaulting Purchaser.

 

Section 2.22         Legend.
Each Note shall bear the following legend:

 

THIS NOTE WAS ISSUED IN A PRIVATE PLACEMENT,
WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR THE SECURITIES LAWS OF ANY STATE,
AND MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
ACT AND APPLICABLE STATE SECURITIES LAWS COVERING THE TRANSFER OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS
OF SUCH ACT AND SUCH LAWS.

 

    	 	49	 

     

    

 

Section 2.23         Transfer
and Exchange of Notes. Upon surrender of any Note to the Issuer at the address and to the attention of the designated officer,
for registration of transfer or exchange (and in the case of a surrender for registration of transfer accompanied by a written
instrument of transfer duly executed by the registered Purchaser or such Purchaser’s attorney duly authorized in writing
and accompanied by the relevant name, address and other information for notices of each transferee of such Note or part thereof)
pursuant to Section 10.4(b), within ten (10) Business Days thereafter, the Issuer shall execute and deliver, at the Issuer’s
expense (except as provided below), one or more new Notes (as requested by the Purchaser) in exchange therefor, in an aggregate
principal amount equal to the unpaid principal amount of the surrendered Note. Subject to Section 10.4, in the case of any
assignment of a Note, each such new Note shall be payable to such Person as such Purchaser may request and shall be substantially
in the form of Exhibit B. Each such new Note shall be dated and bear interest from the date to which interest shall have
been paid on the surrendered Note or dated the date of the surrendered Note if no interest shall have been paid thereon. The Issuer
may require payment of a sum sufficient to cover any stamp tax or governmental charge imposed in respect of any such transfer of
Notes. Each transferee, by its acceptance of a Note registered in its name (or the name of its nominee) will be deemed to have
made the representations set forth in Section 2.25.

 

Section 2.24         Replacement
of Notes. Upon receipt by the Issuer at the address and to the attention of the designated officer of evidence reasonably
satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note, and

 

(a)          in
the case of loss, theft or destruction, an indemnity reasonably satisfactory to it (provided, that, if the Purchaser is, or is
a nominee for, an original purchaser or another Purchaser with a minimum net worth of at least $100,000,000 or a “qualified
institutional buyer” as defined in Rule 144A(a)(1) under the Securities Act, such Person’s own unsecured agreement
of indemnity shall be deemed to be satisfactory), or

 

(b)          in
the case of mutilation, upon surrender and cancellation thereof,

 

within ten (10) Business Days thereafter, the
Issuer at its own expense shall execute and deliver, in lieu thereof, a new Note in an aggregate principal amount equal to the
unpaid principal amount of the Note to be replaced, dated and bearing interest from the date to which interest shall have been
paid on such lost, stolen, destroyed or mutilated Note or dated the date of such lost, stolen, destroyed or mutilated Note if no
interest shall have been paid thereon.

 

Section 2.25         Representations
of Purchasers. Each Purchaser, severally and not jointly, hereby represents and warrants to the Issuer that, as of the
Closing Date and immediately following the closing of the transactions contemplated under this Agreement, the following are true
and correct: (a) such Purchaser is not acquiring the Notes to be purchased by it hereunder with a view to or for sale or resale
in connection with any distribution thereof within the meaning of the Securities Act, (b) such Purchaser (i) is an “accredited
investor” as defined in Rule 501 promulgated under the Securities Exchange Act of 1934 as in effect as of the Closing Date,
and (ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks
of the prospective investment in the Notes being purchased by it and (c) such Purchaser understands that the Notes have not been
registered under the Securities Act and may be resold only if registered pursuant to the provisions of the Securities Act or if
an exemption from registration is available, except under circumstances where neither such registration nor such an exemption is
required by law, and that the Issuer is not required to register the Notes. The purchase of the Notes by each Purchaser on the
Closing Date shall constitute its confirmation of the foregoing representations and warranties. Each Purchaser understands that
such Notes are being sold to it in a transaction which is exempt from the registration requirements of the Securities Act, and
that, in making the representations and warranties contained in Section 4.25, the Issuer is relying, to the extent applicable,
upon the representations and warranties made by the Purchasers herein.

 

    	 	50	 

     

    

 

Section 2.26         Prepayment
Premium. Payment of any Prepayment Premium hereunder constitutes liquidated damages and not a penalty, and the actual amount
of damages to the Purchasers or profits lost by the Purchasers as a result of the relevant prepayment or repayment would be impracticable
and extremely difficult to ascertain. Accordingly, the Prepayment Premium hereunder is provided by mutual agreement of the Issuer
and the Purchasers as a reasonable estimation and calculation of such actual lost profits and other actual damages of the Purchasers.
Without limiting the generality of the foregoing, it is understood and agreed that upon the occurrence of any optional prepayment
of the Notes pursuant to Section 2.8(a), any mandatory prepayment of the Notes pursuant to Section 2.9(a) or (b)
or repayment of the Notes following acceleration pursuant to Section 8.1 (including an automatic acceleration under clause
(g) or (h) of Section 8.1, or to the extent the Notes otherwise become due and payable prior to their maturity
as provided in Section 8.1), except as expressly set forth in the definition of “Prepayment Premium,” the Prepayment
Premium (if any) shall be due and payable as though any prepaid or repaid Notes were voluntarily prepaid as of such date and shall
constitute part of the Obligations secured by the Collateral. The Prepayment Premium shall also be payable in the event the Notes
are satisfied or released by foreclosure (whether by power of judicial proceeding or otherwise), deed in lieu of foreclosure or
by any other means. THE ISSUER HEREBY EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT
OR FUTURE STATUTE OR OTHER LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING PREPAYMENT PREMIUM IN CONNECTION
WITH ANY SUCH EVENT. The Issuer expressly agrees (to the fullest extent it may lawfully do so) that with respect to the Prepayment
Premium payable under the terms of this Agreement: (i) the Prepayment Premium is reasonable and is the product of an arm’s
length transaction between sophisticated business parties, ably represented by counsel; (ii) the Prepayment Premium shall be payable
notwithstanding the then prevailing market rates at the time payment is made; (iii) there has been a course of conduct between
the Purchasers and the Note Parties giving specific consideration in this transaction for such agreement to pay the Prepayment
Premium; and (iv) the Note Parties shall be estopped hereafter from claiming differently than as agreed to in this paragraph. The
Issuer expressly acknowledges that its agreement to pay the Prepayment Premium as herein described is a material inducement to
the Purchasers to provide the Commitments and purchase the Notes.

 

ARTICLE III

CONDITIONS PRECEDENT TO PURCHASE OF NOTES

 

Section 3.1           Conditions
to Effectiveness. The obligations of the Purchasers to purchase the Notes shall not become effective until the date on
which each of the following conditions is satisfied (or waived in accordance with Section 10.2):

 

(a)          The
Collateral Agent and the Purchasers shall have received payment of all fees, expenses and other amounts due and payable on or prior
to the Closing Date, to the extent invoiced in reasonable detail at least one (1) Business Day prior to the Closing Date, including,
without limitation, reimbursement or payment of all reasonable and documented (in summary form) costs and expenses of the Collateral
Agent (including, but not limited to, attorneys’ fees and costs), the Purchasers and their Affiliates, in each case, required
to be reimbursed or paid by the Issuer hereunder, under any other Note Document, the Fee Letters, the Commitment Letter and any
other agreement with the Collateral Agent or the any Purchaser.

 

    	 	51	 

     

    

 

(b)           The
Collateral Agent and the Purchasers (or their respective counsels) shall have received the following, each to be in form and substance
reasonably satisfactory to the Collateral Agent and the Purchasers:

 

(i)          a
counterpart of this Agreement signed by or on behalf of each party hereto;

 

(ii)         a
certificate of the Secretary or Assistant Secretary (or other comparable Responsible Officer) of each Note Party in substantially
the form of Exhibit 3.1(b)(ii), attaching and certifying copies of its bylaws, or partnership agreement or limited liability
company agreement, and of the resolutions of its Governing Body, or comparable organizational documents and authorizations, authorizing
the execution, delivery and performance of the Note Documents to which it is a party and certifying the name, title and true signature
of each officer of such Note Party executing the Note Documents to which it is a party;

 

(iii)        certified
copies of the articles or certificate of incorporation, certificate of organization or limited partnership, or other registered
organizational documents of each Note Party, together with certificates of good standing or existence, as may be available from
the Secretary of State of (A) the jurisdiction of organization of such Note Party and (B) each other jurisdiction where such Note
Party is required to be qualified to do business as a foreign corporation where the failure to be so qualified would reasonably
be expected to have a Material Adverse Effect;

 

(iv)        a
written opinion of Dechert LLP, counsel to the Note Parties, and, if reasonably requested by the Required Purchasers, customary
local counsel opinions with respect to certain Note Parties each addressed to the Collateral Agent and each of the Purchasers,
and covering such matters relating to the Note Parties, the Note Documents and the transactions contemplated therein as the Collateral
Agent or the Required Purchasers shall reasonably request;

 

(v)         a
certificate in substantially the form of Exhibit 3.1(b)(v), dated the Closing Date and signed by a Responsible Officer,
certifying that after giving effect to the purchase of the Notes, (x) since December 31, 2016, no event, act, condition or occurrence
of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding),
whether singularly or in conjunction with any other event or events, act or acts, condition or conditions, occurrence or occurrences
whether or not related, that has resulted in a Material Adverse Effect has occurred, (y) at the time of and immediately after giving
effect to the purchase and sale of the Notes hereunder, the representations and warranties set forth in this Agreement and the
other Note Documents shall be true and correct in all material respects (other than those representations and warranties (i) that
are expressly qualified by a Material Adverse Effect or other materiality, in which case such representations and warranties shall
be true and correct in all respects or (ii) that expressly relate to an earlier date, in which case such representations and warranties
shall be true and correct in all material respects as of such earlier date), and (z) at the time of and immediately after giving
effect to the purchase and sale of the Notes hereunder, no Default or Event of Default shall exist;

 

(vi)        a
report setting forth the sources and uses of the proceeds of the Notes;

 

    	 	52	 

     

    

 

(vii)       the
ABDC Intercreditor Agreement, duly executed and delivered by the parties thereto;

 

(viii)      certified
copies of all material consents, approvals, authorizations, registrations, filings and orders required to be made or obtained under
any Requirement of Law, or by any material Contractual Obligation of any Note Party, in connection with the execution, delivery,
performance, validity and enforceability of the Note Documents or any of the transactions contemplated thereby, if any, and such
consents, approvals, authorizations, registrations, filings and orders shall be in full force and effect and all applicable waiting
periods shall have expired,;

 

(ix)         copies
of (A) the financial statements described in Section 4.4(a) and (B) the Issuer and its Subsidiaries’ statement of
profit and loss for May 2017;

 

(x)          the
Guaranty and Security Agreement, duly executed by the Issuer and each of its Domestic Subsidiaries (but excluding any Specified
Strategic Joint Venture (in each case, if formed prior to the Closing Date)), together with (A) UCC financing statements and other
applicable documents under the laws of all necessary or appropriate jurisdictions with respect to the perfection of the Liens granted
under the Guaranty and Security Agreement, as reasonably requested by the Collateral Agent, acting at the direction of the Required
Purchasers, or the Required Purchasers in order to perfect such Liens, duly authorized by the Note Parties, (B) copies of
favorable UCC, tax, judgment and fixture lien search reports in all necessary or appropriate jurisdictions and under all legal
and trade names of the Note Parties, as reasonably requested by the Collateral Agent, acting at the direction of the Required Purchasers,
or the Required Purchasers, indicating that there are no prior Liens on any of the Collateral other than Specified Permitted Liens
and Liens to be released on the Closing Date, (C) an Information and Collateral Disclosure Certificate, duly completed and executed
by the Note Parties, (D) as necessary, duly executed Patent Security Agreements, Trademark Security Agreements and Copyright Security
Agreements, and (E) original certificates evidencing all issued and outstanding shares of Capital Stock of all Subsidiaries owned
directly by any Note Party (or, in the case of any Foreign Subsidiary directly owned by a Note Party, not more than 65% of the
issued and outstanding voting Capital Stock of such Foreign Subsidiary), in each case, to the extent certificated prior to the
Closing Date, and related stock or membership interest powers or other appropriate instruments of transfer executed in blank;

 

(xi)         a
summary, which may include a flow chart and summary of the Note Parties’ and their Subsidiaries’ cash management system,
setting forth in reasonable detail the principal bank accounts of the Note Parties and their Subsidiaries where any cash balances
and proceeds of receivables are collected, aggregated and/or maintained in the ordinary course of business, other than Excluded
Accounts;

 

(xii)        subject
to Section 5.16 and the Issuer’s use of commercially reasonable efforts, with respect to the chief executive office
of the Issuer and each additional leased property where books or records are stored or located, a copy of the underlying lease,
as applicable, and a Collateral Access Agreement from the landlord of such leased property; provided that if such Note Party
is unable to deliver any such Collateral Access Agreement after using its commercially reasonable efforts to do so, the Required
Purchasers shall waive the foregoing requirement in their reasonable discretion;

 

(xiii)       copies
of duly executed payoff letters with respect to any existing Indebtedness in respect of the Existing Credit Agreement and the other
Loan Documents (as defined in the Existing Credit Agreement) and the Existing Priming Credit Agreement and the other Loan Documents
(as defined in the Existing Priming Credit Agreement), together with (A) UCC-3 or other appropriate termination statements releasing
all liens of the existing lenders upon any of the personal property of the Issuer and its Subsidiaries and authorizations to file
such UCC-3s, (B) cancellations and releases releasing all liens of the existing lenders upon any real property owned by the Issuer
and its Subsidiaries, and (C) any other releases, terminations or other documents reasonably required by the Required Purchasers
to evidence the payoff of such Indebtedness;

 

    	 	53	 

     

    

 

(xiv)      the
First Lien/Second Lien Intercreditor Agreement, duly executed and delivered by the parties thereto;

 

(xv)       (A)
certificates of insurance describing the types and amounts of insurance (property and liability) maintained by any of the Note
Parties, in each case naming the Collateral Agent as loss payee or additional insured, as the case may be, and (B) subject to Section
5.16, a lender’s loss payable endorsement (in the case of each of the foregoing clauses (A) and (B), other than with
respect to any director and officer indemnification policies, workers’ compensation policies and any policies that provide
coverage for property that does not constitute Collateral);

 

(xvi)      documentation
and information required by regulatory authorities under applicable “know your customer” and anti-money laundering
laws at least five (5) Business Days prior to the Closing Date to the extent that such documentation and information was requested
by the Collateral Agent or any Purchaser at least ten (10) days prior to the Closing Date; and

 

(xvii)     a
certificate, dated the Closing Date and signed by a Responsible Officer of the Issuer on behalf of each Note Party, confirming
that after giving effect to the execution and delivery of the Note Documents, the incurrence on the Closing Date of the Notes (and
the use of proceeds thereof on the Closing Date), and the other transactions contemplated herein to occur on the Closing Date,
the Issuer and its Subsidiaries on a consolidated basis are Solvent.

 

(c)            The
Note Parties shall have used commercially reasonable efforts to deliver Account Control Agreements and Government Receivables Account
Agreements, duly executed by each Permitted Third Party Bank and the applicable Note Party to the Collateral Agent and the Purchasers;
provided that, if such Account Control Agreements and Government Receivables Account Agreements are not delivered by the
Closing Date, the applicable Note Party shall deliver such Account Control Agreements and Government Receivables Account Agreements
within ninety (90) days following the Closing Date.

 

(d)            There
shall be no Indebtedness for borrowed money of the Issuer or any of its Subsidiaries to any Person, other than the Notes, the Second
Lien Notes, the Senior Notes and other Indebtedness reasonably satisfactory to the Purchasers.

 

(e)            There
shall not be any pending or threatened in writing litigation, investigation or other proceedings or inquiry (private or governmental)
seeking to enjoin the transactions contemplated by this Agreement and the other Note Documents.

 

(f)            The
Issuer shall have received the cash proceeds of the purchase of the Second Lien Notes.

 

(g)           (i)
The Issuer shall have complied in all material respects with and be in compliance in all material respects with all of the of terms
and conditions of the Commitment Letter and the Ares Closing Payment Letter and (b) the representations and warranties of the Issuer
set forth under the heading “Evaluation Material” in the Commitment Letter shall be true and correct in all material
respects (other than those representations and warranties that are expressly qualified by materiality, in which case such representations
and warranties shall be true and correct in all respects) as of the Closing Date.

 

    	 	54	 

     

    

 

Without limiting the generality
of the provisions of this Section, for purposes of determining compliance with the conditions specified in this Section, each Purchaser
that has signed this Agreement shall be deemed to have consented to, approved of, accepted or been satisfied with each document
or other matter required thereunder to be consented to, approved by or acceptable or satisfactory to a Purchaser unless the Issuer
shall have received notice from such Purchaser prior to the proposed Closing Date specifying its objection thereto.

 

Section 3.2           Delivery
of Documents. All of the Note Documents, certificates and other documents and papers referred to in this Article, unless
otherwise specified, shall be delivered to each of the Purchasers and shall be in form and substance reasonably satisfactory in
all respects to each of the Purchasers.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES

 

The Issuer represents and
warrants to the Collateral Agent and each Purchaser as follows:

 

Section 4.1           Existence;
Power. The Issuer and each of its Subsidiaries (i) is duly organized, validly existing and in good standing as a corporation,
partnership or limited liability company under the laws of the jurisdiction of its organization, (ii) has all requisite power and
authority to carry on its business as now conducted, and (iii) is duly qualified to do business, and is in good standing,
in each jurisdiction where such qualification is required, except where a failure to be so qualified would not reasonably be expected
to result in a Material Adverse Effect.

 

Section 4.2           Organizational
Power; Authorization. The execution, delivery and performance by each Note Party of the Note Documents to which it is a
party are within such Note Party’s organizational powers and have been duly authorized by all necessary organizational and,
if required, shareholder, partner or member action. Each of this Agreement and the other Note Documents has been duly executed
and delivered by the Issuer and the other Note Parties party thereto and constitutes valid and binding obligations of the
Issuer or such Note Party (as the case may be), enforceable against it in accordance with their respective terms, except as may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’
rights generally and by general principles of equity.

 

Section 4.3           Governmental
Approvals; No Conflicts. The execution, delivery and performance by each Note Party of the Note Documents to which it is
a party (a) do not require any consent or approval of, registration or filing with, or any action by, any Governmental Authority
or any Person with respect to which the Issuer or any of its Subsidiaries has any Contractual Obligation, except those as have
been obtained or made and are in full force and effect and except for filings necessary to perfect or maintain perfection of the
Liens created under the Note Documents, (b) will not violate any Requirement of Law applicable to the Issuer or any of its Subsidiaries
or any judgment, order or ruling of any Governmental Authority, (c) will not violate or result in a default under any material
Contractual Obligation of the Issuer or any of its Subsidiaries or any of its assets or give rise to a right thereunder to accelerate
the obligations of the Issuer or any of its Subsidiaries thereunder (whether accomplished by a mandatory prepayment, a redemption,
or otherwise) and (d) will not result in the creation or imposition of any Lien on any asset of the Issuer or any of its Subsidiaries,
except Liens (if any) created under the Note Documents.

 

    	 	55	 

     

    

 

Section 4.4           Financial
Statements; Material Adverse Effect. 

 

(a)          The
Issuer has furnished to each Purchaser (i) the audited consolidated balance sheet of the Issuer and its Subsidiaries as of December
31, 2016, and the related audited consolidated statements of income, shareholders’ equity and cash flows for the Fiscal Year
then ended, prepared by Ernst & Young LLP and (ii) the unaudited consolidated balance sheet of the Issuer and its Subsidiaries
as of March 31, 2017, and the related unaudited consolidated statements of income and cash flows for the Fiscal Quarter and year-to-date
period then ended, certified by a Responsible Officer. Such financial statements fairly present in all material respects the consolidated
financial condition of the Issuer and its Subsidiaries as of such dates and the consolidated results of operations for such periods
in conformity with GAAP (as in effect at the time such financial statements were prepared and subject to Section 1.3) consistently
applied (except as expressly noted therein), subject to year-end audit adjustments and the absence of footnotes in the case of
the statements referred to in clause (ii). All Profit Plans delivered to the Purchasers after the Closing Date pursuant to Section
5.1(e) have been prepared by the Issuer in good faith based on assumptions believed by the Issuer to be reasonable at the time
made; provided that it is expressly understood and agreed that financial projections (including all Profit Plans) are not
to be viewed as facts, are inherently uncertain and are not a guarantee of financial performance and actual results may differ
from financial projections and such differences may be material.

 

(b)          Since
December 31, 2016, there have been no changes with respect to, or event affecting, the Issuer and its Subsidiaries which have had
or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.

 

Section 4.5           Litigation
and Environmental Matters.

 

(a)          No
litigation, investigation or proceeding (including any whistleblower action) of or before any arbitrators or Governmental Authorities
is pending against or, to the knowledge of the Issuer, threatened in writing against the Issuer or any of its Subsidiaries (i)
that would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect or (ii) which in
any manner draws into question the validity or enforceability of this Agreement or any other Note Document.

 

(b)          Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, neither the Issuer
nor any of its Subsidiaries (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any permit,
license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has
received notice of any claim with respect to any Environmental Liability or (iv) knows of any basis for any Environmental Liability.

 

Section 4.6           Compliance
with Laws and Agreements. Except for non-compliance which would not reasonably be expected to result in a Material Adverse
Effect, the Issuer and each of its Subsidiaries is in compliance with (a) all Requirements of Law and all judgments, decrees and
orders of any Governmental Authority and (b) all Material Agreements.

 

Section 4.7           Investment
Company Act. Neither the Issuer nor any of its Subsidiaries is (a) an “investment company” or is “controlled”
by an “investment company”, as such terms are defined in, or subject to regulation under, the Investment Company Act
of 1940, as amended and in effect from time to time, or (b) otherwise subject to any other regulatory scheme limiting its ability
to incur debt or requiring any approval or consent from, or registration or filing with, any Governmental Authority in connection
therewith.

 

    	 	56	 

     

    

 

Section 4.8           Taxes.
The Issuer and its Subsidiaries and each other Person for whose taxes the Issuer or any of its Subsidiaries could become liable
have timely filed or caused to be filed all Federal income tax returns and all other material tax returns that are required to
be filed by them, and have paid all taxes shown to be due and payable on such returns or on any assessments made against it or
its property and all other taxes, fees or other charges imposed on it or any of its property by any Governmental Authority, except
where the same are currently being contested in good faith by appropriate proceedings and for which the Issuer or such Subsidiary,
as the case may be, has set aside on its books adequate reserves in accordance with GAAP. The charges, accruals and reserves on
the books of the Issuer and its Subsidiaries in respect of such taxes are adequate, and no tax liabilities that could be materially
in excess of the amount so provided are anticipated.

 

Section 4.9           Margin
Regulations. None of the proceeds of any of the Notes will be used, directly or indirectly, for “purchasing”
or “carrying” any “margin stock” within the respective meanings of each of such terms under Regulation
U or for any purpose that violates the provisions of Regulation T, Regulation U or Regulation X. Neither the Issuer nor any of
its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose
of purchasing or carrying “margin stock”.

 

Section 4.10         ERISA.
Each Plan is in substantial compliance in form and operation with its terms and with ERISA and the Code (including, without
limitation, the Code provisions compliance with which is necessary for any intended favorable tax treatment) and all other applicable
laws and regulations, except as would not reasonably be expected to have a Material Adverse Effect. Each Plan (and each related
trust, if any) which is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter
from the Internal Revenue Service to the effect that it meets the requirements of Sections 401(a) and 501(a) of the Code covering
all applicable tax law changes, or is comprised of a master or prototype plan that has received a favorable opinion letter from
the Internal Revenue Service, and nothing has occurred since the date of such determination that would adversely affect such determination
(or, in the case of a Plan with no such determination, nothing has occurred that would adversely affect the issuance of a favorable
determination letter or otherwise adversely affect such qualification), except as would not reasonably be expected to have a Material
Adverse Effect. No ERISA Event has occurred that has had or would reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect. There exists no Unfunded Pension Liability with respect to any Plan and no Plan is in, or
is expected to be, in at risk status under Title IV of ERISA such that a Material Adverse Effect would be expected in the foreseeable
future to occur with respect thereto. There are no actions, suits or claims pending against or involving a Plan (other than routine
claims for benefits) or, to the knowledge of the Issuer, any of its Subsidiaries or any ERISA Affiliate, threatened, which would
reasonably be expected to be asserted successfully against any Plan and, if so asserted successfully, would reasonably be expected
either singly or in the aggregate to have a Material Adverse Effect. The Issuer, each of its Subsidiaries and each ERISA Affiliate
have made all contributions to or under each Plan and Multiemployer Plan required by law within the applicable time limits prescribed
thereby, by the terms of such Plan or Multiemployer Plan, respectively, or by any contract or agreement requiring contributions
to a Plan or Multiemployer Plan, except as would not reasonably be expected to have a Material Adverse Effect. Each Non-U.S. Plan
has been maintained in compliance with its terms and with the requirements of any and all applicable laws, statutes, rules, regulations
and orders and has been maintained, where required, in good standing with applicable regulatory authorities, except as would not
reasonably be expected to result in liability to the Issuer or any of its Subsidiaries. All contributions required to be made with
respect to a Non-U.S. Plan have been timely made. Neither the Issuer nor any of its Subsidiaries has incurred any obligation in
connection with the termination of, or withdrawal from, any Non-U.S. Plan. The present value of the accrued benefit liabilities
(whether or not vested) under each Non-U.S. Plan, determined as of the end of the Issuer’s most recently ended fiscal year
on the basis of reasonable actuarial assumptions, did not exceed the current value of the assets of such Non-U.S. Plan allocable
to such benefit liabilities.

 

    	 	57	 

     

    

 

Section 4.11         Ownership
of Property; Insurance.

 

(a)          As
of the Closing Date, all interests in real property owned by the Issuer or any of its Subsidiaries (collectively, and together
with any additional real estate acquired after the Closing Date, the “Real Estate”) or leased by the Issuer
or any of its Subsidiaries are listed on Schedule 4.11(a). Each of the Issuer and its Subsidiaries has good title to, or
valid leasehold interests in, all Real Estate, leased real property and all other personal property material to the operation of
its business (except as sold or otherwise disposed of in the ordinary course of business or in a transaction permitted hereunder),
in each case free and clear of Liens (other than Liens not prohibited by Section 7.2). All leases that individually are
material to the business or operations of the Issuer and its Subsidiaries are valid and are in full force. As of the Closing Date,
all permits required to have been issued or appropriate to enable the Real Estate or any leased real property to be lawfully occupied
and used for all of the purposes for which it is currently occupied and used have been lawfully issued and are in full force and
effect, except where the failure to be so issued or in full force and effect would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

(b)          The
Intellectual Property Rights owned by the Issuer and its Subsidiaries, together with the Intellectual Property Rights licensed
to the Issuer and its Subsidiaries under license agreements, constitute all of the Intellectual Property Rights material to their
respective businesses.

 

(c)          Set
forth on Schedule 4.11(c) is a complete and accurate summary of the insurance maintained by the Issuer and its Subsidiaries
as of the Closing Date. The Issuer and its Subsidiaries have insurance meeting the requirements of Section  5.8, and
such insurance policies are in full force and effect.

 

(d)          All
assets of the Issuer and its Subsidiaries, whether owned, leased, or managed, are in good repair, working order and condition,
ordinary wear and tear excepted, in accordance with the terms and conditions of any applicable lease or license agreement, except
where the failure to be in such good repair, working order or condition would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

Section 4.12         Disclosure.
Each of the written reports (including, without limitation, all reports that the Issuer is required to file with the Securities
and Exchange Commission), financial statements, certificates or other information (other than the Profit Plans, pro formas, budgets,
other forward-looking information (which shall be subject solely to the representation set forth in the last sentence of Section
4.4(a)), information regarding third parties and general economic or industry information) (but only to the Issuer’s
knowledge with respect to any information provided by another Person that is not an Affiliate) furnished by or on behalf of the
Issuer to the Collateral Agent or any Purchaser in connection with the negotiation of this Agreement or any other Note Document
or delivered hereunder or thereunder (as modified or supplemented by any other information so furnished), is or will be, when furnished
and taken as a whole, complete and correct in all material respects and does not or will not, when furnished and taken as a whole,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained
therein not materially misleading in light of the circumstances under which such statements are made (as modified or supplemented
by any other information so furnished).

 

    	 	58	 

     

    

 

Section 4.13         Labor
Relations. There are no strikes, lockouts or other material labor disputes or grievances against the Issuer or any of its
Subsidiaries, or, to the Issuer’s knowledge, threatened against or affecting the Issuer or any of its Subsidiaries, and no
significant unfair labor practice charges or grievances are pending against the Issuer or any of its Subsidiaries, or, to the Issuer’s
knowledge, threatened against any of them before any Governmental Authority. All payments due from the Issuer or any of its Subsidiaries
pursuant to the provisions of any collective bargaining agreement have been paid or accrued as a liability on the books of the
Issuer or any such Subsidiary, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.

 

Section 4.14         Subsidiaries.
Schedule 4.14 sets forth the name of, the ownership interest of the applicable Note Party in, the jurisdiction of incorporation
or organization of, and the organizational type of each Subsidiary of the Issuer and the other Note Parties and identifies each
Subsidiary that is a Subsidiary Note Party, in each case as of the Closing Date. As of the Closing Date, the Issuer has no Subsidiaries
other than those specifically disclosed on Schedule 4.14 and no Note Party owns any Capital Stock in any Person other than
those specifically disclosed on Schedule 4.14. All of the outstanding Capital Stock in each of the Issuer’s Subsidiaries
that is a corporation has been validly issued, is fully paid and non-assessable, and all such Capital Stock owned by any Note Party
is owned by the record owners in the amounts specified on Schedule 4.14 as of the Closing Date, free and clear of all Liens
except those created under the Collateral Documents, the Second Lien Collateral Documents and nonconsensual Liens that arise by
operation of law. None of the Note Parties or any of their Subsidiaries has, as of the Closing Date, any issued and outstanding
Disqualified Capital Stock except as otherwise specifically disclosed on Schedule 4.14.

 

Section 4.15         Solvency.
After giving effect to the execution and delivery of the Note Documents, the issuance and purchase of the Notes under this
Agreement and the consummation of all transactions contemplated by such Note Documents, the Issuer and its Subsidiaries on a consolidated
basis are Solvent.

 

Section 4.16         Deposit
and Disbursement Accounts. Schedule 4.16 lists all banks and other financial institutions at which any Note Party
maintains deposit accounts, lockbox accounts, disbursement accounts, investment accounts or other similar accounts as of the Closing
Date, and such Schedule correctly identifies the name, address and telephone number of each financial institution, the name in
which the account is held, the type of the account, the complete account number therefor, and whether such account is a Government
Receivables Account.

 

Section 4.17         Collateral
Documents.

 

(a)          The
Guaranty and Security Agreement and each other Collateral Document is effective to create in favor of the Collateral Agent, for
the ratable benefit of the Secured Parties, a legal, valid and enforceable security interest in the Collateral described therein
and proceeds thereof to the extent such a security interest can be created by authentication of a written security agreement under
Articles 8 and 9 of the UCC. In the case of certificated Capital Stock pledged pursuant to the Guaranty and Security Agreement,
when certificates representing such Capital Stock are delivered to the Collateral Agent, and in the case of the other Collateral
described in the Guaranty and Security Agreement or any other Collateral Document (other than deposit accounts and investment property)
in which a Lien may be perfected by the filing of a financing statement, when financing statements are filed in the appropriate
filing offices as specified in Article 9 of the UCC (which, as of the Closing Date, for each of the Note Parties is the filing
office set forth for each Note Party on Schedule 3 to the Guaranty and Security Agreement), in each case, the Collateral Agent,
for the benefit of the Secured Parties, shall have a fully perfected Lien on, and security interest in, all right, title and interest
of the Note Parties in such Collateral (including such Capital Stock) and the proceeds thereof, as security for the Obligations,
in each case prior and superior in right to any other Person (except for Specified Permitted Liens). In the case of Collateral
that consists of deposit accounts (other than a Government Receivables Account) or investment property, when an Account Control
Agreement is executed and delivered by all parties thereto with respect to such deposit accounts or investment property, the Collateral
Agent, for the benefit of the Secured Parties, shall have a fully perfected Lien on, and security interest in, all right, title
and interest of the Note Parties in such Collateral and the proceeds thereof, as security for the Obligations, prior and superior
to any other Person (except for Specified Permitted Liens) except as provided under the applicable Account Control Agreement with
respect to the financial institution party thereto.

 

    	 	59	 

     

    

 

(b)          When
the filings in clause (a) of this Section are made and when, if applicable, the Copyright Security Agreements are filed in the
United States Copyright Office, the Collateral Agent, for the benefit of the Secured Parties, shall have a fully perfected Lien
on, and security interest in, all right, title and interest of the Note Parties in the Copyrights subject to such Copyright Security
Agreement, if any, in which a security interest may be perfected by filing, recording or registering a security agreement, financing
statement or analogous document in the United States Copyright Office, as applicable, in each case prior and superior in right
to any other Person (except for Specified Permitted Liens).

 

(c)          Each
Mortgage, if any, is effective to create in favor of the Collateral Agent for the ratable benefit of the Secured Parties a legal,
valid and enforceable Lien on all of such Note Party’s right, title and interest in and to the Real Estate of such Note Party
covered thereby and the proceeds thereof, and when such Mortgage is filed in the real estate records where the respective Mortgaged
Property is located, such Mortgage shall constitute a fully perfected Lien on, and security interest in, all right, title and interest
of such Note Party in such Real Estate and the proceeds thereof, in each case prior and superior in right to any other Person,
other than with respect to Permitted Encumbrances and Specified Permitted Liens.

 

Section 4.18         Material
Agreements. As of the Closing Date, all Material Agreements of the Issuer and its Subsidiaries are listed on Schedule
4.18, and each such Material Agreement is in full force and effect. As of the Closing Date, the Issuer has delivered to the
Purchasers a true, complete and correct copy of each Material Agreement (including all schedules, exhibits, amendments, supplements,
modifications, assignments and all other documents delivered pursuant thereto or in connection therewith).

 

Section 4.19         Sanctions;
Anti-Terrorism and Anti-Corruption Laws. 

 

(a)          None
of the Issuer nor any of its Affiliates or, to the Issuer’s and its Subsidiaries’ knowledge, their respective officers,
directors, brokers or agents of such Person or Affiliate (i) has violated any Anti-Terrorism Laws or Sanction, (ii) has engaged
in any transaction, investment, undertaking or activity that conceals the identity, source or destination of the proceeds from
any category of prohibited offenses designated by the Organization for Economic Co-operation and Development’s Financial
Action Task Force on Money Laundering, (iii) is a Person whose name appears on the list of Specially Designated Nationals and Blocked
Persons published by OFAC (an “OFAC Listed Person”) or is otherwise a Sanctioned Person, (iv) is an agent, department,
or instrumentality of, or is otherwise beneficially owned by, controlled by or acting on behalf of, directly or indirectly, (A)
any OFAC Listed Person or (B) any other Sanctioned Person or Sanctioned Country, or (v) is otherwise blocked, the subject or target
of Sanctions or engaged in any activity in violation of Sanctions or Anti-Terrorism Laws (each OFAC Listed Person, Sanctioned Person,
Sanctioned Country and each other Person, entity, organization and government of a country described in clauses (iii), (iv) or
(v), a “Blocked Person”). Neither the Issuer nor any Controlled Affiliate thereof has been notified that its
name appears or may in the future appear on a list of Persons that engage in investment or other commercial activities in Iran
or any other Sanctioned Country. No part of the proceeds from the Notes issued and purchased hereunder constitutes or will constitute
funds obtained on behalf of any Blocked Person or will otherwise be used by the Issuer, directly or indirectly, or lent, contributed
or otherwise made available to any Person (x) in connection with any investment in, or any transactions or dealings with, any Blocked
Person, (y) to fund any activities or business of or with any Sanctioned Person, or in any Sanctioned Country or (z) otherwise
in any manner that would result in a violation of Sanctions by any Person (including any Person participating in the Notes, whether
as underwriter, advisor, investor or otherwise).

 

    	 	60	 

     

    

 

(b)          Neither
the Issuer nor any of its Affiliates or, to the Issuer’s knowledge, their respective officers, directors, brokers or agents
acting or benefiting in any capacity in connection with the Notes (i) deals in or otherwise engages, or has dealt or otherwise
engaged, in any transaction related to, any property or interests in property blocked pursuant to any Anti-Terrorism Law or Sanction,
(ii) engages in or conspires to, or engaged or conspired to, engage in any transaction that evades or avoids, or has the purpose
of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law or Sanction, (iii)
has been found in violation of, charged with, or convicted under any Anti-Terrorism Law, (iv) to the Issuer’s knowledge after
making due inquiry, is under investigation by any Governmental Authority for possible violation of Anti-Terrorism Laws or any Sanctions,
(v) has been assessed civil penalties under any Anti-Terrorism Laws or any Sanctions, or (vi) has had any of its funds seized or
forfeited in an action under any Anti-Terrorism Laws. The Issuer has established policies, procedures and controls which are designed
(and otherwise comply with applicable law) to ensure that each of the Issuer and each Controlled Affiliate thereof, and each of
their respective directors, officers, employees and agents, is and will continue to be in compliance with all applicable current
and future Anti-Terrorism Laws and Sanctions.

 

(c)          None
of the Issuer nor any of its Affiliates (i) has been charged with, or convicted of bribery or any other anti-corruption related
activity under any applicable Anti-Corruption Laws, (ii) to the Issuer’s knowledge after making due inquiry, is under investigation
by any Governmental Authority for possible violation of Anti-Corruption Laws, or (iii) has been assessed civil or criminal penalties
under any Anti-Corruption Laws. The Issuer and its Subsidiaries will not use any part of the proceeds of the Notes, directly or
indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate
for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any
improper advantage, in violation of the Anti-Corruption Laws. The Issuer and, to the Issuer’s knowledge, its respective directors,
officers and employees and agents are in compliance with all Anti-Corruption Laws, and the Issuer has established policies, procedures
and controls which are designed (and otherwise comply with applicable law) to ensure that the Issuer and each Controlled Affiliate
thereof, and each of their respective directors, officers, employees and agents, is and will continue to be in compliance with
all applicable current and future Anti-Corruption Laws.

 

    	 	61	 

     

    

 

Section 4.20         Compliance
with Healthcare Laws.

 

(a)          The
Issuer and each of its Subsidiaries is in compliance in all respects with all Healthcare Laws, except for such non-compliance which
would not reasonably be expected to have a Healthcare Material Adverse Effect. The Issuer and its Subsidiaries participate in and
have not been excluded from the Governmental Payor Arrangements listed on Schedule 4.20(a). A list of all of the Issuer’s
and its Subsidiaries’ existing (i) Medicare provider numbers and Medicaid provider numbers, (ii) Medicare supplier numbers
and Medicaid supplier numbers, and (iii) all other Governmental Payor provider agreements and numbers, excluding TRICARE and CHAMPUS,
CHAMPVA and the Veteran’s Administration, pertaining to the business of the Issuer or any of its Subsidiaries as of the Closing
Date or, if such contracts do not exist, other documentation evidencing such participation as of the Closing Date are set forth
on Schedule 4.20(a). Each of the Issuer’s and its Subsidiaries’ existing Third Party Payor Arrangements pursuant
to which Issuer and its Subsidiaries received $500,000 or more in payment in calendar year 2016 is set forth on Schedule 4.20(a).
Each of the Issuer and its Subsidiaries has entered into and maintains all Governmental Payor Arrangements and Third Party Payor
Arrangements as are necessary to conduct its respective business as currently conducted. The Governmental Payor Arrangements and
Third Party Payor Arrangements to which the Issuer or a Subsidiary is a party constitute valid and binding obligations of the Issuer
or such Subsidiary, enforceable against the Issuer or such Subsidiary in accordance with their respective terms (except as may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’
rights generally and by general principles of equity) and, to the knowledge of the Issuer, are in full force and effect, except
as would not, either individually or in the aggregate, reasonably be expected to have a Healthcare Material Adverse Effect or as
disclosed on Schedule 4.20(a). To the knowledge of the Issuer, neither the Issuer nor any of its Subsidiaries is in default
under any Governmental Payor Arrangement or Third Party Payor Arrangement to which it is a party and, to the knowledge of the Issuer,
the other parties thereto are not in default thereunder, except as would not have a Healthcare Material Adverse Effect. Each of
the Issuer and its Subsidiaries (i) duly holds, and is in good standing with respect to, such Licenses as are necessary to own
its respective assets and to conduct its respective business (including without limitation such Licenses as are required under
such Healthcare Laws as are applicable thereto, and all Reimbursement Approvals), except where the absence of such a License would
not reasonably be expected to have a Healthcare Material Adverse Effect and (ii) where applicable to its business, has obtained
and maintains Medicaid and Medicare provider and supplier numbers. Schedule 4.20(a) sets forth all such healthcare Licenses
held by each of the Issuer and its Subsidiaries as of the Closing Date. There is no pending or, to the knowledge of the Issuer,
threatened material Limitation of any such License, Medicaid provider or supplier number, or Medicare provider or supplier number
of the Issuer or any of its Subsidiaries, except for such Limitations as would not reasonably be expected to have a Healthcare
Material Adverse Effect.

 

(b)          For
purposes of the Stark Law, to the extent that any services provided by the Issuer or its Subsidiaries are designated health services
(as defined by the Stark Law), (i) none of such services involve, arise from, or occur in connection with “referrals”
as defined by Stark Law or as proscribed thereunder absent the applicability or availability of a statutory or regulatory exception
to the referral prohibitions set forth thereunder, and (ii) none of such services are provided by the Issuer or any of its Subsidiaries
for the benefit of any of the foregoing, absent the applicability or availability of a statutory or regulatory exception to the
referral prohibitions set forth thereunder, in each case in the case of the immediately preceding clauses (i) and (ii), except
to the extent that such failures, violations or non-compliance would not reasonably be expected to have a Healthcare Material Adverse
Effect.

 

(c)          Except
as would not reasonably be expected to have a Material Adverse Effect, each of the Issuer and its Subsidiaries holds all Accreditations
necessary or required by applicable Requirements of Law for the operation of its business (including accreditation by an appropriate
organization necessary to receive payment and compensation and to participate under Medicare and Medicaid) (individually, a “Company
Accreditation,” and collectively, the “Company Accreditations”). There is no pending or, to the knowledge
of the Issuer, threatened Limitation of any such Company Accreditations, except as would not, either individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. Except as would not, either individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect, each of the Issuer and its Subsidiaries is in compliance with the terms of the Company
Accreditations.

 

(d)          Each
employee of the Issuer and each of its Subsidiaries duly holds all Licenses (to the extent required) to provide professional services
to patients by each state or state agency or commission, or any other Governmental Authority having jurisdiction over the provision
of such services required to enable such employee to provide the professional services necessary to enable each of the Issuer and
its Subsidiaries to operate its business as currently operated and in connection with the duties performed by such employee, except
as would not reasonably be expected to have a Material Adverse Effect. There is no pending or, to the knowledge of the Issuer,
threatened Limitation of any such required Licenses with respect to any employee of the Issuer and each of its Subsidiaries, except
where such Limitation would not, either individually or in the aggregate, reasonably be expected to have a Healthcare Material
Adverse Effect. Except as would not, either individually or in the aggregate, reasonably be expected to have a Healthcare Material
Adverse Effect, each employee of the Issuer and its Subsidiaries is in compliance with the terms of all such Licenses.

 

    	 	62	 

     

    

 

(e)          All
reports, documents, schedules, statements, filings, submissions, forms, registrations, notices, approvals and other documents required
to be filed, obtained, maintained or furnished pursuant to any Governmental Payor Arrangement, Third Party Payor Arrangement, License,
Company Accreditation, and other applicable Healthcare Laws by the Issuer or any of its Subsidiaries to any Governmental Authority
(individually, “Company Regulatory Filings” and collectively, “Company Regulatory Filings”)
have been so filed, obtained, maintained or furnished, and all such Company Regulatory Filings were complete and correct on the
date filed (or were corrected in or supplemented by a subsequent filing), except where such failure would not reasonably be expected
to have a Healthcare Material Adverse Effect, and each of the Issuer and its Subsidiaries has timely paid all amounts, Taxes, fees
and assessments due and payable in connection therewith, except where the failure to make such payments on a timely basis would
not reasonably be expected to have a Healthcare Material Adverse Effect. The Issuer and each of its Subsidiaries has maintained
all records required to be maintained under all applicable Requirements of Law with any Governmental Authorities (including all
Governmental Payor Arrangements in which it participates, as required by Healthcare Laws), except where the failure to do so would
not reasonably be expected to have a Healthcare Material Adverse Effect.

 

(f)          Since
December 31, 2016, none of the Issuer nor any of its Subsidiaries, nor, to the knowledge of the Issuer, any employee or contractor
of the Issuer or any of its Subsidiaries has been, or to the knowledge of the Issuer has been threatened to be, (i) excluded from
any Governmental Payor Arrangement pursuant to 42 U.S.C. § 1320a-7b and related regulations, (ii) “suspended”
or “debarred” from selling products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation,
relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or other applicable
Requirements of Law, (iii) debarred, disqualified, suspended or excluded from participation in Medicare, Medicaid or any other
governmental health care program or is listed on the General Services Administration list of excluded parties, nor is any such
debarment, disqualification, suspension or exclusion, to the knowledge of a Note Party, threatened or pending, or (iv) made a party
to any other action by any Governmental Authority that may prohibit it from selling products or providing services to any Governmental
Authority or other purchaser pursuant to any Requirement of Law. Except for the payment of the amounts expressly provided for in
the Exjade Settlement, none of the Issuer nor any of its Subsidiaries nor, to the knowledge of the Issuer, any employee or contractor
of the Issuer or any of its Subsidiaries is party to a corporate integrity agreement, consent order, consent decree, permanent
injunction or other settlement agreement with any Governmental Authority or Third Party Payor or otherwise pursuant to any Governmental
Payor Arrangement, Third Party Payor Arrangement, License, or Company Accreditation, including, without limitation, any additional
corporate integrity agreement, consent order, consent decree, permanent injunction or other settlement agreement arising out of
allegations involving the Issuer and the prescription drug known as Exjade, which individually (or, together with any related Settlements
(other than the Exjade Settlement), in the aggregate) (i) would reasonably be expected to have a Healthcare Material Adverse Effect
or (ii) requires the payment of money in an amount in excess of $12,500,000.

 

    	 	63	 

     

    

 

(g)          Schedule
4.20(g) sets forth a list of all notices received since December 31, 2016 of material noncompliance (including FDA 483 letters,
FDA correspondence, board of pharmacy inspection reports, and similar notices), requests for material remedial action, investigations,
return of overpayment or imposition of fines (whether ultimately paid or otherwise resolved) by any Governmental Authority or Third
Party Payor or pursuant to any Governmental Payor Arrangement, Third Party Payor Arrangement, License, or Company Accreditation,
but does not include Routine Payor Audits (the “Health Care Audits”). Each of the Issuer and its Subsidiaries
has prepared and submitted timely all corrective action plans or responses required to be prepared and submitted in response to
any Health Care Audits and has implemented all of the corrective actions described in such corrective action plans, except where
the failure to do so would not reasonably be expected to have a Healthcare Material Adverse Effect. Neither the Issuer nor any
of its Subsidiaries has any (A) uncured deficiency that could lead to the imposition of a remedy, (B) existing accrued and/or unpaid
indebtedness or overpayment to any Governmental Authority or Governmental Payor, including Medicare or Medicaid, or (C) existing
accrued and/or unpaid overpayment amounts owing under any finally resolved audit or investigation by any Governmental Payor or
Third Party Payor, excepting any of the foregoing that would not reasonably be expected to have a Healthcare Material Adverse Effect.

 

(h)          The
execution and delivery of the Note Documents, and each of the Issuer’s and its Subsidiaries’ performance thereunder
(including the performance of the pre- and post- closing notices and applications as provided in the Note Documents) will not (i)
result in the loss of or limitation of any License, Company Accreditations or Company Reimbursement Approvals or (ii) reduce receipt
of the ongoing payments or reimbursements pursuant to the Company Reimbursement Approvals that the Issuer or any of its Subsidiaries
is receiving as of the date hereof.

 

(i)          The
Issuer and its Subsidiaries currently maintain a corporate compliance program and quality management program reasonably designed
to promote compliance with applicable Healthcare Laws (except for noncompliance that would not reasonably be expected to have a
Healthcare Material Adverse Effect).

 

Section 4.21         HIPAA/HITECH
Compliance. To the extent that and for so long as the Issuer or any of its Subsidiaries is a “covered entity”
within the meaning of HIPAA and the HITECH Act, each of the Issuer and its Subsidiaries (a) has undertaken or will promptly undertake
all necessary compliance efforts required by HIPAA and the HITECH Act; (b) has developed or will develop a detailed plan for becoming
HIPAA and HITECH Compliant (a “HIPAA/HITECH Compliance Plan”); and (c) has implemented or will implement those
provisions of such HIPAA/HITECH Compliance Plan necessary to ensure that each of the Issuer and its Subsidiaries is or becomes
HIPAA and HITECH Compliant, except to the extent in each case that such failures would not reasonably be expected to have a Healthcare
Material Adverse Effect. For purposes hereof, “HIPAA and HITECH Compliant” shall mean that each of the Issuer
and its Subsidiaries (i) is or will be in compliance (except for non-compliance that would not reasonably be expected to have a
Healthcare Material Adverse Effect) with (A) each of the applicable requirements of the so-called “Administrative Simplification”
provisions of HIPAA and (B) any or all requirements set forth in the HITECH Act, including, but not limited to, any breach notification
requirements, and (ii) is not and would not reasonably be expected to become the subject of any civil or criminal penalty, process,
claim, action or proceeding, or any administrative or other regulatory review, survey, process or proceeding (other than routine
surveys or reviews conducted by any Government Payor or other accreditation entity) that would reasonably be expected to have a
Healthcare Material Adverse Effect.

 

    	 	64	 

     

    

 

Section 4.22         Reimbursement.

 

(a)          Except
as disclosed in Schedule 4.22(a), with respect to billings by each of the Issuer and its Subsidiaries as of the Closing
Date, each of the Issuer and its Subsidiaries is in compliance with all Requirements of Law and the written material reimbursement
policies, rules and regulations of Governmental Payors and Third Party Payors, including, without limitation, adjustments under
any capitation arrangement, fee schedule, discount formula or cost-based reimbursement except the failure to comply with which
would not reasonably be expected to have a Healthcare Material Adverse Effect. Except as would not be expected to have a Healthcare
Material Adverse Effect, each of the Issuer and its Subsidiaries holds all Reimbursement Approvals necessary for the operation
of its business as currently operated (individually, a “Company Reimbursement Approval,” and collectively, the
“Company Reimbursement Approvals”). There is no pending or, to the knowledge of the Issuer, threatened Limitation
of any such Company Reimbursement Approvals, except as would not reasonably be expected to have a Healthcare Material Adverse Effect
or as disclosed on Schedule 4.22(a). Except as would not reasonably be expected to have a Healthcare Material Adverse Effect
or as disclosed on Schedule 4.22(a), each of the Issuer and its Subsidiaries is in compliance with the terms of the Company
Reimbursement Approvals.

 

(b)          Except
as would not reasonably be expected to have a Healthcare Material Adverse Effect, the accounts receivable of each of the Issuer
and its Subsidiaries have been properly adjusted in all material respects to reflect the reimbursement policies under all applicable
Requirements of Law and other Governmental Payor Arrangements or Third Party Payor Arrangements, to which the Issuer or any of
its Subsidiaries is subject, and such accounts receivable do not exceed amounts the Issuer or such Subsidiary is entitled to receive
under any capitation agreement, fee schedule, discount formula, cost-based reimbursement or other adjustment or limitation to usual
charges. There has been no intentional overbilling or overcollection pursuant to any Governmental Payor Arrangements or Third Party
Payor Arrangement other than as created by routine adjustments and disallowances made in the ordinary course of business by the
Governmental Payors and Third Party Payors with respect to such billings.

 

Section 4.23         Fraud
and Abuse. Except as would not, individually or in the aggregate, reasonably be expected to have a Healthcare Material
Adverse Effect, neither the Issuer nor any of its Subsidiaries has engaged in any activities that (a) are prohibited under 42 U.S.C.
§§ 1320a-7b, or the regulations promulgated thereunder, or related Requirements of Law, or (b) are prohibited by rules
of professional conduct, or (c) are prohibited under any statute or the regulations promulgated pursuant to such statutes, including,
without limitation, the following: (i) knowingly and willfully making or causing to be made a false statement or misrepresentation
of a material fact in any application for any benefit or payment; (ii) knowingly and willfully making or causing to be made any
false statement or misrepresentation of a material fact for use in determining rights to any benefit or payment; (iii) failure
to disclose knowledge by a claimant of the occurrence of any event affecting the initial or continued right to any benefit or payment
on its own behalf or on behalf of another with intent to secure such benefit or payment fraudulently; and (iv) knowingly and willfully
soliciting or receiving any illegal remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or
covertly, in cash or in kind or offering to pay or receive such remuneration (x) in return for referring an individual to a Person
for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part by
any Governmental Payor, or (y) in return for purchasing, leasing, or ordering or arranging for or recommending purchasing, leasing
or ordering any good facility, service, or item for which payment may be made in whole or in part by any Governmental Payor. Between
January 1, 2017 and the Closing Date, neither the Issuer nor any of its Subsidiaries has received a subpoena issued by any Governmental
Authority with respect to a possible violation of Healthcare Laws by the Issuer or any of its Subsidiaries (but excluding Routine
Payor Audits).

 

Section 4.24         EEA
Financial Institutions; Other Regulations. No Note Party is an EEA Financial Institution.

 

    	 	65	 

     

    

 

Section 4.25         Offer
of Notes; Private Offering. Subject to the accuracy of each Purchaser’s several (and not joint) representations and
warranties set forth in Section 2.25:

 

(a)          during
the six-month period ending on the commencement of the offer of the Notes and concurrently with the offering of the Notes, no Note
Party, its respective Rule 501 Affiliates or any person acting on its or any of their behalf, directly or indirectly, offered the
Notes or any part thereof or any similar securities for issue or sale to, or solicited any offer to buy any of the same from, any
person other than the Purchasers and less than 15 other Persons;

 

(b)          no
form of general solicitation or general advertising was used by any Note Party or any of their representatives in connection with
the offer or sale of the Notes to the Purchasers; and

 

(c)          no
registration of the Notes pursuant to the provisions of the Securities Act or the state securities “blue sky” laws
will be required for the offer, sale or issuance of the Notes by the Issuer to the Purchasers pursuant to this Agreement and it
has not taken and will not take any actions which would bring the issuance and sale of the Notes within the provisions of Section
5 of the Securities Act or the registration or qualification provisions of any such Laws; and

 

(d)          
the Notes are being offered and sold only to “accredited investors” (as defined in Rule 501 under the Securities Act).

 

Section 4.26         Designation
as Credit Facilities. As contemplated by the definition of “Credit Facilities” contained in the Senior Notes
Indenture, the Notes, this Agreement, the Second Lien Notes and the Second Lien Note Purchase Agreement each qualify, and each
hereby is designated as, a “Credit Facility” for purposes of the Senior Notes Indenture and shall be included in the
definition of “Credit Facilities” as so set forth in the Senior Notes Indenture.

 

ARTICLE V

AFFIRMATIVE COVENANTS

 

The Issuer covenants and
agrees that so long as any Purchaser has a Commitment hereunder or any Obligation remains unpaid or outstanding (other than Hedging
Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other
contingent obligations not then due and payable and as to which no claim has been made):

 

Section 5.1           Financial
Statements and Other Information. The Issuer will deliver to each Purchaser:

 

(a)          as
soon as available and in any event within 90 days after the end of each Fiscal Year of the Issuer, a copy of the annual audited
report for such Fiscal Year for the Issuer and its Subsidiaries, containing a consolidated balance sheet of the Issuer and its
Subsidiaries as of the end of such Fiscal Year and the related consolidated statements of income, stockholders’ equity and
cash flows (together with all footnotes thereto) of the Issuer and its Subsidiaries for such Fiscal Year, setting forth in each
case in comparative form the figures for the previous Fiscal Year, and reported on by independent public accountants of nationally
recognized standing (without a “going concern” or like qualification, exception or explanation and without any qualification
or exception as to the scope of such audit (except any such qualification arising as a result of the impending Maturity Date (as
a result of clause (i) of such definition) or “Maturity Date” (as defined in the Second Lien Note Purchase Agreement)
(as a result of clause (i) of such definition)) to the effect that such financial statements present fairly in all material respects
the financial condition and the results of operations of the Issuer and its Subsidiaries for such Fiscal Year on a consolidated
basis in accordance with GAAP (as in effect at the time such financial statements were prepared and subject to Section 1.3)
consistently applied (except as expressly noted therein) and that the examination by such accountants in connection with such consolidated
financial statements has been made in accordance with generally accepted auditing standards;

 

    	 	66	 

     

    

 

(b)          as
soon as available and in any event within 45 days after the end of each Fiscal Quarter of the Issuer (other than the last Fiscal
Quarter in each Fiscal Year), an unaudited consolidated balance sheet of the Issuer and its Subsidiaries as of the end of such
Fiscal Quarter and the related unaudited consolidated statements of income and cash flows of the Issuer and its Subsidiaries for
such Fiscal Quarter and the then elapsed portion of such Fiscal Year, setting forth in each case in comparative form the figures
for the corresponding Fiscal Quarter and the corresponding portion of the Issuer’s previous Fiscal Year and the corresponding
figures for the Profit Plan for the current Fiscal Year;

 

(c)          concurrently
with the delivery of the financial statements referred to in clauses (a) and (b) of this Section, a Compliance Certificate signed
by an appropriate Responsible Officer of the Issuer (i) certifying as to whether there exists a Default or Event of Default on
the date of such certificate and, if a Default or an Event of Default then exists, specifying the details thereof and the action,
if any, which the Issuer has taken or proposes to take with respect thereto, (ii) if applicable, setting forth in reasonable detail
calculations demonstrating compliance with the financial covenant set forth in Article VI, (iii) specifying any change in
the identity of the Subsidiaries as of the end of such Fiscal Year or Fiscal Quarter from the Subsidiaries identified to the Purchasers
on the Closing Date or as of the most recent Fiscal Year or Fiscal Quarter, as the case may be, and (iv) stating whether any change
in GAAP or the application thereof has occurred since the date of the most recently delivered audited financial statements of the
Issuer and its Subsidiaries, and, if any change has occurred, specifying the effect of such change on the financial statements
accompanying such Compliance Certificate;

 

(d)          concurrently
with the delivery of the financial statements referred to in clause (a) above, a certificate of the accounting firm that reported
on such financial statements (which may be included in the opinion or other reports delivered by such accounting firm pursuant
to clause (a)) stating that, in making the examination necessary to prepare such financial statements, no knowledge was actually
obtained of the occurrence and continuance of any Default or Event of Default, except as specified in such certificate (it being
understood that no special or separate inquiry or review will have been made or shall be required to be made with respect to the
existence of any Default or Event of Default and that such certificate shall be limited to the items that independent certified
public accountants are permitted to cover in such certificates pursuant to their professional standards and customs of the profession);

 

(e)          as
soon as available and in any event within 90 days after the commencement of any Fiscal Year, a Profit Plan for such Fiscal Year;

 

(f)          promptly
after the same become publicly available, copies of all periodic and other reports, proxy statements and other materials filed
with the Securities and Exchange Commission, or any Governmental Authority succeeding to any or all functions of said Commission,
or with any national securities exchange, or distributed by the Issuer to its shareholders generally, as the case may be;

 

(g)          promptly
following any request therefor, such other reports or information including with respect to the results of operations, business
affairs and financial condition of the Issuer or any of its Subsidiaries as the Collateral Agent or any Purchaser may reasonably
request; and

 

    	 	67	 

     

    

 

(h)          until
Consolidated EBITDA for the period of four Fiscal Quarters ending on the last day of the most recent Fiscal Quarter for which financial
statements have been (or were required to be) delivered hereunder exceeds $45,000,000, deliver to each private-side Purchaser as
soon as available and in any event within 30 days after the end of each fiscal month of the Issuer, an unaudited consolidated balance
sheet of the Issuer and its Subsidiaries as of the end of such fiscal month and the related unaudited consolidated statements of
income and cash flows of the Issuer and its Subsidiaries for such fiscal month and the then elapsed portion of such Fiscal Year,
setting forth in each case in comparative form the corresponding figures for the Profit Plan for the current Fiscal Year; provided
the Purchasers acknowledge and agree that (x) the financial statements described in this clause (h) are confidential and constitute
material non-public information of the Issuer and (y) no Purchaser (including any private-side Purchaser) shall distribute or furnish
a copy of all or any portion of the financial statements described in this clause (h) to any Purchaser that is not a private-side
Purchaser other as expressly permitted under Section 10.11(iv).

 

So long as the Issuer is
required to file periodic reports under Section 13(a) or Section 15(d) of the Exchange Act, the Issuer may satisfy its obligation
to deliver the financial statements referred to in clauses (a) and (b) above by delivering the Issuer’s Form 10-K or 10-Q
filed with the Securities and Exchange Commission within the applicable time periods set forth in clauses (a) and (b), as applicable.

 

Section 5.2           Notices
of Material Events. The Issuer will furnish to the Collateral Agent and each Purchaser prompt written notice of the following:

 

(a)          the
occurrence of any Default or Event of Default;

 

(b)          the
filing or commencement of, or any material development in, any action, suit or proceeding by or before any arbitrator or Governmental
Authority against the Issuer or any of its Subsidiaries which would reasonably be expected to result in a Material Adverse Effect;

 

(c)          the
occurrence of any event or any other development by which the Issuer or any of its Subsidiaries (i) fails to comply with any Environmental
Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) becomes
subject to any Environmental Liability, (iii) receives written notice of any claim with respect to any Environmental Liability,
or (iv) becomes aware of any basis for any Environmental Liability, in each case which, either individually or in the aggregate,
would reasonably be expected to result in a Material Adverse Effect;

 

(d)          promptly
and in any event within 15 days after (i) the Issuer or any of its Subsidiaries knows or has reason to know that any ERISA Event
that (individually or together with all other ERISA Events) would reasonably be expected to have a Material Adverse Effect has
occurred, a certificate of the chief financial officer of the Issuer describing such ERISA Event and the action, if any, proposed
to be taken with respect to such ERISA Event and a copy of any notice filed with the PBGC or the IRS pertaining to such ERISA Event
and any notices received by the Issuer or such Subsidiary (or, if applicable, an ERISA Affiliate) from the PBGC or any other governmental
agency with respect thereto and (ii) becoming aware that there has been a material increase in Unfunded Pension Liabilities (not
taking into account Plans with negative Unfunded Pension Liabilities) or a Plan is, or is expected to be, in at risk status under
Title IV of ERISA since the date the representations hereunder are given or deemed given, or from any prior notice, as applicable
such that the resulting Unfunded Pension Liabilities, if incurred, or the at risk status, as applicable, would reasonably be expected
to have a Material Adverse Effect, a detailed written description thereof from the chief financial officer of the Issuer;

 

(e)          the
receipt by the Issuer or any of its Subsidiaries of any written notice of an alleged default or event of default, with respect
to the Second Lien Note Purchase Agreement or any Material Indebtedness of the Issuer or any of its Subsidiaries;

 

    	 	68	 

     

    

 

(f)          upon
receipt thereof, copies of all final audit reports and all final management letters relating to the Issuer or any of its Subsidiaries
submitted by the Issuer’s primary accountants or primary auditors in connection with each annual, interim or special audit
of the books of the Issuer or any of its Subsidiaries (provided that, in the event that the Issuer engages such accountants
or auditors to perform a specific review, test, valuation or other analysis of all or any portion of the Issuer’s financial
condition or financial performance, the results of such engagement shall not be required to be delivered to the Collateral Agent
or the Purchasers to the extent that such results are not otherwise required to be delivered pursuant to another provision of this
Agreement);

 

(g)          written
notice of the receipt by the Issuer or any of its Subsidiaries from any Governmental Authority or other Person of (1) any notice
asserting any failure by the Issuer or any of its Subsidiaries to be in compliance with applicable Requirements of Law or that
threatens the taking of any action against the Issuer or any of its Subsidiaries or sets forth circumstances in any such event
where the failure or the taking of action would reasonably be expected to have a Material Adverse Effect, (2) any notice of any
actual or threatened in writing Limitation with respect to any Governmental Payor Arrangement, Third Party Payor Arrangement, License,
or Company Accreditation of the Issuer or any of its Subsidiaries, where such action would, either individually or in the aggregate
with other similar actions, reasonably be expected to have a Material Adverse Effect, or (3) any subpoena, search warrant, civil
investigative demand, criminal action or threat of criminal action, FDA warning letter, FDA 483 letter or other request or investigation
by a Governmental Authority with respect to a possible violation of Healthcare Laws by the Issuer or any of its Subsidiaries (but
excluding (A) state licensure and Medicare certification and participation surveys by a Governmental Authority with respect to
a possible violation of Healthcare Laws, unless any deficiencies are of a kind that do result or likely will result in the issuance
of a notice of suspension or termination of any License, payment, or provider or supplier number or agreement, and (B) Routine
Payor Audits);

 

(h)          if
any Default or Event of Default is in existence, if requested by any Purchaser, furnish to each Purchaser, to the maximum extent
permitted by applicable Requirements of Law, (i) copies of all Company Regulatory Filings, (ii) copies of all Licenses, Company
Accreditations and Company Reimbursement Approvals, as the same may be renewed or amended; (iii) copies of all Health Care Audits
and correspondence related thereto and corrective action plans prepared and submitted in response thereto, and (iv) a report of
the status of all recoupments, holdbacks, offsets, vendor holds, denials and appeals of amounts owed pursuant to any Company Reimbursement
Approvals, in each case outside the ordinary course of business (and ordinary course of business shall be deemed to exclude recoupments,
holdbacks, offsets, denials and vendor holds resulting from, related to or arising out of allegations of fraud or patterns of practices
of contracting, billing or claims submission inconsistent with Requirements of Law), all subject to any limitations on disclosure
included in any Requirement of Law;

 

(i)          any
default or material amendment under, or termination of, (i) that certain Facility Participation Agreement effective as of June
1, 2009, with United HealthCare Insurance Company, contracting on behalf of its Oxford Health Plans (NJ), (ii) that certain Facility
Participation Agreement effective as of June 1, 2009, with United HealthCare Insurance Company, contracting on behalf of itself
and UnitedHealthcare of the Midwest, (iii) that certain Ancillary Provider Participation Agreement effective as of June 1, 2009,
with United HealthCare Insurance Company, contracting on behalf of itself and UnitedHealthcare of New York, or (iv) that certain
Ancillary Provider Participation Agreement effective as of June 1, 2009, with UnitedHealthcare of New York, Inc.; and

 

(j)          any
other development that results in, or would reasonably be expected to result in, a Material Adverse Effect.

 

    	 	69	 

     

    

 

The Issuer will furnish to
the Collateral Agent and each Purchaser the following:

 

(x)          promptly
and in any event at least 30 days prior thereto, notice of any change (i) in any Note Party’s legal name, (ii) in any Note
Party’s chief executive office, its principal place of business or any office in which it maintains books or records, (iii)
in any Note Party’s identity or legal structure, (iv) in any Note Party’s federal taxpayer identification number
or organizational number or (v) in any Note Party’s jurisdiction of organization; and

 

(y)          promptly
upon request therefor, such other information and reports relating to the past, present or anticipated future financial condition,
operations, plans, budgets and projections of the Issuer and each of its Subsidiaries, as the Collateral Agent or any Purchaser
at any time or from time to time may reasonably request.

 

Each notice or other document
delivered under this Section shall be accompanied by a written statement of a Responsible Officer setting forth the details of
the event or development requiring such notice or other document and any action taken or proposed to be taken with respect thereto.

 

Section 5.3           Existence;
Conduct of Business. The Issuer will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary
to preserve, renew and maintain in full force and effect its legal existence and its respective material rights, licenses, permits,
privileges, franchises, Patents, Copyrights, Trademarks, trade names and all other Intellectual Property Rights that are material
for the conduct of its business, except where failure to do so would not reasonably be expected to result in a Material Adverse
Effect; provided that nothing in this Section shall prohibit any transaction that is expressly permitted hereunder.

 

Section 5.4           Compliance
with Laws. The Issuer will, and will cause each of its Subsidiaries to, comply with all laws, rules, regulations and requirements
of any Governmental Authority applicable to its business and properties, including, without limitation, all Environmental Laws,
ERISA and OSHA, except where the failure to do so, either individually or in the aggregate, would not reasonably be expected to
result in a Material Adverse Effect. The Issuer will, and will cause each of its Subsidiaries to, maintain in effect policies,
procedures and controls designed to ensure compliance by the Issuer and its Subsidiaries, the Controlled Affiliates thereof and,
to the Issuer’s knowledge, their respective directors, officers, employees and agents with Sanctions, Anti-Corruption Laws,
and Anti-Terrorism Laws.

 

Section 5.5           Payment
of Obligations. The Issuer will, and will cause each of its Subsidiaries to, pay and discharge at or before maturity all
of its material obligations and liabilities (including, without limitation, all taxes, assessments and other governmental charges,
levies and all other claims that could result in a statutory Lien) before the same shall become delinquent or in default, except
where (a) the validity or amount thereof is being contested in good faith by appropriate proceedings, (b) the Issuer or such Subsidiary
has set aside on its books adequate reserves with respect thereto in accordance with GAAP and (c) the failure to make payment pending
such contest would not reasonably be expected to result in a Material Adverse Effect.

 

Section 5.6           Books
and Records. The Issuer will, and will cause each of its Subsidiaries to, keep proper books of record and account
in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities
to the extent necessary to prepare the consolidated financial statements of the Issuer in conformity with GAAP (subject to the
terms of this Agreement with respect to such financial statements).

 

    	 	70	 

     

    

 

Section 5.7           Visitation
and Inspection. The Issuer will, and will cause each of its Subsidiaries to, permit any representative of the Collateral
Agent or any Purchaser to visit and inspect its properties, to examine its books and records and to make copies and take extracts
therefrom, and to discuss its affairs, finances and accounts with any of its officers and with its independent certified public
accountants (provided that the Issuer is provided reasonable prior notice of any discussion with its auditors or accountants
and is afforded an opportunity to participate in such discussions), all at such reasonable times and subject to reasonable prior
notice to the Issuer or such Subsidiary; provided that, so long as no Event of Default has occurred and is continuing, visits
and inspections under this Section 5.7 shall be limited to one time per Fiscal Year for the Collateral Agent and all Purchasers.
Any Related Party of the Collateral Agent or any Purchaser that attends or participates in any such visit or inspection shall,
prior to such attendance or participation, expressly agree to be subject to and bound by the confidentiality provisions of this
Agreement or shall otherwise be bound by professional ethics rules to maintain such confidentiality.

 

Section 5.8           Maintenance
of Properties; Insurance; Credit Ratings. The Issuer will, and will cause each of its Subsidiaries to, (a) keep and maintain
all property material to the conduct of its business in good working order and condition, ordinary wear and tear, casualty and
condemnation excepted, (b) maintain with financially sound and reputable insurance companies which are not Affiliates of the Issuer
(i) insurance with respect to its properties and business, and the properties and business of its Subsidiaries, against loss or
damage of the kinds customarily insured against by companies in the same or similar businesses operating in the same or similar
locations (including, in any event, flood insurance as described in the definition of Real Estate Documents) and (ii) all insurance
required to be maintained pursuant to the Collateral Documents, and will, upon request of any Purchaser, furnish to each Purchaser
at reasonable intervals a certificate of a Responsible Officer setting forth the nature and extent of all insurance maintained
by the Issuer and its Subsidiaries in accordance with this Section, (c) at all times shall cause the applicable insurance provider
to name the Collateral Agent as an additional insured on all liability policies of the Issuer and its Subsidiaries and as a loss
payee (pursuant to a loss payee endorsement reasonably satisfactory to the Collateral Agent) on all casualty and property insurance
policies of the Issuer and its Subsidiaries, in each case, other than any director and officer indemnification policies, workers’
compensation policies and any policies that provide coverage for property that does not constitute Collateral, and (d) use commercially
reasonable efforts at all times following the date that is 60 days after the Closing Date (or such longer period as the Required
Purchasers may reasonably agree) to maintain ratings for the Notes issued hereunder and the corporate family credit of the Issuer
and its Subsidiaries by both S&P and Moody’s.

 

Section 5.9           Use
of Proceeds; Margin Regulations. 

 

(a)          The
Issuer will use the proceeds of all Notes on the Closing Date (together with the proceeds of the Second Lien Notes) (i) to refinance
existing Indebtedness of the Note Parties under the Existing Credit Agreement and the Existing Priming Credit Agreement, (ii) to
pay fees and expenses incurred in connection with the execution and delivery of this Agreement and the other Note Documents, the
issuance and purchase of the Notes and the transactions contemplated to occur in connection therewith and (iii) for working capital
and general corporate purposes of the Issuer and its Subsidiaries.

 

No part of the proceeds of
any Note will be used, whether directly or indirectly, for any purpose that would violate any rule or regulation of the Board of
Governors of the Federal Reserve System, including Regulation T, Regulation U or Regulation X.

 

    	 	71	 

     

    

 

Section 5.10         Casualty
and Condemnation. The Issuer (a) will furnish to the Collateral Agent and the Purchasers prompt written notice of any casualty
or other insured damage to any material portion of the Collateral or the commencement of any action or proceeding by any Governmental
Authority for the taking of any material portion of the Collateral or any material interest therein under power of eminent domain
or by condemnation or similar proceeding and (b) will ensure that the Net Cash Proceeds of any such Prepayment Event (whether in
the form of insurance proceeds, condemnation awards or otherwise) are collected and applied in accordance with the applicable provisions
of this Agreement and the Collateral Documents.

 

Section 5.11         Cash
Management. The Issuer shall, and shall cause each Subsidiary Note Party to, maintain the cash management systems described
below:

 

(a)          Maintain
all cash management and treasury business with a Permitted Third Party Bank, including, without limitation, all deposit accounts,
disbursement accounts, investment accounts and lockbox accounts, other than Excluded Accounts (each such deposit account, disbursement
account, investment account and lockbox account, other than any Excluded Account, a “Controlled Account”).

 

(b)          Each
Controlled Account shall (i) be a cash collateral account, with all cash, checks and other similar items of payment in such account
securing payment of the Obligations, and in which the Issuer and each of its Subsidiaries shall have granted a first priority Lien
(subject to non-consensual Liens arising by operation of law) to the Collateral Agent, on behalf of the Secured Parties, and (ii)
be subject to an Account Control Agreement.

 

(c)          Subject
to Section 5.11(e), deposit promptly, and in any event no later than five (5) Business Days after the date of receipt thereof,
all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all
accounts and other Collateral into Controlled Accounts, in each case except for cash, checks, drafts, other similar payment items
and Cash Equivalents the aggregate value of which does not exceed $3,000,000 at any time.

 

(d)          At
any time after the occurrence and during the continuance of an Event of Default and at all times subject to the First Lien/Second
Lien Intercreditor Agreement, at the request of the Required Purchasers, the Issuer will, and will cause each other Note Party
to, cause all payments constituting proceeds of accounts or other Collateral to be directed into lockbox accounts under agreements
in form and substance reasonably satisfactory to the Collateral Agent and the Required Purchasers.

 

(e)          For
each deposit account into which the Issuer or any Subsidiary Note Party receives payments from Federal/State Health Care Program
Account Debtors (a “Government Receivables Account”), the Issuer or such Subsidiary Note Party shall enter into
an agreement (a “Government Receivables Account Agreement”) with the Permitted Third Party Bank at which such
Government Receivables Account is located, in such form as may be reasonably approved by the Collateral Agent and the Required
Purchasers, which agreement shall provide that all funds deposited into such Government Receivables Account shall be transferred
promptly (but in any event within one (1) Business Day of deposit) to a Controlled Account of the Issuer or such Subsidiary Note
Party. Neither the Issuer nor any Subsidiary Note Party shall terminate or modify a Government Receivables Account Agreement without
the approval of the Required Purchasers, which approval (or non-approval, as the case may be) shall be communicated to the Issuer
by the Purchasers within five (5) Business Days of any such request for approval and which approval shall not be unreasonably withheld,
conditioned or delayed.

 

    	 	72	 

     

    

 

Section 5.12         Additional
Subsidiaries and Collateral.

 

(a)          In
the event that, subsequent to the Closing Date, any Person (but specifically excluding any Specified Strategic Joint Venture) becomes
a Domestic Subsidiary, whether pursuant to formation, acquisition or otherwise, (x) the Issuer shall promptly notify the Collateral
Agent and the Purchasers thereof and (y) within 30 days (or such longer period as the Required Purchasers shall agree in writing)
after such Person becomes a Domestic Subsidiary, the Issuer shall cause such Domestic Subsidiary (i) to become a new Guarantor
and to grant Liens in favor of the Collateral Agent in all of its personal property that is not Excluded Property by executing
and delivering to the Collateral Agent a supplement to the Guaranty and Security Agreement in form and substance reasonably satisfactory
to the Collateral Agent and the Required Purchasers, executing and delivering a Copyright Security Agreement, Patent Security Agreement
and Trademark Security Agreement, as applicable, and authorizing, delivering and filing such UCC financing statements or similar
instruments necessary to perfect and maintain the Liens in favor of the Collateral Agent and granted under any of the Note Documents,
(ii) in accordance with Section 5.13, to grant Liens in favor of the Collateral Agent in all fee ownership interests in
Real Estate having a fair market value in excess of $2,500,000 as of the date such Person becomes a Domestic Subsidiary by executing
and delivering to the Collateral Agent such Real Estate Documents necessary to perfect and maintain the Collateral Agent’s
security interest, and (iii) to deliver all such other customary and reasonable documentation (including, without limitation, certified
organizational documents, resolutions, lien searches, title insurance policies, surveys, environmental reports and legal opinions)
and to take all such other actions as such Subsidiary would have been required to deliver and take pursuant to Section 3.1
if such Subsidiary had been a Note Party on the Closing Date or that such Subsidiary would be required to deliver pursuant to Section
5.13 with respect to any Real Estate. In addition, within 30 days (or such longer period as the Required Purchasers shall permit
in writing in their sole discretion) after the date any Person becomes a Domestic Subsidiary, the Issuer shall, or shall cause
the applicable Note Party to (i) pledge all of the Capital Stock of such Domestic Subsidiary to the Collateral Agent as security
for the Obligations by executing and delivering a supplement to the Guaranty and Security Agreement in form and substance reasonably
satisfactory to the Collateral Agent and the Required Purchasers, and (ii) deliver the original certificates evidencing such pledged
Capital Stock (to the extent that such Capital Stock is certificated) to the Collateral Agent, together with appropriate powers
executed in blank, in each case, other than any such Capital Stock that constitutes Excluded Property.

 

(b)          In
the event that, subsequent to the Closing Date, any Person becomes a Foreign Subsidiary, whether pursuant to formation, acquisition
or otherwise, (i) the Issuer shall promptly notify the Collateral Agent and the Purchasers thereof and (ii) to the extent such
Foreign Subsidiary is owned directly by any Note Party, within 60 days after such Person becomes a Foreign Subsidiary (or such
longer period as the Required Purchasers shall agree in writing), the Issuer shall, or shall cause the applicable Note Party to,
(A) pledge not more than 65% of the issued and outstanding voting Capital Stock of such Foreign Subsidiary to the Collateral Agent
as security for the Obligations pursuant to a pledge agreement in form and substance reasonably satisfactory to the Collateral
Agent and the Required Purchasers, (B) deliver the original certificates evidencing such pledged Capital Stock (to the extent that
such Capital Stock or portion thereof is certificated) to the Collateral Agent, together with appropriate powers executed in blank
and (C) deliver all such other customary and reasonable documentation (including, without limitation, certified organizational
documents, resolutions, lien searches and legal opinions) and to take all such other actions as the Collateral Agent or the Required
Purchasers may reasonably request.

 

(c)          The
Issuer agrees that, following the delivery of any Collateral Documents required to be executed and delivered by this Section, the
Collateral Agent shall have a valid and enforceable, first priority perfected Lien (subject to Specified Permitted Liens) on the
property required to be pledged pursuant to clauses (a) and (b) of this Section (to the extent that such Lien can be perfected
by execution, delivery and/or recording of the Collateral Documents or by filing UCC financing statements, or by taking actual
possession of such Collateral), free and clear of all Liens other than Liens expressly permitted by Section 7.2. All actions
to be taken pursuant to this Section shall be at the expense of the Issuer or the applicable Note Party, and shall be taken to
the reasonable satisfaction of the Collateral Agent and the Required Purchasers.

 

    	 	73	 

     

    

 

Section 5.13         Additional
Real Estate; Leased Locations.

 

(a)          If
any Note Party proposes to acquire after the Closing Date a fee ownership interest in Real Estate having a fair market value in
excess of $2,500,000 as of the date of the acquisition thereof, it shall within ninety (90) days following such acquisition provide
to the Collateral Agent and each Purchaser the Real Estate Documents with respect to such Real Estate. If, at any time, the fair
market value of all Real Estate with respect to which the Note Parties hold a fee ownership interest and have not delivered Real
Estate Documents is in excess of $5,000,000, the Note Parties shall within 90 days provide to the Collateral Agent and each Purchaser
Real Estate Documents with respect to a sufficient portion of such Real Estate such that, after giving effect to the delivery of
such Real Estate Documents, the fair market value of all Real Estate with respect to which the Note Parties hold a fee ownership
interest and have not delivered Real Estate Documents does not exceed $5,000,000.

 

(b)          If
any Note Party proposes to lease any real property that will serve as such Note Party’s chief executive office or the location
at which such Note Party’s books or records will be stored or located, it shall provide to the Collateral Agent and each
Purchaser a copy of such lease and, within sixty (60) days following the effectiveness of such lease, a Collateral Access Agreement
from the landlord of such leased property or the bailee with respect to any warehouse or other location where such books, records
or Collateral will be stored or located; provided that if such Note Party is unable to deliver any such Collateral Access
Agreement after using its commercially reasonable efforts to do so, the Required Purchasers shall waive the foregoing requirement
in their reasonable discretion.

 

Section 5.14         Further
Assurances. The Issuer will, and will cause each other Note Party to, execute any and all further documents, financing
statements, agreements and instruments, and take all such further actions (including the filing and recording of financing statements,
fixture filings, Mortgages and other documents), which may be required under any applicable law, or which the Collateral Agent
or the Required Purchasers may reasonably request, to effectuate the transactions contemplated by the Note Documents or to grant,
preserve, protect or perfect the Liens created by the Collateral Documents or the validity or priority of any such Lien, all at
the expense of the Note Parties. The Issuer also agrees to provide to the Collateral Agent or any Purchaser, from time to time
upon request, evidence reasonably satisfactory to the Collateral Agent or such Purchaser as to the perfection and priority of the
Liens created or intended to be created by the Collateral Documents.

 

Section 5.15         Healthcare
Matters. 

 

(a)          Without
limiting the generality of any other covenant contained in this Agreement, and except as would not reasonably be expected to have
a Material Adverse Effect, the Issuer will, and will cause each of its Subsidiaries to (i) conduct its operations in compliance
with all applicable Healthcare Laws, (ii) maintain and comply with all Governmental Payor Arrangements, Third Party Payor Arrangements,
Licenses, Company Accreditations and Company Reimbursement Approvals, (iii) timely file, or cause to be filed, all Company Regulatory
Filings in accordance with all Requirements of Law, (iv) timely pay all amounts, Taxes, fees and assessments, if any, due and payable
in connection with Company Regulatory Filings, (v) timely submit and implement all corrective action plans required to be prepared
and submitted in response to any Health Care Audits, (vi) timely refund all overpayments (other than those appealed through the
ordinary administrative processes of any applicable Governmental Authority) determined to exist by any Governmental Authority under
any Healthcare Law or pursuant to any Governmental Payor Arrangement, (vii) timely repay any overpayment amounts owing under any
finally resolved audit or investigation by any Third Party Payor, and (viii) process credit balances received from Third Party
Payors in a manner consistent with the Issuer’s internal policies and applicable Requirements of Law. The Issuer will, and
will cause each of its Subsidiaries to, notify the Collateral Agent and each Purchaser promptly after the Issuer or any of its
Subsidiaries becomes aware of any violation of Healthcare Laws by the Issuer or any of its Subsidiaries that would reasonably be
expected to have a Material Adverse Effect.

 

    	 	74	 

     

    

 

(b)          Without
limiting the foregoing, the Issuer will, and will cause each of its Subsidiaries to, promptly furnish or cause to be furnished
to the Collateral Agent and each Purchaser (x) copies of all reports of investigational/inspectional observations or reports issued
to and received by the Issuer or any of its Subsidiaries and issued by any Governmental Authority, (y) copies of all correspondence
as well as other documents received by the Issuer or any of its Subsidiaries from any Governmental Authority relating to or arising
out of the conduct applicable to the business of Issuer or any of its Subsidiaries that asserts past or ongoing material non-compliance
with applicable Healthcare Laws and (z) notice of any investigation or audit or similar proceeding by any Governmental Authority,
except in each case where the failure to do so would not reasonably be expected to have a Material Adverse Effect.

 

Notwithstanding anything to the contrary in
any Note Document, neither the Issuer nor any of its Subsidiaries shall be required to furnish to the Collateral Agent or any Purchaser
any protected health information or any patient-related information, to the extent such disclosure to the Collateral Agent or such
Purchaser is prohibited by any Requirements of Law.

 

Section 5.16         Post-Closing
Covenants. The Issuer will, and will cause each of its Subsidiaries to, as applicable, not later than the dates specified
therefor on Schedule 5.16 (or such later dates as the Required Purchasers may agree in writing in their sole discretion),
satisfy each of the requirements set forth on Schedule 5.16.

 

Section 5.17         Second
Lien Credit Enhancements. If the Second Lien Collateral Agent or any “Secured Party” under the Second Lien
Note Documents, in its capacity as such, receives any additional guaranty or additional collateral agreement after the Closing
Date, without limitation of any Event of Default that may arise as a result thereof, the Issuer shall, substantially concurrently
with such receipt, use commercially reasonable efforts to cause the same to be granted to the Collateral Agent, for its own benefit
and the benefit of the Secured Parties (subject to and without limitation of the terms of the First Lien/Second Lien Intercreditor
Agreement).

 

Section 5.18         Second
Lien Note Documents. Notwithstanding anything in this Agreement to the contrary, if any amendment or modification to the
Second Lien Note Documents amends or modifies any representation and warranty, covenant (including any financial covenant), event
of default or other term contained in the Second Lien Note Documents (or any related definitions), in each case, in a manner that
is more restrictive upon the Note Parties or if any amendment or modification to the Second Lien Note Purchase Agreement or other
Second Lien Note Document adds an additional representation and warranty, covenant or event of default therein, the Issuer and
the other Note Parties acknowledge and agree that this Agreement or the other Note Documents, as the case may be, shall be automatically
amended or modified to effect similar amendments or modifications with respect to this Agreement or such other Note Documents,
without the need for any further action or consent by the Issuer, the Note Parties, or any other party. In furtherance of the foregoing,
the Issuer and the other Note Parties permit the Collateral Agent and the Purchasers to document each such similar amendment or
modification to this Agreement or such other Note Documents or insert a corresponding new representation and warranty, covenant,
event of default or other provision in this Agreement or such other Note Documents without any need for any further action or consent
by the Issuer, the other Note Parties or any other party.

 

    	 	75	 

     

    

 

Section 5.19         Corporate
Compliance and Quality Management Program. The Issuer will, and will cause each of its Subsidiaries to, maintain a corporate
compliance and quality management program that is reasonably designed to ensure compliance with applicable Healthcare Laws, except
where the failure to do so would not reasonably be expected to have a Material Adverse Effect. For the avoidance of doubt, the
corporate compliance and quality management program will include policies and procedures relating to internal claims auditing and
auditing for compliance to Governmental Authority requirements for the operation of a compounding pharmacy.

 

ARTICLE VI

FINANCIAL COVENANT

 

The Issuer covenants and
agrees that so long as any Purchaser has a Commitment hereunder or any Obligation remains unpaid or outstanding (other than Hedging
Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other
contingent obligations not then due and payable and as to which no claim has been made):

 

(a)          The
Issuer shall not permit the Consolidated Covenant Testing Net Leverage Ratio as of the last day of the most recently ended Fiscal
Quarter for which financial statements have been delivered (or were required to be delivered) pursuant to Section 5.1(a)
or 5.1(b), as applicable, for the period of four (4) consecutive Fiscal Quarters ending on such date, to be greater than
the ratio set forth below opposite such Fiscal Quarter:

 

	Fiscal Quarter Ending 	 	Consolidated Covenant Testing Net Leverage Ratio
	 	 	 
	September 30, 2017	 	9.00:1.00
	 	 	 
	December 31, 2017 and each Fiscal Quarter thereafter	 	8.00:1.00

 

ARTICLE VII

NEGATIVE COVENANTS

 

The Issuer covenants and
agrees that so long as any Purchaser has a Commitment hereunder or any Obligation remains outstanding (other than Hedging Obligations
owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations
not then due and payable and as to which no claim has been made):

 

Section 7.1           Indebtedness
and Disqualified Capital Stock. 

 

(a)            The
Issuer will not, and will not permit any of its Subsidiaries to, create, incur, assume or suffer to exist any Indebtedness, except:

 

(i)          Indebtedness
created pursuant to the Note Documents;

 

(ii)         Indebtedness
of the Issuer and its Subsidiaries existing on the Closing Date and set forth on Schedule 7.1 and extensions, renewals and
replacements of any such Indebtedness that do not increase the outstanding principal amount thereof immediately prior to giving
effect to such extension, renewal or replacement (except in respect of costs and expenses in connection therewith or any interest
that is paid-in-kind and capitalized to the principal amount thereof in connection with such extension, renewal or replacement)
or shorten the maturity or the Weighted Average Life to Maturity thereof;

 

    	 	76	 

     

    

 

(iii)        Indebtedness
of the Issuer or any of its Subsidiaries incurred to finance the acquisition, construction or improvement of any fixed or capital
assets, including Capital Lease Obligations, and any Indebtedness assumed in connection with the acquisition of any such assets
or secured by a Lien on any such assets prior to the acquisition thereof (provided that such Indebtedness is incurred prior
to or within 90 days after such acquisition or the completion of such construction or improvements), and extensions, renewals or
replacements of any such Indebtedness that do not increase the outstanding principal amount thereof immediately prior to giving
effect to such extension, renewal or replacement (except in respect of costs and expenses in connection therewith or any interest
that is paid-in-kind and capitalized to the principal amount thereof in connection with such extension, renewal or replacement)
or shorten the maturity or the Weighted Average Life to Maturity thereof; provided, that the aggregate principal amount
of Indebtedness outstanding under this clause (iii) at any time (including any of such Indebtedness which is set forth on Schedule
7.1) does not exceed the greater of (A) $12,500,000 and (B) 1.50% of Consolidated Total Assets;

 

(iv)        (A)
intercompany Indebtedness between or among the Issuer and any Subsidiary Note Party and (B) intercompany Indebtedness between or
among the Issuer and any Subsidiary that is not a Note Party permitted by Section 7.4(d);

 

(v)         (A)
Guarantees by the Issuer of Indebtedness of any Subsidiary Note Party and by any Subsidiary Note Party of Indebtedness of the Issuer
or any other Subsidiary Note Party and (B) Guarantees by the Issuer of Indebtedness of any Subsidiary that is not a Note Party
and by any Subsidiary of Indebtedness of the Issuer or any other Subsidiary that is not a Note Party permitted by Section 7.4(d);

 

(vi)        Indebtedness
in respect of performance, bid, surety, indemnity, appeal bonds, completion guarantees and other obligations of like nature and
guarantees and/or obligations as an account party in respect of the face amount of letters of credit in respect thereof, in each
case securing obligations not constituting Indebtedness for borrowed money (including workers’ compensation claims, environmental
remediation and other environmental matters and obligations in connection with self-insurance or similar requirements) provided
in the ordinary course of business;

 

(vii)       Indebtedness
arising from the endorsement of instruments in the ordinary course of business;

 

(viii)      Indebtedness
consisting of contingent liabilities in respect of any indemnification, working capital adjustment, purchase price adjustment,
non-compete, consulting, deferred compensation, earn-out obligations, contingent consideration, contributions, and similar obligations,
incurred in connection with any Investment permitted under Section 7.4 or any disposition permitted under Section 7.6;
provided that, with respect to any earn-out or other deferred or contingent purchase consideration in respect of a Permitted
Acquisition, (x) such earn-out or other deferred or contingent purchase consideration shall be subordinated in right of payment
to the Obligations and the Second Lien Obligations on terms acceptable to the Required Purchasers and the Required Purchasers (as
defined in the Second Lien Note Purchase Agreement), (y) such earn-out or other deferred or contingent purchase consideration such
shall be unsecured and (z) there shall be no obligors (including guarantors) in respect of such earn-out or other deferred or contingent
purchase consideration other than (I) in the case of an Acquisition of the type described in clause (b) of the definition of Acquisition,
the Person acquiring the assets of the applicable Target, (II) in the case of an Acquisition of the type described in clause (a)
of the definition of Acquisition, the applicable Target (and for the avoidance of doubt, no subsidiaries of the applicable Target
shall be obligors) and (III) in each case, any parent company of the Person acquiring such asset or Target, which parent company
is a newly-formed holding company that holds no material assets, and has no material liabilities, other than equity interests in
the Person acquiring such assets or Target;

 

    	 	77	 

     

    

 

(ix)         Indebtedness
consisting of the financing of insurance premiums required by this Agreement or otherwise incurred in the ordinary course of business;

 

(x)          cash
management obligations (including Bank Product Obligations) and other Indebtedness in respect of netting services, automatic clearinghouse
arrangements, overdraft protections, employee credit card programs and other cash management and similar arrangements, in each
case, in the ordinary course of business and any Guarantees thereof;

 

(xi)         Hedging
Obligations not prohibited by Section 7.10;

 

(xii)        Indebtedness
of the Issuer or any of its Subsidiaries owed to any supplier or vendor of Inventory incurred to finance the acquisition of Inventory
from such supplier or vendor, including the ABDC Obligations; provided that, immediately after giving effect to any incurrence
of Indebtedness under this clause (xii) on any date of determination, the aggregate principal amount of Indebtedness outstanding
under this clause (xii) does not exceed $20,000,000 for any period of more than twenty (20) consecutive days after a Responsible
Officer of the Issuer becomes aware of such excess outstanding amount;

 

(xiii)       (A)
unsecured Indebtedness evidenced by the Senior Notes outstanding on the Closing Date and (B) Permitted Refinancing Indebtedness
in respect thereof;

 

(xiv)      obligations
arising under indemnity agreements or other arrangements with title insurers to cause such title insurers to issue title policies
in the ordinary course of business;

 

(xv)       Indebtedness
representing deferred compensation or reimbursable expenses owed to employees of the Issuer or any of its Subsidiaries incurred
in the ordinary course of business;

 

(xvi)      Guarantees
by the Issuer in the ordinary course of business of any obligations of any Subsidiary Note Party under an operating lease to which
such Subsidiary Note Party is a party;

 

(xvii)     other
unsecured Indebtedness (other than Indebtedness for borrowed money); provided that the aggregate principal amount of Indebtedness
outstanding under this clause (xvii) at any time does not exceed the greater of (A) $5,000,000 and (B) 1.00% of Consolidated Total
Assets;

 

(xviii)    the
Second Lien Obligations to the extent all such obligations constitute “Second Lien Obligations” under the First Lien/Second
Lien Intercreditor Agreement;

 

(xix)       Indebtedness
in respect of stand-by letters of credit; provided that the aggregate principal amount of Indebtedness outstanding under
this clause (xix) shall not exceed $7,200,000; and

 

(xx)        Permitted
Seller Financing in respect of any Permitted Acquisition.

 

    	 	78	 

     

    

 

For purposes of determining
compliance with this Section 7.1(a), in the event that any item of Indebtedness meets the criteria of more than one of the
categories described in clauses (a)(i) through (a)(xvii), the Issuer and its Subsidiaries shall be permitted to incur any such
Indebtedness in any manner that complies with this Section 7.1(a) and may rely at the time of incurrence upon more than
one of the categories described above; provided that the ABDC Obligations shall be incurred and shall remain outstanding
solely under clause (a)(xii) above.

 

(b)          The
Issuer will not, and will not permit any Subsidiary to, issue or permit to exist any Disqualified Capital Stock of any such Person.
 

 

Section 7.2           Liens.
The Issuer will not, and will not permit any of its Subsidiaries to, create, incur, assume or suffer to exist any Lien on any
of its assets or property now owned or hereafter acquired, except:

 

(a)          Liens
securing the Obligations; provided that no Liens may secure Hedging Obligations or Bank Product Obligations without securing
all other Obligations on a basis at least pari passu with such Hedging Obligations or Bank Product Obligations and subject
to the priority of payments set forth in Section 2.18 and Section 8.2;

 

(b)          Liens
created under any Second Lien Note Document and securing the Second Lien Obligations permitted hereunder, so long as such Liens
are securing the Second Lien Obligations in accordance with, and are subject to, the terms of the First Lien/Second Lien Intercreditor
Agreement;

 

(c)          Permitted
Encumbrances;

 

(d)          Liens
on any property or asset of the Issuer or any of its Subsidiaries existing on the date hereof and set forth on Schedule 7.2;
provided that such Liens shall not apply to any other property or asset of the Issuer or any Subsidiary;

 

(e)          Liens
securing Indebtedness incurred pursuant to Section 7.1(a)(iii); provided that (i) such Lien attaches to such asset concurrently
or within ninety (90) days after the acquisition or the completion of the construction or improvements thereof, (ii) such Lien
granted is limited to the specific fixed assets acquired, constructed or improved and the proceeds thereof and (iii) the aggregate
principal amount of Indebtedness initially secured by such Lien is not more than the acquisition cost of the specific fixed assets
on which such Lien is granted;

 

(f)          Liens
(other than the ABDC Lien) securing Indebtedness incurred pursuant to Section 7.1(a)(xii); provided that (i) such
Lien granted is limited to the specific Inventory acquired and (ii) the aggregate principal amount of Indebtedness initially secured
by such Lien is not more than the acquisition cost of the Inventory on which such Lien is granted; provided, further,
that if, at any time after the Closing Date, the Issuer or any of its Subsidiaries grants such a Lien to a supplier or vendor and
the aggregate principal amount of Indebtedness outstanding that is owed to such supplier or vendor and its Affiliates is in excess
of $10,000,000, the Issuer or such Subsidiary shall use commercially reasonable efforts to enter into an intercreditor agreement
(which shall contain terms and conditions that are substantially consistent with, but no less favorable to the Purchasers than,
the ABDC Intercreditor Agreement) pursuant to which the Lien securing such Indebtedness owed to such supplier or vendor (and its
affiliates) shall be subordinated to the Liens securing the Obligations;

 

(g)          any
Lien existing on any fixed assets prior to the acquisition thereof by the Issuer or any of its Subsidiaries or existing on any
fixed assets of any Person that becomes a Subsidiary; provided that (i) such Lien was not created in contemplation of or
in connection with such acquisition or such Person becoming a Subsidiary, (ii) such Lien does not apply to any other property of
the Issuer or any of its Subsidiaries, and (iii) such Lien secures only those obligations which it secures on the date of such
acquisition or the date such Person becomes a Subsidiary;

 

    	 	79	 

     

    

 

(h)          extensions,
renewals, or replacements of any Lien referred to in clauses (b) through (g) of this Section; provided that the principal
amount of the Indebtedness secured thereby is not increased (except in respect of costs and expenses in connection therewith or
any interest that is paid-in-kind and capitalized to the principal amount thereof in connection with such extension, renewal or
replacement) and that any such extension, renewal or replacement is limited to the assets originally encumbered thereby;

 

(i)          the
ABDC Lien so long as such Liens are subordinated to the Liens securing the Obligations pursuant to the terms of the ABDC Intercreditor
Agreement; and

 

(j)          Liens
on cash collateral for letters of credit permitted pursuant to Section 7.1(a)(xix); provided that the amount of such
cash collateral shall not exceed 105% of the face amount of such letters of credit.

 

Section 7.3           Fundamental
Changes.

 

(a)          The
Issuer will not, and will not permit any of its Subsidiaries to, merge into or consolidate into any other Person, or permit any
other Person to merge into or consolidate with it, or sell, lease, transfer or otherwise dispose of (in a single transaction or
a series of transactions) all or substantially all of its assets (in each case, whether now owned or hereafter acquired) (except
as permitted by Section 7.6) or all or substantially all of the Capital Stock of any of its Subsidiaries (in each
case, whether now owned or hereafter acquired) or liquidate or dissolve; provided that if, at the time thereof and
immediately after giving effect thereto, no Event of Default shall have occurred and be continuing, (i) the Issuer or any Subsidiary
may merge with a Person if the Issuer (or such Subsidiary if the Issuer is not a party to such merger) is the surviving Person,
(ii) any Subsidiary may merge into another Subsidiary, provided that if any party to such merger is a Subsidiary Note Party,
the Subsidiary Note Party shall be the surviving Person, (iii) any Subsidiary may sell, transfer, lease or otherwise dispose of
all or substantially all of its assets to the Issuer or to a Subsidiary Note Party, and (iv) any Subsidiary may liquidate or dissolve
if the Issuer determines in good faith that such liquidation or dissolution is in the best interests of the Issuer.

 

(b)          The
Issuer will not, and will not permit any of its Subsidiaries to, engage in any business other than a Permitted Business.

 

Section 7.4           Investments,
Loans. The Issuer will not, and will not permit any of its Subsidiaries to, purchase, hold or acquire (including pursuant
to any merger with any Person that was not a wholly owned Subsidiary prior to such merger) any Capital Stock, evidence of Indebtedness
or other securities (including any option, warrant, or other right to acquire any of the foregoing) of, make or permit to exist
any loans or advances to, Guarantee any obligations of, or make or permit to exist any investment or any other interest in, any
other Person, or make any Acquisition (all of the foregoing being collectively called “Investments”), or purchase
or otherwise acquire (in one transaction or a series of transactions) any assets of any other Person that constitute a business
unit, or create or form any Subsidiary, except:

 

(a)          Investments
existing on the date hereof and set forth on Schedule 7.4 (including Investments in Subsidiaries that are Note Parties);

 

    	 	80	 

     

    

 

(b)          Investments
in cash and Cash Equivalents;

 

(c)          Guarantees
by the Issuer and its Subsidiaries constituting Indebtedness permitted by Section 7.1;

 

(d)          Investments
made by the Issuer in or to any Subsidiary and by any Subsidiary to the Issuer or in or to another Subsidiary; provided,
that (i) in the case of any Investment in the form of Indebtedness owed by a Note Party to a Subsidiary that is not a Note Party,
such Indebtedness (and any related Guarantee provided by any Note Party) shall be subordinated to the Obligations on terms and
pursuant to documentation in form and substance reasonably satisfactory to the Required Purchasers and (ii) the aggregate principal
amount of all Investments made by a Note Party to a Subsidiary that is not a Note Party shall not exceed the greater of (A) $10,000,000
and (B) 1.50% of Consolidated Total Assets (net of cash actually received by the Issuer or any such Subsidiary in respect of any
such Investments and determined without regard to any write-downs or write-offs of any investments, loans or advances in connection
therewith);

 

(e)          loans
or advances to employees, officers or directors of the Issuer or any of its Subsidiaries in the ordinary course of business for
travel, entertainment, relocation and related expenses; provided that the aggregate amount of all such loans and
advances shall not exceed $2,000,000 at any time outstanding;

 

(f)          Hedging
Transactions not prohibited by Section 7.10;

 

(g)          Investments
received in satisfaction or partial satisfaction from financially troubled debtors or in connection with the bankruptcy or reorganization
of suppliers or customers;

 

(h)          Investments
consisting of deposits, expense prepayments, accounts receivable arising, trade debt granted and other credits extended to suppliers,
distributors or marketers in the ordinary course of business;

 

(i)          Investments
received as the non-cash portion of consideration received for dispositions not prohibited by Section 7.6;

 

(j)          other
Investments (other than Investments in any Subsidiary that is not a Note Party) which do not exceed $8,000,000 in the aggregate
over the term of this Agreement; and

 

(k)          Permitted
Acquisitions.

 

Notwithstanding the foregoing,
in no event shall the Issuer or any of its Subsidiaries make any investment in any Subsidiary formed for the purpose of holding
assets of the Issuer and its Subsidiaries constituting the Issuer’s and its Subsidiaries’ PBM line of business.

 

For purposes of determining
the amount of any Investment outstanding for purposes of this Section 7.4, such amount shall be deemed to be the cost of
such Investment when made, purchased or acquired, net of any amount representing return of (but not return on) such Investment
and without regard to any forgiveness of Indebtedness.

 

    	 	81	 

     

    

 

Section 7.5           Restricted
Payments. The Issuer will not, and will not permit any of its Subsidiaries to, declare or make, or
agree to pay or make, directly or indirectly, any Restricted Payment, except:

 

(a)          dividends
payable by the Issuer solely in interests of any class of its common equity;

 

(b)          Restricted
Payments made by any Subsidiary to the Issuer or to another Subsidiary; provided that (i) if such Restricted Payment is
made by a Subsidiary that is not wholly owned by the Issuer or another wholly owned Subsidiary of the Issuer, such Restricted Payment
shall be made on at least a pro rata basis with any other shareholders of such non-wholly owned Subsidiary and (ii) other than
any Restricted Payments consisting solely of required tax payments arising by virtue of any Subsidiary Note Party being a pass-through
entity or being a member of a consolidated or other similar group for income tax purposes, if such Restricted Payment is made by
a Subsidiary Note Party to a Subsidiary that is not a Note Party, no Default or Event of Default has occurred and is continuing
before and immediately after giving effect to such payment;

 

(c)          payments
made by the Issuer under the ABDC Prime Vendor Agreement, to the extent permitted by the ABDC Intercreditor Agreement;

 

(d)          scheduled
payments of principal, interest and other amounts with respect to Subordinated Debt to the extent permitted by the terms of such
Indebtedness and by the terms of any subordination agreement applicable thereto;

 

(e)          Restricted
Payments in the form of a non-cash repurchase of Capital Stock of the Issuer that is deemed to occur upon the exercise of stock
options, warrants or other convertible or exchangeable securities to the extent that such Capital Stock represents a portion of
the exercise price of those securities, in each case, pursuant to any equity-based compensation or incentive plan of the Issuer;

 

(f)          dividends
made in cash in lieu of the issuance of fractional shares of Capital Stock of the Issuer in connection with the exercise of warrants,
options or other securities convertible into, or exchangeable for, Capital Stock of the Issuer pursuant to any equity-based compensation
or incentive plan of the Issuer; and

 

(g)          cash
dividends, distributions, and share repurchases by the Issuer in respect of the Issuer’s common Capital Stock so long as:
(i) the aggregate amount of such cash dividends, distributions, and share repurchases does not exceed the Available Amount, (ii)
after giving pro forma effect to such cash dividend, distribution, or share repurchase, the Consolidated Total Net Leverage Ratio
is less than or equal to 2.50 to 1.00, calculated as of the last day of the most recently ended Fiscal Quarter for which financial
statements are required to have been delivered pursuant to Section 5.1(b), and (iii) at the time of such cash dividend, distribution,
or share repurchase and after giving effect thereto, no Default or Event of Default exists.

 

Section 7.6           Sale
of Assets. The Issuer will not, and will not permit any of its Subsidiaries to, convey, sell, lease, assign, transfer or
otherwise dispose of any of its assets, business or property or, in the case of any Subsidiary, any shares of such Subsidiary’s
Capital Stock, in each case whether now owned or hereafter acquired, to any Person other than the Issuer or a Subsidiary Note Party
(or to qualify directors if required by applicable law), except:

 

(a)          the
sale or other disposition of damaged, scrap, obsolete or worn out property disposed of in the ordinary course of business;

 

    	 	82	 

     

    

 

(b)          the
sale of inventory in the ordinary course of business;

 

(c)          the
sale or other disposition of cash and Cash Equivalents in the ordinary course of business;

 

(d)          the
issuance of Capital Stock by any Subsidiary of the Issuer issued to the Issuer or any Subsidiary Note Party so long as such issuance
does not result in a Change in Control;

 

(e)          the
occurrence of any casualty event, condemnation, eminent domain or other similar proceeding with respect to any assets or property
of the Issuer or any of its Subsidiaries (provided that the Net Cash Proceeds thereof are used to prepay the Notes in accordance
with Section 2.9(a)); and

 

(f)          any
other sale or disposition of assets not otherwise described in this Section 7.6 not to exceed $1,000,000 in the aggregate
over the term of this Agreement, so long as (i) at least 75% of the aggregate consideration received in respect of such sale or
disposition is received in cash or Cash Equivalents, (ii) such sales and dispositions shall be for fair market value (provided
that the Net Cash Proceeds thereof are used to prepay the Notes in accordance with Section 2.9(a)) and (iii) such sales
and dispositions are made to a Person that is not an Affiliate of the Issuer.

 

Section 7.7           Transactions
with Affiliates. The Issuer will not, and will not permit any of its Subsidiaries to, sell, lease or otherwise transfer
any property or assets to, or purchase, lease or otherwise acquire any property or assets from, or otherwise engage in any other
transactions with, any of its Affiliates, except:

 

(a)          in
the ordinary course of business at prices and on terms and conditions not less favorable to the Issuer or such Subsidiary than
could be obtained on an arm’s-length basis from unrelated third parties;

 

(b)          transactions
(i) between or among the Issuer and any Subsidiary Note Party not involving any other Affiliates (other than any other Subsidiary
Note Party) or (ii) between or among the Issuer or any Subsidiary Note Party and any Subsidiary that is not a Note Party that are
not otherwise prohibited by this Agreement (in each case, subject to the terms and conditions therefor, if any);

 

(c)          any
Restricted Payment permitted by Section 7.5;

 

(d)          transactions
in respect of compensation or employment, separation and severance of officers, directors or employees and the establishment and
maintenance of benefit programs or arrangements with employees, officers or directors, including vacation plans, health and life
insurance plans, deferred compensation plans and retirement or savings plans and similar plans or equity incentive or equity option
plans, in each case, in the ordinary course of business; and

 

(e)          any
transaction set forth on Schedule 7.7 as of the Closing Date.

 

    	 	83	 

     

    

 

Section 7.8           Restrictive
Agreements. The Issuer will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur
or permit to exist any agreement that prohibits, restricts or imposes any condition upon (a) the ability of the Issuer or any of
its Subsidiaries to create, incur or permit any Lien upon any of its assets or properties, whether now owned or hereafter acquired,
or (b) the ability of any of its Subsidiaries to pay dividends or other distributions with respect to its Capital Stock, to
make or repay loans or advances to the Issuer or any other Subsidiary thereof, to Guarantee Indebtedness of the Issuer or any other
Subsidiary thereof or to transfer any of its property or assets to the Issuer or any other Subsidiary thereof; provided
that (i) the foregoing shall not apply to restrictions or conditions imposed by law or by this Agreement, any other Note Document,
the Second Lien Note Purchase Agreement or any other Second Lien Note Documents, (ii) the foregoing shall not apply to customary
restrictions and conditions contained in agreements relating to the sale of a Subsidiary pending such sale, provided such
restrictions and conditions apply only to the Subsidiary that is sold and such sale is permitted hereunder, (iii) clause (a) shall
not apply to restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Agreement if
such restrictions and conditions apply only to the property or assets securing such Indebtedness, (iv) clause (a) shall not apply
to customary provisions in leases, licenses, licensing agreements and other contracts restricting the assignment thereof and (v)
the foregoing shall not apply to any restrictions and conditions imposed on any Foreign Subsidiary by the terms of any Indebtedness
of such Foreign Subsidiary permitted to be incurred hereunder, and (vi) the foregoing shall not apply to any Specified Strategic
Joint Venture.

 

Section 7.9           Sale
and Leaseback Transactions. The Issuer will not, and will not permit any of its Subsidiaries to, enter into any arrangement,
directly or indirectly, whereby it shall sell or transfer any property, real or personal, used or useful in its business, whether
now owned or hereinafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially
the same purpose or purposes as the property sold or transferred.

 

Section 7.10         Hedging
Transactions. The Issuer will not, and will not permit any of its Subsidiaries to, enter into any Hedging Transaction,
other than Hedging Transactions entered into in the ordinary course of business to hedge or mitigate risks to which the Issuer
or any of its Subsidiaries is exposed in the conduct of its business or the management of its liabilities. Solely for the avoidance
of doubt, the Issuer acknowledges that a Hedging Transaction entered into for speculative purposes or of a speculative nature (which
shall be deemed to include any Hedging Transaction under which the Issuer or any of its Subsidiaries is or may become obliged to
make any payment (a) in connection with the purchase by any third party of any Capital Stock or any Indebtedness or (b) as a result
of changes in the market value of any Capital Stock or any Indebtedness) is not a Hedging Transaction entered into in the ordinary
course of business to hedge or mitigate risks.

 

Section 7.11         Amendment
to Material Documents. The Issuer will not, and will not permit any of its Subsidiaries to, amend, modify or waive any
of its rights under (a) its certificate of incorporation, bylaws or other organizational documents in any manner that would reasonably
be expected to be materially adverse to the Purchasers (it being agreed that any such amendment or modification effected in accordance
with Section 5.2(x) or in order to consummate a transaction permitted by Section 7.3 shall not be deemed to be materially
adverse to the Purchasers), (b) any Material Agreements (other than to the extent expressly covered by clauses (c) and (d) below)
in any manner that would reasonably be expected to be adverse to the Purchasers in any material respect, (c) any Second Lien Note
Document, except as permitted by the First Lien/Second Lien Intercreditor Agreement or (d) the Senior Notes Indenture or the Senior
Notes (or any documentation governing any Permitted Refinancing Indebtedness) if, after giving effect to any such amendment, modification
or waiver, the Senior Notes Indenture and the Senior Notes (or such documentation governing any Permitted Refinancing Indebtedness)
as so amended, modified or waived would not meet each of the requirements set forth in the proviso to the definition of “Permitted
Refinancing Indebtedness”.

 

Section 7.12         Accounting
Changes. The Issuer will not, and will not permit any of its Subsidiaries to, make any significant change in accounting
treatment or reporting practices, except as required by GAAP, or change the Fiscal Year of the Issuer or of any of its Subsidiaries,
except to change the Fiscal Year of a Subsidiary to conform its Fiscal Year to that of the Issuer.

 

    	 	84	 

     

    

 

Section 7.13         Compliance
with Anti-Terrorism and Anti-Corruption Laws and Sanctions. No Note Party shall, and no Note Party shall permit any of
its Affiliates to: (a) (i) violate any Anti-Terrorism Laws or Anti-Corruption Laws, (ii) engage in any transaction, investment,
undertaking or activity that conceals the identity, source or destination of the proceeds from any category of prohibited offenses
designated by the Organization for Economic Co-operation and Development’s Financial Action Task Force on Money Laundering,
(iii) become (including by virtue of being owned or controlled by a Blocked Person), own or control a Blocked Person or any other
Sanctioned Person or (iv) knowingly permit any of their respective Affiliates to violate these laws or engage in these actions;
(b) use, directly or indirectly, the proceeds of the Notes, or lend, contribute or otherwise make available such proceeds to any
Person, (x) to fund any activities or business of or with any Sanctioned Person or Sanctioned Country, or (y) in any other manner
that would result in a violation of Sanctions or any Anti-Terrorism Laws or Anti-Corruption Laws by any Person (including any Person
participating in the Notes, whether as underwriter, advisor, investor, or otherwise); or (c) (i) deal in, or otherwise engage in
any transaction related to, any property or interests in property blocked pursuant to any Anti-Terrorism Law or Sanctions, or (ii)
engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempt
to violate, any of the prohibitions set forth in any Anti-Terrorism Law or Sanctions or (iii) knowingly permit any of their respective
Affiliates to do any of the foregoing.

 

Section 7.14         Health
Care Matters. Without limiting or being limited by any other provision of any Note Document, and except as would not reasonably
be expected to have a Material Adverse Effect, the Issuer will not, and will not permit any of its Subsidiaries to, (i) fail to
maintain in effect all Licenses, Company Accreditations and Company Reimbursement Approvals, or (ii) engage in any activity that
constitutes or, with the giving of notice, the passage of time, or both, would (a) result in a violation of any License, Company
Accreditation or Company Reimbursement Approval or any Healthcare Laws, or (b) cause the Issuer or any of its Subsidiaries not
to be in compliance with any Healthcare Laws.

 

Section 7.15         ERISA.
No Note Party shall, or shall cause or permit any ERISA Affiliate to, cause or permit to occur an ERISA Event to the extent
such ERISA Event would reasonably be expected to have a Material Adverse Effect.

 

Section 7.16         Payments
in Respect of Senior Notes. Except for the refinancing of the Senior Notes with the proceeds of Permitted Refinancing Indebtedness,
the Issuer will not, and will not permit any of its Subsidiaries to, make any optional payment or optional prepayment of principal
of, premium, if any, interest, fees or other amounts on or with respect to, or any redemption, purchase, retirement, defeasance,
sinking fund or similar payment or claim for rescission with respect to, the Senior Notes (or any Permitted Refinancing Indebtedness).

 

Section 7.17         Anti-Layering.
Notwithstanding anything herein to the contrary, no Note Party shall, and no Note Party shall permit any of its Subsidiaries
to, create or incur any Indebtedness which is secured by a Lien on the Collateral, which Lien is subordinated in right of priority
to the Lien securing the Second Lien Obligations, unless the Lien securing such Indebtedness is also subordinated in right of priority
in the same manner and to the same extent, to the Lien securing the Obligations.

 

Section 7.18         Second
Lien Obligations. No Note Party shall, and no Note Party shall permit any Subsidiary or Affiliate of such Note Party to,
hold any Second Lien Obligations.

 

    	 	85	 

     

    

 

ARTICLE VIII

EVENTS OF DEFAULT

 

Section 8.1           Events
of Default. If any of the following events (each, an “Event of Default”) shall occur:

 

(a)          the
Issuer shall fail to pay any principal of any Note, when and as the same shall become due and payable, whether at the due date
thereof or at a date fixed for prepayment or otherwise; or

 

(b)          the
Issuer shall fail to pay any interest on any Note or any fee, Prepayment Premium, premium or any other amount (other than an amount
payable under clause (a) of this Section or an amount related to a Bank Product Obligation) payable under this Agreement or any
other Note Document, when and as the same shall become due and payable, and such failure shall continue unremedied for a period
of five (5) Business Days; or

 

(c)          any
representation or warranty made or deemed made by or on behalf of the Issuer or any of its Subsidiaries in or in connection with
this Agreement or any other Note Document (including the Schedules attached hereto and thereto), or in any amendments or modifications
hereof or waivers hereunder, or in any certificate, report, financial statement or other document submitted to the Collateral Agent
or the Purchasers by any Note Party or any representative of any Note Party pursuant to or in connection with this Agreement or
any other Note Document shall prove to be incorrect in any material respect (other than any representation or warranty that is
expressly qualified by a Material Adverse Effect or other materiality, in which case such representation or warranty shall prove
to be incorrect in any respect) when made or deemed made; or

 

(d)          the
Issuer shall fail to observe or perform any covenant or agreement contained in (i) Section 5.1 and such failure shall remain
unremedied for five (5) days or (ii) Section 5.2, 5.3 (with respect to the Issuer’s legal existence), 5.7,
5.9, 5.11, 5.16, Article VI or Article VII; or

 

(e)          (i)
any Note Party shall fail to observe or perform any covenant or agreement contained in this Agreement (other than those referred
to in clauses (a), (b) and (d) of this Section) or any other Note Document or related to any Bank Product Obligation, and such
failure shall remain unremedied for 30 days after the earlier of (A) any Responsible Officer of the Issuer becomes aware
of such failure, or (B) written notice thereof shall have been given to the Issuer by the Collateral Agent or any Purchaser or
(ii) any “Event of Default” as defined in any Note Document shall have occurred and be continuing; or

 

    	 	86	 

     

    

 

(f)          (i)
the Issuer or any of its Subsidiaries (whether as primary obligor or as guarantor or other surety) shall fail to pay any principal
of, or premium or interest on, or any other amount owed under the ABDC Obligations, any Material Indebtedness (other than any Hedging
Obligations) or any Material Permitted Seller Financing that is outstanding, in each case, when and as the same shall become due
and payable (whether at scheduled maturity, required prepayment, acceleration, demand or otherwise), and such failure shall continue
after the applicable grace period, if any, specified in the agreement or instrument evidencing or governing the ABDC Obligations,
such Material Indebtedness or such Material Permitted Seller Financing, as applicable; or any other event shall occur or condition
shall exist under any agreement or instrument relating to the ABDC Obligations (including, without limitation, any default under
the ABDC Prime Vendor Agreement), any Material Indebtedness or any Material Permitted Seller Financing and shall continue after
the applicable grace period, if any, specified in such agreement or instrument, if the effect of such event or condition is to
accelerate, or permit the acceleration of, the maturity of the ABDC Obligations, such Material Indebtedness or such Material Permitted
Seller Financing; or the ABDC Obligations, any Material Indebtedness or any Material Permitted Seller Financing shall be declared
to be due and payable, or required to be prepaid or redeemed (other than by a regularly scheduled required prepayment or redemption),
purchased or defeased, or any offer to prepay, redeem, purchase or defease the ABDC Obligations, such Indebtedness or such Material
Permitted Seller Financing shall be required to be made, in each case prior to the stated maturity thereof or (ii) there occurs
under any Hedging Transaction an Early Termination Date (as defined in such Hedging Transaction) resulting from (A) any event of
default under such Hedging Transaction as to which the Issuer or any of its Subsidiaries is the Defaulting Party (as defined in
such Hedging Transaction) and the Hedge Termination Value owed by the Issuer or such Subsidiary as a result thereof is greater
than $12,500,000 or (B) any Termination Event (as so defined) under such Hedging Transaction as to which the Issuer or any Subsidiary
is an Affected Party (as so defined) and the Hedge Termination Value owed by the Issuer or such Subsidiary as a result thereof
is greater than $12,500,000 and is not paid; or

 

(g)          the
Issuer or any of its Subsidiaries shall (i) commence a voluntary case or other proceeding or file any petition seeking liquidation,
reorganization or other relief under any federal, state or foreign bankruptcy, insolvency or other similar law now or hereafter
in effect or seeking the appointment of a custodian, trustee, receiver, liquidator or other similar official of it or any substantial
part of its property, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding
or petition described in clause (i) of this Section, (iii) apply for or consent to the appointment of a custodian, trustee, receiver,
liquidator or other similar official for the Issuer or any such Subsidiary or for a substantial part of its assets, (iv) file an
answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment
for the benefit of creditors, or (vi) take any action for the purpose of effecting any of the foregoing; or

 

(h)          an
involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or
other relief in respect of the Issuer or any of its Subsidiaries or its debts, or any substantial part of its assets, under any
federal, state or foreign bankruptcy, insolvency or other similar law now or hereafter in effect or (ii) the appointment of a custodian,
trustee, receiver, liquidator or other similar official for the Issuer or any of its Subsidiaries or for a substantial part of
its assets, and in any such case, such proceeding or petition shall remain undismissed for a period of 60 days or an order or decree
approving or ordering any of the foregoing shall be entered; or

 

(i)          the
Issuer or any of its Subsidiaries shall become unable to generally pay, shall admit in writing its inability to generally pay,
or shall fail to pay, its debts as they become due; or

 

(j)          (i)
an ERISA Event shall have occurred that, when taken together with other ERISA Events that have occurred, would reasonably be expected
to result in liability to the Issuer and its Subsidiaries in an aggregate amount exceeding $12,500,000, (ii) there is or arises
an Unfunded Pension Liability (not taking into account Plans with negative Unfunded Pension Liability) in an aggregate amount exceeding
$12,500,000, or (iii) there is or arises any potential Withdrawal Liability in an aggregate amount exceeding $12,500,000; or

 

(k)          any
final non-consensual judgment or order for the payment of money (to the extent not covered by insurance as to which the insurer
has been notified of such judgment and has not denied coverage in writing) in excess of $12,500,000 individually (or, together
with any related non-consensual judgment or order, in the aggregate) shall be rendered against the Issuer or any of its Subsidiaries,
and either (i) enforcement proceedings shall have been commenced by any creditor upon such non-consensual judgment or order or
(ii) such non-consensual judgment or order remains unvacated, unbounded or unstayed for a period of 30 consecutive days; or

 

    	 	87	 

     

    

 

(l)          any
final non-monetary judgment or order shall be rendered against the Issuer or any of its Subsidiaries that would reasonably
be expected, either individually or in the aggregate, to have a Material Adverse Effect, and there shall be a period of 30 consecutive
days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in
effect; or

 

(m)          a
Change in Control shall occur or exist; or

 

(n)          all
or any material portion or provision of the Guaranty and Security Agreement, the ABDC Intercreditor Agreement, the First Lien/Second
Lien Intercreditor Agreement, or any other Note Document shall for any reason (other than (x) solely as a result of any action
or inaction on the part of the Collateral Agent or any Purchaser, or (y) in accordance with its terms) cease to be valid and binding
on, or enforceable against, any Note Party, or any Note Party shall so state in writing, or any Note Party shall seek to terminate
its obligation under the Guaranty and Security Agreement, the ABDC Intercreditor Agreement, the First Lien/Second Lien Intercreditor
Agreement, or any other Note Document (other than the release of any guaranty or collateral in accordance with Section 9.11
or any other release in accordance with the terms of such document or otherwise in accordance with the terms hereof); or

 

(o)          any
Lien purported to be created under any Collateral Document shall fail or cease to be, or shall be asserted by any Note Party not
to be, a valid and perfected, and, except for Specified Permitted Liens, first priority Lien on any Collateral (other than, in
each case, solely as a result of any action or inaction on the part of any Purchaser); or

 

(p)          (i)
the commencement by any Governmental Authority of any proceeding or hearing relating to the criminal and/or civil violation of
any Governmental Payor Arrangement or License of the Issuer or any of its Subsidiaries, to the extent such proceeding or hearing
would reasonably be expected to have a Material Adverse Effect; (ii) there shall have occurred the involuntary termination of,
or the receipt by the Issuer or any of its Subsidiaries of notice of the involuntary termination of, or the occurrence of any event
or condition which would, with the passage of time or the giving of notice or both, constitute an event of default under or permit
the involuntary termination of, any Governmental Payor Arrangement, Third Party Payor Arrangement, License, or Company Accreditation
of the Issuer or any of its Subsidiaries, except for involuntary terminations that would not be expected to have a Material Adverse
Effect; or (iii) the imposition of any overpayment in an amount in excess of $5,000,000 by any Governmental Authority or
Third Party Payor under any Healthcare Law or pursuant to any Governmental Payor Arrangement or Third Party Payor Arrangement,
as applicable; or

 

(q)          the
Issuer or any of its Subsidiaries or any of their respective directors or officers is criminally convicted under any law or Requirement
of Law that would reasonably be expected to lead to (i) a forfeiture of a portion of Collateral or (ii) exclusion from participation
in any federal or state health care program, including Medicare or Medicaid, and such exclusion would reasonably be expected to
result in a Material Adverse Effect;

 

then, and in every such event (other than an
event with respect to the Issuer described in clause (g) or (h) of this Section) and at any time thereafter during the continuance
of such event, the Required Purchasers may, by notice to the Issuer, take any or all of the following actions, at the same or different
times: (i) terminate the Commitments, whereupon the Commitment of each Purchaser shall terminate immediately, (ii) declare
the principal of and any accrued interest on the Notes, and all other Obligations owing hereunder, to be, whereupon the same shall
become, due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby
waived by the Issuer, (iii) exercise all remedies contained in any other Note Document, and (iv) exercise any other remedies available
at law or in equity; provided that, if an Event of Default specified in either clause (g) or (h) shall occur, the Commitments
shall automatically terminate and the principal of the Notes then outstanding, together with accrued interest thereon, and all
fees and all other Obligations shall automatically become due and payable, without presentment, demand, protest or other notice
of any kind, all of which are hereby waived by the Issuer.

 

    	 	88	 

     

    

 

If the Notes are accelerated or otherwise become
due prior to their maturity date, in each case, as a result of an Event of Default (including, but not limited to, upon the occurrence
of an Event of Default specified in clause (g) or (h) of Section 8.1 (including the acceleration of claims by operation
of law)), the amount of principal of and premium on the Notes that becomes due and payable shall equal 100% of the principal amount
of the Notes plus the Prepayment Premium in effect on the date of such acceleration or such other prior due date, as if such acceleration
or other occurrence were a voluntary prepayment of the Notes accelerated or otherwise becoming due. Without limiting the generality
of the foregoing, it is understood and agreed that if the Notes are accelerated or otherwise become due prior to their maturity
date, in each case, in respect of any Event of Default (including, but not limited to, upon the occurrence of an Event of Default
specified in clause (g) or (h) of Section 8.1 (including the acceleration of claims by operation of law)), the Prepayment
Premium applicable with respect to a voluntary prepayment of the Notes will also be due and payable on the date of such acceleration
or such other prior due date as though the Notes were voluntarily prepaid as of such date and shall constitute part of the Obligations,
in view of the impracticability and extreme difficulty of ascertaining actual damages and by mutual agreement of the parties as
to a reasonable calculation of each Purchaser’s lost profits as a result thereof.

 

Section 8.2           Application
of Proceeds from Collateral. All proceeds from each sale of, or other realization upon, all or any part of the Collateral
by any Secured Party after an Event of Default arises shall be applied as follows:

 

(a)          first,
to the reimbursable expenses of the Collateral Agent incurred in connection with such sale or other realization upon the Collateral,
until the same shall have been paid in full;

 

(b)          second,
to all amounts owed to the Collateral Agent then due and payable pursuant to any of the Note Documents, until the same shall have
been paid in full;

 

(c)          third,
to all reimbursable expenses, if any, of the Purchasers then due and payable pursuant to any of the Note Documents, until the same
shall have been paid in full;

 

(d)          fourth,
to the fees, interest, Prepayment Premiums and premiums then due and payable under the terms of this Agreement, until the same
shall have been paid in full;

 

(e)          fifth,
to the aggregate outstanding principal amount of the Notes, the Bank Product Obligations and the Net Mark-to-Market Exposure of
the Hedging Obligations that constitute Obligations, until the same shall have been paid in full, allocated pro rata among
the Secured Parties based on their respective pro rata shares of the aggregate amount of such Notes, Bank Product Obligations
and Net Mark-to-Market Exposure of such Hedging Obligations; provided, however, that no amount received from any
Guarantor (including any proceeds of any sale of, or other realization upon, all or any part of the Collateral owned by such Guarantor)
shall be applied to any Excluded Swap Obligation of such Guarantor; and

 

(f)          sixth,
to the extent any proceeds remain, to the Issuer or as otherwise provided by a court of competent jurisdiction.

 

    	 	89	 

     

    

 

All amounts allocated pursuant
to the foregoing clauses third through fifth to the Purchasers as a result of amounts owed to the Purchasers under
the Note Documents shall be allocated among, and distributed to, the Purchasers pro rata based on their respective Pro Rata
Shares.

 

Notwithstanding the foregoing,
Bank Product Obligations and Hedging Obligations shall be excluded from the application described above if the Collateral Agent
has not received written notice thereof (to the extent required by the terms hereof), together with such supporting documentation
as the Collateral Agent may request, from the Bank Product Provider or the Purchaser-Related Hedge Provider, as the case may be.
Each Bank Product Provider or Purchaser-Related Hedge Provider that has given the notice contemplated by the preceding sentence
shall, by such notice, be deemed to have acknowledged and accepted the appointment of the Collateral Agent pursuant to the terms
of Article IX hereof for itself and its Affiliates as if a “Purchaser” party hereto.

 

ARTICLE IX

THE COLLATERAL AGENT

 

Section 9.1           Appointment
of the Collateral Agent.

 

(a)          Each
Purchaser irrevocably appoints Wells Fargo Bank, National Association as the Collateral Agent and authorizes it to take such actions
on its behalf and to exercise such powers as are delegated to the Collateral Agent under this Agreement and the other Note Documents.
The Collateral Agent may perform any of its duties hereunder or under the other Note Documents by or through any one or more sub-agents
or attorneys-in-fact appointed by the Collateral Agent, and the Collateral Agent shall not be liable for the negligence or misconduct
of such sub-agents or attorneys-in-fact appointed with due care. The Collateral Agent and any such sub-agent or attorney-in-fact
may perform any and all of its duties and exercise its rights and powers through their respective Related Parties. The exculpatory
provisions set forth in this Article shall apply to any such sub-agent, attorney-in-fact or Related Party. Without limiting the
generality of the foregoing, each Secured Party (other than the Collateral Agent) acknowledges that it has received a copy of the
First Lien/Second Lien Intercreditor Agreement, consents to and authorizes the Collateral Agent’s execution and delivery
thereof on behalf of such Secured Party and agrees to be bound by the terms and provisions thereof, including any purchase option
contained therein.

 

    	 	90	 

     

    

 

Section 9.2           Nature
of Duties of the Collateral Agent. The Collateral Agent shall not have any duties or obligations except those expressly
set forth in this Agreement and the other Note Documents. Without limiting the generality of the foregoing, (a) the Collateral
Agent shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or an Event of Default has
occurred and is continuing, (b) the Collateral Agent shall not have any duty to take any discretionary action or exercise any discretionary
powers, except those discretionary rights and powers expressly contemplated by the Note Documents that the Collateral Agent is
directed to exercise in writing by the Required Purchasers (or such other number or percentage of the Purchasers as shall be necessary
under the circumstances as provided in Section 10.2), and the Collateral Agent shall, subject to the immediately following
proviso, take any action as directed by the Required Purchasers (or such other number or percentage of the Purchasers as shall
be necessary under the circumstances as provided in Section 10.2), provided that the Collateral Agent shall not be
required to take any action that, in its opinion or the opinion of its counsel, may expose the Collateral Agent to liability or
that is contrary to any Note Document or applicable law, including for the avoidance of doubt any action that may be in violation
of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a
Defaulting Purchaser in violation of any Debtor Relief Law; and (c) except as expressly set forth in the Note Documents, the Collateral
Agent shall not have any duty to disclose (unless required by a court or regulatory body), and shall not be liable for the failure
to disclose, any information relating to the Issuer or any of its Subsidiaries that is communicated to or obtained by the Collateral
Agent or any of its Affiliates in any capacity. The Collateral Agent shall not be liable for any action taken or not taken by it,
its sub-agents or its attorneys-in-fact with the consent or at the request of the Required Purchasers (or such other number or
percentage of the Purchasers set forth herein or in the other Note Documents). The Collateral Agent shall not be deemed to have
knowledge of any Default or Event of Default unless a Responsible Officer of the Collateral Agent (i) has actual knowledge thereof
or (ii) receives written notice thereof (which notice shall include an express reference to such event being a “Default”
or “Event of Default” hereunder), and the Collateral Agent shall not be responsible for or have any duty to ascertain
or inquire into (i) any statement, warranty or representation made in or in connection with any Note Document, (ii) the contents
of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the
performance or observance of any of the covenants, agreements, or other terms and conditions set forth in any Note Document, (iv)
the validity, enforceability, effectiveness or genuineness of any Note Document or any other agreement, instrument or document,
(v) the satisfaction of any condition set forth in Article III or elsewhere in any Note Document, other than to confirm
receipt of items expressly required to be delivered to the Collateral Agent, or (vi) any other matter hereunder or under the other
Note Documents. The Collateral Agent may consult with legal counsel (including counsel for the Issuer) concerning all matters pertaining
to such duties. In the event that the Collateral Agent receives any notice or other communication pursuant to the First Lien/Second
Lien Intercreditor Agreement, the ABDC Intercreditor Agreement or any other intercreditor agreement or subordination agreement,
the Collateral Agent shall promptly deliver a copy of such notice or other communication to each of the Purchasers.

 

Section 9.3           Lack
of Reliance on the Collateral Agent. Each of the Purchasers acknowledges that it has, independently and without reliance
upon the Collateral Agent or any other Purchaser and based on such documents and information as it has deemed appropriate, made
its own credit analysis and decision to enter into this Agreement, and that the Collateral Agent has not been, and will not be,
acting as an advisor, agent or fiduciary for such Purchaser. Each of the Purchasers also acknowledges that it will, independently
and without reliance upon the Collateral Agent or any other Purchaser and based on such documents and information as it has deemed
appropriate, continue to make its own decisions in taking or not taking any action under or based on this Agreement, any related
agreement or any document furnished hereunder or thereunder.

 

Section 9.4           Certain
Rights of the Collateral Agent. 

 

(a)          Notwithstanding
anything else to the contrary herein, whenever reference is made in this Agreement to any discretionary action by, consent, designation,
specification, requirement or approval of, notice, request or other communication from, or other direction given or action to be
undertaken or to be (or not to be) suffered or omitted by the Collateral Agent or to any election, decision, opinion, acceptance,
use of judgment, expression of satisfaction, reasonable satisfaction or other exercise of discretion, rights or remedies to be
made (or not to be made) by the Collateral Agent, it is understood that in all cases the Collateral Agent shall be acting at the
direction of the Required Purchasers. In all cases, the Collateral Agent shall be fully justified in failing or refusing to take
any such action under this Agreement if it shall not have received such written instruction, advice or concurrence of the Required
Purchasers, as it deems appropriate. Without limiting the foregoing, no Purchaser shall have any right of action whatsoever against
the Collateral Agent as a result of the Collateral Agent acting or refraining from acting hereunder in accordance with the instructions
of the Required Purchasers where required by the terms of this Agreement. If instructed to take action outside of the scope of
its duties set forth herein, the Collateral Agent shall not be required to act until it shall have received such indemnity or security
from the Purchasers as it may reasonably require for all costs, claims, losses, expenses (including reasonable legal fees and expenses)
and liabilities which it will or may expend or incur in complying or continuing to comply with such instructions.

 

    	 	91	 

     

    

 

(b)          For
purposes of clarity, phrases such as “satisfactory to the Collateral Agent”, “approved by the Collateral Agent”,
“acceptable to the Collateral Agent”, “in the Collateral Agent’s discretion”, and phrases of similar
import, except as otherwise expressly provided herein, authorize and permit the Collateral Agent to act or decline to act in its
discretion.

 

Section 9.5           Reliance
by the Collateral Agent. The Collateral Agent shall be entitled to rely upon, and shall not incur any liability for relying
upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message,
posting or other distribution) believed by it to be genuine and to have been signed, sent or made by the proper Person. The Collateral
Agent may also rely upon any statement made to it orally or by telephone and shall not incur any liability for relying thereon.
The Collateral Agent may consult with legal counsel (including counsel for the Issuer), independent public accountants and other
experts selected by it and shall not be liable for any action taken or not taken by it in accordance with the advice of such counsel,
accountants or experts.

 

Section 9.6           The
Collateral Agent in its Individual Capacity. The Person serving as the Collateral Agent shall have the same rights and
powers under this Agreement and any other Note Document in its capacity as a Purchaser (if such Person is a Purchaser) as any other
Purchaser and may exercise or refrain from exercising the same as though it were not the Collateral Agent; and the terms “Purchasers”,
“Required Purchasers”, or any similar terms shall, unless the context clearly otherwise indicates, include the Collateral
Agent in its individual capacity (if the Collateral Agent in its individual capacity is a Purchaser). The Person acting as the
Collateral Agent and its Affiliates may accept deposits from, lend money to, and generally engage in any kind of business with
the Issuer or any Subsidiary or Affiliate of the Issuer as if it were not the Collateral Agent hereunder.

 

Section 9.7           No
Filing Obligation. For the avoidance of doubt, nothing herein shall require the Collateral Agent to file financing statements,
termination statements or continuation statements, or be responsible for maintaining the security interests purported to be created
as described herein (except for the safe custody of any Collateral in its possession and the accounting for moneys actually received
by it hereunder or under any other Note Documents) and such responsibility shall be solely that of the Note Parties; provided
that, upon the written direction of the Required Purchasers, the Collateral Agent shall file financing statements, termination
statements or continuation statements. The Collateral Agent shall not be responsible for and makes no representation as to the
existence, genuineness, value or protection of any Collateral, for the legality, effectiveness or sufficiency of any Note Document,
or for the creation, perfection (or maintenance of such perfection), priority, sufficiency or protection of any liens securing
the Obligations.

 

Section 9.8           Successor
Collateral Agent.

 

(a)          The
Collateral Agent may resign at any time by giving notice thereof to the Purchasers and the Issuer. Upon any such resignation, the
Required Purchasers shall have the right to appoint a successor Collateral Agent, subject to approval by the Issuer provided that
no Default or Event of Default shall exist at such time. If no successor Collateral Agent shall have been so appointed, and shall
have accepted such appointment within 30 days after the retiring Collateral Agent gives notice of resignation, then the retiring
Collateral Agent may, on behalf of the Purchasers, appoint a successor Collateral Agent which shall be organized under the laws
of the United States or any state thereof or maintain an office in the United States.

 

    	 	92	 

     

    

 

(b)          Upon
the acceptance of its appointment as the Collateral Agent hereunder by a successor, such successor Collateral Agent shall thereupon
succeed to and become vested with all the rights, powers, privileges and duties of the retiring Collateral Agent, and the retiring
Collateral Agent shall be discharged from its duties and obligations under this Agreement and the other Note Documents. If,
within 45 days after written notice is given of the retiring Collateral Agent’s resignation under this Section, no successor
Collateral Agent shall have been appointed and shall have accepted such appointment, then on such 45th day (i) the retiring
Collateral Agent’s resignation shall become effective (except the retiring Collateral Agent shall continue to hold such collateral
security as nominee until such time as a successor Collateral Agent is appointed or the Collateral Agent can apply to a court of
competent jurisdiction to deposit funds with such court), (ii) the retiring Collateral Agent shall thereupon be discharged from
its duties and obligations under the Note Documents and (iii) the Required Purchasers shall thereafter perform all duties of the
retiring Collateral Agent under the Note Documents until such time as the Required Purchasers appoint a successor Collateral Agent
as provided above. After any retiring Collateral Agent’s resignation hereunder, the rights, protections and indemnities afforded
to the Collateral Agent in the Note Documents shall continue in effect for the benefit of such retiring or removed Collateral Agent
and its representatives and agents in respect of any actions taken or not taken by any of them while it was serving as the Collateral
Agent.

 

(c)          Any
corporation into which the Collateral Agent may be merged or converted or with which it may be consolidated, or any corporation
resulting from any merger, conversion or consolidation to which the Collateral Agent shall be a party, or any corporation succeeding
to all or substantially all of the Collateral Agent’s business, shall be the successor of the Collateral Agent hereunder,
provided such corporation shall be otherwise qualified and eligible under this Article, without the execution or filing of any
paper or any further act on the part of any of the parties hereto.

 

Section 9.9           The
Collateral Agent May File Proofs of Claim.

 

(a)          In
case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition
or other judicial proceeding relative to any Note Party, the Collateral Agent (irrespective of whether the principal of any Note
shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Collateral Agent
shall have made any demand on the Issuer) shall be entitled and empowered, by intervention in such proceeding or otherwise:

 

(i)          to
file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Notes and all other
Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims
of the Purchasers and the Collateral Agent (including any claim for the reasonable compensation, expenses, disbursements and advances
of the Purchasers and the Collateral Agent and its agents and counsel and all other amounts due the Purchasers and the Collateral
Agent hereunder or in connection herewith) allowed in such judicial proceeding; and

 

(ii)         to
collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same.

 

(b)          Any
custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby
authorized by each Purchaser to make such payments to the Collateral Agent and, if the Collateral Agent shall consent to the making
of such payments directly to the Purchasers, to pay to the Collateral Agent any amount due for the reasonable compensation, expenses,
disbursements and advances of the Collateral Agent and its agents and counsel, and any other amounts due the Collateral Agent under
this Agreement.

 

    	 	93	 

     

    

 

Nothing contained herein
shall be deemed to authorize the Collateral Agent to authorize or consent to or accept or adopt on behalf of any Purchaser any
plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Purchaser or to authorize
the Collateral Agent to vote in respect of the claim of any Purchaser in any such proceeding.

 

Section 9.10         Authorization
to Execute Other Note Documents. Each Purchaser hereby authorizes the Collateral Agent to execute on behalf of all Purchasers
all Note Documents (including, without limitation, the First Lien/Second Lien Intercreditor Agreement, the Collateral Documents
and any subordination agreements) other than this Agreement.

 

Section 9.11         Collateral
and Guaranty Matters. The Purchasers irrevocably authorize the Collateral Agent, at its option and in its discretion:

 

(a)          to
release any Lien on any property granted to or held by the Collateral Agent under any Note Document (i) upon the payment in full
of all Obligations (other than Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product
Obligations and indemnities and other contingent obligations not then due and payable and as to which no claim has been made),
(ii) that is sold or to be sold as part of or in connection with any sale permitted hereunder or under any other Note Document,
or (iii) if approved, authorized or ratified in writing in accordance with Section 10.2; and

 

(b)          to
release any Note Party from its obligations under the applicable Collateral Documents if such Person ceases to be a Subsidiary
as a result of a transaction permitted hereunder.

 

Upon confirmation in writing from the Required
Purchasers of the Collateral Agent’s authority to release its interest in particular types or items of property, or to release
any Note Party from its obligations under the applicable Collateral Documents pursuant to this Section, the Collateral Agent will
so release its interest such types or items of property, or release such Note Party from its obligations under the applicable Collateral
Documents. In each case as specified in this Section, the Collateral Agent is authorized, at the Issuer’s expense, to execute
and deliver to the applicable Note Party such documents as such Note Party may reasonably request to evidence the release of such
item of Collateral from the Liens granted under the applicable Collateral Documents, or to release such Note Party from its obligations
under the applicable Collateral Documents, in each case in accordance with the terms of the Note Documents and this Section.

 

Section 9.12         Right
to Realize on Collateral and Enforce Guarantee. Anything contained in any of the Note Documents to the contrary notwithstanding,
the Issuer, the Collateral Agent and each Purchaser hereby agree that (i) no Purchaser shall have any right individually to realize
upon any of the Collateral or to enforce the Collateral Documents, it being understood and agreed that all powers, rights and remedies
under the Collateral Documents may be exercised solely by the Collateral Agent, and (ii) in the event of a foreclosure by the Collateral
Agent on any of the Collateral pursuant to a public or private sale or other disposition, the Collateral Agent or any Purchaser
may be the purchaser or licensor of any or all of such Collateral at any such sale or other disposition and the Collateral Agent,
as agent for and representative of the Purchasers (but not any Purchaser or Purchasers in its or their respective individual capacities
unless the Required Purchasers shall otherwise agree in writing), shall be entitled, for the purpose of bidding and making settlement
or payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of
the Obligations as a credit on account of the purchase price for any collateral payable by the Collateral Agent at such sale or
other disposition.

 

    	 	94	 

     

    

 

Section 9.13         Secured
Bank Product Obligations and Hedging Obligations. No Bank Product Provider or Purchaser-Related Hedge Provider that obtains
the benefits of Section 8.2, the Collateral Documents or any Collateral by virtue of the provisions hereof or of any other
Note Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under
any other Note Document or otherwise in respect of the Collateral (including the release or impairment of any Collateral) other
than in its capacity as a Purchaser and, in such case, only to the extent expressly provided in the Note Documents. Notwithstanding
any other provision of this Article to the contrary, the Collateral Agent shall not be required to verify the payment of, or that
other satisfactory arrangements have been made with respect to, Bank Product Obligations and Hedging Obligations unless the Collateral
Agent has received written notice of such Obligations, together with such supporting documentation as the Collateral Agent may
request, from the applicable Bank Product Provider or Purchaser-Related Hedge Provider, as the case may be.

 

Section 9.14         ABDC
INTERCREDITOR AGREEMENT. EACH PURCHASER (A) AGREES THAT IT WILL BE BOUND BY, AND WILL TAKE NO ACTIONS CONTRARY TO, THE
PROVISIONS OF THE ABDC INTERCREDITOR AGREEMENT, (B) AUTHORIZES AND INSTRUCTS THE COLLATERAL AGENT TO ENTER INTO THE ABDC INTERCREDITOR
AGREEMENT AS COLLATERAL AGENT ON BEHALF OF SUCH PURCHASER, AND TO TAKE ALL ACTIONS (AND EXECUTE ALL DOCUMENTS) REQUIRED (OR DEEMED
ADVISABLE) IN ACCORDANCE WITH THE TERMS OF THE ABDC INTERCREDITOR AGREEMENT, AND (C) ACKNOWLEDGES THAT A COPY OF THE ABDC INTERCREDITOR
AGREEMENT WAS MADE AVAILABLE TO SUCH PURCHASER AND THAT SUCH PURCHASER REVIEWED THE ABDC INTERCREDITOR AGREEMENT. NOT IN LIMITATION
OF THE FOREGOING, EACH PURCHASER HEREBY AGREES THAT THE COLLATERAL AGENT SHALL EXERCISE ALL RIGHTS AND REMEDIES UNDER THE ABDC
INTERCREDITOR AGREEMENT ON BEHALF OF SUCH PURCHASER.

 

Section 9.15         FIRST
LIEN/SECOND LIEN INTERCREDITOR AGREEMENT. EACH PURCHASER (A) AGREES THAT IT WILL BE BOUND BY, AND WILL TAKE NO ACTIONS
CONTRARY TO, THE PROVISIONS OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT, (B) AUTHORIZES AND INSTRUCTS THE COLLATERAL
AGENT TO ENTER INTO THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT AS COLLATERAL AGENT ON BEHALF OF SUCH PURCHASER, AND TO
TAKE ALL ACTIONS (AND EXECUTE ALL DOCUMENTS) REQUIRED (OR DEEMED ADVISABLE) IN ACCORDANCE WITH THE TERMS OF THE FIRST LIEN/SECOND
LIEN INTERCREDITOR AGREEMENT, AND (C) ACKNOWLEDGES THAT A COPY OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT WAS MADE AVAILABLE
TO SUCH PURCHASER AND THAT SUCH PURCHASER REVIEWED THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT. EACH PURCHASER IS RESPONSIBLE
FOR MAKING ITS OWN ANALYSIS OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT AND THE TERMS AND PROVISIONS THEREOF, AND NEITHER
THE COLLATERAL AGENT NOR ANY OF ITS AFFILIATES MAKES ANY REPRESENTATION TO ANY PURCHASER AS TO THE SUFFICIENCY OR THE ADVISABILITY
OF THE PROVISIONS CONTAINED THEREIN. NOT IN LIMITATION OF THE FOREGOING, EACH PURCHASER HEREBY AGREES THAT THE COLLATERAL AGENT
SHALL EXERCISE ALL RIGHTS AND REMEDIES UNDER THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT ON BEHALF OF SUCH PURCHASER AND
IN THE EVENT OF AN INCONSISTENCY BETWEEN THIS AGREEMENT AND THE TERMS OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT, THE
TERMS OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT SHALL GOVERN. THE FOREGOING PROVISIONS ARE INTENDED AS AN INDUCEMENT
TO THE PURCHASERS UNDER THE SECOND LIEN NOTE PURCHASE AGREEMENT TO PURCHASE NOTES PURSUANT THERETO AND SUCH PURCHASERS ARE THE
INTENDED THIRD PARTY BENEFICIARIES OF SUCH PROVISIONS AND THE PROVISIONS OF THE FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT.

 

    	 	95	 

     

    

 

ARTICLE X

MISCELLANEOUS

 

Section 10.1         Notices.

 

(a)           Written
Notices.

 

(i)          Except
in the case of notices and other communications expressly permitted to be given by telephone, all notices and other communications
to any party herein to be effective shall be in writing and shall be delivered by hand or overnight courier service, mailed by
certified or registered mail or sent by telecopy, as follows:

 

	To the Issuer:	BioScrip, Inc.
	 	1600 Broadway, Suite 700
	 	Denver, CO 80202
	 	Attn:  Stephen Deitsch, Senior Vice President, Chief Financial Officer & Treasurer
	 	Telecopy Number: (720) 468-4040
	 	 
	With a copy to (for Information purposes only):	Dechert LLP
	 	1095 Avenue of the Americas 
	 	New York, New York 10036
	 	Attention: Scott M. Zimmerman 
	 	Telecopy Number: (212) 698-3599
	 	 
	To the Collateral Agent:	Wells Fargo Bank, National Association 
	 	9062 Old Annapolis Road
	 	Columbia, Maryland 21045
	 	Attention: Jason Prisco – BioScrip, Inc. First Lien NPA
	 	Email: CTSBankDebtAdministrationTeam@wellsfargo.com
	 	 
	To any other Purchaser:	the address set forth on the applicable signature page hereto

 

Any party hereto may change
its address or telecopy number for notices and other communications hereunder by notice to the other parties hereto. All such notices
and other communications shall be effective upon actual receipt by the relevant Person or, if delivered by overnight courier service,
upon the first Business Day after the date deposited with such courier service for overnight (next-day) delivery or, if sent by
telecopy, upon transmittal in legible form by facsimile machine or, if mailed, upon the third Business Day after the date deposited
into the mail or, if delivered by hand, upon delivery; provided that notices delivered to the Collateral Agent or any Purchaser
shall not be effective until actually received by such Person at its address specified in this Section.

 

    	 	96	 

     

    

 

(ii)         Any
agreement of the Collateral Agent or any Purchaser herein to receive certain notices by telephone or facsimile is solely for the
convenience and at the request of the Issuer. The Collateral Agent and each Purchaser shall be entitled to rely on the authority
of any Person purporting to be a Person authorized by the Issuer to give such notice and the Collateral Agent and the Purchasers
shall not have any liability to the Issuer or other Person on account of any action taken or not taken by the Collateral Agent
or any Purchaser in reliance upon such telephonic or facsimile notice. The obligation of the Issuer to repay the Notes and all
other Obligations hereunder shall not be affected in any way or to any extent by any failure of the Collateral Agent or any Purchaser
to receive written confirmation of any telephonic or facsimile notice or the receipt by the Collateral Agent or any Purchaser of
a confirmation which is at variance with the terms understood by the Collateral Agent and such Purchaser to be contained in any
such telephonic or facsimile notice.

 

(b)           Electronic
Communications.

 

(i)          Notices
and other communications to the Collateral Agent and each Purchaser hereunder may be delivered or furnished by electronic communication
(including e-mail and Internet or intranet websites) pursuant to procedures approved by such Person. The Issuer may, in its discretion,
agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by
it; provided that approval of such procedures may be limited to particular notices or communications.

 

(ii)         Unless
the Collateral Agent or any Purchaser otherwise prescribes, (i) notices and other communications sent to an e-mail address of such
Person shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the
“return receipt requested” function, as available, return e-mail or other written acknowledgement); provided
that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication
shall be deemed to have been sent at the opening of business on the next Business Day for the recipient, and (ii) notices or communications
posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail
address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying
the website address therefor.

 

Section 10.2         Waiver;
Amendments.

 

(a)          No
failure or delay by the Collateral Agent or any Purchaser in exercising any right or power hereunder or under any other Note Document,
and no course of dealing between the Issuer and the Collateral Agent or any Purchaser, shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such
right or power, preclude any other or further exercise thereof or the exercise of any other right or power hereunder or thereunder.
The rights and remedies of the Collateral Agent and the Purchasers hereunder and under the other Note Documents are cumulative
and are not exclusive of any rights or remedies provided by law. No waiver of any provision of this Agreement or of any other Note
Document or consent to any departure by the Issuer or any other Note Party therefrom shall in any event be effective unless the
same shall be permitted by clause (b) of this Section, and then such waiver or consent shall be effective only in the specific
instance and for the purpose for which given. Without limiting the generality of the foregoing, the purchase of a Note shall not
be construed as a waiver of any Default or Event of Default, regardless of whether the Collateral Agent or any Purchaser may have
had notice or knowledge of such Default or Event of Default at the time.

 

    	 	97	 

     

    

 

(b)           No
amendment or waiver of any provision of this Agreement or of the other Note Documents (other than the Fee Letters), nor consent
to any departure by the Issuer or any other Note Party therefrom, shall in any event be effective unless the same shall be in writing
and signed by the Issuer and the Required Purchasers, or the Issuer and the Collateral Agent with the consent of the Required Purchasers,
and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which
given; provided that, in addition to the consent of the Required Purchasers, no amendment, waiver or consent shall:

 

(i)          increase
the Commitment of any Purchaser without the written consent of such Purchaser;

 

(ii)         reduce
the principal amount of any Note or reduce the rate of interest thereon, or reduce any fees payable hereunder, without the written
consent of each Purchaser affected thereby (except that any waiver of post-default rates of interests shall not constitute a reduction
in the rate of interest or fees for purposes of this clause (ii));

 

(iii)        postpone
or extend the date fixed for any payment of any principal of, or interest on, any Note or any fees hereunder or reduce the amount
of, waive or excuse any such payment, or postpone the scheduled date for the termination or reduction of any Commitment, without
the written consent of each Purchaser affected thereby (it being understood that a waiver of any condition precedent or the waiver
of any Default, Event of Default or mandatory prepayment shall not constitute a postponement, extension or increase of any Note
or Commitment hereunder);

 

(iv)        change
Section 8.2 without the written consent of each Purchaser affected thereby;

 

(v)         change
Section 2.18 in a manner that would alter the pro rata sharing of payments required thereby, without the written
consent of each Purchaser;

 

(vi)        change
any of the provisions of this clause (b) or the definition of “Required Purchasers” or any other provision hereof specifying
the number or percentage of Purchasers which are required to waive, amend or modify any rights hereunder or make any determination
or grant any consent hereunder, without the consent of each Purchaser;

 

(vii)       except
in connection with a transaction otherwise not prohibited by this Agreement or any other Note Document, release all or substantially
all of the value of any Guarantee guarantying any of the Obligations, or release all or substantially all of the guarantors, or
limit the liability of such guarantors, under any guaranty agreement guaranteeing any of the Obligations, in each case, without
the written consent of each Purchaser; or

 

(viii)      release
all or substantially all of the Collateral securing the Obligations, without the written consent of each Purchaser;

 

provided, further, that no such
amendment, waiver or consent shall amend, modify or otherwise affect the rights, duties or obligations of the Collateral Agent
without the prior written consent of the Collateral Agent.

 

Notwithstanding anything
to the contrary herein, no Defaulting Purchaser shall have any right to approve or disapprove any amendment, waiver or consent
hereunder, except that the Commitment of such Purchaser may not be increased or extended, and amounts payable to such Purchaser
hereunder may not be permanently reduced, without the consent of such Purchaser (other than reductions in fees and interest in
which such reduction does not disproportionately affect such Purchaser).

 

    	 	98	 

     

    

 

Section 10.3         Expenses;
Indemnification.

 

(a)          The
Issuer shall pay (i) the expenses required to be reimbursed pursuant to the Commitment Letter, (ii) all fees agreed to from time
to time between the Issuer and the Collateral Agent and the reasonable and documented costs and expenses of the Collateral Agent
and its Affiliates in connection with the preparation and administration of the Note Documents and all reasonable and documented
costs and expenses of the Collateral Agent, the Purchasers and their respective Affiliates in connection with any amendments, modifications
or waivers thereof (whether or not the transactions contemplated in this Agreement or any other Note Document shall be consummated),
and the due diligence relating thereto (including the reasonable and documented fees, disbursements, and expenses of one outside
counsel to the Collateral Agent and one outside counsel to each Purchaser (and any required special or local counsel)), and (iii)
all documented costs and expenses incurred by the Collateral Agent or any Purchaser (including the documented fees, disbursements,
and expenses of one outside counsel to each such party (and any required special or local counsel to each such party)) in connection
with the enforcement or protection of its rights, and the discharge of its duties, in connection with the Note Documents, including
its rights under this Section, or in connection with the Notes purchased hereunder, including all such documented costs and expenses
incurred during any workout, restructuring or negotiations in respect of such Notes.

 

(b)          The
Issuer shall indemnify the Collateral Agent and each Purchaser, and each Related Party of any of the foregoing Persons (each such
Person and Related Party being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any
and all losses, claims, damages, liabilities and expenses (including the fees, disbursements, and expenses of any counsel for any
Indemnitee), and shall reimburse each Indemnitee upon demand for any legal or other expenses incurred in connection with investigating
or defending any of the following, incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Issuer
or any other Note Party or any of their Subsidiaries or Affiliates arising out of, in connection with, or as a result of (i) the
execution or delivery of this Agreement, any other Note Document or any agreement or instrument contemplated hereby or thereby,
the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions
contemplated hereby or thereby, (ii) any Note or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged
presence or Release of Hazardous Materials on or from any property owned or operated by the Issuer or any of its Subsidiaries,
or any Environmental Liability related in any way to the Issuer or any of its Subsidiaries, or (iv) any actual or prospective suit,
claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory,
whether brought by a third party or by the Issuer or any other Note Party or by the Issuer’s equity holders, Affiliates or
creditors, and regardless of whether any Indemnitee or the Issuer is a party thereto; provided that such indemnity shall
not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or other expenses are determined
by a court of competent jurisdiction by final and non-appealable judgment to have resulted from (A) the gross negligence or willful
misconduct of such Indemnitee or (B) other than with respect to the Collateral Agent and its Related Parties, a material breach
by such Indemnitee of any of its undertakings, obligations or commitments under this Agreement or any other Note Documents (except
that, regardless of its action or inaction, the Collateral Agent shall have no liability in connection with (iii) above). No Indemnitee
shall be responsible or liable for any damages arising from the use by others of any information or other materials obtained through
Syndtrak, Intralinks, any other Internet or intranet website, or any other electronic, telecommunications or other information
transmission systems, except to the extent that such damages are determined by a court of competent jurisdiction by final and non-appealable
judgment to have resulted from (A) the gross negligence or willful misconduct of such Indemnitee or (B) other than with respect
to the Collateral Agent and its Related Parties, a material breach by such Indemnitee of any of its undertakings, obligations or
commitments under this Agreement or any other Note Documents.

 

    	 	99	 

     

    

 

(c)          This
Section 10.3 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, liabilities
and related expenses arising from any non-Tax claim.

 

(d)          To
the extent that the Issuer fails to pay any amount required to be paid to the Collateral Agent under clause (a), (b) or (c) hereof,
each Purchaser severally agrees to pay to the Collateral Agent such Purchaser’s pro rata share (in accordance with
the aggregate outstanding principal amount of the Note(s) held by it determined as of the time that the unreimbursed expense or
indemnity payment is sought) of such unpaid amount; provided that the unreimbursed expense or indemnified payment, claim,
damage, liability or related expense, as the case may be, was incurred by or asserted against the Collateral Agent in its capacity
as such. Additionally, each Purchaser shall not assert any claim against the Collateral Agent on any theory of liability for special,
consequential, exemplary or punitive damages arising out of or in connection with any Note Document.

 

(e)          To
the extent permitted by applicable law, the Issuer shall not assert, and hereby waives, any claim against any Indemnitee, on any
theory of liability, for special, indirect, consequential, exemplary or punitive damages (as opposed to actual or direct damages)
arising out of, in connection with or as a result of this Agreement, any other Note Document or any agreement or instrument contemplated
hereby, the transactions contemplated therein, any Note or the use of proceeds thereof.

 

(f)          All
amounts due under this Section shall be payable promptly after written demand therefor.

 

Section 10.4         Successors
and Assigns.

 

(a)          The
provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns permitted hereby, except that the Issuer may not assign or otherwise transfer any of its rights or obligations hereunder
without the prior written consent of the Collateral Agent and each Purchaser, and no Purchaser may assign or otherwise transfer
any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of clause (b) of this Section,
(ii) by way of participation in accordance with the provisions of clause (d) of this Section or (iii) by way of pledge or assignment
of a security interest subject to the restrictions of clause (f) of this Section (and any other attempted assignment or transfer
by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon
any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent
provided in clause (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Collateral
Agent and the Purchasers) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 

(b)          Any
Purchaser may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including
all or a portion of its Commitments and Notes at the time owing to it); provided that any such assignment shall be subject
to the following conditions:

 

(i)            Minimum
Amounts.

 

(A)         in
the case of an assignment of the entire remaining amount of the assigning Purchaser’s Commitments and Notes at the time owing
to it or in the case of an assignment to a Purchaser, an Affiliate of a Purchaser or an Approved Fund, no minimum amount need be
assigned; and

 

    	 	100	 

     

    

 

(B)         in
any case not described in clause (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes
Notes outstanding thereunder) or, if the applicable Commitment is not then in effect, the outstanding principal balance of the
Notes of the assigning Purchaser subject to each such assignment (determined as of the date the Assignment and Assumption with
respect to such assignment is delivered to the Issuer or, if “Trade Date” is specified in the Assignment and Assumption,
as of the Trade Date) shall not be less than $1,000,000 and in minimum increments of $1,000,000, unless, so long as no Event of
Default has occurred and is continuing, the Issuer otherwise consents (each such consent not to be unreasonably withheld or delayed).

 

(ii)           Proportionate
Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Purchaser’s
rights and obligations under this Agreement with respect to the Notes or the Commitments assigned.

 

(iii)          Required
Consents. No consent shall be required for any assignment except to the extent required by clause (b)(i)(B) of this Section
and, in addition:

 

(A)         the
consent of the Issuer (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default
has occurred and is continuing at the time of such assignment or (y) such assignment is to a Purchaser, an Affiliate of such
Purchaser or an Approved Fund of such Purchaser; provided, that the Issuer shall be deemed to have consented to any such
assignment unless it objects thereto by written notice to the assigning Purchaser within five (5) Business Days after having received
notice thereof; provided, further, that any refusal by the Issuer to consent to an assignment to a Disqualified Institution
shall not be deemed unreasonable.

 

(iv)          Assignment
and Assumption. The parties to each assignment shall deliver to the Issuer (A) a duly executed Assignment and Assumption, together
with any Note subject to such assignment, (B) unless the assignee is already a Purchaser, a designation of one or more contacts
to whom all Note information (which may contain material non-public information about the Issuer and its Subsidiaries and their
Related Parties or their securities) will be made available and who may receive such information in accordance with the assignee’s
compliance procedures and applicable law, Federal, state and foreign securities laws and (C) the documents required under Section
2.17(f), and the Issuer shall record such assignment in the Register.

 

(v)           No
Assignment to the certain Persons. No such assignment shall be made to (A) the Issuer or any of the Issuer’s Affiliates
or Subsidiaries, (B) any Defaulting Purchaser or any of its Subsidiaries, or any Person who, upon becoming a Purchaser hereunder,
would constitute any of the foregoing Persons described in this clause (B), (C) so long as no Event of Default is in existence,
any Disqualified Institution or (D) any Person (other than an existing Purchaser or an Affiliate or Approved Fund of an existing
Purchaser) that is not an “accredited investor” (as defined in Regulation D of the Securities Act).

 

(vi)          No
Assignment to Natural Persons. No such assignment shall be made to a natural person.

 

    	 	101	 

     

    

 

Subject to acceptance and recording thereof
by the Issuer pursuant to clause (c) of this Section, from and after the effective date specified in each Assignment and Assumption,
the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption,
have the rights and obligations of a Purchaser under this Agreement, and the assigning Purchaser thereunder shall, to the extent
of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the
case of an Assignment and Assumption covering all of the assigning Purchaser’s rights and obligations under this Agreement,
such Purchaser shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 2.15,
2.16, 2.17 and 10.3 with respect to facts and circumstances occurring prior to the effective date of such
assignment; provided that, except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting
Purchaser will constitute a waiver or release of any claim of any party hereunder arising from such Purchaser’s having been
a Defaulting Purchaser.  Any assignment or transfer by a Purchaser of rights or obligations under this Agreement that does
not comply with this clause shall be treated for purposes of this Agreement as a sale by such Purchaser of a participation in such
rights and obligations in accordance with clause (d) of this Section. If the consent of the Issuer to an assignment is required
hereunder (including a consent to an assignment which does not meet the minimum assignment thresholds specified above), the Issuer
shall be deemed to have given its consent unless it shall object thereto by written notice to assigning Purchaser within five (5)
Business Days after notice thereof has actually been delivered by the assigning Purchaser to the Issuer.

 

(c)          The
Issuer shall maintain at one of its offices in Denver, CO a copy of each Assignment and Acceptance delivered to it and a register
for the recordation of the names and addresses of the Purchasers, and the Commitments of, and principal and interest amount of
the Notes owing to, each Purchaser pursuant to the terms hereof from time to time (the “Register”). The entries
in the Register shall be conclusive absent manifest error, and the Issuer, the Collateral Agent and the Purchasers shall treat
each Person whose name is recorded in the Register pursuant to the terms hereof as a Purchaser hereunder for all purposes of this
Agreement. Information contained in the Register with respect to any Purchaser shall be available for inspection by such Purchaser
at any reasonable time and from time to time upon reasonable prior notice. The Collateral Agent shall have the right, at any time,
to request a copy of the Register.

 

(d)          Any
Purchaser may at any time, without the consent of, or notice to, the Issuer, sell participations to any Person (other than a natural
person, the Issuer, any of the Issuer’s Affiliates or Subsidiaries, or any Competitor) (each, a “Participant”)
in all or a portion of such Purchaser’s rights and/or obligations under this Agreement (including all or a portion of its
Commitment and/or the Notes owing to it); provided that (i) such Purchaser’s obligations under this Agreement
shall remain unchanged, (ii) such Purchaser shall remain solely responsible to the other parties hereto for the performance
of such obligations and (iii) the Issuer, the Collateral Agent and the other Purchasers shall continue to deal solely and
directly with such Purchaser in connection with such Purchaser’s rights and obligations under this Agreement.

 

Any agreement or instrument
pursuant to which a Purchaser sells such a participation shall provide that such Purchaser shall retain the sole right to enforce
this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such
agreement or instrument may provide that such Purchaser will not, without the consent of the Participant, agree to any amendment,
modification or waiver with respect to the following to the extent affecting such Participant: (i) increase the Commitment of such
Purchaser; (ii) reduce the principal amount of any Note or reduce the rate of interest thereon, or reduce any fees payable
hereunder; (iii) postpone the date fixed for any payment of any principal of, or interest on, any Note or any fees hereunder
or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date for the termination or reduction of any
Commitment; (iv) change Section 2.18 in a manner that would alter the pro rata sharing of payments required thereby;
(v) change any of the provisions of Section 10.2(b) or the definition of “Required Purchasers” or any other
provision hereof specifying the number or percentage of Purchasers which are required to waive, amend or modify any rights hereunder
or make any determination or grant any consent hereunder; (vi) release all or substantially all of the guarantors, or limit the
liability of such guarantors, under any guaranty agreement guaranteeing any of the Obligations; or (vii) release all or substantially
all collateral (if any) securing any of the Obligations. Subject to clause (e) of this Section, the Issuer agrees that each Participant
shall be entitled to the benefits of Sections 2.15, 2.16, and 2.17 to the same extent as if it were a Purchaser
and had acquired its interest by assignment pursuant to clause (b) of this Section; provided that such Participant agrees
to be subject to Section 2.19 as though it were a Purchaser. To the extent permitted by law, each Participant also shall
be entitled to the benefits of Section 10.7 as though it were a Purchaser; provided that such Participant agrees
to be subject to Section 2.18 as though it were a Purchaser.

 

    	 	102	 

     

    

 

Each Purchaser that sells
a participation shall, acting solely for this purpose as an agent of the Issuer, maintain a register in the United States on which
it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s
interest in the Notes or other obligations under the Note Documents (the “Participant Register”). The entries
in the Participant Register shall be conclusive, absent manifest error, and such Purchaser shall treat each person whose name is
recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any
notice to the contrary. The Issuer shall have inspection rights to such Participant Register (upon reasonable prior notice to the
applicable Purchaser) solely for purposes of demonstrating that such Notes or other obligations under the Note Documents are in
“registered form” for purposes of the Code.

 

(e)          A
Participant shall not be entitled to receive any greater payment under Sections 2.15 and 2.17 than the applicable
Purchaser would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the
participation to such Participant is made with the Issuer’s prior written consent. A Participant shall not be entitled to
the benefits of Section 2.17 unless the Issuer is notified of the participation sold to such Participant and
such Participant agrees, for the benefit of the Issuer, to comply with Section 2.17(e) and (f) as though it were
a Purchaser.

 

(f)          Any
Purchaser may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure
obligations of such Purchaser, including, without limitation, any pledge or assignment to secure obligations to a Federal Reserve
Bank; provided that no such pledge or assignment shall release such Purchaser from any of its obligations hereunder or substitute
any such pledgee or assignee for such Purchaser as a party hereto.

 

Section 10.5         Governing
Law; Jurisdiction; Consent to Service of Process.

 

(a)          This
Agreement and the other Note Documents and any claims, controversy, dispute or cause of action (whether in contract or tort or
otherwise) based upon, arising out of or relating to this Agreement or any other Note Document (except, as to any other Note Document,
as expressly set forth therein) and the transactions contemplated hereby and thereby shall be construed in accordance with and
be governed by the law of the State of New York.

 

(b)          The
Issuer hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the United
States District Court for the Southern District of New York, and of the Supreme Court of the State of New York sitting in New York
county, and of any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or
any other Note Document or the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment,
and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in such District Court or New York state court or, to the extent permitted by applicable law, such
appellate court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and
may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement
or any other Note Document shall affect any right that the Collateral Agent or any Purchaser may otherwise have to bring any action
or proceeding relating to this Agreement or any other Note Document against the Issuer or its properties in the courts of any jurisdiction.

 

    	 	103	 

     

    

 

(c)          The
Issuer irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue of any
such suit, action or proceeding described in clause (b) of this Section and brought in any court referred to in clause (b) of this
Section. Each of the parties hereto irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient
forum to the maintenance of such action or proceeding in any such court.

 

(d)          Each
party to this Agreement irrevocably consents to the service of process in the manner provided for notices in Section 10.1.
Nothing in this Agreement or in any other Note Document will affect the right of any party hereto to serve process in any other
manner permitted by law.

 

Section 10.6         WAIVER
OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF THIS AGREEMENT OR ANY OTHER NOTE DOCUMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A)
CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER
PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES
HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER NOTE DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION.

 

Section 10.7         Right
of Set-off. In addition to any rights now or hereafter granted under applicable law and not by way of limitation of any
such rights, each Purchaser shall have the right, at any time or from time to time upon the occurrence and during the continuance
of an Event of Default, without prior notice to the Issuer, any such notice being expressly waived by the Issuer to the extent
permitted by applicable law, to set off and apply against all deposits (general or special, time or demand, provisional or final)
of the Issuer at any time held or other obligations at any time owing by such Purchaser to or for the credit or the account of
the Issuer against any and all Obligations held by such Purchaser, irrespective of whether such Purchaser shall have made demand
hereunder and although such Obligations may be unmatured; provided that in the event that any Defaulting Purchaser shall
exercise any such right of setoff, (x) all amounts so set off shall be applied in accordance with the provisions of Section
2.21(a) and, pending such application, shall be segregated by such Defaulting Purchaser from its other funds and deemed held
in trust for the benefit of the applicable recipients, and (y) the Defaulting Purchaser shall provide promptly to the Collateral
Agent and the other Purchasers a statement describing in reasonable detail the Obligations owing to such Defaulting Purchaser as
to which it exercised such right of setoff. Each Purchaser agrees promptly to notify the Issuer after any such set-off and any
application made by such Purchaser; provided that the failure to give such notice shall not affect the validity of such
set-off and application. Each Purchaser agrees to apply all amounts collected from any such set-off to the Obligations before applying
such amounts to any other Indebtedness or other obligations owed by the Issuer and any of its Subsidiaries to such Purchaser.

 

Section 10.8         Counterparts;
Integration. This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts,
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. This Agreement, the Fee
Letters, the other Note Documents, and any separate letter agreements relating to any fees payable to the Collateral Agent and
its Affiliates constitute the entire agreement among the parties hereto and thereto and their affiliates regarding the subject
matters hereof and thereof and supersede all prior agreements and understandings, oral or written, regarding such subject matters.
Delivery of an executed counterpart to this Agreement or any other Note Document by facsimile transmission or by electronic mail
in pdf format shall be as effective as delivery of a manually executed counterpart hereof.

 

    	 	104	 

     

    

 

Section 10.9         Survival.
All covenants, agreements, representations and warranties made by the Issuer herein and in the certificates, reports, notices
or other instruments delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by
the other parties hereto and shall survive the execution and delivery of this Agreement and the other Note Documents and the issuance
and purchase of any Notes, regardless of any investigation made by any such other party or on its behalf and notwithstanding that
the Collateral Agent or any Purchaser may have had notice or knowledge of any Default or incorrect representation or warranty at
the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued
interest on any Note or any fee or any other amount payable under this Agreement is outstanding and unpaid and so long as the Commitments
have not expired or terminated. The provisions of Sections 2.15, 2.16, 2.17, and 10.3 and Article
IX shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby,
the repayment of the Notes, the expiration or termination of the Commitments or the termination of this Agreement or any provision
hereof.

 

Section 10.10         Severability.
Any provision of this Agreement or any other Note Document held to be illegal, invalid or unenforceable in any jurisdiction,
shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting
the legality, validity or enforceability of the remaining provisions hereof or thereof; and the illegality, invalidity or unenforceability
of a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other
jurisdiction.

 

Section 10.11         Confidentiality.
Each of the Collateral Agent and the Purchasers agrees to take normal and reasonable precautions to maintain the confidentiality
of any information relating to the Issuer or any of its Subsidiaries or any of their respective businesses, to the extent designated
in writing as confidential and provided to it by the Issuer or any of its Subsidiaries, other than any such information that is
available to the Collateral Agent or any Purchaser on a non-confidential basis prior to disclosure by the Issuer or any of its
Subsidiaries, except that such information may be disclosed (i) to any Related Party of the Collateral Agent or any such Purchaser
including, without limitation, accountants, legal counsel and other advisors (and to other persons authorized by the Collateral
Agent or a Purchaser to organize, present or disseminate such information in connection with disclosures otherwise made in accordance
with this Section 10.11), (ii) to the extent required by applicable laws or regulations or by any subpoena or similar legal
process, (iii) to the extent requested by any regulatory agency or authority purporting to have jurisdiction over it (including
any self-regulatory authority such as the National Association of Insurance Commissioners), (iv) to the extent that such information
becomes publicly available other than as a result of a breach of this Section, or which becomes available to the Collateral Agent,
any Purchaser or any Related Party of any of the foregoing on a non-confidential basis from a source other than the Issuer or any
of its Subsidiaries, (v) in connection with the exercise of any remedy hereunder or under any other Note Documents or any suit,
action or proceeding relating to this Agreement or any other Note Documents or the enforcement of rights hereunder or thereunder,
(vi) subject to execution by such Person of an agreement containing provisions substantially the same as those of this Section,
to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under
this Agreement, or (B) any actual or prospective party (or its Related Parties) to any swap or derivative or other transaction
under which payments are to be made by reference to the Issuer and its obligations, this Agreement or payments hereunder, (vii)
to any rating agency, (viii) to the CUSIP Service Bureau or any similar organization, (ix) to any Purchaser’s financing sources;
provided that, prior to any disclosure, such financing source is informed of the confidential nature of such information,
or (x) with the consent of the Issuer. Any Person required to maintain the confidentiality of any information as provided for in
this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of
care to maintain the confidentiality of such information as such Person would accord its own confidential information. Furthermore,
the Note Parties and the Purchasers shall not, without the prior written consent of the applicable Purchaser, in each instance,
(a) use in advertising, publicity, or otherwise the name of such Purchaser or any of its Affiliates, or any partner or employee
of such Purchaser or any of its Affiliates, or (b) represent that any product or any service provided has been approved or endorsed
by any Purchaser, or any of its Affiliates. In the event of any conflict between the terms of this Section and those of any other
Contractual Obligation entered into with any Note Party (whether or not a Note Document), the terms of this Section shall govern.

 

    	 	105	 

     

    

 

Section 10.12         Interest
Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Note,
together with all fees, charges and other amounts which may be treated as interest on such Note under applicable law (collectively,
the “Charges”), shall exceed the maximum lawful rate of interest (the “Maximum Rate”) which
may be contracted for, charged, taken, received or reserved by a Purchaser holding such Note in accordance with applicable law,
the rate of interest payable in respect of such Note hereunder, together with all Charges payable in respect thereof, shall be
limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such
Note but were not payable as a result of the operation of this Section shall be cumulated and the interest and Charges payable
to such Purchaser in respect of other Notes or periods shall be increased (but not above the Maximum Rate therefor) until such
cumulated amount, together with interest thereon at the Federal Funds Rate to the date of repayment (to the extent permitted by
applicable law), shall have been received by such Purchaser.

 

Section 10.13         Waiver
of Effect of Corporate Seal. The Issuer represents and warrants that neither it nor any other Note Party is required to
affix its corporate seal to this Agreement or any other Note Document pursuant to any Requirement of Law, agrees that this Agreement
is delivered by the Issuer under seal and waives any shortening of the statute of limitations that may result from not affixing
the corporate seal to this Agreement or such other Note Documents.

 

Section 10.14         Patriot
Act. The Collateral Agent and each Purchaser hereby notifies the Note Parties that, pursuant to the requirements of the
Patriot Act, it is required to obtain, verify and record information that identifies each Note Party, which information includes
the name and address of such Note Party and other information that will allow such Purchaser or the Collateral Agent, as applicable,
to identify such Note Party in accordance with the Patriot Act. The Note Parties agree to cooperate with the Collateral Agent and
each Purchaser and provide the information required in this Section.

 

    	 	106	 

     

    

 

Section 10.15         No
Advisory or Fiduciary Responsibility. 

 

(a)          In
connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other
modification hereof or of any other Note Document), the Issuer and each other Note Party acknowledges and agrees and acknowledges
its Affiliates’ understanding that (i) (A) the services regarding this Agreement provided by the Collateral Agent and/or
the Purchasers are arm’s-length commercial transactions between the Issuer, each other Note Party and their respective Affiliates,
on the one hand, and the Collateral Agent and the Purchasers, on the other hand, (B) each of the Issuer and the other Note Parties
have consulted their own legal, accounting, regulatory and tax advisors to the extent they have deemed appropriate, and (C) the
Issuer and each other Note Party is capable of evaluating and understanding, and understands and accepts, the terms, risks and
conditions of the transactions contemplated hereby and by the other Note Documents; (ii) (A) each of the Collateral Agent and the
Purchasers is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties,
has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Issuer, any other Note Party or any of their
respective Affiliates, or any other Person, and (B) neither the Collateral Agent nor any Purchaser has any obligation to the
Issuer, any other Note Party or any of their Affiliates with respect to the transaction contemplated hereby except those obligations
expressly set forth herein and in the other Note Documents; and (iii) the Collateral Agent, the Purchasers and their respective
Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Issuer, the other
Note Parties and their respective Affiliates, and each of the Collateral Agent and the Purchasers has no obligation to disclose
any of such interests to the Issuer, any other Note Party or any of their respective Affiliates.  To the fullest extent permitted
by law, each of the Issuer and the other Note Parties hereby waives and releases any claims that it may have against the Collateral
Agent or any Purchaser with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of
any transaction contemplated hereby.

 

(b)          The
Issuer agrees that the relationship between the Collateral Agent and the Issuer and between each Purchaser and the Issuer is that
of creditor and debtor and not that of partners or joint venturers. This Agreement does not constitute a partnership agreement
or any other association between the Collateral Agent and the Issuer or between any Purchaser and the Issuer. The Issuer acknowledges
that each Purchaser has acted at all times only as a creditor to the Issuer within the normal and usual scope of the activities
normally undertaken by a creditor and in no event has the Collateral Agent or any Purchaser attempted to exercise any control over
the Issuer or its business or affairs. The Issuer further acknowledges that the Collateral Agent and each Purchaser has not taken
or failed to take any action under or in connection with its respective rights under this Agreement or any of the other Note Documents
that in any way, or to any extent, has interfered with or adversely affected the Issuer's ownership of Collateral.

 

Section 10.16         First
Lien/Second Lien Intercreditor Agreement. Notwithstanding anything herein to the contrary, the lien and security interest
granted to Collateral Agent or any other Secured Parties pursuant to or in connection with the Note Documents and the exercise
of any right or remedy by thereby or thereunder are subject to the provisions of the First Lien/Second Lien Intercreditor Agreement.
In the event of any conflict between the terms of the First Lien/Second Lien Intercreditor Agreement and this Agreement, the terms
of the First Lien/Second Lien Intercreditor Agreement shall govern and control. Notwithstanding the foregoing, each Note Party
expressly acknowledges and agrees that the First Lien/Second Lien Intercreditor Agreement is solely for the benefit of the parties
thereto, and that notwithstanding the fact that the exercise of certain of Collateral Agent’s and the Purchasers’ rights
under this Agreement or any other Note Document may be subject to the First Lien/Second Lien Intercreditor Agreement, no action
taken or not taken by Collateral Agent or any other Purchaser in accordance with the terms of the First Lien/Second Lien Intercreditor
Agreement shall constitute, or be deemed to constitute, a waiver by Collateral Agent or any other Purchaser of any rights such
Person has with respect to any Note Party under this Agreement or any other Note Document.

 

Section 10.17         Captions.
Captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect
the interpretation of any provision of this Agreement.

 

    	 	107	 

     

    

 

Section 10.18         Acknowledgement
and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in any Note Document or
in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability
of any EEA Financial Institution arising under any Note Document, to the extent such liability is unsecured, may be subject to
the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to
be bound by:

 

(a)           the
application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which
may be payable to it by any party hereto that is an EEA Financial Institution; and

 

(b)           the
effects of any Bail-in Action on any such liability, including, if applicable:

 

(i)          a
reduction in full or in part or cancellation of any such liability;

 

(ii)         a
conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution,
its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or
other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement
or any other Note Document; or

 

(iii)        the
variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution
Authority.

 

Section 10.19         Force
Majeure. In no event shall the Collateral Agent be responsible or liable for any failure or delay in the performance of
its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation,
strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or
acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services;
it being understood that the Collateral Agent shall use reasonable efforts which are consistent with accepted practices in the
banking industry to resume performance as soon as practicable under the circumstances..

 

(remainder of page left intentionally blank)

 

    	 	108	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year
first above written.

 

	 	BIOSCRIP, INC.
	 	 	 
	 	By:	/s/ Stephen Deitsch
	 	 	Name: Stephen Dietsch
	 	 	Title: Senior Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Note Purchase
Agreement]

 

     

     

    

 

	
        

         
	WELLS FARGO BANK, NATIONAL ASSOCIATION
	 	as the Collateral Agent
	 	 	 
	 	By:	/s/ Michael Pinzon 
	 	 	Name: Michael Pinzon 
	 	 	Title: Vice President 
	 	 	 
	 	Address for Notices:
	 	 
	 	Wells Fargo Bank, National Association
	 	9062 Old Annapolis Road
	 	Columbia, Maryland 21045
	 	Attention: Jason Prisco – BioScrip, Inc. First Lien NPA
	 	Email: CRSBankDebtAdministrationTeam@wellsfargo.com

 

[Signature Page to First Lien Note Purchase
Agreement]

 

     

     

    

 

	 	ASSF IV AIV B HOLDINGS II, L.P.
	 	as a Purchaser
	 	 
	 	By: ASSF IV AIV B Holdings GP LLC, its general partner
	 	 
	 	By: ASSF IV AIV B, L.P., its sole member
	 	 
	 	By: ASSF Management IV, L.P., its general partner
	 	 
	 	By: ASSF Management IV GP LLC, its general partner
	 	 	 
	 	 	 
	 	By:	/s/ Scott L. Graves
	 	 	Name: Scott L. Graves
	 	 	Title: Authorized Signatory 
	 	 	 
	 	Address for Notices:
	 	 
	 	c/o Ares Management LLC
	 	2000 Avenue of the Stars, 12th Floor
	 	Los Angeles, CA 90067
	 	 
	 	Funding Office:
	 	 
	 	c/o Ares Management LLC
	 	2000 Avenue of the Stars, 12th Floor
	 	Los Angeles, CA 90067

 

[Signature Page to First Lien Note Purchase
Agreement]

 

     

     

    

 

	
        
	J.P. MORGAN SECURITIES LLC
	 	as a Purchaser
	 	 	 
	 	By:	/s/ Jeffrey L. Panzo
	 	 	Name: Jeffrey L. Panzo
	 	 	Title: Attorney in fact
	 	 	 
	 	Address for Notices:
	 	 
	 	J.P. Morgan Securities LLC
	 	4 New York Plaza, 15th Floor, Mail Code NY1-E054
	 	New York, New York 10004
	 	Attention: Jeffrey L. Panzo
	 	Email: Jeffrey.L.Panzo@JPMorgan.com
	 	Phone No.: (212) 499-1435
	 	 
	 	Funding Office:
	 	 
	 	JPMorgan Chase Bank, N.A.
	 	4 New York Plaza, 15th Floor
	 	New York, New York 10004

 

[Signature Page to First Lien Note
Purchase Agreement]

 

     

     

    

 

	 	GOLDMAN SACHS & CO. LLC
	 	as a Purchaser
	 	 	 
	 	By:	/s/ Daniel Oneglia 
	 	 	Name: Daniel Oneglia
	 	 	Title: Managing Director 
	 	 	 
	 	Address for Notices:
	 	 
	 	Goldman Sachs & Co. LLC
	 	200 West Street, 26th Floor
	 	Attn: Paul Burningham
	 	New York, New York 10282
	 	 
	 	Funding Office:
	 	 
	 	Goldman Sachs & Co. LLC
	 	200 West Street, 26th Floor
	 	Attn: Paul Burningham and Paige Cataruozolo
	 	New York, New York 10282
	 	Email: ficc-amssg-mo@gs.com
	 	Phone No.: (917) 343-8393 (Paul Burningham), (917) 343-3096 (Paige Cataruozolo)

 

[Signature Page to First Lien Note Purchase Agreement]

 

     

     

    

 

	 	Verizon Investment Management Corporation - Domestic Fixed Income
	 	Western Asset Opportunistic US$ High Yield Securities Portfolio, LLC
	 	Stichting Pensioenfonds DSM Netherland
	 	Western Asset High Yield Fund
	 	CGCM High Yield Investments
	 	Western Asset Floating Rate High Income Fund, LLC
	 	Legg Mason Western Asset US High Yield Fund
	 	Employees' Retirement System of the State of Hawaii
	 	Kern County Employees' Retirement Association
	 	Western Asset High Income Opportunity Fund Inc.
	 	Western Asset Management Strategic Bond Opportunities Portfolio
	 	Western Asset Global High Yield Bond Fund
	 	Legg Mason Western Asset Global High Yield Bond Fund
	 	Western Asset Global High Income Fund, Inc.
	 	Western Asset High Income Fund II, Inc.
	 	Legg Mason Partners Variable Income Trust
	 	Western Asset Short Duration High Income Fund
	 	Western Asset Corporate Bond Fund
	 	Western Asset Global Strategic Income Fund
	 	Bayer Corporation Master Trust
	 	Western Asset Strategic US$ High Yield Portfolio, LLC
	 	Western Asset Investment Grade Defined Opportunity Trust Inc.

 

[Signature Page to First Lien Note Purchase Agreement]

 

     

     

    

 

	
         

         
	WA High Income Corporate Bond (Multi-Currency) Fund
	 	Western Asset High Yield Defined Opportunity Fund Inc
	 	Western Asset Multi-Asset Credit Portfolio Master Fund, Ltd.
	 	Russell Long Duration Fixed Income Fund
	 	Western Asset US Bank Loan (Multi-Currency) Fund
	 	Western Asset Bank Loan (Offshore) Fund
	 	1199 SEIU Health Care Employees Pension Fund
	 	William Barron Hilton Charitable Remainder Unitrust
	 	2006 Barron Hilton Charitable Remainder Unitrust
	 	each as a Purchaser

 

	 	By: Western Asset Management Company, as its Investment Manager and Agent
	 	 	 
	 	By:	/s/ Adam Wright 
	 	 	Name: Adam Wright 
	 	 	Title: Manager, U.S. Legal Affairs 
	 	 	 
	 	Address for Notices:
	 	 
	 	Western Asset Management Company
	 	385 East Colorado Boulevard
	 	Pasadena, California 91101
	 	Attention: Legal Department
	 	 
	 	Funding Office:
	 	 
	 	Western Asset Management Company
	 	385 East Colorado Boulevard
	 	Pasadena, California 91101

 

[Signature Page to First Lien Note Purchase
Agreement]

 

     

     

    

 

SCHEDULE II

 

Competitors

 

CVS/Coram

OptionCare

Axelacare/UHCExhibit 10.2

 

EXECUTION VERSION

 

FIRST
LIEN GUARANTY AND SECURITY AGREEMENT

 

dated as of June June 29, 2017

 

made by

 

BIOSCRIP, INC. 

as Issuer

 

and

 

The
other Grantors From Time to Time Party Hereto

 

in favor of

 

WELLS FARGO BANK, NATIONAL ASSOCIATION

as Collateral Agent

 

     

     

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	ARTICLE I Definitions	1
	 	 	 
	Section 1.1	Definitions	1
	 	 	 
	Section 1.2	Other Definitional Provisions; References	5
	 	 	 
	ARTICLE II Guarantee	6
	 	 	 
	Section 2.1	Guarantee	6
	 	 	 
	Section 2.2	Payments	8
	 	 	 
	ARTICLE III Grant of Security Interest	8
	 	 	 
	Section 3.1	Grant of Security Interest	8
	 	 	 
	Section 3.2	Transfer of Pledged Securities	9
	 	 	 
	Section 3.3	Grantors Remain Liable under Accounts, Chattel Paper and Payment Intangibles	9
	 	 	 
	ARTICLE IV Acknowledgments, Waivers and Consents	10
	 	 	 
	Section 4.1	Acknowledgments, Waivers and Consents	10
	 	 	 
	Section 4.2	No Subrogation, Contribution or Reimbursement	13
	 	 	 
	ARTICLE V Representations and Warranties	13
	 	 	 
	Section 5.1	Confirmation of Representations in Note Purchase Agreement	13
	 	 	 
	Section 5.2	Benefit to the Guarantors	13
	 	 	 
	Section 5.3	Pledged Securities; Promissory Notes	13
	 	 	 
	Section 5.4	First Priority Liens	14
	 	 	 
	Section 5.5	Legal Name, Organizational Status, Chief Executive Office	14
	 	 	 
	Section 5.6	Prior Names, Prior Chief Executive Offices	14
	 	 	 
	Section 5.7	Chattel Paper	14
	 	 	 
	Section 5.8	Truth of Information; Accounts	14
	 	 	 
	Section 5.9	Governmental Obligors	15
	 	 	 
	Section 5.10	Intellectual Property Rights	15
	 	 	 
	ARTICLE VI Covenants	15
	 	 	 
	Section 6.1	Covenants in Note Purchase Agreement	15
	 	 	 
	Section 6.2	Maintenance of Perfected Security Interest; Further Documentation	15
	 	 	 
	Section 6.3	Maintenance of Records	16
	 	 	 
	Section 6.4	Right of Inspection	17
	 	 	 
	Section 6.5	Further Identification of Collateral	17
	 	 	 
	Section 6.6	Changes in Names, Locations	17
	 	 	 
	Section 6.7	Pledged Securities	17

 

    -i-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 6.8	Limitations on Modifications, Waivers, Extensions of Agreements Giving Rise to Accounts	18
	 	 	 
	Section 6.9	Instruments and Tangible Chattel Paper	19
	 	 	 
	Section 6.10	Copyrights, Patents and Trademarks	19
	 	 	 
	Section 6.11	Commercial Tort Claims	20
	 	 	 
	ARTICLE VII Remedial Provisions	20
			 
	Section 7.1	Pledged Securities	20
	 	 	 
	Section 7.2	Collections on Accounts	22
	 	 	 
	Section 7.3	Proceeds	22
	 	 	 
	Section 7.4	UCC and Other Remedies	23
	 	 	 
	Section 7.5	Private Sales of Pledged Securities	23
	 	 	 
	Section 7.6	Deficiency	24
	 	 	 
	Section 7.7	Non-Judicial Enforcement	24
	 	 	 
	ARTICLE VIII The Collateral Agent	24
	 	 	 
	Section 8.1	The Collateral Agent’s Appointment as Attorney-in-Fact	24
	 	 	 
	Section 8.2	Duty of the Collateral Agent	26
	 	 	 
	Section 8.3	Filing of Financing Statements	26
	 	 	 
	Section 8.4	Authority of the Collateral Agent	27
	 	 	 
	ARTICLE IX Subordination of Indebtedness	27
	 	 	 
	Section 9.1	Subordination of All Guarantor Claims	27
	 	 	 
	Section 9.2	Claims in Bankruptcy	27
	 	 	 
	Section 9.3	Payments Held for Benefit of Collateral Agent	27
	 	 	 
	Section 9.4	Liens Subordinate	28
	 	 	 
	Section 9.5	Notation of Records	28
	 	 	 
	ARTICLE X Miscellaneous	28
	 	 	 
	Section 10.1	Waiver	28
	 	 	 
	Section 10.2	Notices	28
	 	 	 
	Section 10.3	Payment of Expenses, Indemnities	28
	 	 	 
	Section 10.4	Amendments in Writing	29
	 	 	 
	Section 10.5	Successors and Assigns	29
	 	 	 
	Section 10.6	Severability	29
	 	 	 
	Section 10.7	Counterparts	29
	 	 	 
	Section 10.8	Survival	30
	 	 	 

 

    -ii-

     

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	Section 10.9	Captions	30
	 	 	 
	Section 10.10	No Oral Agreements	30
	 	 	 
	Section 10.11	Governing Law; Submission to Jurisdiction	30
	 	 	 
	Section 10.12	WAIVER OF JURY TRIAL	31
	 	 	 
	Section 10.13	Acknowledgments	31
	 	 	 
	Section 10.14	Additional Grantors	32
	 	 	 
	Section 10.15	Set-Off	32
	 	 	 
	Section 10.16	Releases	32
	 	 	 
	Section 10.17	Reinstatement	33
	 	 	 
	Section 10.18	Acceptance	33
	 	 	 
	Section 10.19	Keepwell	33
	 	 	 
	Section 10.20	Relation to Other Note Documents	33
	 	 	 
	Section 10.21	Intercreditor Agreement	34
	 	 	 
	Section 10.22	Collateral Agent Rights	34

 

    -iii-

     

    

 

Schedules

 

	Schedule 1	-	Notice Addresses 
	Schedule 2	-	Pledged Securities; Promissory Notes
	Schedule 3	-	Filings and Other Actions Required to Perfect Security Interests
	Schedule 4	-	Legal Name, Organizational Status, Chief Executive Office
	Schedule 5	-	Prior Names and Prior Chief Executive Offices
	Schedule 6	-	Records Locations
	Schedule 7	-	Patents and Patent Licenses
	Schedule 8	-	Trademarks and Trademark Licenses
	Schedule 9	-	Copyrights and Copyright Licenses
	Schedule 10	-	Commercial Tort Claims

 

 

Annexes

 

	Annex I	-	Form of Joinder Agreement
	Annex II	-	Form of Intellectual Property Security Agreement
	Annex III	-	Form of Acknowledgment and Consent

 

    -iv-

     

    

 

FIRST
LIEN GUARANTY AND SECURITY AGREEMENT

 

THIS FIRST LIEN
GUARANTY AND SECURITY AGREEMENT, dated as of June 29, 2017, is made by BIOSCRIP, INC., a Delaware corporation (the “Issuer”),
and certain Subsidiaries of the Issuer identified on the signature pages hereto as “Guarantors” (together with the
Issuer and any other Subsidiary of the Issuer that becomes a party hereto from time to time after the date hereof, each, a “Grantor”
and, collectively, the “Grantors”), in favor of WELLS FARGO BANK, NATIONAL ASSOCIATION, as collateral agent
(in such capacity, together with its successors and assigns, the “Collateral Agent”) for itself and the other
Secured Parties (as defined below).

 

WHEREAS, the
Issuer is entering into that certain First Lien Note Purchase Agreement dated as of the date hereof (as amended, restated, supplemented,
or otherwise modified from time to time, the “Note Purchase Agreement”) by and among the Issuer, the purchasers
from time to time party thereto (collectively, the “Purchasers”) and the Collateral Agent, providing for, among
other things, the issuance by the Issuer and the purchase by the Purchasers of the Notes, subject to the terms set forth therein;
and

 

WHEREAS, it
is a condition precedent to the obligations of the Purchasers and the Collateral Agent under the Note Documents that the Grantors
enter into this Agreement, pursuant to which, subject to the terms and conditions herein, the Grantors (other than the Issuer)
shall guaranty all Obligations of the Issuer and the Grantors (including the Issuer) shall grant first-priority Liens on substantially
all of their personal property to the Collateral Agent, on behalf of the Secured Parties, to secure the Grantors’ respective
Obligations.

 

NOW, THEREFORE,
in consideration of the premises and to induce the Collateral Agent and the Purchasers to enter into the Note Purchase Agreement
and to induce the Purchasers to purchase the Notes pursuant thereto, each Grantor hereby agrees with the Collateral Agent, for
the ratable benefit of the Secured Parties, as follows:

 

ARTICLE
I

Definitions

 

Section 1.1           Definitions.

 

(a)          Each
term defined above shall have the meaning set forth above for all purposes of this Agreement. Unless otherwise defined herein,
terms defined in the Note Purchase Agreement and used herein shall have the meanings assigned to such terms in the Note Purchase
Agreement, and the terms “Account Debtor”, “Account”, “Cash Proceeds”, “Certificated
Security”, “Chattel Paper”, “Commercial Tort Claim”, “Deposit Account”, “Document”,
“Electronic Chattel Paper”, “Equipment”, “Fixture”, “General Intangible”, “Goods”,
“Instrument”, “Inventory”, “Investment Property”, “Letter-of-Credit Right”, “Noncash
Proceeds”, “Payment Intangible”, “Proceeds”, “Securities Account”, “Security”,
“Security Entitlement”, “Software”, “Supporting Obligations”, and “Tangible Chattel Paper”
shall have the meanings assigned to such terms in the UCC as in effect in the State of New York on the date hereof:

 

(b)          The
following terms shall have the following meanings:

 

“Agreement”
shall mean this First Lien Guaranty and Security Agreement, as amended, restated, supplemented or otherwise modified from time
to time.

 

“Avoidance Provisions”
shall have the meaning set forth in Section 2.1(d).

 

     

     

    

 

“Bankruptcy
Code” shall have the meaning set forth in Section 2.1(c)(i).

 

“Collateral”
shall have the meaning set forth in Section 3.1.

 

“Copyright Licenses”
shall mean any and all present and future agreements with respect to which a Grantor is a party providing for the granting of any
right in or to Copyrights (whether the applicable Grantor is licensee or licensor thereunder).

 

“Copyrights”
shall mean, collectively, with respect to each Grantor, all copyrights, whether registered or unregistered, owned by
or assigned to such Grantor and all registrations and applications for the foregoing (whether by statutory or common law, whether
established or registered in the United States, any State thereof, or any other country or any political subdivision thereof and,
in each case, whether owned by or assigned to such Grantor), together with any and all (i) rights and privileges arising under
applicable law with respect to such Grantor’s use of any copyrights, (ii) extensions and renewals thereof and amendments
thereto, (iii) income, fees, royalties, damages and payments now and hereafter due and/or payable thereunder and with respect
thereto, including damages, claims and payments for past, present or future infringements thereof, (iv) rights corresponding
thereto throughout the world and (v) rights to sue for past, present or future infringements thereof. As of the Closing Date, all
Copyright registrations and applications of the Grantors are set forth on Schedule 9.

 

“Excluded Capital
Stock” shall mean (i) any Capital Stock or Stock Equivalent of any Subsidiary of any Grantor that is not a wholly owned
Subsidiary of such Grantor and of any joint venture, in each case, to the extent a pledge thereof is not permitted by the terms
of such Person’s organizational documents or joint venture documents (provided that such Grantor shall use commercially
reasonable efforts to ensure that such organizational documents or joint venture documents permit a pledge of such Capital Stock
or Stock Equivalent) and (ii) any Capital Stock of any Foreign Subsidiary owned by any Grantor in excess of 65% of the issued and
outstanding voting Capital Stock of such Foreign Subsidiary; provided, that “Excluded Capital Stock” shall not
include any proceeds, products, substitutions or replacements of Excluded Capital Stock (unless such proceeds, products, substitutions
or replacements would otherwise constitute Excluded Capital Stock).

 

    	 	2	 

     

    

 

“Excluded Property”
shall mean (i) any fee-owned Real Estate with a fair market value of less than $2,500,000 (as of the date of the acquisition of
such Real Estate) (provided that the fair market value of all fee-owned Real Estate constituting Excluded Property shall
not exceed $5,000,000) and all Real Estate constituting leasehold interests; (ii) any motor vehicles and other assets subject to
certificates of title to the extent that a security interest therein cannot be perfected by the filing of a UCC financing statement;
(iii) any Letter-of-Credit Rights (except to the extent constituting a support obligation for other Collateral as to which the
perfection of security interests in such other Collateral and the support obligation is accomplished solely by the filing of a
UCC financing statement) and Commercial Tort Claims, in each case, with a value of less than $1,000,000; (iv) Excluded Capital
Stock; (v) any license, Instrument, agreement or other General Intangible (other than Proceeds and Accounts thereof) to the extent,
and so long as, the pledge thereof as Collateral would violate the terms thereof or result in a breach by any Grantor of any agreement
related thereto, but only to the extent, and only for so long as, such prohibition is not terminated or rendered unenforceable
or otherwise deemed ineffective by the UCC, the Bankruptcy Code or any other Requirement of Law and such prohibition is not prohibited
under Section 7.8 of the Note Purchase Agreement (provided, that such assets shall cease to be Excluded Property at such
time as such prohibition or restriction is terminated, rendered unenforceable, or deemed ineffective or otherwise ceases to be
in effect and, upon such prohibition or restriction being terminated, rendered unenforceable, deemed ineffective or otherwise ceasing
to be in effect, the Lien granted herein shall be deemed to have automatically attached to such assets); (vi) Excluded Accounts;
(vii) any United States intent-to-use trademark applications for which an amendment to allege use or statement of use has not been
filed under 15 U.S.C. § 1051(c) or 15 U.S.C. § 1051(d), respectively, or if filed, has not been deemed in conformance
with 15 U.S.C. § 1051(a) or examined and accepted, respectively, by the United States Patent and Trademark Office (provide
that, upon such filing and acceptance, such intent-to-use applications shall cease to be Excluded Property); (viii) any other assets
to the extent the pledge thereof is prohibited by any Requirement of Law (other than Proceeds and Accounts thereof), but only to
the extent, and for so long as, such prohibition is not terminated or rendered unenforceable or otherwise deemed ineffective by
the UCC, the Bankruptcy Code or any other Requirement of Law (provided, that such assets shall cease to be Excluded Property
at such time as such prohibition is terminated, rendered unenforceable, or deemed ineffective or otherwise ceases to be in effect
and, upon such prohibition being terminated, rendered unenforceable, deemed ineffective or otherwise ceasing to be in effect, the
Lien granted herein shall be deemed to have automatically attached to such assets); (ix) those assets of the Grantors as to which
the Collateral Agent (at the direction of the Required Purchasers) shall reasonably determine that the costs of obtaining or perfecting
such security interest are excessive in relation to the value of the security to the Secured Parties to be afforded thereby; and
(x) such other assets of the Grantors as may be agreed by the Collateral Agent (at the direction of the Required Purchasers); provided,
that “Excluded Property” shall not include any proceeds, products, substitutions or replacements of Excluded Property
(unless such proceeds, products, substitutions or replacements would otherwise constitute Excluded Property).

 

“Guaranteed
Obligations” shall have the meaning set forth in Section 2.1(a).

 

“Guarantors”
shall mean, collectively, each Grantor other than the Issuer.

 

“Intellectual
Property Licenses” shall mean any and all Trademark Licenses, Copyright Licenses and Patent Licenses.

 

“Intellectual
Property Rights” shall mean any and all Trademarks, Copyrights, Patents, Software (including source code, object code,
data and related documentation), internet domain names, trade secrets and other confidential business information and other intellectual
property or proprietary rights.

 

“Patent Licenses”
shall mean any and all present and future agreements with respect to which a Grantor is a party providing for the granting of any
right in or to Patents (whether the applicable Grantor is licensee or licensor thereunder).

 

“Patents”
shall mean, collectively, with respect to each Grantor, all letters patent owned by or issued or assigned to, and all patent applications
and registrations made by, such Grantor (whether established or registered or recorded in the United States, or any other country
or any political subdivision thereof and, in each case, whether owned by or assigned to such Grantor) and all (i) rights and privileges
arising under applicable law with respect to such Grantor’s use of any patents, (ii) inventions and improvements described
and claimed therein, (iii) reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof and amendments
thereto, and rights to obtain any of the foregoing, (iv) income, fees, royalties, damages, claims and payments now or hereafter
due and/or payable thereunder and with respect thereto including damages and payments for past, present or future infringements
thereof, (v) rights corresponding thereto throughout the world and (vi) rights to sue for past, present or future infringements
thereof. As of the Closing Date, all Patents of the Grantors are set forth on Schedule 7.

 

    	 	3	 

     

    

 

“Pledged Certificated
Stock” shall mean all Certificated Securities and any other Capital Stock or Stock Equivalent of any Person, other than
Excluded Property, evidenced by a certificate, instrument or other similar document, in each case, now owned or at any time hereafter
acquired by any Grantor, and any dividend or distribution of cash, instruments or other property made on, in respect of or in exchange
for the foregoing from time to time. As of the Closing Date, all Pledged Certificated Stock of the Grantors is set forth on Schedule 2.

 

“Pledged Securities”
shall mean, collectively, all Pledged Certificated Stock, all Pledged Uncertificated Stock and all Promissory Notes held by a Grantor
and pledged to the Collateral Agent hereunder.

 

“Pledged Security
Issuers” shall mean, collectively, each issuer of a Pledged Security.

 

“Pledged Uncertificated
Stock” shall mean any Capital Stock or Stock Equivalent of any Person, other than Pledged Certificated Stock and Excluded
Property, in each case now owned or at any time hereafter acquired by any Grantor, including all right, title and interest of any
Grantor as a limited or general partner in any partnership or as a member of any limited liability company not constituting Pledged
Certificated Stock, all right, title and interest of any Grantor in, to and under any organizational document of any partnership
or limited liability company to which it is a party, and any dividend or distribution of cash, instruments, or other property made
on, in respect of, or in exchange for the foregoing from time to time. As of the Closing Date, all Pledged Uncertificated Stock
of the Grantors is set forth on Schedule 2.

 

“Promissory
Note” shall mean an instrument within the description of “promissory note” as defined in Article 9 of the
UCC.

 

“Qualified ECP
Guarantor” shall mean, in respect of any Swap Obligation, each Note Party that has total assets exceeding $10,000,000
at the time the relevant Guarantee or grant of the relevant security interest becomes effective with respect to such Swap Obligation
or such other person as constitutes an “eligible contract participant” as defined in the Commodity Exchange Act or
any regulations promulgated thereunder and can cause another person to qualified as an “eligible contract participant”
at such time by entering into a keepwell under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.

 

“Secured Obligations”
shall have the meaning set forth in Section 3.1.

 

“Secured Parties”
shall mean, collectively, the Collateral Agent, the Purchasers, the Purchaser-Related Hedge Providers and the Bank Product Providers.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended and in effect from time to time.

 

“Stock Equivalents”
shall mean all Securities convertible into or exchangeable for Capital Stock or any other Stock Equivalent and all warrants, options
or other rights to purchase, subscribe for or otherwise acquire any Capital Stock or any other Stock Equivalent, whether or not
presently convertible, exchangeable or exercisable.

 

“Swap Obligations”
shall mean any obligation to pay or perform under any agreement, contract or transaction that constitutes a “swap”
within the meaning of section 1a(47) of the Commodity Exchange Act.

 

“Termination
Date” shall have the meaning set forth in Section 10.16(a).

 

    	 	4	 

     

    

 

“Trademark Licenses”
shall mean any and all present and future agreements with respect to which a Grantor is a party providing for the granting of any
right in or to Trademarks (whether the applicable Grantor is licensee or licensor thereunder).

 

“Trademarks”
shall mean, collectively, with respect to each Grantor, all trademarks, service marks, slogans, logos, certification
marks, trade dress, corporate names, trade names and other source or business identifiers, whether registered or unregistered,
owned by or assigned to such Grantor and all registrations and applications for the foregoing (whether by statutory or common law,
whether established or registered in the United States, any State thereof, or any other country or any political subdivision thereof
and, in each case, whether owned by or assigned to such Grantor), and all goodwill associated therewith, now existing or hereafter
adopted or acquired, together with any and all (i) rights and privileges arising under applicable law with respect to such
Grantor’s use of any trademarks, (ii)  extensions and renewals thereof and amendments thereto, (iii) income, fees,
royalties, damages and payments now and hereafter due and/or payable thereunder and with respect thereto, including damages, claims
and payments for past, present or future infringements thereof, (iv) rights corresponding thereto throughout the world and
(v) rights to sue for past, present or future infringements thereof. As of the Closing Date, all Trademark registrations and
applications of the Grantors are set forth on Schedule 8.

 

“UCC”
shall mean the Uniform Commercial Code as in effect from time to time in the State of New York.

 

Section 1.2           Other
Definitional Provisions; References. The definition of terms herein shall apply equally to the singular and plural forms
of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter
forms. The words “include”, “includes” and “including” shall be deemed to be followed by the
phrase “without limitation”. The word “will” shall be construed to have the same meaning and effect as
the word “shall”. Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument
or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended,
restated, amended and restated, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s successors
and assigns, (c) the words “herein”, “hereof” and “hereunder”, and words of similar import,
shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (d) all references herein
to Articles, Sections, Exhibits, Schedules and Annexes shall, unless otherwise stated, be construed to refer to Articles and Sections
of, and Exhibits, Schedules and Annexes to, this Agreement and (e) the words “asset” and “property” shall
be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including
cash, securities, accounts and contract rights. Where the context requires, terms relating to the Collateral or any part thereof,
when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. The words “knowledge
of any Grantor” or any like term shall mean the actual knowledge of a Responsible Officer of any Grantor.

 

    	 	5	 

     

    

 

ARTICLE
II

 

Guarantee

 

Section 2.1           Guarantee.

 

(a)          Each
Guarantor unconditionally guarantees, jointly with the other Guarantors and severally, as a primary obligor and not merely as a
surety, (i) the due and punctual payment of all Obligations of the Issuer and the other Note Parties including (A) the
principal of and premium, if any, and interest (including interest accruing during the pendency of any bankruptcy, insolvency,
receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding) on the Notes, when and
as due, whether at maturity, by acceleration, upon one or more dates set for prepayment or otherwise and (B) all other monetary
obligations, including fees, costs, expenses and indemnities, whether primary, secondary, direct, contingent, fixed or otherwise
(including monetary obligations incurred during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding,
regardless of whether allowed or allowable in such proceeding), of the Note Parties to the Collateral Agent and the Purchasers
under the Note Purchase Agreement and the other Note Documents; (ii) the due and punctual performance of all covenants, agreements,
obligations and liabilities of the Note Parties under or pursuant to the Note Purchase Agreement and the other Note Documents;
(iii) the due and punctual payment of all Bank Product Obligations; and (iv) the due and punctual payment and performance
of all Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge Provider (other than any Excluded Swap Obligations
with respect to such Guarantor) (all the monetary and other obligations referred to in the preceding clauses (i) through
(iv) being collectively called the “Guaranteed Obligations”). Each Guarantor further agrees that the Guaranteed
Obligations may be extended or renewed, in whole or in part, without notice to or further assent from such Guarantor and that such
Guarantor will remain bound by its guarantee notwithstanding any extension or renewal of any Guaranteed Obligations made in accordance
with the Note Purchase Agreement.

 

(b)          Each
Guarantor further agrees that its guarantee constitutes a joint and several obligation and a guarantee of payment when due and
not of collection, and waives to the extent permitted by applicable law: (i) promptness and diligence, (ii) notice of acceptance
and any other notice with respect to any of the Guaranteed Obligations under this Article II and any requirement that the Secured
Parties exhaust any right or take any action against any Note Party or any other Person or any Collateral, (iii) any right
to compel or direct any Secured Party to seek payment or recovery of any amounts owed under this Article II from any one particular
fund or source or to exhaust any right or take any action against any other Note Party, any other Person or any Collateral and
(iv) any requirement that any Secured Party exhaust any right to take any action against any Note Party, any other Person or any
Collateral.

 

(c)          It
is the intent of each Guarantor and the Collateral Agent that the maximum obligations of the Guarantors hereunder shall be, but
not in excess of:

 

(i)          in
a case or proceeding commenced by or against any Guarantor under the provisions of Title 11 of the United States Code, 11 U.S.C.
§§101 et seq., as amended and in effect from time to time (the “Bankruptcy Code”), on
or within one year from the date on which any of the Guaranteed Obligations are incurred, the maximum amount which would not otherwise
cause the Guaranteed Obligations to be avoidable or unenforceable against such Guarantor under (A) Section 548 of the Bankruptcy
Code or (B) any state fraudulent transfer or fraudulent conveyance act or statute applied in any such case or proceeding by virtue
of Section 544 of the Bankruptcy Code; or

 

(ii)         in
a case or proceeding commenced by or against any Guarantor under the Bankruptcy Code subsequent to one year from the date on which
any of the Guaranteed Obligations are incurred, the maximum amount which would not otherwise cause the Guaranteed Obligations to
be avoidable or unenforceable against such Guarantor under any state fraudulent transfer or fraudulent conveyance act or statute
applied in any such case or proceeding by virtue of Section 544 of the Bankruptcy Code; or

 

    	 	6	 

     

    

 

(iii)        in
a case or proceeding commenced by or against any Guarantor under any law, statute or regulation other than the Bankruptcy Code
(including, without limitation, any other bankruptcy, reorganization, arrangement, moratorium, readjustment of debt, dissolution,
liquidation or similar debtor relief laws), the maximum amount which would not otherwise cause the Guaranteed Obligations to be
avoidable or unenforceable against such Guarantor under such law, statute or regulation, including, without limitation, any state
fraudulent transfer or fraudulent conveyance act or statute applied in any such case or proceeding.

 

(d)          The
substantive laws under which the possible avoidance or unenforceability of the Guaranteed Obligations as may be determined in any
case or proceeding shall hereinafter be referred to as the “Avoidance Provisions”. To the extent set forth in
subsections (c)(i), (ii) and (iii) of this Section, but only to the extent that the Guaranteed Obligations would otherwise be subject
to avoidance or found unenforceable under the Avoidance Provisions, if any Guarantor is not deemed to have received valuable consideration,
fair value or reasonably equivalent value for the Guaranteed Obligations, or if the Guaranteed Obligations would render such Guarantor
insolvent, or leave such Guarantor with an unreasonably small capital to conduct its business, or cause such Guarantor to have
incurred debts (or to have intended to have incurred debts) beyond its ability to pay such debts as they mature, in each case as
of the time any of the Guaranteed Obligations are deemed to have been incurred under the Avoidance Provisions and after giving
effect to the contribution rights set forth in Section 2.1(g) hereof and any other indemnifications payments due to such
Guarantor by any other Guarantor, the maximum Guaranteed Obligations for which such Guarantor shall be liable hereunder shall be
reduced to that amount which, after giving effect thereto, would not cause the Guaranteed Obligations, as so reduced, to be subject
to avoidance or unenforceability under the Avoidance Provisions (such maximum amount, the “Allocable Amount”).

 

(e)          This
Section is intended solely to preserve the rights of the Collateral Agent and the Secured Parties hereunder to the maximum extent
that would not cause the Guaranteed Obligations of such Guarantor to be subject to avoidance or unenforceability under the Avoidance
Provisions, and neither the Grantors nor any other Person shall have any right or claim under this Section as against the Collateral
Agent or any Secured Party that would not otherwise be available to such Person under the Avoidance Provisions.

 

(f)          Each
Guarantor agrees that if the maturity of any of the Guaranteed Obligations is accelerated by bankruptcy or otherwise, such maturity
shall also be deemed accelerated for the purpose of this guarantee without demand or notice to such Guarantor. The guarantee contained
in this Article shall remain in full force and effect until the earlier of (i) the Termination Date and (ii) in respect of any
Guarantor, the release of such Guarantor from this Agreement in accordance with the provisions of Section 10.16(b) hereof.

 

(g)          To
the extent that any Guarantor shall make a payment under this guarantee of all or any of the Guaranteed Obligations (a “Guarantor
Payment”) which, taking into account all other Guarantor Payments then previously or concurrently made by such Guarantor,
exceeds the amount which such Guarantor would otherwise have paid if each Guarantor had paid the aggregate Guaranteed Obligations
satisfied by such Guarantor Payment in the same proportion that such Guarantor’s Allocable Amount (in effect immediately
prior to such Guarantor Payment) bore to the aggregate Allocable Amounts of all of the Guarantors in effect immediately prior to
the making of such Guarantor Payment, then, following payment in full of the Guaranteed Obligations (other than Hedging Obligations
owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations
not then due and payable and as to which no claim has been made), such Guarantor shall be entitled to receive contribution and
indemnification payments from, and be reimbursed by, each of the other Guarantors for the amount of such excess, pro rata based
upon their respective Allocable Amounts in effect immediately prior to such Guarantor Payment. This Section 2.1(g) is intended
only to define the relative rights of Guarantors and nothing set forth in this Section 2.1(g) is intended to or shall impair
the obligations of the Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable
in accordance with the terms of this Agreement.

 

    	 	7	 

     

    

 

Section 2.2           Payments.
Each Guarantor hereby agrees and guarantees that payments hereunder will be paid to the Secured Parties without set-off or counterclaim
in Dollars at the office or to the bank account of each such Secured Party provided for in the Note Purchase Agreement.

 

ARTICLE
III

 

Grant
of Security Interest

 

Section 3.1           Grant
of Security Interest. Each Grantor hereby pledges and grants to the Collateral Agent, for the ratable benefit of the Secured
Parties, a first-priority security interest in and lien on all right, title and interest of such Grantor in all of the following
property, wherever located and whether now owned or at any time hereafter acquired by such Grantor or in which such Grantor now
has or at any time in the future may acquire any right, title or interest and whether now existing or hereafter coming into existence
(collectively, the “Collateral”), as collateral security for the prompt and complete payment and performance
when due (whether at the stated maturity, by acceleration or otherwise) of the Obligations, other than any Excluded Swap Obligation
with respect to such Grantor (collectively, the “Secured Obligations”):

 

(a)          all
Accounts, including, without limitation, all Accounts owing by any Governmental Authority (including, without limitation, any and
all accounts arising or reimbursable under Medicare, Medicaid or any other Governmental Payor Arrangement), and Chattel Paper (whether
tangible or electronic);

 

(b)          all
Commercial Tort Claims described on Schedule 10 hereto as such Schedule may be updated from time to time;

 

(c)           all
contracts together with all contract rights arising thereunder;

 

(d)          all
money, cash, cash equivalents, Deposit Accounts, Securities Accounts, commodities accounts and lockboxes and all money, cash, Securities
and other Investment Property deposited therein;

 

(e)          all
Documents;

 

(f)           all
General Intangibles;

 

(g)          all
Goods (including, without limitation, all Inventory, all Equipment and all Fixtures);

 

(h)          all
Instruments;

 

(i)          all
Investment Property;

 

(j)          all
Letter-of-Credit Rights;

 

(k)         all
Notes (including, without limitation, all intercompany Notes) and all other intercompany obligations between the Note Parties;

 

    	 	8	 

     

    

 

(l)            all
Pledged Securities;

 

(m)          all
Intellectual Property Rights;

 

(n)          all
Intellectual Property Licenses;

 

(o)          all
books and records, Supporting Obligations and related letters of credit or other claims and causes of action, in each case to the
extent pertaining to the Collateral; and

 

(p)          to
the extent not otherwise included, substitutions, replacements, accessions, products and other Proceeds (whether tangible or intangible
and including, without limitation, insurance proceeds, licenses, royalties, income, payments, claims, damages, proceeds of suit,
Cash Proceeds and Noncash Proceeds) of any or all of the foregoing and all collateral security, guarantees and other Supporting
Obligations given with respect to any of the foregoing;

 

provided that,
notwithstanding the foregoing, no Lien or security interest is hereby granted on, and the Collateral shall not include, any Excluded
Property, and, to the extent that any Collateral later becomes Excluded Property, the Lien granted hereunder will automatically
be deemed to have been released; provided, further, that if and when any property shall cease to be Excluded Property,
a Lien on and security interest in such property shall automatically be deemed granted therein.

 

Section 3.2           Transfer
of Pledged Securities. All certificates and instruments representing or evidencing the Pledged Certificated Stock shall
be delivered to the Collateral Agent or a Person designated by the Collateral Agent in accordance with the terms of the Note Purchase
Agreement and shall be held pursuant hereto by the Collateral Agent or a Person designated by the Collateral Agent and, in the
case of an instrument or certificate in registered form, shall be duly indorsed to the Collateral Agent or in blank by an effective
endorsement (whether on the certificate or instrument or on a separate writing), and accompanied by any required transfer tax stamps
to effect the pledge of the Pledged Securities to the Collateral Agent. Notwithstanding the preceding sentence, all Pledged Certificated
Stock must be delivered or transferred in such manner, and each Grantor shall take all such further action as is necessary to permit
the Collateral Agent to be a “protected purchaser” to the extent of its security interest as provided in Section 8-303
of the UCC.

 

Section 3.3           Grantors
Remain Liable under Accounts, Chattel Paper and Payment Intangibles. Anything herein to the contrary notwithstanding, each
Grantor shall remain liable under each of the Accounts, Chattel Paper and Payment Intangibles owned or held by it to observe and
perform all of the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of
any agreement giving rise to each such Account, Chattel Paper or Payment Intangible. Neither the Collateral Agent nor any other
Secured Party shall have any obligation or liability under any Account, Chattel Paper or Payment Intangible (or any agreement giving
rise thereto) by reason of or arising out of this Agreement or the receipt by the Collateral Agent or any such other Secured Party
of any payment relating to such Account, Chattel Paper or Payment Intangible pursuant hereto, nor shall the Collateral Agent or
any other Secured Party be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Account,
Chattel Paper or Payment Intangible (or any agreement giving rise thereto) to make any payment, to make any inquiry as to the nature
or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party under any Account, Chattel
Paper or Payment Intangible (or any agreement giving rise thereto), to present or file any claim, to take any action to enforce
any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any
time or times.

 

    	 	9	 

     

    

 

ARTICLE
IV

 

Acknowledgments,
Waivers and Consents

 

Section 4.1           Acknowledgments,
Waivers and Consents.

 

(a)          Each
Guarantor acknowledges and agrees that the obligations undertaken by it under this Agreement involve the guarantee of, and each
Grantor acknowledges and agrees that the obligations undertaken by it under this Agreement involve the provision of security in
the Collateral for, obligations of Persons other than such Grantor and that such Grantor’s guarantee and provision of security
in the Collateral for the Secured Obligations are absolute, irrevocable and unconditional under any and all circumstances (subject
to the terms of this Agreement and the other Note Documents and subject to any Requirements of Law). Each Guarantor acknowledges
that it will receive direct and indirect benefits from the financing arrangements contemplated herein and in the Note Purchase
Agreement and that the waivers set forth in clause (ii) below are knowingly made in contemplation of such benefits.
In full recognition and furtherance of the foregoing, each Grantor understands and agrees, to the fullest extent permitted under
applicable law and except as may otherwise be expressly and specifically provided in the Note Documents, that each Grantor shall
remain obligated hereunder (including with respect to each Guarantor, the guarantee made by it herein and, with respect to each
Grantor, the security in the Collateral provided by such Grantor herein), and the enforceability and effectiveness of this Agreement
and the liability of such Grantor, and the rights, remedies, powers and privileges of the Collateral Agent and the other Secured
Parties under this Agreement and the other Note Documents, shall not be affected, limited, reduced, discharged or terminated in
any way and hereby agrees that:

 

(i)          notwithstanding
that, without any reservation of rights against any Grantor and without notice to or further assent by any Grantor, in each case,
subject to and in accordance with the terms of the Note Documents, (A) any demand for payment of any of the Secured Obligations
made by the Collateral Agent or any other Secured Party may be rescinded by the Collateral Agent or such other Secured Party and
any of the Secured Obligations continued; (B) the Secured Obligations, the liability of any other Person upon or for any part thereof
or any collateral security or guarantee therefor or right of offset with respect thereto may, from time to time, in whole or in
part, be renewed, extended, amended, restated, modified, accelerated, compromised, waived, surrendered or released by, or any indulgence
or forbearance in respect thereof granted by, the Collateral Agent or any other Secured Party; (C) the Note Purchase Agreement,
the other Note Documents and all other documents executed and delivered in connection therewith or in connection with Hedging Obligations
and Bank Product Obligations included as Obligations may be amended, restated, modified, supplemented or terminated, in whole or
in part, as the Collateral Agent (or the Required Purchasers, all Purchasers, or the other parties thereto, as the case may be)
may deem advisable from time to time; (D) the Issuer, any Guarantor or any other Person may from time to time accept or enter into
new or additional agreements, security documents, guarantees or other instruments in addition to, in exchange for or relative to
any Note Document, all or any part of the Secured Obligations or any Collateral now or in the future serving as security for the
Secured Obligations; (E) any collateral security, guarantee or right of offset at any time held by the Collateral Agent or any
other Secured Party for the payment of the Secured Obligations may be sold, exchanged, waived, surrendered or released; and (F)
any other event shall occur which constitutes a defense or release of sureties generally (other than a defense of payment or performance
in full of all Guaranteed Obligations and Secured Obligations (other than Hedging Obligations owed by any Note Party to any Purchaser-Related
Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations not then due and payable and as to which
no claim has been made)); and

 

    	 	10	 

     

    

 

(ii)         regardless
of, and each Grantor hereby expressly waives to the fullest extent permitted by law, any defense now or in the future arising by
reason of, (A) the illegality, invalidity or unenforceability of the Note Purchase Agreement, any other Note Document, any of the
Secured Obligations or any other security in the Collateral therefor or guarantee or right of offset with respect thereto at any
time or from time to time held by the Collateral Agent or any other Secured Party (other than any such illegality, invalidity or
unenforceability that occurs solely as a result of any action or inaction on the part of the Collateral Agent or any Purchaser);
(B) any defense, set-off or counterclaim which may at any time be available to or be asserted by any Grantor or any other Person
against the Collateral Agent or any other Secured Party; (C) the insolvency, bankruptcy arrangement, reorganization, adjustment,
composition, liquidation, disability, dissolution or lack of corporate or other organizational power of any Grantor or any other
Person at any time liable for the payment of all or part of the Secured Obligations or the failure of the Collateral Agent or any
other Secured Party to file or enforce a claim in bankruptcy or other proceeding with respect to any Person, or any sale, lease
or transfer of any or all of the assets of any Grantor, or any changes in the shareholders of any Grantor; (D) the fact that any
Collateral or Lien contemplated or intended to be given, created or granted as security for the repayment of the Secured Obligations
shall not be properly perfected or created, or shall prove to be unenforceable or subordinate to any other Lien (other than solely
as a result of any action or inaction on the part of the Collateral Agent or any Purchaser), it being recognized and agreed by
each of the Grantors that it is not entering into this Agreement in reliance on, or in contemplation of the benefits of, the validity,
enforceability, collectability or value of any of the Collateral for the Secured Obligations; (E) any failure of the Collateral
Agent or any other Secured Party to marshal assets in favor of any Grantor or any other Person, to exhaust any Collateral for all
or any part of the Secured Obligations, to pursue or exhaust any right, remedy, power or privilege it may have against any Grantor
or any other Person or to take any action whatsoever to mitigate or reduce any Grantor’s liability under this Agreement or
any other Note Document; (F) any law which provides that the obligation of a surety or guarantor must neither be larger in amount
nor in other respects more burdensome than that of the principal or which reduces a surety’s or guarantor’s obligation
in proportion to the principal obligation (but subject to Section 2.1(c)-(g) hereof); (G) the possibility that the Secured
Obligations may at any time and from time to time exceed the aggregate liability of such Grantor under this Agreement; (H) any
change in the time, manner or place of payment of, or in any other term of, all or any of the Guaranteed Obligations, or any other
amendment or waiver of or any consent to departure from any Note Document, including, without limitation, any increase in the Guaranteed
Obligations resulting from the extension of additional credit to any Note Party or otherwise; or (I) any other circumstance or
act whatsoever, including any action or omission of the type described in subsection (a)(i) of this Section (with or without notice
to or knowledge of any Grantor), which constitutes, or might be construed to constitute, an equitable or legal discharge or defense
of the Issuer for the Obligations, or of such Guarantor under the guarantee contained in Article II, or with respect to
the collateral security provided by such Grantor herein, or which might be available to a surety or guarantor, in bankruptcy or
in any other instance (other than, in the case of clauses (A) through (I) hereof, (x) a defense of payment or performance
in full of all Guaranteed Obligations and Secured Obligations (other than Hedging Obligations owed by any Note Party to any Purchaser-Related
Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations not then due and payable and as to which
no claim has been made) or (y) a defense that an Event of Default has not occurred under the Note Purchase Agreement or any other
Note Document).

 

    	 	11	 

     

    

 

(b)          Each
Grantor hereby waives to the extent permitted by law and, in each case, except as expressly provided otherwise in any Note Document,
(i) all notices to such Grantor, or to any other Person, including, but not limited to, notices of the acceptance of this Agreement,
the guarantee contained in Article II or the provision of security in the Collateral provided herein, or the creation, renewal,
extension, modification or accrual of any Secured Obligations, or notice of or proof of reliance by the Collateral Agent or any
other Secured Party upon the guarantee contained in Article II or upon the security in the Collateral provided herein, or
of default in the payment or performance of any of the Secured Obligations owed to the Collateral Agent or any other Secured Party
and enforcement of any right or remedy with respect thereto, or notice of any other matters relating thereto; the Secured Obligations,
and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived,
in reliance upon the guarantee contained in Article II and the security in the Collateral provided herein and no notice
of creation of the Secured Obligations or any extension of credit already or hereafter contracted by or extended to the Issuer
need be given to any Grantor, and all dealings between the Issuer and any of the Grantors, on the one hand, and the Collateral
Agent and the other Secured Parties, on the other hand, likewise shall be conclusively presumed to have been had or consummated
in reliance upon the guarantee contained in Article II and on the security in the Collateral provided herein; (ii) diligence
and demand of payment, presentment, protest, dishonor and notice of dishonor; (iii) any statute of limitations affecting any Grantor’s
liability hereunder or the enforcement thereof; (iv) all rights of revocation with respect to the Secured Obligations, the guarantee
contained in Article II and the provision of security in the Collateral herein and acknowledges that Article II
and the provision of security in the Collateral herein is continuing in nature and applies to all Guaranteed Obligations, whether
existing now or in the future; and (v) all principles or provisions of law which conflict with the terms of this Agreement and
which can, as a matter of law, be waived.

 

(c)          When
making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor, the Collateral Agent or
any other Secured Party may, but shall be under no obligation to, join or make a similar demand on or otherwise pursue or exhaust
such rights and remedies as it may have against the Issuer, any other Grantor or any other Person or against any collateral security
or guarantee for the Secured Obligations or any right of offset with respect thereto, and any failure by the Collateral Agent or
any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from the Issuer,
any other Grantor or any other Person or to realize upon any such collateral security or guarantee or to exercise any such right
of offset, or any release of the Issuer, any other Grantor or any other Person or any such collateral security, guarantee or right
of offset, shall not relieve any Grantor of any obligation or liability hereunder, and shall not impair or affect the rights and
remedies, whether express, implied or available as a matter of law, of the Collateral Agent or any other Secured Party against
any Grantor. For the purposes hereof, “demand” shall include the commencement and continuance of any legal proceedings.
Neither the Collateral Agent nor any other Secured Party shall have any obligation to protect, secure, perfect or insure any Lien
at any time held by it as security for the Secured Obligations or for the guarantee contained in Article II or any property
subject thereto.

 

    	 	12	 

     

    

 

Section 4.2           No
Subrogation, Contribution or Reimbursement. Until all Secured Obligations are satisfied in full (other than Hedging Obligations
owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations
not then due and payable and as to which no claim has been made) and all Commitments of each Purchaser under the Note Purchase
Agreement or any other Note Document have been terminated, notwithstanding any payment made by any Grantor hereunder or any set-off
or application of funds of any Grantor by the Collateral Agent or any other Secured Party, each Grantor’s right of subrogation
to any of the rights of the Collateral Agent or any other Secured Party against the Issuer or any other Grantor or any collateral
security or guarantee or right of offset held by the Collateral Agent or any other Secured Party for the payment of the Secured
Obligations shall be subordinated, and no Grantor shall seek or be entitled to seek any indemnity, exoneration, participation,
contribution or reimbursement from the Issuer or any other Grantor in respect of payments made by such Grantor hereunder, and each
Grantor hereby expressly agrees not to exercise any or all such rights of subrogation, reimbursement, indemnity and contribution
until the payment in full in cash of the Secured Obligations (other than Hedging Obligations owed by any Note Party to any Purchaser-Related
Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations not then due and payable and as to which
no claim has been made). Each Grantor further agrees that to the extent that such waiver and release set forth herein is found
by a court of competent jurisdiction to be void or voidable for any reason, any rights of subrogation, reimbursement, indemnity
and contribution such Grantor may have against the Issuer or any other Grantor or against any collateral or security or guarantee
or right of offset held by the Collateral Agent or any other Secured Party shall be junior and subordinate to any rights the Collateral
Agent and the other Secured Parties may have against the Issuer and such Grantor and to all right, title and interest the Collateral
Agent and the other Secured Parties may have in such collateral or security or guarantee or right of offset. In accordance with
the terms hereof, the Collateral Agent, for the benefit of the Secured Parties, may use, sell or dispose of any item of Collateral
or security as it sees fit without regard to any subrogation rights any Grantor may have, and upon any disposition or sale of such
Collateral by the Collateral Agent in accordance with the terms hereof, any rights of subrogation any Grantor may have that specifically
attach to such Collateral shall terminate.

 

ARTICLE
V

 

Representations
and Warranties

 

To induce the Collateral
Agent and the other Secured Parties to enter into the Note Purchase Agreement and the other Note Documents, to induce the Purchasers
to purchase the Notes pursuant to the Note Purchase Agreement and to induce the Purchaser-Related Hedge Providers and the Bank
Product Providers to enter into Hedging Obligations and Bank Product Obligations with the Grantors, each Grantor represents and
warrants to the Collateral Agent and each other Secured Party as follows:

 

Section 5.1           Confirmation
of Representations in Note Purchase Agreement. Each Guarantor represents and warrants to the Secured Parties that the
representations and warranties set forth in Article IV of the Note Purchase Agreement that specifically relate to such Guarantor
(in its capacity as a Note Party or a Subsidiary of the Issuer, as the case may be) are true and correct in all material respects
(or if already qualified by materiality or Material Adverse Effect, in all respects); provided that each reference in each
such representation and warranty to the Issuer’s knowledge shall, for the purposes of this Section, be deemed to be a reference
to such Guarantor’s knowledge.

 

Section 5.2           Benefit
to the Guarantors. As of the Closing Date, the Issuer is a member of an affiliated group of companies that includes each
Guarantor, and the Issuer and the Guarantors are engaged in related businesses permitted pursuant to Section 5.3 of the
Note Purchase Agreement. Each Guarantor is a Subsidiary of the Issuer, and the guaranty and surety obligations of each Guarantor
pursuant to this Agreement reasonably may be expected to benefit, directly or indirectly, such Guarantor; and each Guarantor has
determined that this Agreement is necessary and convenient to the conduct and promotion of the business of such Guarantor and the
Issuer.

 

Section 5.3           Pledged
Securities; Promissory Notes. As of the Closing Date, Schedule 2 correctly sets forth (a) all duly authorized, issued
and outstanding Capital Stock of each Guarantor and each other Person that is beneficially owned by each Grantor and (b) all Notes
held by each Grantor, in each case on the Closing Date. No Pledged Security issued by a limited liability company or a limited
partnership is a “Security” within the meaning of Article 8 of the UCC, unless such Pledged Security is evidenced by
a certificate.

 

    	 	13	 

     

    

 

Section 5.4           First
Priority Liens. The Liens granted to the Collateral Agent, for the benefit of the Secured Parties, pursuant to this Agreement
shall be valid, first-priority, fully perfected Liens on, and security interests in, all right, title and interest of the Grantors
in the Collateral and the proceeds thereof, as security for the Secured Obligations, prior to and superior to any other Person
(except for Specified Permitted Liens) upon the occurrence of the following with respect to such Collateral: (i) in the case of
Pledged Certificated Stock, when certificates representing such Pledged Certificated Stock together with transfer powers thereto
are delivered to the Collateral Agent or its designee, (ii) in the case of deposit accounts (other than Excluded Accounts) or Investment
Property, when an Account Control Agreement is executed and delivered by all parties thereto with respect to such deposit accounts
or Investment Property, (iii) (x) in the case of Copyrights, when the filings in subsection (iv) of this Section are made and when,
if applicable, the Copyright Security Agreements in the form attached hereto as Annex II are filed in the United States Copyright
Office, and (y) in the case of Trademarks or Patents, when the filings in subsection (iv) of this Section are made and when, if
applicable, the Trademark Security Agreements or the Patent Security Agreements, as applicable, in the form attached hereto as
Annex II are filed in the United States Patent and Trademark Office and (iv) in the case of the other Collateral described in this
Agreement in which a Lien may be perfected by the filing of a financing statement, when UCC financing statements are filed in the
appropriate filing offices as specified in Article 9 of the UCC (which, as of the Closing Date, for each of the Grantors is the
filing office set forth for each Grantor on Schedule 3).

 

Section 5.5           Legal
Name, Organizational Status, Chief Executive Office. As of the Closing Date, the correct legal name of such Grantor, such
Grantor’s jurisdiction of organization, organizational identification number (if any), federal taxpayer identification number
and the location of such Grantor’s chief executive office or sole place of business are specified on Schedule 4.

 

Section 5.6           Prior
Names, Prior Chief Executive Offices. Schedule 5 correctly sets forth (a) all names and trade names that such Grantor
has used in the five years preceding the Closing Date and (b) each chief executive office of such Grantor in the five years preceding
the Closing Date (if different from that which is set forth in Schedule 4); provided that, with respect to any Grantor
that was acquired during such five-year period preceding the Closing Date, the information set forth on Schedule 5 hereto
shall be correct to the best of such Grantor’s knowledge.

 

Section 5.7           Chattel
Paper. No Collateral constituting Chattel Paper in excess of $1,000,000 or Instruments contains any statement therein to
the effect that such Collateral has been assigned to an identified party other than the Collateral Agent, and the grant of a security
interest in such Collateral in favor of the Collateral Agent hereunder does not violate the rights of any other Person as a secured
party.

 

Section 5.8           Truth
of Information; Accounts. All written information with respect to the Collateral set forth in any schedule, certificate
or other writing (other than the Profit Plans and other forward-looking information (which shall be subject solely to the representation
set forth in the last sentence of Section 4.4(a) of the Note Purchase Agreement), information regarding third parties and general
economic or industry information ) furnished by or on behalf of such Grantor to the Collateral Agent or any other Secured Party
(as modified or supplemented by any other information so furnished), is or will be, when furnished and taken as a whole, complete
and correct in all material respects and does not or will not, when furnished and taken as a whole, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially
misleading in light of the circumstances under which such statements are made. As of the Closing Date, the locations where each
Grantor keeps its books and records concerning any Accounts, Chattel Paper and Payment Intangibles that constitute Collateral are
set forth on Schedule 6.

 

    	 	14	 

     

    

 

Section 5.9           Governmental
Obligors. Except as disclosed to the Collateral Agent from time to time, none of the Account Debtors on such Grantor’s
Accounts, Chattel Paper or Payment Intangibles is a Governmental Authority, except to the extent such Accounts, Chattel Paper or
Payment Intangibles have an aggregate value of less than $1,000,000 at any time outstanding.

 

Section 5.10         Intellectual
Property Rights. Schedule 7 sets forth all Patents and Patent Licenses owned by such Grantor as of the Closing Date;
Schedule 8 sets forth all registered Trademarks and Trademark Licenses owned by such Grantor as of the Closing Date; and
Schedule 9 sets forth all registered Copyrights and Copyright Licenses owned by such Grantor as of the Closing Date, in
each of the foregoing cases, excluding commercially available software and non-exclusive licenses granted by or, to the extent
such licenses are not material to the business of such Grantor, to such Grantor in the ordinary course of business. To the best
of each such Grantor’s knowledge, each such Patent, Trademark and Copyright is valid, subsisting, unexpired and enforceable
and has not been abandoned. Except as set forth in any such Schedule and any non-exclusive licenses made in the ordinary course
of business, none of such Patents, Trademarks and Copyrights is the subject of any licensing or franchise agreement. Except for
the regular course of prosecution, (a) no holding, decision or judgment has been rendered by any Governmental Authority which would
limit, cancel or question the validity of any such Patent, Trademark or Copyright and (b) no action or proceeding is pending (i) seeking
to limit, cancel or question the validity of any such Patent, Trademark or Copyright, or (ii) which, if adversely determined, would
have a material adverse effect on the value of any such Patent, Trademark or Copyright. Each Grantor owns all material Intellectual
Property Rights purported to be owned by such Grantor free and clear of any Liens, other than Liens permitted by Section 7.2
of the Note Purchase Agreement. The Intellectual Property Rights owned by each Grantor do not infringe or otherwise violate any
intellectual property or other proprietary rights of any other Person in a manner that could result in a materially adverse claim.
There is no action pending or, to the best of such Grantor’s knowledge, threatened in writing, alleging any such infringement
or violation or challenging such Grantor’s rights in or to any such Intellectual Property Rights. To the best of each Grantor’s
knowledge, no Person is infringing or otherwise violating any Intellectual Property Rights owned by such Grantor or any rights
of such Grantor in, to or under any Intellectual Property Licenses.

 

ARTICLE
VI

 

Covenants

 

Each Grantor covenants
and agrees with the Collateral Agent and the other Secured Parties that, so long as any Purchaser has a Commitment under the Note
Purchase Agreement or any Secured Obligation remains unpaid or outstanding (other than Hedging Obligations owed by any Note Party
to any Purchaser-Related Hedge Provider, Bank Product Obligations and indemnities and other contingent obligations not then due
and payable and as to which no claim has been made):

 

Section 6.1           Covenants
in Note Purchase Agreement. In the case of each Guarantor, such Guarantor shall take, or shall refrain from taking, as
the case may be, each action that is necessary to be taken or not taken, as the case may be, so that no Default or Event of Default
is caused by the failure to take such action or to refrain from taking such action by such Guarantor or any of its Subsidiaries.

 

Section 6.2           Maintenance
of Perfected Security Interest; Further Documentation.

 

(a)          Such
Grantor shall maintain the security interest created by this Agreement as a perfected security interest having at least the priority
described in Section 5.4 and shall defend such security interest against the claims and demands of all Persons whomsoever,
except for Liens permitted by Section 7.2 of the Note Purchase Agreement.

 

    	 	15	 

     

    

 

(b)          Such
Grantor will execute any and all further documents, financing statements, agreements and instruments, and take all such further
actions (including the filing and recording of financing statements, fixture filings, Mortgages and other documents), which may
be required under any applicable law, or which the Collateral Agent or the Required Purchasers may reasonably request, to effectuate
the transactions contemplated by the Note Documents or to grant, preserve, protect or perfect the Liens created by this Agreement
and the other Collateral Documents or the validity or priority of any such Lien, all at the expense of the Grantors, including
executing and delivering (i) with regard to Copyright registrations and applications, a Copyright Security Agreement substantially
in the form of Annex II to this Agreement for filing with the United States Copyright Office, (ii) with regard to Patents, a Patent
Security Agreement substantially in the form of Annex II to this Agreement for filing with the United States Patent and Trademark
Office and (iii) with regard to Trademark registrations and applications, a Trademark Security Agreement substantially in the form
of Annex II to this Agreement for filing with the United States Patent and Trademark Office. Such Grantor also agrees to provide
to the Collateral Agent and the Purchasers, from time to time upon request, evidence reasonably satisfactory to the Collateral
Agent or the Required Purchasers, as applicable, as to the perfection and priority of the Liens created or intended to be created
by this Agreement and the other Collateral Documents.

 

(c)          Without
limiting the obligations of the Grantors under subsection (b) of this Section, (i) upon the reasonable request of the Collateral
Agent or the Required Purchasers, such Grantor shall take or cause to be taken all actions (other than any actions required to
be taken by the Collateral Agent) reasonably requested by the Collateral Agent or the Required Purchasers to cause the Collateral
Agent to (A) have “control” (within the meaning of Sections 9-104, 9-105, 9-106, and 9-107 of the UCC) over any
Collateral constituting Deposit Accounts, Electronic Chattel Paper, Investment Property (including the Pledged Securities), or
Letter-of-Credit Rights, including, without limitation, executing and delivering any agreements, in form and substance reasonably
satisfactory to the Collateral Agent and the Required Purchasers, with securities intermediaries, issuers or other Persons in order
to establish “control”, and each Grantor shall promptly notify the Collateral Agent and the other Secured Parties of
such Grantor’s acquisition of any such Collateral, and (B) be a “protected purchaser” (as defined in Section
8-303 of the UCC); (ii) with respect to Collateral other than Pledged Certificated Stock and Goods covered by a Document in the
possession of a Person other than such Grantor, the Collateral Agent (or any designee of the Collateral Agent) or any other Secured
Party, such Grantor shall use its commercially reasonable efforts to obtain written acknowledgment that such Person holds possession
for the Collateral Agent’s benefit; and (iii) with respect to any Collateral constituting Goods with a value in excess of
$1,000,000 that are in the possession of a bailee, such Grantor shall provide prompt notice to the Collateral Agent and the other
Secured Parties of any such Collateral then in the possession of such bailee, and such Grantor shall take or cause to be taken
all actions (other than any actions required to be taken by the Collateral Agent or any other Secured Party or any action required
to be taken by such bailee) necessary or reasonably requested by the Collateral Agent or the Required Purchasers to cause the Collateral
Agent to have a perfected security interest in such Collateral under applicable law.

 

Section 6.3           Maintenance
of Records. Such Grantor will keep and maintain at its own cost and expense proper books and records with respect to the
Collateral, including, without limitation, a record of all payments received and all credits granted with respect to the Accounts
comprising any part of the Collateral. For the Collateral Agent’s and the other Secured Parties’ further security,
the Collateral Agent, for the ratable benefit of the Secured Parties, shall have a security interest in all of such Grantor’s
books and records pertaining to the Collateral.

 

    	 	16	 

     

    

 

Section 6.4           Right
of Inspection. Such Grantor will permit any representative of the Collateral Agent or any Purchaser to visit and inspect
its properties, to examine its books and records and to make copies and take extracts therefrom, and to discuss its affairs, finances
and accounts with any of its officers and with its independent certified public accountants (provided that such Grantor
is provided reasonable prior notice of any discussion with its auditors or accountants and is afforded an opportunity to participate
in such discussions), all at such reasonable times and subject to reasonable prior notice to such Grantor; provided that,
so long as no Event of Default has occurred and is continuing, visits and inspections under this Section 6.4 shall
be limited to one time per Fiscal Year for the Collateral Agent and all of the Purchasers. Any Related Party of the Collateral
Agent or any Secured Party that attends or participates in any such visit or inspection shall, prior to such attendance or participation,
expressly agree to be subject to and bound by the confidentiality provisions of the Note Purchase Agreement or shall otherwise
be bound by professional ethics rules to maintain such confidentiality.

 

Section 6.5           Further
Identification of Collateral. Such Grantor will furnish to the Collateral Agent from time to time (but no more than two
(2) times during any twelve month period when no Event of Default has occurred and is continuing), at such Grantor’s sole
cost and expense, statements and schedules further identifying and describing the Collateral and such other reports in connection
with the Collateral as the Collateral Agent or the Required Purchasers may reasonably request, all in reasonable detail.

 

Section 6.6           Changes
in Names, Locations. Such Grantor recognizes that financing statements pertaining to the Collateral have been or may be
filed where such Grantor is organized. Without limitation of any other covenant herein, such Grantor will not cause or permit (i)
any change to be made in its legal name, identity or corporate, limited liability company, or limited partnership structure or
(ii) any change to (A) the identity of any warehouseman, common carrier, other third party transporter, bailee or any agent or
processor in possession or control of any Collateral with a value in excess of $1,000,000 or (B) such Grantor’s jurisdiction
of organization, unless such Grantor shall have first (1) notified the Collateral Agent and the Purchasers of such change
at least 30 days prior to the date of such change, and (2) taken all action necessary and/or reasonably requested by the Collateral
Agent or any other Secured Party for the purpose of maintaining the perfection and priority of the Collateral Agent’s security
interests under this Agreement, and unless such Grantor shall otherwise be in compliance with Section 7.3 of the Note Purchase
Agreement. In any notice furnished pursuant to this Section, such Grantor will expressly state in a conspicuous manner that the
notice is required by this Agreement and contains facts that may require additional filings of financing statements or other notices
for the purposes of continuing perfection of the Collateral Agent’s security interest in the Collateral.

 

Section 6.7           Pledged
Securities.

 

(a)          If
such Grantor shall become entitled to receive or shall receive any Promissory Notes, stock certificate or other instrument (including,
without limitation, any certificate or instrument representing a dividend or a distribution in connection with any reclassification,
increase or reduction of capital or any certificate or instrument issued in connection with any reorganization), option or rights
in respect of the Capital Stock of any Pledged Security Issuer, whether in addition to, in substitution of, as a conversion of,
or in exchange for, any shares (or such other interests) of the Pledged Securities, or otherwise in respect thereof, except as
otherwise provided herein or in the Note Purchase Agreement, such Grantor shall accept the same for the benefit of the Collateral
Agent, hold the same on behalf of and for the benefit of the Collateral Agent and deliver the same forthwith to the Collateral
Agent in the exact form received, duly indorsed by such Grantor to the Collateral Agent, if required, together with an undated
stock power or other equivalent instrument of transfer reasonably acceptable to the Collateral Agent and the Required Purchasers
covering such certificate or instrument duly executed in blank by such Grantor and with, if the Collateral Agent so requests, signature
guaranteed, to be held by the Collateral Agent, subject to the terms hereof, as additional collateral security for the Secured
Obligations.

 

    	 	17	 

     

    

 

(b)          Without
the prior written consent of the Required Purchasers, except to the extent permitted by the Note Purchase Agreement (or pursuant
to or in connection with a transaction permitted by the Note Purchase Agreement), such Grantor will not (i) vote to enable, or
take any other action to cause, any Pledged Security Issuer to issue any Capital Stock or to issue any other securities or interests
convertible into or granting the right to purchase or exchange for any Capital Stock of any Pledged Security Issuer (unless such
Grantor complies with the terms of the Note Documents with respect to any such additional issuance), (ii) sell, assign, transfer,
exchange or otherwise dispose of, or grant any option with respect to, the Pledged Securities or Proceeds thereof, (iii) create,
incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Securities
or Proceeds thereof, or any interest therein, or (iv) enter into any agreement or undertaking restricting the right or ability
of such Grantor or the Collateral Agent to sell, assign or transfer any of the Pledged Securities or Proceeds thereof.

 

(c)          In
the case of each Grantor which is a Pledged Security Issuer, and each other Pledged Security Issuer that executes the Acknowledgment
and Consent in the form of Annex III (which the applicable Grantor shall use its commercially reasonable efforts to obtain
from each such other Pledged Security Issuer), such Pledged Security Issuer agrees that (i) it will be bound by the terms of this
Agreement relating to the Pledged Securities issued by it and will comply with such terms insofar as such terms are applicable
to it, (ii) it will notify the Collateral Agent promptly in writing of the occurrence of any of the events described in subsection
(a) of this Section with respect to the Pledged Securities issued by it and (iii) the terms of Section 7.1(c) and Section
7.5 shall apply to it, mutatis mutandis, with respect to all actions that may be required of it pursuant to Section
7.1(c) or Section 7.5 with respect to the Pledged Securities issued by it.

 

(d)          Such
Grantor shall furnish to the Collateral Agent such powers and other equivalent instruments of transfer as may be reasonably required
by the Collateral Agent or the Required Purchasers and/or is necessary to assure the transferability of and the perfection of the
security interest in the Pledged Securities when and as often as may be reasonably requested by the Collateral Agent or the Required
Purchasers.

 

(e)          Each
Grantor acknowledges and agrees that, to the extent any interest in any limited liability company or limited partnership constituting
Pledged Securities hereunder is a “Security” within the meaning of Article 8 of the UCC and is governed by Article
8 of the UCC, such interest shall be represented by a certificate. Each Grantor further acknowledges and agrees that with respect
to any interest in any limited liability company or limited partnership constituting Pledged Securities hereunder that is not a
“Security” within the meaning of Article 8 of the UCC, such Grantor shall at no time elect to treat any such interest
as a “Security” within the meaning of Article 8 of the UCC, unless such election and such interest is thereafter represented
by a certificate that is promptly delivered to the Collateral Agent pursuant to the terms hereof.

 

(f)          If
any Grantor acquires any Capital Stock or Stock Equivalents that do not constitute Excluded Capital Stock or any Promissory Notes
after executing this Agreement, such Capital Stock, Stock Equivalents and Promissory Notes shall automatically constitute Collateral
and, upon the reasonable request of the Collateral Agent or the Required Purchasers, such Grantor shall promptly deliver a revised
Schedule 2 which shall replace the then existing Schedule 2 to this Agreement.

 

Section 6.8           Limitations
on Modifications, Waivers, Extensions of Agreements Giving Rise to Accounts. Such Grantor will not (i) amend, modify, terminate
or waive any provision of any Chattel Paper, Instrument or any agreement giving rise to an Account or Payment Intangible comprising
a portion of the Collateral, or (ii) fail to exercise promptly and diligently each and every right which it may have under any
Chattel Paper, Instrument and each agreement giving rise to an Account or Payment Intangible comprising a portion of the Collateral
(other than any right of termination), except where such action or failure to act, individually or in the aggregate, could not
reasonably be expected to have a Material Adverse Effect.

 

    	 	18	 

     

    

 

Section 6.9           Instruments
and Tangible Chattel Paper. If any amount payable under or in connection with any of the Collateral shall be or become
evidenced by any Instrument or Tangible Chattel Paper and the value of such Instruments and Tangible Chattel Paper in the aggregate
is $1,000,000 or more, each such Instrument or Tangible Chattel Paper shall be delivered to the Collateral Agent as soon as practicable,
duly endorsed in a manner reasonably satisfactory to the Collateral Agent and the Required Purchasers to be held as Collateral
pursuant to this Agreement.

 

Section 6.10         Copyrights,
Patents and Trademarks.

 

(a)          Such
Grantor (either itself or through licensees) will, except with respect to any Trademark that such Grantor shall reasonably determine
is immaterial or as is permitted by Section 7.6 of the Note Purchase Agreement, (i) maintain as in the past the quality of services
offered under such Trademark, (ii) maintain such Trademark in full force and effect, free from any claim of abandonment for non-use,
(iii) employ such Trademark with the appropriate notice of registration, and (iv) not (and not permit any licensee or sublicensee
thereof to) do any act or knowingly omit to do any act whereby any Trademark may become abandoned or invalidated.

 

(b)          Such
Grantor will not, except with respect to any Patent that such Grantor shall reasonably determine is immaterial or as is permitted
by Section 7.6 of the Note Purchase Agreement, do any act, or omit to do any act, whereby any Patent may become abandoned or dedicated.

 

(c)           Such
Grantor will not, except with respect to any Copyright that such Grantor shall reasonably determine is immaterial or as is permitted
by Section 7.6 of the Note Purchase Agreement, do any act, or omit to do any act, whereby any Copyright may become abandoned or
dedicated.

 

(d)           Such
Grantor will notify the Collateral Agent and the Purchasers promptly if it knows, or has reason to know, that any application or
registration relating to any Copyright, Patent or Trademark may become abandoned, invalidated or dedicated (except with respect
to any Copyright, Patent or Trademark that such Grantor shall reasonably determine is immaterial or as is permitted by Section
7.6 of the Note Purchase Agreement), or of any adverse determination or development (including, without limitation, the institution
of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States
Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of any Copyright, Patent or
Trademark or its right to register the same or to keep and maintain the same.

 

(e)           Whenever
a Grantor, either by itself or through any agent, employee, licensee or designee, shall file an application for the registration
of any Copyright, Patent or Trademark with the United States Copyright Office, the United States Patent and Trademark Office or
any similar office or agency in any other country or any political subdivision thereof, such Grantor shall report such filing to
the Collateral Agent and the Purchasers within five (5) Business Days after the last day of the fiscal quarter in which such filing
occurs. Such Grantor shall within thirty (30) days execute and deliver an Intellectual Property Security Agreement substantially
in the form of Annex II, and any and all other agreements, instruments, documents, and papers as are necessary to evidence
the Collateral Agent’s security interest in any such Copyright, Patent or Trademark and the goodwill and General Intangibles
of such Grantor relating thereto or represented thereby.

 

    	 	19	 

     

    

 

(f)           Such
Grantor will take all reasonable and necessary steps, including, without limitation, in any proceeding before the United States
Copyright Office, the United States Patent and Trademark Office, or any similar office or agency in any other country or any political
subdivision thereof, to maintain and pursue each application (and to obtain the relevant registration) and to maintain each registration
of the Copyrights, Patents and Trademarks, including, without limitation, filing of applications for renewal, affidavits of use
and affidavits of incontestability.

 

(g)          In
the event that any Copyright, Patent or Trademark included in the Collateral is infringed, misappropriated or diluted by a third
party, such Grantor shall promptly notify the Collateral Agent and the Purchasers after it learns thereof and shall, unless such
Grantor shall reasonably determine that such Copyright, Patent or Trademark is immaterial to such Grantor, promptly take actions
to remedy or address such infringement, misappropriation or dilution, including to seek injunctive relief where appropriate and
to recover any and all damages for such infringement, misappropriation or dilution, or take such other actions as such Grantor
shall reasonably deem appropriate under the circumstances to protect such Copyright, Patent or Trademark.

 

Section 6.11         Commercial
Tort Claims. If such Grantor shall at any time hold or acquire a Commercial Tort Claim that satisfies the requirements
of the following sentence, such Grantor shall, within 30 days after such Commercial Tort Claim satisfies such requirements, notify
the Collateral Agent and the Purchasers in a writing signed by such Grantor containing a brief description thereof, and granting
to the Collateral Agent (for the benefit of the Secured Parties) in such writing a security interest therein and in the Proceeds
thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to the Collateral
Agent and the Required Purchasers. The provisions of the preceding sentence shall apply only to a Commercial Tort Claim that satisfies
the following requirements: (i) the monetary value claimed by or payable to the relevant Grantor in connection with such Commercial
Tort Claim shall exceed $1,000,000, and (ii) either (A) such Grantor shall have filed a law suit or counterclaim or otherwise commenced
legal proceedings (including, without limitation, arbitration proceedings) against the Person against whom such Commercial Tort
Claim is made, or (B) such Grantor and the Person against whom such Commercial Tort Claim is asserted shall have entered into
a settlement agreement with respect to such Commercial Tort Claim. In addition, to the extent that the existence of any Commercial
Tort Claim held or acquired by any Grantor is disclosed by such Grantor in any public filing with the Securities Exchange Commission
or any successor thereto or analogous Governmental Authority, or to the extent that the existence of any such Commercial Tort Claim
is disclosed in any press release issued by any Grantor, then the relevant Grantor shall, within 30 days after such request is
made, transmit to the Collateral Agent and the Purchasers a writing signed by such Grantor containing a brief description of such
Commercial Tort Claim and granting to the Collateral Agent (for the benefit of the Secured Parties) in such writing a security
interest therein and in the Proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance
reasonably satisfactory to the Collateral Agent and the Required Purchasers.

 

ARTICLE
VII

 

Remedial
Provisions

 

Section 7.1           Pledged
Securities.

 

(a)          Unless
an Event of Default shall have occurred and be continuing and the Collateral Agent (at the direction of the Required Purchasers)
shall have given one (1) Business Day’s prior written notice to the relevant Grantor of the Collateral Agent’s intent
to exercise its corresponding rights pursuant to subsection (b) of this Section, each Grantor shall be permitted to receive all
cash dividends paid in respect of the Pledged Securities paid in the normal course of business of the relevant Pledged Security
Issuer, to the extent permitted by the Note Purchase Agreement, and to exercise all voting and corporate rights with respect to
the Pledged Securities.

 

    	 	20	 

     

    

 

(b)          If
an Event of Default shall occur and be continuing, then at any time in the Required Purchasers’ discretion, upon one (1)
Business Day’s prior written notice to the relevant Grantor, (i) the Purchasers shall have the right to receive any and all
cash dividends, payments or other Proceeds paid in respect of the Pledged Securities and make application thereof to the Obligations
in accordance with Section 2.9(d) of the Note Purchase Agreement, and (ii) any or all of the Pledged Securities shall be registered
in the name of the Collateral Agent or its nominee, and the Collateral Agent or its nominee (at the direction of the Required Purchasers)
may thereafter exercise (x) all voting, corporate and other rights pertaining to such Pledged Securities at any meeting of shareholders
(or other equivalent body) of the relevant Pledged Security Issuer or Pledged Security Issuers or otherwise and (y) any and all
rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Securities
as if it were the absolute owner thereof (including, without limitation, the right to exchange at its discretion any and all of
the Pledged Securities upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the organizational
structure of any Pledged Security Issuer, or upon the exercise by any Grantor or the Collateral Agent of any right, privilege or
option pertaining to such Pledged Securities, and in connection therewith, the right to deposit and deliver any and all of the
Pledged Securities with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions
as the Collateral Agent (at the direction of the Required Purchasers) may determine), all without liability except to account for
property actually received by it, but neither the Collateral Agent nor the Purchasers shall have any duty to any Grantor to exercise
any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.

 

(c)          Each
Grantor hereby authorizes and instructs each Pledged Security Issuer of any Pledged Securities pledged by such Grantor hereunder
(and each Pledged Security Issuer party hereto hereby agrees) to comply with any instruction received by it from the Collateral
Agent in writing (including any instruction to pay any dividends or other payments with respect to such Pledged Securities directly
to the Purchasers or the Collateral Agent, as applicable), in each case, (i) after an Event of Default has occurred and is continuing
and (so long as the Purchasers have complied with the notice provisions of subsection (b) above) (ii) that is otherwise in accordance
with the terms of this Agreement, without any other or further instructions from such Grantor, and each Grantor agrees that each
Pledged Security Issuer shall be fully protected in so complying.

 

(d)          After
the occurrence and during the continuance of an Event of Default, upon notice to the relevant Grantor, if the Pledged Security
Issuer of any Pledged Securities is the subject of bankruptcy, insolvency, receivership, custodianship or other proceedings under
the supervision of any Governmental Authority, then all rights of the Grantor in respect thereof to exercise the voting and other
consensual rights which such Grantor would otherwise be entitled to exercise with respect to the Pledged Securities issued by such
Pledged Security Issuer shall cease, and all such rights shall thereupon become vested in the Collateral Agent who shall thereupon
have the sole right to exercise such voting and other consensual rights (at the direction of the Required Purchasers), but neither
the Collateral Agent nor the Purchasers shall have any duty to exercise any such voting or other consensual rights and shall not
be responsible for any failure to do so or delay in so doing.

 

    	 	21	 

     

    

 

Section 7.2           Collections
on Accounts. The Collateral Agent hereby authorizes each Grantor to collect upon the Accounts, Instruments, Chattel Paper
and Payment Intangibles until the occurrence and during the continuance of an Event of Default. Upon the request of the Collateral
Agent or the Required Purchasers, at any time after the occurrence and during the continuance of an Event of Default, each Grantor
shall notify the applicable Account Debtors that the applicable Accounts, Chattel Paper and Payment Intangibles have been assigned
to the Collateral Agent for the ratable benefit of the Secured Parties and that payments in respect thereof shall be made directly
to the Collateral Agent. Upon the occurrence of and during the continuance of an Event of Default, the Collateral Agent may in
its own name or in the name of the applicable Grantor communicate with the applicable Account Debtors to verify with them to its
satisfaction the existence, amount and terms of any applicable Accounts, Chattel Paper or Payment Intangibles; provided that the
applicable Grantor shall have a reasonable opportunity to be present for or participate in any such communications between the
Account Debtor and the Collateral Agent.

 

Section 7.3           Proceeds.
If required by the Collateral Agent (at the direction of the Required Purchasers) at any time after the occurrence and during the
continuance of an Event of Default, any payments of Accounts, Instruments, Chattel Paper and Payment Intangibles comprising a portion
of the Collateral, when collected or received by each Grantor, and any other cash or non-cash Proceeds received by each Grantor
upon the sale or other disposition of any Collateral, shall be forthwith (and, in any event, within two (2) Business Days) deposited
by such Grantor in the exact form received, duly indorsed by such Grantor to the Collateral Agent in a special collateral account
maintained by the Collateral Agent subject to withdrawal by the Collateral Agent for the ratable benefit of the Secured Parties
only, as hereinafter provided, and, until so turned over, shall be held by such Grantor on behalf of and for the benefit of the
Collateral Agent for the ratable benefit of the Secured Parties segregated from other funds of any such Grantor. Each deposit of
any such Proceeds shall be accompanied by a report identifying in detail the nature and source of the payments included in the
deposit. All Proceeds of the Collateral (including, without limitation, Proceeds constituting collections of Accounts, Chattel
Paper, Instruments or Payment Intangibles comprising a portion of the Collateral) while held by the Collateral Agent (or by any
Grantor on behalf of and for the benefit of the Collateral Agent for the ratable benefit of the Secured Parties) shall continue
to be collateral security for all of the Secured Obligations and shall not constitute payment thereof until applied as hereinafter
provided. At such intervals as may be agreed upon by each Grantor and the Collateral Agent (at the direction of the Required Purchasers),
or, if an Event of Default shall have occurred and be continuing, at any time at the Collateral Agent’s (at the direction
of the Required Purchasers) election, the Collateral Agent shall apply all or any part of the Proceeds on deposit in said special
collateral account on account of the Secured Obligations in the order set forth in Section 8.2 of the Note Purchase Agreement,
and any part of such Proceeds which the Collateral Agent elects not so to apply and deems not required as collateral security for
the Secured Obligations shall be paid over from time to time by the Collateral Agent to each Grantor or to whomsoever may be lawfully
entitled to receive the same. After an Event of Default specified in Section 8.1(g) or 8.1(h) of the Note Purchase Agreement, any
expenses incurred or services rendered by the Collateral Agent or any Purchaser in connection therewith (including the reasonable
expenses of its counsel) shall constitute expenses of administration under the Bankruptcy Code.

 

    	 	22	 

     

    

 

Section 7.4           UCC
and Other Remedies.

 

(a)          If
an Event of Default shall occur and be continuing, the Collateral Agent, on behalf of the Secured Parties, may exercise (at the
direction of the Required Purchasers), in addition to all other rights, remedies, powers and privileges granted to them in this
Agreement, the other Note Documents, and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations,
all rights, remedies, powers and privileges of a secured party under the UCC (regardless of whether the UCC is in effect in the
jurisdiction where such rights, remedies, powers or privileges are asserted) or any other applicable law or otherwise available
at law or equity. Without limiting the generality of the foregoing, the Collateral Agent, without demand of performance or other
demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below or required
by the Note Documents) to or upon any Grantor or any other Person (all and each of which demands, presentments, protests, advertisements
and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral,
or any part thereof, and/or may forthwith sell, lease, assign, give option or options to purchase, or otherwise dispose of and
deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private
sale or sales, at any exchange, broker’s board or office of the Collateral Agent or elsewhere upon such terms and conditions
as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption
of any credit risk. The Collateral Agent shall have the right upon any such public sale or sales, and, to the extent permitted
by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or
equity of redemption in any Grantor, which right or equity is hereby waived and released. If an Event of Default shall occur and
be continuing, each Grantor further agrees, at the Collateral Agent’s request (at the direction of the Required Purchasers),
to assemble the Collateral and make it available to the Collateral Agent at places which the Collateral Agent shall reasonably
select, whether at such Grantor’s premises or elsewhere. Any such sale or transfer by the Collateral Agent either to itself
or to any other Person shall be absolutely free from any claim of right by any Grantor, including any equity or right of redemption,
stay or appraisal which such Grantor has or may have under any rule of law, regulation or statute now existing or hereafter adopted.
Upon any such sale or transfer, the Collateral Agent shall have the right to deliver, assign and transfer to the purchaser or transferee
thereof the Collateral so sold or transferred. The Collateral Agent shall apply the net proceeds of any action taken by it pursuant
to this Section, after deducting all documented out-of-pocket costs, fees and expenses incurred in connection therewith or incidental
to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of the Collateral Agent
hereunder, including, without limitation, documented out-of-pocket attorneys’ fees and disbursements, to the payment in whole
or in part of the Obligations, in accordance with Section 8.2 of the Note Purchase Agreement, and only after such application and
after the payment by the Collateral Agent of any other amount required by any provision of law, including, without limitation,
Section 9-615 of the UCC, need the Collateral Agent account for the surplus, if any, to any Grantor. To the extent permitted by
applicable law, each Grantor waives all claims, damages and demands it may acquire against the Collateral Agent arising out of
the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required
by law, such notice shall be deemed reasonable and proper if given at least 10 days before such sale or other disposition.

 

(b)          In
the event that the Collateral Agent elects not to sell the Collateral, the Collateral Agent retains its rights to dispose of or
utilize the Collateral or any part or parts thereof in any manner authorized or permitted by law or in equity and to apply the
proceeds of the same towards payment of the Secured Obligations. Each and every method of disposition of the Collateral described
in this Agreement shall constitute disposition in a commercially reasonable manner. The Collateral Agent may appoint any Person
as agent to perform any act or acts necessary or incident to any sale or transfer of the Collateral.

 

Section 7.5           Private
Sales of Pledged Securities. Each Grantor recognizes that the Collateral Agent may be unable to effect a public sale of
any or all the Pledged Securities, by reason of certain prohibitions contained in the Securities Act and applicable state securities
laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers which
will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view
to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and
other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private
sale shall be deemed to have been made in a commercially reasonable manner. The Collateral Agent shall be under no obligation to
delay a sale of any of the Pledged Securities for the period of time necessary to permit the Pledged Security Issuer thereof to
register such securities for public sale under the Securities Act, or under applicable state securities laws, even if such Pledged
Security Issuer would agree to do so. Each Grantor agrees to use its best efforts to do or cause to be done all such other acts
as may reasonably be necessary to make such sale or sales of all or any portion of the Pledged Securities pursuant to this Section
valid and binding and in compliance with any and all other applicable Requirements of Law. Each Grantor further agrees that a breach
of any of the covenants of such Grantor contained in this Section will cause irreparable injury to the Collateral Agent and the
other Secured Parties, that the Collateral Agent and the other Secured Parties have no adequate remedy at law in respect of such
breach and, as a consequence, that each and every covenant contained in this Section shall be specifically enforceable against
such Grantor, and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of
such covenants.

 

    	 	23	 

     

    

 

Section 7.6           Deficiency.
Each Grantor shall remain jointly and severally liable for any deficiency if the proceeds of any sale or other disposition of the
Collateral are insufficient to pay its Obligations or Guaranteed Obligations, as the case may be, and the documented out-of-pocket
fees and disbursements of any attorneys employed by the Collateral Agent or any other Secured Party to collect such deficiency.

 

Section 7.7           Non-Judicial
Enforcement. The Collateral Agent may enforce its rights hereunder without prior judicial process or judicial hearing,
and, to the extent permitted by law, each Grantor expressly waives any and all legal rights which might otherwise require the Collateral
Agent to enforce its rights by judicial process (to the extent permitted to be waived by applicable law).

 

ARTICLE
VIII

 

The
Collateral Agent

 

Section 8.1           The
Collateral Agent’s Appointment as Attorney-in-Fact.

 

(a)          Each
Grantor hereby irrevocably constitutes and appoints the Collateral Agent, after the occurrence and during the continuance of an
Event of Default, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority
in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the
terms of this Agreement, to take any and all reasonably appropriate action and to execute any and all documents and instruments
which may be reasonably necessary or desirable to accomplish the purposes of this Agreement, and, without limiting the generality
of the foregoing, each Grantor hereby gives the Collateral Agent the power and right, on behalf of such Grantor, without notice
to or assent by such Grantor, after the occurrence and during the continuance of an Event of Default, to do any or all of the following:

 

(i)          pay
or discharge Taxes and Liens levied or placed on or threatened against the Collateral, effect any repairs or any insurance called
for by the terms of this Agreement and pay all or any part of the premiums therefor and the costs thereof;

 

(ii)         execute,
in connection with any sale provided for in Section 7.4 or Section 7.5, any endorsements, assignments or other instruments
of conveyance or transfer with respect to the Collateral; and

 

    	 	24	 

     

    

 

(iii)        (A)
direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due
thereunder directly to the Collateral Agent or as the Collateral Agent shall direct; (B) take possession of and indorse and collect
any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Account, Instrument, General
Intangible, Chattel Paper or Payment Intangible constituting Collateral or with respect to any other Collateral, and to file any
claim or to take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by the Collateral
Agent for the purpose of collecting any or all such moneys due under any Account, Instrument or General Intangible constituting
Collateral or with respect to any other Collateral whenever payable; (C) ask or demand for, collect, and receive payment of and
receipt for any and all moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral;
(D) sign and indorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors,
assignments, verifications, notices and other documents in connection with any of the Collateral; (E) receive, change the address
for delivery, open and dispose of mail addressed to any Grantor, and execute, assign and indorse negotiable and other instruments
for the payment of money, documents of title or other evidences of payment, shipment or storage for any form of Collateral on behalf
of and in the name of any Grantor; (F) commence and prosecute any suits, actions or proceedings at law or in equity in any court
of competent jurisdiction to collect the Collateral or any portion thereof and to enforce any other right in respect of any Collateral;
(G) defend any suit, action or proceeding brought against such Grantor with respect to any Collateral; (H) settle, compromise or
adjust any such suit, action or proceeding and, in connection therewith, give such discharges or releases as the Collateral Agent
(at the reasonable direction of the Required Purchasers) or the Required Purchasers may deem appropriate; (I) assign any Patent
or Trademark (along with the goodwill of the business to which any such Trademark pertains) throughout the world for such term
or terms, on such conditions, and in such manner as the Required Purchasers shall in their sole discretion determine; and (J) generally,
sell, transfer, pledge and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely
as though the Collateral Agent were the absolute owner thereof for all purposes, and do, at the Collateral Agent’s option
(at the direction of the Required Purchasers) and such Grantor’s expense, at any time, or from time to time, all acts and
things which the Collateral Agent (at the direction of the Required Purchasers) deems necessary to protect, preserve or realize
upon the Collateral and the Collateral Agent’s and the other Secured Parties’ security interests therein and to effect
the intent of this Agreement, all as fully and effectively as such Grantor might do.

 

Other than as required
by Section 7.1, the Collateral Agent shall give the relevant Grantor notice of any action taken pursuant to this subsection
when reasonably practicable; provided that the Collateral Agent shall have no liability for the failure to provide any such
notice.

 

(b)          If
any Grantor fails to perform or comply with any of its agreements contained herein within the applicable grace periods, the Collateral
Agent, at its option (at the direction of the Required Purchasers), but without any obligation so to do, may perform or comply,
or otherwise cause performance or compliance, with such agreement, in accordance with the terms hereof.

 

(c)          The
documented out-of-pocket fees and expenses of the Collateral Agent incurred in connection with actions undertaken as provided in
this Section shall be payable by such Grantor to the Collateral Agent on demand.

 

(d)          Each
Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof and in compliance herewith,
subject in all respects to the terms hereof. All powers, authorizations and agencies contained in this Agreement are coupled with
an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.

 

    	 	25	 

     

    

 

Section 8.2           Duty
of the Collateral Agent. The Collateral Agent’s sole duty with respect to the custody, safekeeping and physical preservation
of the Collateral in its possession, under Section 9-207 of the UCC or otherwise, shall be to deal with it in the same manner as
the Collateral Agent deals with similar property and the Collateral Agent shall be deemed to have exercised reasonable care in
the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to
that which comparable secured parties accord comparable collateral. Neither the Collateral Agent, any other Secured Party nor any
of their respective officers, directors, employees or agents shall be liable for failure to demand, collect or realize upon any
of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral
upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to the Collateral or any
part thereof. The powers conferred on the Collateral Agent hereunder are solely to protect the Collateral Agent’s and the
other Secured Parties’ interests in the Collateral and shall not impose any duty upon the Collateral Agent to exercise any
such powers. The Collateral Agent and the other Secured Parties shall be accountable only for amounts that they actually receive
as a result of the exercise of such powers, and neither they nor any of their officers, directors, employees or agents shall be
responsible to any Grantor for any act or failure to act hereunder, except, with respect to any Secured Party, as determined by
a court of competent jurisdiction in a final and non-appealable judgment to have resulted from (a) its own gross negligence or
willful misconduct or (b) other than with respect to the Collateral Agent and its officers, directors, employees and agents, a
material breach by such Secured Party of any of its undertakings, obligations or commitments under this Agreement or any other
Note Document. To the fullest extent permitted by applicable law and except as required by this Agreement, the Collateral Agent
shall be under no duty whatsoever to make or give any presentment, notice of dishonor, protest, demand for performance, notice
of non-performance, notice of intent to accelerate, notice of acceleration, or other notice or demand in connection with any Collateral,
or to take any steps necessary to preserve any rights against any Grantor or other Person or ascertaining or taking action with
respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Collateral, whether or not it has
or is deemed to have knowledge of such matters. Each Grantor, to the extent permitted by applicable law, waives any right of marshaling
in respect of any and all Collateral, and waives any right to require the Collateral Agent or any other Secured Party to proceed
against any Grantor or other Person, exhaust any Collateral or enforce any other remedy which the Collateral Agent or any other
Secured Party now has or may hereafter have against any Grantor or other Person.

 

Section 8.3           Filing
of Financing Statements. Pursuant to the UCC and any other applicable law, each Grantor authorizes the Collateral Agent,
its counsel or its representative, at any time and from time to time, to file or record financing statements, continuation statements,
amendments thereto and other filing or recording documents or instruments with respect to the Collateral without the signature
of such Grantor in such form and in such offices as the Collateral Agent reasonably determines appropriate to perfect the security
interests of the Collateral Agent under this Agreement. Additionally, each Grantor authorizes the Collateral Agent, its counsel
or its representative, at any time and from time to time, to file or record such financing statements that describe the collateral
covered thereby as “all assets of the Grantor”, “all personal property of the Grantor” or words of similar
effect. A photographic or other reproduction of this Agreement shall be sufficient as a financing statement or other filing or
recording document or instrument for filing or recording in any jurisdiction. For the avoidance of doubt, nothing herein shall
require the Collateral Agent to file financing statements, termination statements or continuation statements, or be responsible
for maintaining the security interests purported to be created as described herein (except for the safe custody of any Collateral
in its possession and the accounting for moneys actually received by it hereunder or under any other Note Documents) and such responsibility
shall be solely that of the Note Parties; provided that, upon the written direction of the Required Purchasers, the Collateral
Agent shall file financing statements, termination statements or continuation statements.

 

    	 	26	 

     

    

 

Section 8.4           Authority
of the Collateral Agent. Each Grantor acknowledges that the rights and responsibilities of the Collateral Agent under this
Agreement with respect to any action taken by the Collateral Agent or the exercise or non-exercise by the Collateral Agent of any
option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement
shall, as between the Collateral Agent and the other Secured Parties, be governed by the Note Purchase Agreement and by such other
agreements with respect thereto as may exist from time to time among them, but, as between the Collateral Agent and the Grantors,
the Collateral Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority
so to act or refrain from acting, and no Grantor shall be under any obligation, or entitlement, to make any inquiry respecting
such authority.

 

ARTICLE
IX

 

Subordination
of Indebtedness

 

Section 9.1           Subordination
of All Guarantor Claims. As used herein, the term “Guarantor Claims” shall mean all debts and obligations of
the Issuer or any Grantor owing to any other Grantor, whether such debts and obligations now exist or are hereafter incurred or
arise, or whether the obligation of the debtor thereon be direct, contingent, primary, secondary, several, joint and several, or
otherwise, and irrespective of whether such debts or obligations be evidenced by note, contract, open account, or otherwise, and
irrespective of the manner in which they have been or may hereafter be acquired. After the occurrence and during the continuation
of an Event of Default, no Grantor shall receive or collect, directly or indirectly, from any obligor in respect thereof any amount
on account of the Guarantor Claims.

 

Section 9.2           Claims
in Bankruptcy. In the event of receivership, bankruptcy, reorganization, arrangement, debtor’s relief or other insolvency
proceedings involving any Grantor, the Collateral Agent on behalf of the Secured Parties shall have the right to prove their claim
in any proceeding, so as to establish their rights hereunder and receive directly from the receiver, trustee or other court custodian
payments which would otherwise be payable upon the Guarantor Claims. After the occurrence and during the continuance of an Event
of Default, each Grantor hereby assigns such payments to the Collateral Agent for the benefit of the Secured Parties for application
against the Secured Obligations as provided under Section 8.2 of the Note Purchase Agreement. Should the Collateral Agent
or any other Secured Party receive, for application upon the Secured Obligations, any such payment which is otherwise payable to
any Grantor, and which, as between such Grantor, shall constitute a credit upon the Guarantor Claims, then upon payment in full
of the Secured Obligations (other than Hedging Obligations owed by any Note Party to any Purchaser-Related Hedge Provider, Bank
Product Obligations, and indemnities and other contingent obligations not then due and payable and as to which no claim has been
made) and termination of all Commitments, the intended recipient shall become subrogated to the rights of the Collateral Agent
and the other Secured Parties to the extent that such payments to the Collateral Agent and the other Secured Parties on the Guarantor
Claims have contributed toward the liquidation of the Secured Obligations, and such subrogation shall be with respect to that proportion
of the Secured Obligations which would have been unpaid if the Collateral Agent and the other Secured Parties had not received
payments upon the Guarantor Claims.

 

Section 9.3           Payments
Held for Benefit of Collateral Agent. In the event that, notwithstanding Section 9.1 and Section 9.2, any
Grantor should receive any funds, payments, claims or distributions which are prohibited by such Sections, then it agrees (a) to
hold on behalf of and for the benefit of the Collateral Agent and the other Secured Parties an amount equal to the amount of all
funds, payments, claims or distributions so received, (b) that it shall have absolutely no dominion over the amount of such
funds, payments, claims or distributions except to pay them promptly to the Collateral Agent for the benefit of the Secured Parties,
and (c) to promptly pay the same to the Collateral Agent for the benefit of the Secured Parties.

 

    	 	27	 

     

    

 

Section 9.4           Liens
Subordinate. Each Grantor agrees that, until the Termination Date, any Liens securing payment of the Guarantor Claims shall
be and remain inferior and subordinate to any Liens securing payment of the Secured Obligations, regardless of whether such encumbrances
in favor of such Grantor, the Collateral Agent or any other Secured Party presently exist or are hereafter created or attach. Without
the prior written consent of the Collateral Agent (at the direction of the Required Purchasers), until the Termination Date, no
Grantor shall (a) exercise or enforce any creditor’s right it may have against any debtor in respect of the Guarantor Claims,
or (b) foreclose, repossess, sequester or otherwise take steps or institute any action or proceeding (judicial or otherwise, including,
without limitation, the commencement of or joinder in any liquidation, bankruptcy, rearrangement, debtor’s relief or insolvency
proceeding) to enforce any Lien held by it.

 

Section 9.5           Notation
of Records. Upon the request of the Collateral Agent (at the direction of the Required Purchasers), all promissory notes
and all accounts receivable ledgers or other evidence of the Guarantor Claims accepted by or held by any Grantor shall contain
a specific written notice thereon that the indebtedness evidenced thereby is subordinated under the terms of this Agreement.

 

ARTICLE
X

 

Miscellaneous

 

Section 10.1         Waiver.
No failure on the part of the Collateral Agent or any other Secured Party to exercise and no delay by any such Person in exercising,
and no course of dealing with respect to, any right, remedy, power or privilege under any of the Note Documents shall operate as
a waiver thereof, nor shall any single or partial exercise of any right, remedy power or privilege under any of the Note Documents
preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies,
powers and privileges provided herein are cumulative and not exclusive of any rights, remedies, powers and privileges provided
by law. The exercise by the Collateral Agent of any one or more of the rights, powers and remedies herein shall not be construed
as a waiver of any other rights, powers and remedies, including, without limitation, any rights of set-off.

 

Section 10.2         Notices.
All notices and other communications provided for herein shall be given in the manner and subject to the terms of Section 10.1
of the Note Purchase Agreement; provided that any such notice, request or demand to or upon any Guarantor shall be addressed
to such Guarantor at its notice address set forth on Schedule 1.

 

Section 10.3         Payment
of Expenses, Indemnities.

 

(a)          Each
Grantor agrees to pay or promptly reimburse the Collateral Agent and each other Secured Party for all documented fees, advances,
charges, costs and expenses (including, without limitation, all documented costs and expenses of holding, preparing for sale and
selling, collecting or otherwise realizing upon the Collateral and all documented fees, disbursements, and expenses of one outside
counsel to each such party (and any required special or local counsel to each such party) and court costs) incurred by any Secured
Party in connection with the enforcement or protection of its rights in connection with this Agreement, including, without limitation,
in connection with (i) the preservation of the Lien of, or the rights of the Collateral Agent or any other Secured Party under,
this Agreement, (ii) any actual or attempted sale, lease, disposition, exchange, collection, compromise, settlement or other realization
in respect of, or care of, the Collateral, including all such costs and expenses incurred in any bankruptcy, reorganization, workout
or other similar proceeding, or (iii) collecting against such Grantor under the guarantee contained in Article II or otherwise
enforcing or preserving any rights under this Agreement and the other Note Documents to which such Grantor is a party.

 

    	 	28	 

     

    

 

(b)          Each
Grantor shall, jointly and severally, indemnify each Indemnitee against, and hold each Indemnitee harmless from, any and all losses,
claims, damages, liabilities and expenses (including the fees, disbursements, and expenses of any counsel for any Indemnitee),
and shall reimburse each Indemnitee upon demand for any legal or other expenses incurred in connection with investigating or defending
any of the following, incurred by any Indemnitee or asserted against any Indemnitee by any third party or by any Grantor or any
of their Subsidiaries or Affiliates arising out of, in connection with, or as a result of (i) the execution or delivery of this
Agreement, the performance by the parties hereto of their respective obligations hereunder or the consummation of the transactions
contemplated hereby, (ii) the Collateral (including any exercise of rights or remedies in connection therewith), or (iii) any actual
or prospective suit, claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract,
tort or any other theory, whether brought by a third party or by any Grantor or any Grantor’s equity holders, Affiliates
or creditors, and regardless of whether any Indemnitee or such Grantor is a party thereto; provided that such indemnity
shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or other expenses are
determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from (x) the gross negligence
or willful misconduct of such Indemnitee or (y) other than with respect to the Collateral Agent and its Related Parties, a material
breach by such Indemnitee of any of its undertakings, obligations or commitments under this Agreement.

 

(c)          To
the extent permitted by applicable law, the Grantors shall not assert, and hereby waive, any claim against any Indemnitee, on any
theory of liability, for special, indirect, consequential, exemplary or punitive damages (as opposed to actual or direct damages)
arising out of, in connection with or as a result of this Agreement, any other Note Document or any agreement or instrument contemplated
hereby, the transactions contemplated therein.

 

(d)          All
amounts for which any Grantor is liable pursuant to this Section shall be due and payable by such Grantor to the Collateral Agent
or any Secured Party upon demand.

 

Section 10.4         Amendments
in Writing. None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise modified
except in accordance with Section 10.2 of the Note Purchase Agreement.

 

Section 10.5         Successors
and Assigns. This Agreement shall be binding upon the successors and assigns of each Grantor and shall inure to the benefit
of the Collateral Agent and the other Secured Parties and their respective successors and permitted assigns; provided that
no Grantor may assign, transfer or delegate any of its rights or Secured Obligations under this Agreement without the prior written
consent of the Collateral Agent and the Purchasers.

 

Section 10.6         Severability.
Any provision of this Agreement held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability
of the remaining provisions hereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate
such provision in any other jurisdiction.

 

Section 10.7         Counterparts.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument,
and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed counterpart to
this Agreement by facsimile transmission or by electronic mail in pdf format shall be as effective as delivery of a manually executed
counterpart hereof.

 

    	 	29	 

     

    

 

Section 10.8         Survival.
The obligations of the parties under Section 10.3 shall survive the repayment of the Secured Obligations and the termination
of the Note Purchase Agreement, the Commitments, the Hedging Obligations and the Bank Product Obligations and, as applicable, removal
or resignation of the Collateral Agent under the Note Documents. To the extent that any payments on the Secured Obligations or
proceeds of any Collateral are subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be
repaid to a trustee, debtor in possession, receiver or other Person under any bankruptcy law, common law or equitable cause, then,
to such extent, the Secured Obligations so satisfied shall be revived and continue as if such payment or proceeds had not been
received and the Collateral Agent’s and the other Secured Parties’ Liens, security interests, rights, powers and remedies
under this Agreement and each other applicable Collateral Document shall continue in full force and effect. In such event, each
applicable Collateral Document shall be automatically reinstated and each Grantor shall take such action as may be reasonably requested
by the Collateral Agent and the other Secured Parties to effect such reinstatement.

 

Section 10.9         Captions.
Captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect
the interpretation of any provision of this Agreement.

 

Section 10.10         No
Oral Agreements. The Note Documents embody the entire agreement and understanding between the parties and supersede all
other agreements and understandings between such parties relating to the subject matter hereof and thereof. The Note Documents
represent the final agreement between the parties and may not be contradicted by evidence of prior, contemporaneous or subsequent
oral agreements of the parties. There are no unwritten oral agreements between the parties.

 

Section 10.11         Governing
Law; Submission to Jurisdiction.

 

(a)          This
Agreement and the other Note Documents any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise)
based upon, arising out of or relating to this Agreement or any other Note Document (except, as to any other Note Document, as
expressly set forth therein) and the transactions contemplated hereby and thereby shall be construed in accordance with and be
governed by the law of the State of New York.

 

(b)          Each
Grantor hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the
United States District Court for the Southern District of New York, and of the Supreme Court of the State of New York sitting in
New York county, and of any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement
or any other Note Document or the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment,
and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in such District Court or such New York state court or, to the extent permitted by applicable law,
such appellate court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement
or any other Note Document shall affect any right that the Collateral Agent or any Purchaser may otherwise have to bring any action
or proceeding relating to this Agreement or any other Note Document against the Issuer or its properties in the courts of any jurisdiction.

 

(c)          Each
Grantor irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue of
any such suit, action or proceeding described in subsection (b) of this Section and brought in any court referred to in subsection
(b) of this Section. Each of the parties hereto irrevocably waives, to the fullest extent permitted by applicable law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

    	 	30	 

     

    

 

(d)          Each
party to this Agreement irrevocably consents to the service of process in the manner provided for notices in Section 10.2.
Nothing in this Agreement or in any other Note Document will affect the right of any party hereto to serve process in any other
manner permitted by law.

 

Section 10.12         WAIVER
OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF THIS AGREEMENT OR ANY OTHER NOTE DOCUMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A)
CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER
PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES
HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER NOTE DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION.

 

Section 10.13         Acknowledgments.

 

(a)          Each
Grantor hereby acknowledges that:

 

(i)          it
has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Note Documents to which
it is a party;

 

(ii)         neither
the Collateral Agent nor any other Secured Party has any fiduciary relationship with or duty to any Grantor arising out of or in
connection with this Agreement or any of the other Note Documents, and the relationship between the Grantors, on the one hand,
and the Collateral Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is solely that of
debtor and creditor; and

 

(iii)        no
joint venture is created hereby or by the other Note Documents or otherwise exists by virtue of the transactions contemplated hereby
among the Secured Parties or among the Grantors and the Purchasers.

 

(b)          Each
of the parties hereto specifically agrees that it has a duty to read this Agreement and the other Note Documents to which it is
a party and agrees that it is charged with notice and knowledge of the terms of this Agreement and the other Note Documents to
which it is a party; that it has in fact read this Agreement and the other Note Documents to which it is a party and is fully informed
and has full notice and knowledge of the terms, conditions and effects of this Agreement and the other Note Documents to which
it is a party; that it has been represented by independent legal counsel of its choice throughout the negotiations preceding its
execution of this Agreement and the other Note Documents to which it is party; and has received the advice of its attorney in entering
into this Agreement and the other Note Documents to which it is a party; and that it recognizes that certain of the terms of this
Agreement and other Note Documents to which it is a party result in one party assuming the liability inherent in some aspects of
the transaction and relieving the other party of its responsibility for such liability. Each Grantor agrees and covenants that
it will not contest the validity or enforceability of any exculpatory provision of this Agreement or the other Note Documents to
which it is a party on the basis that such Grantor had no notice or knowledge of such provision or that the provision is not “conspicuous”.

 

    	 	31	 

     

    

 

(c)          Each
Grantor warrants and agrees that each of the waivers and consents set forth in this Agreement are made voluntarily and unconditionally
after consultation with outside legal counsel and with full knowledge of their significance and consequences, with the understanding
that events giving rise to any defense or right waived may diminish, destroy or otherwise adversely affect rights which such Grantor
otherwise may have against any other Grantor, the Collateral Agent, the other Secured Parties or any other Person or against any
Collateral. If, notwithstanding the intent of the parties that the terms of this Agreement shall control in any and all circumstances,
any such waivers or consents are determined to be unenforceable under applicable law, such waivers and consents shall be effective
to the maximum extent permitted by law.

 

Section 10.14      Additional
Grantors. Each Person that is required to become a party to this Agreement pursuant to Section 5.12 of the Note Purchase
Agreement and is not a signatory hereto shall become a Grantor for all purposes of this Agreement upon execution and delivery
by such Person of a Joinder Agreement in the form of Annex I.

 

Section 10.15      Set-Off.
Each Grantor agrees that, in addition to (and without limitation of) any right of set-off, bankers’ lien or counterclaim
a Secured Party may otherwise have, each Secured Party shall have the right and be entitled, at its option, to offset (i) balances
held by it or by any of its Affiliates (or any other Secured Party) for account of any Grantor or any of its Subsidiaries at any
of its offices, in dollars or in any other currency, and (ii) Obligations then due and payable to such Secured Party (or any Affiliate
of such Secured Party), which are not paid when due, in which case it shall promptly notify the Issuer and the Collateral Agent
thereof, provided that such Secured Party’s failure to give such notice shall not affect the validity thereof.

 

Section 10.16      Releases.

 

(a)          Release
Upon Payment in Full. Upon the indefeasible complete payment in full of all Secured Obligations (other than Hedging Obligations
owed by any Note Party to any Purchaser-Related Hedge Provider, Bank Product Obligations, indemnities and other contingent obligations
not then due and payable and as to which no claim has been made) in cash and the termination of the Note Purchase Agreement, and
all Commitments thereunder (the “Termination Date”), this Agreement shall be of no further force and effect
and the Collateral Agent, at the written request and expense of the Issuer, and written direction of the Required Purchasers, shall
promptly execute and deliver to such Grantor all releases or other documents and reassign, release, transfer or deliver the Collateral
then in the possession of the Collateral Agent to the Grantors, without recourse, representation, warranty or other assurance of
any kind.

 

(b)          Further
Assurances. If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted
by the Note Purchase Agreement, then the Collateral Agent, at the request and sole expense of such Grantor, shall promptly execute
and deliver to such Grantor all releases or other documents reasonably necessary for the release of the Liens created hereby on
such Collateral and the Capital Stock of such Grantor, made without recourse, representation, warranty or other assurance of any
kind. At the request and sole expense of the Issuer, a Grantor shall be released from its obligations hereunder in the event that
all the Capital Stock of such Grantor shall be sold, transferred or otherwise disposed of in a transaction permitted by the Note
Purchase Agreement; provided that the Issuer shall have delivered to the Collateral Agent and the Purchasers, at least 10
Business Days prior to the date of the proposed release, a written request for release identifying the relevant Grantor and the
terms of the sale or other disposition in reasonable detail, including the price thereof and any expenses in connection therewith,
together with a certification by the Issuer stating that such transaction is in compliance with the Note Purchase Agreement and
the other Note Documents.

 

    	 	32	 

     

    

 

(c)          Retention
in Satisfaction. Except as may be expressly applicable pursuant to Section 9-620 of the UCC, no action taken or omission to
act by the Collateral Agent or the other Secured Parties hereunder, including, without limitation, any exercise of voting or consensual
rights or any other action taken or inaction, shall be deemed to constitute a retention of the Collateral in satisfaction of the
Secured Obligations or otherwise to be in full satisfaction of the Secured Obligations, and the Secured Obligations shall remain
in full force and effect, until the Collateral Agent and the other Secured Parties shall have applied payments (including, without
limitation, collections from Collateral) towards the Secured Obligations in the full amount then outstanding or until such subsequent
time as is provided in subsection (a) of this Section.

 

Section 10.17      Reinstatement.
The obligations of each Grantor under this Agreement (including, without limitation, with respect to the guarantee contained in
Article II and the provision of collateral herein) shall continue to be effective, or be reinstated, as the case may be,
if at any time payment, or any part thereof, of any of the Obligations is rescinded or must otherwise be restored or returned by
the Collateral Agent or any other Secured Party upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of
the Issuer or any other Grantor, or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee
or similar officer for, the Issuer or any other Grantor or any substantial part of its property, or otherwise, all as though such
payments had not been made.

 

Section 10.18      Acceptance.
Each Grantor hereby expressly waives notice of acceptance of this Agreement, acceptance on the part of the Collateral Agent and
the other Secured Parties being conclusively presumed by their request for this Agreement and delivery of the same to the Collateral
Agent.

 

Section 10.19      Keepwell.
Each Qualified ECP Guarantor hereby jointly and severally, absolutely, unconditionally and irrevocably undertakes to provide such
funds or other support as may be needed from time to time by each other Note Party to honor all of such Note Party’s obligations
under its Guarantee under the Note Documents in respect of Swap Obligations (provided, however, that each Qualified
ECP Guarantor shall only be liable under this Section 10.19 for the maximum amount of such liability that can be hereby
incurred without rendering its obligations under this Section 10.19, or otherwise under its Guarantee, voidable under applicable
law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). The obligations of each Qualified
ECP Guarantor under this Section 10.19 shall remain in full force and effect until termination of all Commitments and payment
in full of all Obligations (other than any obligations or rights which according to the Note Purchase Agreement shall survive the
termination of the Commitments). Each Qualified ECP Guarantor intends that this Section 10.19 constitute, and this Section
10.19 shall be deemed to constitute, a “keepwell, support, or other agreement” for the benefit of each other Note
Party for all purposes of Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.

 

Section 10.20       Relation
to Other Note Documents. The provisions of this Agreement shall be read and construed with the other Note Documents referred
to below in the manner so indicated.

 

(a)          Note
Purchase Agreement. In the event of any conflict between any provision in this Agreement and a provision in the Note Purchase
Agreement, such provision of the Note Purchase Agreement shall control.

 

(b)          Intellectual
Property Security Agreements. The provisions of any Intellectual Property Security Agreement are supplemental to the provisions
of this Agreement, and nothing contained in any Intellectual Property Security Agreement shall limit any of the rights or remedies
of Collateral Agent hereunder.

 

    	 	33	 

     

    

 

Section 10.21      Intercreditor
Agreement. Notwithstanding anything herein to the contrary, each Grantor and the Collateral Agent (on behalf of each Secured
Party) agrees that the Lien and security interest granted to the Collateral Agent pursuant to this Agreement and the exercise
of any right or remedy by the Collateral Agent hereunder, after the execution and delivery thereof, are subject to the provisions
of the First Lien/Second Lien Intercreditor Agreement, the ABDC Intercreditor Agreement and each other intercreditor agreement
entered into by the Collateral Agent with respect to the Secured Obligations. In the event of any conflict between the terms of
the First Lien/Second Lien Intercreditor Agreement, the ABDC Intercreditor Agreement or any other intercreditor agreement entered
into by the Collateral Agent with respect to the Secured Obligations and the terms of this Agreement (other than Article II hereof),
the terms of the First Lien/Second Lien Intercreditor Agreement, the ABDC Intercreditor Agreement or such other intercreditor
agreement shall govern and control at any time that the First Lien/Second Lien Intercreditor Agreement, the ABDC Intercreditor
Agreement or such other intercreditor agreement is in effect. Notwithstanding anything to the contrary contained herein, the Collateral
Agent acknowledges and agrees that no Grantor shall be required to take or refrain from taking any action at the request of the
Collateral Agent with respect to the Collateral if such action or inaction would be inconsistent with the terms of the ABDC Intercreditor
Agreement or any other intercreditor agreement entered into by the Collateral Agent with respect to the Secured Obligations.

 

Section 10.22      Collateral
Agent Rights. The Collateral Agent shall be entitled to all of the rights, protections, indemnities and immunities set
forth in the Note Purchase Agreement as if set forth herein.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK.]

 

    	 	34	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year
first above written.

 

	 	ISSUER:
	 	 
	 	BIOSCRIP, INC.
	 	 	 
	 	By:	/s/ Stephen Deitsch
	 	Name: Stephen Deitsch
	 	Title: Senior Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

  

GUARANTORS:

 

	APPLIED HEALTH CARE, LLC	 	BIOSCRIP INFUSION MANAGEMENT, LLC
	 	 	 
	By:	/s/ Stephen
    Deitsch	 	By: 	/s/ Stephen
    Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer
	 	 	 
	BIOSCRIP INFUSION SERVICES, INC.	 	BIOSCRIP INFUSION SERVICES, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer
	 	 	 
	BIOSCRIP Medical Supply
    SERVICES, LLC	 	BIOSCRIP NURSING SERVICES, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer
	 	 	 
	BIOSCRIP PBM SERVICES, LLC	 	BIOSCRIP PHARMACY (NY), INC.
	 	 	
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer 
	 	 	 
	BIOSCRIP PHARMACY, INC.	 	BIOSCRIP PHARMACY SERVICES, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer
	 	 	 
	CHS HOLDINGS, INC.	 	BRADHURST SPECIALTY PHARMACY, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen
    Deitsch	 	Name: Stephen
    Deitsch
	Title: Senior
    Vice President, Chief Financial Officer and Treasurer	 	Title: Senior
    Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

 

	DEACONESS ENTERPRISES, LLC	 	CHRONIMED, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	EAST GOSHEN PHARMACY, INC.	 	CRITICAL HOMECARE SOLUTIONS, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	INFUCENTERS, LLC	 	DEACONESS HOMECARE, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	INFUSCIENCE HHA, LLC	 	HOMECHOICE PARTNERS, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	INFUSCIENCE SOUTH CAROLINA, LLC	 	INFUSAL PARTNERS
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	INFUSION PARTNERS, LLC	 	INFUSCIENCE, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	INFUSION PARTNERS OF MELBOURNE, LLC	 	INFUSCIENCE SUB, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

 

 

	INFUSION THERAPY SPECIALISTS, INC.	 	INFUSION PARTNERS OF BRUNSWICK, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	NATIONAL HEALTH INFUSION, INC.	 	INFUSION SOLUTIONS, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	NEW ENGLAND HOME THERAPIES, INC.	 	KNOXVILLE HOME THERAPIES, LLC
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	PROFESSIONAL HOME CARE SERVICES, INC.	 	NATURAL LIVING, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	SCOTT-WILSON,  INC.	 	OPTION HEALTH, LTD.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	WILCOX MEDICAL, INC.	 	REGIONAL AMBULATORY DIAGNOSTICS, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

 

	PHCS ACQUISITION CO, INC.	 	SPECIALTY PHARMA, INC.
	 	 	 
	By:	/s/ Stephen Deitsch	 	By:	/s/ Stephen Deitsch
	Name: Stephen Deitsch	 	Name: Stephen Deitsch
	Title: Senior Vice President, Chief Financial Officer and Treasurer	 	Title: Senior Vice President, Chief Financial Officer and Treasurer
	 	 	 
	 	 	NUTRI USA INC.
	 	 	 
	 	 	By:	/s/ Stephen Deitsch
	 	 	Name: Stephen Deitsch
	 	 	Title: Senior Vice President, Chief Financial Officer and Treasurer

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

 

Acknowledged and Agreed to as of the date
hereof:

 

	COLLATERAL AGENT:	 
	 	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION	 
	 	 	 
	By:	 /s/ Michael Pinzon	 
	 	Name: Michael Pinzon	 
	 	Title: Vice President 	 

 

[Signature Page to First Lien Guaranty and
Security Agreement]

 

     

     

    

  

ANNEX I

 

Form of Joinder Agreement

 

THIS JOINDER AGREEMENT,
dated as of [_____] (this “Joinder Agreement”), is made by [name
of new Subsidiary], a [__________] (the “Additional Grantor”), in favor of WELLS FARGO BANK,
NATIONAL ASSOCIATION, as Collateral Agent (in such capacity, together with its successors and assigns, the “Collateral
Agent”) for the Secured Parties (as defined in the Guaranty and Security Agreement referred to below). All capitalized
terms not defined herein shall have the meanings assigned to them in the Guaranty and Security Agreement.

 

WHEREAS, BioScrip,
Inc., a Delaware corporation (the “Issuer”) has entered into that certain First Lien Note Purchase Agreement
dated as of June 29, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “Note Purchase
Agreement”), by and among the Issuer, the purchasers from time to time party thereto and the Collateral Agent, providing
for, among other things, the issuance by the Issuer and the purchase by the Purchasers of the Notes, subject to the terms set forth
therein;

 

WHEREAS, in
connection with the Note Purchase Agreement, the Issuer and certain of its Subsidiaries have entered into that certain First Lien
Guaranty and Security Agreement dated as of June 29, 2017 (as amended, restated, supplemented or otherwise modified from time to
time, the “Guaranty and Security Agreement”), in favor of the Collateral Agent for the benefit of the Secured
Parties;

 

WHEREAS, the
Note Purchase Agreement requires the Additional Grantor to become a party to the Guaranty and Security Agreement; and

 

WHEREAS, the
Additional Grantor has agreed to execute and deliver this Joinder Agreement in order to become a party to the Guaranty and Security
Agreement;

 

NOW, THEREFORE,
it is agreed:

 

SECTION 1.
     Guaranty and Security Agreement. By executing and delivering this Joinder Agreement, the Additional Grantor, as
provided in Section 10.14 of the Guaranty and Security Agreement, hereby becomes a party to the Guaranty and Security Agreement
as a Grantor thereunder with the same force and effect as if originally named therein as a Grantor and, without limiting the generality
of the foregoing, hereby expressly assumes all obligations and liabilities of a Grantor thereunder and hereby pledges and grants
to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in and lien on all right, title and
interest of the Additional Grantor in all property of such Additional Grantor that constitutes Collateral, wherever located and
whether now owned or at any time hereafter acquired by the Additional Grantor, or in which the Additional Grantor now has or at
any time in the future may acquire any right, title or interest and whether now existing or hereafter coming into existence, as
collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration
or otherwise) of the Secured Obligations (other than any Excluded Swap Obligation with respect to such Grantor). The information
set forth in Schedule A hereto is hereby added to the information set forth in Schedules 1 through 9 to the Guaranty and
Security Agreement and the Additional Grantor represents and warrants that all information set forth on Schedule A is true,
correct and complete in all respects as of the date hereof. The Additional Grantor hereby represents and warrants that each of
the representations and warranties contained in Article V of the Guaranty and Security Agreement is true and correct in all material
respects (or if already qualified by materiality or Material Adverse Effect, in all respects) on and as of the date hereof (after
giving effect to this Joinder Agreement) as if made by such Additional Grantor on and as of the date hereof. Not in limitation
of the foregoing, the Additional Grantor hereby confirms that by execution of this Joinder Agreement, it is jointly and severally
liable with the other Guarantors for all Guaranteed Obligations (other than any Excluded Swap Obligation with respect to such
Grantor), whether now existing or hereafter arising, in accordance with and subject to the terms of the Guaranty and Security
Agreement. Each reference to a “Grantor” or a “Guarantor” in the Guaranty and Security Agreement shall
be deemed to include the Additional Grantor.

 

     

     

    

 

SECTION 2.       Governing
Law. THIS JOINDER AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK.

 

SECTION 3.        Acknowledgement.
The Additional Grantor acknowledges and confirms that it has received a copy of the Note Purchase Agreement, the Guaranty
and Security Agreement, and the other Note Documents and, in each case, all schedules and exhibits thereto.

 

SECTION 4.        Further
Assurances. The Additional Grantor agrees that at any time and from time to time, upon the written request of the Collateral
Agent or the Required Purchasers, it will execute and deliver such further documents and do such further acts and things as the
Collateral Agent or the Required Purchasers may reasonably request in order to effect the purposes of this Joinder Agreement in
accordance with and subject to the terms of the Guaranty and Security Agreement.

 

SECTION 5.        Counterparts.
This Joinder Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and
the same instrument, and any of the parties hereto may execute this Joinder Agreement by signing any such counterpart. Delivery
of an executed counterpart to this Joinder Agreement by facsimile transmission or by electronic mail in pdf format shall be as
effective as delivery of a manually executed counterpart hereof.

 

SECTION 6.        Note
Document. Except as expressly supplemented hereby, the Note Documents shall remain in full force and effect. For avoidance
of doubt, the Additional Grantor and the Collateral Agent hereby acknowledge and agree that this Joinder Agreement is a Note Document.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK.]

 

Annex I

 

     

     

    

 

IN WITNESS WHEREOF,
the undersigned has caused this Joinder Agreement to be duly executed and delivered as of the date first above written.

 

	 	[NAME OF ADDITIONAL GRANTOR]
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

Acknowledged and Agreed to as of the date hereof:

 

	COLLATERAL AGENT:	 
	 	 	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

SCHEDULE A

 

Supplement to Schedules of

First Lien Guaranty and Security Agreement

 

 

Annex I

 

     

     

    

  

ANNEX II

 

Form of Intellectual Property Security
Agreement (First Lien)

 

THIS [COPYRIGHT][PATENT][TRADEMARK]
SECURITY AGREEMENT (FIRST LIEN), dated as of [_____] (this “Security Agreement”), is made by [name
of Grantor], a [__________] (the “Grantor”), in favor of WELLS FARGO BANK, NATIONAL ASSOCIATION,
as collateral agent (in such capacity, together with its successors and assigns, the “Collateral Agent”) for
the Secured Parties (as defined in the Guaranty and Security Agreement referred to below).

 

WHEREAS, BioScrip,
Inc., a Delaware corporation (the “Issuer”) has entered into that certain First Lien Note Purchase Agreement
dated as of June 29, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “Note Purchase
Agreement”), by and among the Issuer, the purchasers from time to time party thereto and the Collateral Agent, providing
for, among other things, the issuance by the Issuer and the purchase by the Purchasers of the Notes, subject to the terms set forth
therein;

 

WHEREAS, in
connection with the Note Purchase Agreement, the Issuer and certain of its Subsidiaries have entered into that certain First Lien
Guaranty and Security Agreement dated as of June 29, 2017 (as amended, restated, supplemented or otherwise modified from time to
time, the “Guaranty and Security Agreement”), in favor of the Collateral Agent for the benefit of the Secured
Parties; and

 

WHEREAS, the
Guaranty and Security Agreement requires the Grantor to execute and deliver this Security Agreement;

 

NOW, THEREFORE,
in consideration of the premises and in order to ensure compliance with the Note Purchase Agreement, the Grantor hereby agrees
as follows:

 

SECTION 1.          Defined
Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

 

SECTION 2.          Grant
of Security Interest in [Copyright][Patent][Trademark] Collateral. The Grantor, as collateral security for the prompt and
complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations
(other than any Excluded Swap Obligation with respect to such Grantor), hereby pledges and grants to the Collateral Agent, for
the ratable benefit of the Secured Parties, a security interest in and lien on all right, title and interest of the Grantor in,
to and under the following Collateral (in each case, other than Excluded Property) (the “[Copyright][Patent][Trademark]
Collateral”):

 

[(a)          all
of its Copyrights and all Copyright Licenses;

 

(b)          all
renewals, reversions and extensions of the foregoing; and

 

(c)           all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing,
including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement,
misappropriation, dilution, violation or other impairment thereof.]

 

[(a)          all
of its Patents and all Patent Licenses;

 

     

     

    

 

(b)           all
reissues, reexaminations, continuations, continuations-in-part, divisions, renewals and extensions of the foregoing; and

 

(c)           all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing,
including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement,
misappropriation, dilution, violation or other impairment thereof.]

 

[(a)          all
of its Trademarks and all Trademark Licenses;

 

(b)           all
renewals and extensions of the foregoing;

 

(c)           all
goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

 

(d)           all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing,
including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement,
misappropriation, dilution, violation or other impairment thereof.]

 

As of the date of this
Security Agreement, all of the Grantor’s [Copyright][Patent][Trademark] Collateral is set forth on Schedule I hereto.

 

SECTION 3.        Guaranty
and Security Agreement. The security interest granted pursuant to this Security Agreement is granted in conjunction with
the security interest granted to the Collateral Agent pursuant to the Guaranty and Security Agreement, and the Grantor hereby
acknowledges and agrees that the rights and remedies of the Collateral Agent with respect to the security interest in the [Copyright][Patent][Trademark]
Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of
which are incorporated by reference herein as if fully set forth herein. In the event of any conflict or inconsistency between
this Security Agreement and the Guaranty and Security Agreement (or any portion hereof or thereof), the terms of the Guaranty
and Security Agreement shall prevail.

 

SECTION 4.         Termination.
This Security Agreement shall terminate and the Lien on and security interest in the [Copyright] [Patent] [Trademark] Collateral
shall be released in accordance with Section 10.16 of the Guaranty and Security Agreement. Upon the termination of this Security
Agreement, the Collateral Agent shall, at the sole cost and expense of the Note Parties, promptly execute all documents, make all
filings and take all other actions reasonably requested by the Grantors to evidence and record the release of the Lien on and security
interests in the [Copyright] [Patent] [Trademark] Collateral granted herein.

 

SECTION 5.        Grantor
Remains Liable. The Grantor hereby agrees that, anything herein to the contrary notwithstanding, the Grantor shall retain
full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection
with the [Copyright][Patent][Trademark] Collateral subject to a security interest hereunder.

 

SECTION 6.         Governing
Law. THIS SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK.

 

Annex II

 

     

     

    

  

SECTION 7.         Counterparts.
This Security Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the
same instrument, and any of the parties hereto may execute this Security Agreement by signing any such counterpart. Delivery of
an executed counterpart to this Security Agreement by facsimile transmission or by electronic mail in pdf format shall be as effective
as delivery of a manually executed counterpart hereof.

 

SECTION 8.        Note
Document.  For avoidance of doubt, the Grantor and the Collateral Agent hereby acknowledge and agree that this Security
Agreement is a Note Document.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK.]

 

Annex II

 

     

     

    

 

IN WITNESS WHEREOF,
the Grantor has caused this [Copyright][Patent][Trademark] Security Agreement to be executed and delivered by its duly authorized
officer as of the date first set forth above.

 

	 	[NAME OF GRANTOR]
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

Acknowledged and Agreed to as of the date hereof:

 

	COLLATERAL AGENT:	 
	 	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

 

Annex II

 

     

     

    

  

SCHEDULE I

 

[Copyrights][Patents][Trademarks]
and [Copyright][Patent][Trademark] Licenses

 

		I.	REGISTERED [COPYRIGHTS][PATENTS][TRADEMARKS]

 

[Include registration number and date]

 

		II.	[COPYRIGHT][PATENT][TRADEMARK] APPLICATIONS

 

[Include application number and date]

 

		III.	[COPYRIGHT][PATENT][TRADEMARK] LICENSES

 

[Include complete legal description of agreement (name
of agreement, parties and date)]

 

     

     

    

 

ANNEX III

 

Form of Acknowledgment and Consent

 

The undersigned hereby
acknowledges receipt of a copy of that certain First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (as amended,
restated, supplemented or otherwise modified from time to time, the “Agreement”), made by BIOSCRIP, INC., a
Delaware corporation and the other Grantors party thereto for the benefit of WELLS FARGO BANK, NATIONAL ASSOCIATION, as collateral
agent (in such capacity, together with its successors and assigns, the “Collateral Agent”). The undersigned
agrees for the benefit of the Collateral Agent and the Secured Parties defined therein as follows:

 

1.          The
undersigned will be bound by the terms of the Agreement relating to the Pledged Securities issued by the undersigned and will comply
with such terms insofar as such terms are applicable to the undersigned.

 

2.          The
terms of Sections 7.1(c) and 7.5 of the Agreement shall apply to it, mutatis mutandis, with respect to all actions that
may be required of it pursuant to Sections 7.1(c) or 7.5 of the Agreement with respect to the Pledged Securities issued by the
undersigned.

 

	 	[NAME OF PLEDGED SECURITY ISSUER]
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

	 	Address for Notices:
	 	[_____]
	 	[_____]
	 	Attention: [_____]
	 	Telecopy Number: [_____]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]